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Abstract	
Tumor Protein D52 (TPD52) is an oncogene whose overexpression has been 
demonstrated in tumours of diverse cellular origins and associated with poor 
prognosis.  Although the breadth and clinical significance of TPD52 overexpression in 
cancer is now well-established, there remains a long-standing deficit in our 
understanding of its functional significance. The TPD52 gene is located on the 
frequently gained chromosome band 8q21, where we propose that it is an important 
amplification target. We first undertook a detailed analysis of the frequency, 
magnitude, and context of TPD52 amplification in 995 cancer cell lines. We then 
investigated whether TPD52 amplification and/or overexpression was broadly 
associated with altered lipid storage and/or metabolism in a selection of these cancer 
cells.  We demonstrated that there was a significant positive association between 
TPD52 expression and lipid droplet staining, with a dramatic increase in lipid droplet 
number and size upon the exogenous overexpression of TPD52 in MDAMB231 cells. 
Furthermore, TPD52 was found to interact directly with the lipid droplet-associated 
proteins, adipophilin and TIP47.  This suggests a role for TPD52 in intracellular lipid 
storage, which is particularly important to cancer cells since their rapid proliferation is 
contingent upon having a sufficient supply of lipid for membrane synthesis. We 
therefore hypothesised that TPD52 overexpression could be applied clinically as a 
predictive marker for cancers likely to respond to drugs that interfere with lipid 
pathways. We performed predictive modelling, using publicly-available 
pharmacogenomic datasets, to investigate for the first time whether TPD52 
amplification and/or overexpression was broadly associated with altered sensitivity or 
resistance to different drugs.  These analyses identified several compounds for future 
experimental validation, of which the lipid-relevant drugs fatostatin and brefeldin A 
were pursued in in vitro studies.  Collectively, the findings presented in this thesis 
represent a significant step forward in our understanding of how TPD52 amplification 
and/or overexpression may contribute to the development of cancer at a molecular 
level, and how this could be applied to improve cancer treatment. 
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Chapter 1 
 
Introduction. 
 
 
1.1   The genomic foundations of cancer  
The genomic changes that occur within cancers are immensely complex.  
Uncovering which of these changes contribute to cancer development, and the 
pathways through which these altered genes function, is one of the most pressing 
needs in basic cancer research.  Over the last two decades, intensive research efforts 
have cemented the driving role of several key genes in tumour initiation and 
progression, while advances in genome characterisation technologies have uncovered 
the genomic landscapes of many different cancer types.  However, much of these 
landscapes remain uncharted and the functional significance of many of the altered 
genes is yet to be elucidated.  A better understanding of the full complement of 
changes that comprise the genomic landscapes of cancers, particularly those changes 
that occur less frequently or affect less-studied genes, may provide important new 
insights for cancer treatment.  The following sections will review our current 
appreciation of the genomic changes that take place during tumour development and 
the opportunities these provide for therapeutic intervention, with a focus on genes that 
are targeted by amplification events. 
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1.1.1 Genomic changes during tumour development  
The development of cancer is a multi-step process that is driven by the 
progressive acquisition of genomic alterations.  The initiating lesion is thought to 
occur in a single somatic cell, furnishing it with a selective growth advantage and 
causing it to become the progenitor of a clonal population that outcompetes 
neighbouring cells (Nowell, 1976).  This expanding clonal mass undergoes successive 
rounds of selection as additional gene alterations arise and are perpetuated throughout 
the population according to their effects on the cancer cell (Nowell, 1976).  Different 
gene alterations may occur within individual cells and, if these confer similar fitness 
increases, cause these cells to become progenitors of separate clonal populations, 
leading to intratumour heterogeneity (reviewed in Davis et al., 2017).  The continuous 
nature of clonal selection means that the molecular fingerprint of a cancer can change 
over time, which has important implications for treatment methodologies and the 
emergence of resistance to targeted therapies (reviewed in Schmitt et al., 2016). 
The genomic changes that arise during tumour development are remarkably 
diverse, both within and across cancer types.  Despite this, these complex genomic 
changes are thought to endow cancer cells with a limited number of acquired 
attributes, or ‘hallmarks’, that characterise most, if not all, cancers (Figure 1.1).  Six 
essential hallmarks were initially recognised: the ability to sustain cell cycling in the 
absence of growth-stimulatory signals (‘self-sufficiency’); the disregard for growth-
inhibitory signals; the evasion of apoptosis; the infinite capacity for replication 
(‘immortality’); sustained angiogenesis; and tissue invasion and metastasis (Hanahan 
and Weinberg, 2000).  Dysregulated or reprogrammed cellular metabolism and the 
ability to evade immune surveillance were subsequently proposed as additional 
hallmarks, while genomic instability and tumour-promoting inflammation were 
suggested as commonly-acquired capacities that enable the emergence of the 
aforementioned hallmarks (Kroemer and Pouyssegur, 2008; Colotta et al., 2009; 
Negrini et al., 2010; Hanahan and Weinberg, 2011).  Furthermore, five stress 
phenotypes have been recognised as being commonly displayed by cancer cells: 
metabolic stress; proteotoxic stress; mitotic stress; oxidative stress; and DNA damage 
or replication stress (Luo et al., 2009).  Intricate molecular networks connect many of 
these hallmarks and stress phenotypes, such that the underlying genomic changes can 
have multifarious effects (Luo et al., 2009). 
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Figure 1.1. Hallmarks and stress phenotypes of cancer.  The commonly-acquired 
attributes of cancer include the six classical hallmarks (upper half, white symbols), 
plus the evasion of immune surveillance (lower left, coloured symbol) and the 
dysregulation of cellular metabolism (not shown), as well as five stress phenotypes 
(lower half, coloured symbols).  Two enabling capacities, namely genomic instability 
and tumour-promoting inflammation, are not shown here.  Several of the cellular 
consequences of these hallmarks and stress phenotypes are shown inside the circle to 
illustrate their potential interplay.  Abbreviations: ROS, reactive oxygen species.  
Figure reproduced from Luo et al., 2009. 
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1.1.2 Oncogene activation and addiction 
The genes that play a driving role in tumour development are classed as either 
oncogenes or tumour suppressor genes.  The product of an activated oncogene 
contributes to cellular transformation by promoting processes related to cell growth or 
survival, whereas the deactivation of a tumour suppressor gene contributes to cellular 
transformation by withdrawing the normal checks placed on cell growth.  Proto-
oncogenes typically encode proteins involved in positively regulating proliferative 
signals or the possession of an immature phenotype with the capacity for self-renewal.  
These proteins can be grouped into six broad categories: transcription factors, 
chromatin remodellers, growth factors, growth factor receptors, signal transducers, and 
apoptosis regulators (Croce, 2008).  Oncogenes may be activated via several 
mechanisms including: mutations, which generate a structurally-altered protein with 
increased or constitutive activity; chromosomal rearrangements and translocations, 
which produce gene fusions or juxtapose the proto-oncogene to a strong promoter or 
enhancer element to dysregulate its expression; and increased gene copy number or 
amplification, which leads to overexpression of a structurally-normal protein (Croce, 
2008).  Some microRNA genes can also function as oncogenes if they down-regulate 
the expression of tumour suppressor genes, and have been shown to undergo 
rearrangement and amplifications in cancer cells (Calin et al., 2004).  Finally, 
epigenetic modifications can also contribute to the overexpression of certain 
oncogenes (reviewed in Flavahan et al., 2017). 
Interestingly, despite the extensive genomic alterations that are found in cancer 
cells, many tumours have been shown to be reliant upon the activity of a single 
dominant oncogene for their growth and survival.  This phenomenon is known as 
‘oncogene addiction’ (Weinstein, 2000; Weinstein, 2002).  A wealth of evidence now 
exists, ranging from experiments in human cancer cell lines and mouse models to 
clinical trials with molecularly-targeted drugs, which demonstrates that disrupting the 
expression and/or function of these key oncogenes can be sufficient to produce tumour 
regression or stabilisation (reviewed in Weinstein and Joe, 2006; Sharma and 
Settleman, 2007; Torti and Trusolino, 2011).  Three mechanistic models have been 
proposed to account for oncogene addiction, with each of these models being 
experimentally validated and able to explain different but complementary aspects of 
this phenomenon.  The first model, genetic streamlining, postulates that the cellular 
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pathways which prove to be non-essential for an oncogene-addicted cancer cell 
become inactivated during tumour evolution and are therefore unable to compensate 
for the subsequent withdrawal of the dominant signal (Mills et al., 2001; Kamb, 2003).  
The second model, oncogenic shock, relies on the observation that many dominant 
oncogenes simultaneously sustain both pro-survival and pro-apoptotic signals, such 
that the sudden inhibition of that oncogene upsets the balance in favour of the longer-
lasting apoptotic signals (Sharma et al., 2006a; Sharma et al., 2006b; Sharma and 
Settleman, 2006).  Finally, the third model proposes that synthetic lethality may occur 
where the loss of the addictive oncogene is combined with the previous loss of another 
gene with a common downstream substrate or effector (Kaelin, 2005).  
Oncogenes that are activated through amplification (or mutation), rather than 
overexpression, are thought to be more closely aligned with oncogene addiction 
because they likely reflect the ‘hard-wiring’ of cancer cells, and these alterations are 
likely present in the progenitor cancer cells as well as the resultant clonal populations 
(Weinstein and Joe, 2008).  In fact, the well-known amplification targets MYC and 
ERBB2 both served as compelling early examples of oncogene addiction.  Dependence 
on the continued expression of MYC has been demonstrated in cell lines derived from 
human haematopoietic cancers (Yokoyama and Imamoto, 1987; Loke et al., 1988), as 
well as in conditional Myc-driven mouse models of lymphoma and leukaemia (Felsher 
and Bishop, 1999; Arvanitis and Felsher, 2006; Wu et al., 2007), pancreas b-cell 
cancer (Pelengaris et al., 2002), osteogenic sarcoma (Jain et al., 2002), and breast 
cancer (D’Cruz et al., 2001).  Similarly, dependence on the continued expression of 
ERBB2 was shown in ERBB2-amplified human breast cancer cell lines (Hudziak et 
al., 1989; Brysch et al., 1994; Colomer et al., 1994), in a conditional ERBB2-driven 
mouse model of mammary cancer (Moody et al., 2002; Moody et al., 2005), and in 
xenograft models (Ohnishi et al., 1995; Tokuda et al., 1996; Xia et al., 2002; 
Rabindran et al., 2004; Wong et al., 2006).  ERBB2 was also one of the first addiction-
conferring oncogenes to be targeted therapeutically, with clinical trials demonstrating 
significant improvements in disease-free survival for women with ERBB2-positive 
breast cancer following treatment with trastuzumab, a recombinant monoclonal 
antibody against ERBB2 (Slamon et al., 2001; Piccart-Gebhart et al., 2005). 
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1.1.3 Non-oncogene addiction 
The concept of ‘non-oncogene addiction’ was subsequently developed to 
describe the heightened dependence of cancer cells on genes and pathways that support 
oncogenic phenotypes (Solimini et al., 2007; Luo et al., 2009; Nagel et al., 2016).  
This concept recognises that oncogene-addicted cancers often rely on extensive 
complementary adaptations, which therefore become vulnerabilities that may be 
exploited therapeutically.  The stress phenotypes exhibited by cancer cells (Figure 1.1) 
are major sources of non-oncogene addiction, since the proteins and pathways 
involved in buffering these are often not oncogenic themselves but are nevertheless 
required for cell survival (Solimini et al., 2007; Luo et al., 2009).  Figure 1.2 illustrates 
several examples of non-oncogene addictions that are derived from commonly-
acquired attributes of cancers.  For example, the extreme aneuploidy and copy number 
variation in cancer cells can produce both mitotic and proteotoxic stress, which 
necessitates the activation of stress support pathways for proper chromosome 
segregation and protein folding, respectively (Luo et al., 2009).  Aneuploidy and copy 
number variation can also lead to the display of novel epitopes on the cell surface, 
which increases the requirement for pathways that supress the immune response (Luo 
et al., 2009).  These non-oncogene addictions may be targeted by drugs that produce 
additional stress or inhibit the specific salvage pathways that are active within a given 
cancer (Nagel et al., 2016).  Non-oncogene addictions also provide important avenues 
for treating cancers in which the driving oncogene is not readily druggable, such as 
MYC, or in which resistance to targeted treatment frequently emerges, such as ERBB2 
(Nagel et al., 2016). 
 
1.1.4 Gene amplification targets 
1.1.4.1 Mapping gene copy number landscapes  
Advances in genome characterisation technologies have furnished researchers 
with unprecedented access to the genomic landscapes of individual cancers, revealing 
their precise combination of molecular lesions.  Researchers are now embarking upon 
the systematic project of charting these landscapes to identify important genomic 
landmarks.  One branch of this endeavour has been to obtain high-resolution cancer 
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Figure 1.2. Non-oncogene addictions.  Cancer cells feature a variety of alterations 
that distinguish them from normal cells (upper, black text).  These alterations become 
vulnerabilities (middle, black text and symbols) that could be lethal to the cancer cell if 
not buffered by complementary alterations (lower, red text).  The specific proteins 
implicated in these complementary alterations become non-oncogene addictions.  
Abbreviations: TCA, tricarboxylic acid cycle (also known as Krebs cycle).  Figure 
reproduced from Luo et al., 2009. 
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copy number profiles in order to catalogue those genes that are recurrently amplified 
within and across different cancer types.  A seminal study comparing copy number 
profiles from 3,131 cancer specimens, belonging to 26 different histological types, 
revealed that somatic copy number variations are extremely common in cancer, with a 
typical specimen displaying amplification of 17% of the genome, on average, 
compared to just 0.35% for normal tissue specimens (Beroukhim et al., 2010).  
Changes in copy number have been shown to dominate the genomic landscape of 
particular tumour types, including breast and serous ovarian carcinoma, as well as lung 
squamous cell carcinoma (Ciriello et al., 2013).  The cancer genomics field is 
constantly growing as studies are performed for different tumour types or molecular 
subtypes that employ greater specimen numbers.  The cBioPortal, an interactive 
resource for the exploration of cancer genomic datasets, currently provides access to 
over 200 cancer genome studies (Cerami et al., 2012).   
These genomic studies have also provided several significant insights regarding 
the nature of gene copy number change in cancer.  Most copy number increases occur 
either as focal changes affecting a small genomic region, with sometimes very high 
amplitudes, or as gain of a whole chromosome arm, with very low amplitudes that 
usually represented single-copy changes (Beroukhim et al., 2010).  The frequency with 
which focal amplifications occur has been shown to be inversely related to their 
lengths (Beroukhim et al., 2010).  Arm-level gains, on the other hand, occurred 
approximately 30 times more frequently than would have been predicted from the 
inverse-length distribution of focal events, although their frequency did decrease as the 
length of the chromosome arm increased (Beroukhim et al., 2010).  This likely reflects 
a disparity in the mechanisms by which focal and arm-level amplification events are 
produced (Beroukhim et al., 2010).  Finally, these studies have revealed that there can 
be both considerable differences in genomic landscapes between cancers derived from 
the same tissue type and considerable similarities between cancer derived from 
different tissue types (Ciriello et al., 2013).     
 
1.1.4.2 Identifying candidate gene amplification targets 
 One of the major challenges to arise out of the mapping of genomic landscapes 
is how to distinguish those alterations that drive cancer development from the 
passenger alterations that confer little to no fitness change on the tumour.  This 
challenge is even more pronounced for amplification, where recurrently-gained 
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genomic regions may contain several candidate amplification genes (Santarius et al., 
2010; Byrne et al., 2012).  High-resolution mapping of the amplicons present in many 
cancer specimens can help to define a minimal region of genomic gain, to which the 
candidate amplification target is expected to map (Santarius et al., 2010; Byrne et al., 
2012).  Once the potential amplification target genes have been identified, a 
foundational requirement of the true driver gene is that its amplification be 
accompanied by overexpression (Santarius et al., 2010).  A gene’s candidature may 
then be strengthened by the fulfilment of additional functional criteria including the 
phenotypic consequences of overexpression and/or knockdown in cultured cells or 
model organisms, as well as correlation with clinical variables such as patient outcome 
(Santarius et al., 2010).  It is also important to note that the same amplicon can be 
selected for due to different driver genes in different cancer types, or even within 
different subtypes of a given cancer (Santarius et al., 2010).  
 
1.1.4.3 An (incomplete) catalogue of gene amplification targets 
The collective insights derived from large-scale genomic mapping studies have 
allowed for the cataloguing of genes that are recurrently altered in cancer, including 
numerous candidate amplification targets.  It has been proposed that we are 
approaching a plateau in the discovery of driver genes, as the same genes are being ‘re-
discovered’ in different cancer types (Vogelstein et al., 2013).   Although this may be 
the case for genes altered by mutation, it is highly unlikely that the analogous situation 
pertains to genes that are altered by amplification.  When the first census of amplified 
cancer genes was made, there were 384 cancer driver genes with sufficient supporting 
evidence, of which only six were amplification targets (Santarius et al., 2010).  This 
was attributed to the challenges associated with identifying the true target gene on an 
amplicon, since amplification is not a less frequent mechanism for oncogene activation 
(Santarius et al., 2010).  Accordingly, the same year saw 76 significant focal 
amplifications identified in the seminal pan-cancer copy number profiles, of which just 
25 (33%) of the amplicons harboured a previously-validated target (Beroukhim et al., 
2010).  In the intervening years, functional studies (such as those outlined in section 
1.1.4.2) have steadily increased the number of amplification targets for which 
sufficient evidence now exists to support a driving role in cancer development. 
However, this is an ongoing process and we expect that there are many more 
amplification target genes to discover.  
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These novel amplification targets are likely to be found amongst those genes 
that are altered less frequently in cancer.   A key insight derived from the mutational 
landscape of cancers is the ‘mountain and hill’ concept (Wood et al., 2007).  Analyses 
indicated that there are only a few genes which are frequently mutated in most 
specimens of a given cancer type and in multiple cancer types (‘mountains’), whereas 
there is a much greater number of genes which are mutated at lower frequencies and in 
fewer cancer types (‘hills’).  This insight is also applicable to amplification events, 
where a few genes are recurrently amplified across cancer cases, and therefore have 
already been discovered as amplification targets, while genes that are infrequently 
amplified dominate the genomic landscape but are less easily identified because they 
are gained with lower amplitudes, or in specific cancer types or patient subpopulations 
(Byrne et al., 2012).  These ‘hills’ are nonetheless highly significant in those cancers 
in which they occur, as exemplified by ‘exceptional responders’, patients that respond 
unexpectedly to targeted therapies because their tumours harbour comparatively rare 
genomic alterations (Iyer et al., 2012).  Understudied gene amplification target genes 
include tumor protein D52 (TPD52), which is the focus of the current study. 
 
1.2 Tumour metabolism 
The first observation of altered metabolism in cancer cells was made during the 
1920s.  The now well-known ‘Warburg effect’ describes a metabolic switch within 
cancer cells to the production of energy through glycolysis, rather than the more 
efficient process of mitochondrial oxidative phosphorylation, even under aerobic 
conditions (Warburg, 1956).  However, an open question remained as to whether this 
change in cancer metabolism was simply a consequence of oncogenic signalling, or 
whether such changes could be playing a driving role in cancer progression.  With its 
recognition as a ‘new generation’ hallmark of cancer (Hanahan and Weinberg, 2011), 
the dysregulation and reprogramming of cancer cell metabolism has once again 
become the subject of substantial research interest.  In particular, significant changes in 
lipid metabolism have been observed in cancer cells, which contribute to many aspects 
of cancer development.  The following sections will present an overview of lipid 
metabolism and storage, the ways in which these pathways are altered in cancer, and 
current progress towards exploiting these changes therapeutically. 
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1.2.1 Lipid metabolism pathways 
Lipids may either be acquired from dietary sources, as free fatty acids and in 
lipoproteins, or derived via de novo biosynthesis pathways.  Fatty acids are synthesised 
through de novo lipogenesis, while cholesterol is synthesised through the mevalonate 
pathway (Figure 1.3; reviewed in Santos and Schulze, 2012; Currie et al., 2013; 
Kamili and Byrne, 2014).  The precursor for both fatty acid and cholesterol synthesis 
is acetyl-CoA, which is produced from citrate through the activity of ATP citrate lyase 
(ACLY).  During de novo lipogenesis, acetyl-CoA is converted by acetyl-CoA 
carboxylase (ACC) to malonyl-CoA, which is then condensed repeatedly by fatty acid 
synthase (FASN) to generate palmitate, the basic 16-carbon saturated fatty acid.  
Newly-synthesised fatty acid can then be elongated, desaturated, or otherwise 
modified, to generate a variety of more complex lipids, such as phospholipids for cell 
membranes.  Alternatively, free fatty acids may be sent through β-oxidation in the 
mitochondria to generate energy for cellular processes.  Cholesterol biosynthesis, on 
the other hand, begins with the condensation of acetyl-CoA to 3-hydroxy-3-
methylglutaryl (HMG)-CoA, which is then reduced to mevalonate by HMG-CoA 
reductase (HMGCR), with the latter step being the rate limiting reaction.  Several 
subsequent steps are required for the eventual production of cholesterol, which can 
then be incorporated into cell membranes.  The enzymes involved in both de novo 
lipogenesis and cholesterol biosynthesis are subject to transcriptional regulation by the 
sterol regulatory element-binding proteins (SREBPs) (reviewed in Eberle et al., 2004).  
Excess free fatty acids and cholesterol are converted to triacylglycerides and 
cholesterol esters, respectively, and then incorporated into lipid droplets for storage.  
When fatty acids are required by cells, such as during fasting and exercise, these can 
be released through lipolysis.  This is a multistep process that is catalysed by a series 
of lipases: first, adipose triglyceride lipase (ATGL) hydrolyses triacylglyceride to 
produce diacylglyceride and release one fatty acid; second, hormone-sensitive lipase 
(HSL) hydrolyses diacylglyceride to produce monoacylgyceride and release a second 
fatty acid; and third, monoacylglycerol lipase (MAGL) releases the final fatty acid 
from the glycerol backbone (reviewed in Zechner et al., 2009).  In adipocytes, lipolysis 
is tightly regulated by switches between the secretion of insulin (inhibitory) and 
catecholamine (stimulatory) and this signal is transduced through the cell to a  
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Figure 1.3. Simplified overview of lipid metabolism pathways.  Intracellular free 
fatty acid (FFA) may be acquired through fatty acid (FA) uptake or de novo 
lipogenesis.  FFA may then undergo β-oxidation or be converted into phospholipids 
for cell membranes, primarily phosphatidylcholine (PC) and phosphatidyl-
ethanolamine (PE).  Excess FFA is converted into triacylglycerides (TAG) and stored 
in lipid droplets.  Similarly, excess cholesterol that is not incorporated into cell 
membranes is converted into cholesterol esters (CE) and stored in lipid droplets.  The 
release of lipid from these stores occurs via lipolysis.  Figure reproduced from Kamili 
and Byrne, 2014.  
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gate-keeper protein, perilipin, which is located on the surface of the lipid droplet 
(reviewed in Zechner et al., 2009).  Although lipolysis has been predominantly studied 
in adipocytes, a similar process is thought to occur in non-adipose tissue; however, the 
full complement of lipases and/or their effectors, as well as the corresponding 
regulatory mechanisms, have yet to be fully elucidated (reviewed in Currie et al., 
2013).  
 
1.2.2 Intracellular lipid storage 
1.2.2.1 Lipid droplet structure and diversity 
Lipid droplets are specialised organelles for the storage of neutral lipid within 
cells.  They feature a hydrophobic lipid core, comprised mainly of triacylglycerides 
and sterol esters, which is surrounded by a phospholipid monolayer that is decorated 
with numerous associated proteins (Figure 1.4; Krahmer et al., 2009).  This structure is 
highly-conserved, with lipid droplets being found in most eukaryotic cells, as well as 
in some prokaryotes (Yang et al., 2012).  Despite this common structure, lipid droplets 
exhibit considerable diversity both within and between cell types (reviewed in Thiam 
and Beller, 2017).  The most immediately obvious sources of lipid droplet diversity are 
their numbers per cell and their sizes.  Mammalian white adipocytes, which are 
specialised for lipid storage, contain one large (up to 100 µm) lipid droplet for 
maximal storage efficiency, while other cells possess numerous small (100 nm to 1 
µm) lipid droplets for more rapidly-accessible reservoirs of lipid (Suzuki et al., 2011).  
Furthermore, the spatial organisation of lipid droplets can vary between cells.  Lipid 
droplets may be dispersed throughout the cytoplasm or grouped in grape-like clusters 
(Thiam and Beller, 2017).  The subcellular localisation of lipid droplets may also 
depend on the metabolic state of the cell; for example, during starvation, lipid droplets 
are found in close proximity to the mitochondria where the liberated fatty acids will be 
used for energy production (Hesse et al., 2013; Herms et al., 2015). 
Lipid droplets also vary considerably with respect to the specific combination 
of proteins that are found on their surfaces (reviewed in Hodges and Wu, 2010; Yang 
et al., 2012).  This has important functional ramifications and can even define sub-
populations of lipid droplets within an individual cell.  For example, the 
triacylglyceride synthesis enzymes, diacylglycerol acyltransferase 2 (DGAT2) and 
glycerol-3-phosphate acyltransferase 4 (GPAT4), have been shown to localise 
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Figure 1.4. Lipid droplet structure.  Lipid droplets feature a hydrophobic lipid core, 
comprised mainly of triacylglycerides and sterol esters, which is surrounded by a 
phospholipid monolayer that contains numerous associated proteins.  For example, 
shown here are DGAT2 (diacylglycerol acyltransferase 2), Rab18, perilipin, and CCT 
(CTP:phosphocholine cytidylyltransferase).  Figure reproduced from Krahmer et al., 
2009.  
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specifically to a subset of lipid droplets that continue to grow under feeding conditions 
(Wilfling et al., 2013).  Meanwhile, the small GTPase Rab18 has been shown to 
associate specifically with lipolytic lipid droplets (Martin et al., 2005; Pulido et al., 
2011).  Lipid-droplet-associated proteins will be discussed in more detail in section 
1.2.2.4.  Finally, the precise composition of a lipid droplet’s hydrophobic core can also 
differ within and between cell types.  Spatially distinct pools of lipid droplets 
containing predominantly triacylglyceride or cholesterol ester have been observed 
within cultured cells (Hsieh et al., 2012).  The lipid droplets of specialised cell types 
have also been shown to be enriched with uncommon lipids, such as retinyl esters for 
hepatic stellate cells (Blaner et al., 2009; D’Ambrosio et al., 2011), and cis-7-
hexadecanoic acid for foamy monocytes (Guijas et al., 2016).  
 
1.2.2.2 Lipid droplet functions 
Once thought to be inert storage organelles, lipid droplets are currently 
undergoing a renaissance as new and unexpected roles continue to be identified in a 
broad range of cellular processes (reviewed in Welte, 2015).  First and foremost, lipid 
droplets function as reservoirs of neutral lipids, which can be mobilised as required to 
provide substrates for energy production or membrane synthesis (section 1.2.1).  They 
also perform an important protective function by packaging up intracellular free fatty 
acid that would otherwise lead to progressive lipotoxicity and ultimately cell death 
(Listenberger et al., 2003; Williams et al., 2013; Herms et al., 2013).  It has been 
suggested that the observation of small transient lipid droplets may represent a 
protective ‘overflow’ mechanism that is employed when levels of free fatty acids are 
increased, such as during the postprandial phase or in pathological conditions (Thiam 
and Beller, 2017).  Additionally, lipid droplets act as metabolic hubs, harbouring on 
their surfaces key proteins for the coordination of several metabolic processes, 
including the synthesis of triacylglycerides (Wilfling et al., 2013) and membrane 
phospholipids (Krahmer et al., 2011), as well as the regulation of lipolysis (Zechner et 
al., 2009).  Lipid droplets may also play a role in transporting neutral lipid and/or 
phospholipids between membrane-bound cellular organelles (Murphy et al., 2009; 
Zehmer et al., 2009).  In these ways, lipid droplets critically influence both the lipid 
and energy homeostasis of the cell. 
Furthermore, lipid droplets have also been proposed as dynamic protein storage 
sites, with the ability to modulate the functions of resident proteins by influencing their 
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interactions with binding partners, assembly into protein complexes, stability, or 
subcellular localisation (Welte, 2007; Hodges and Wu, 2010).  Proteins found to be 
sequestered in lipid droplets include histones in Drosophila oocytes (Cermelli et al., 
2006; Li et al., 2012; Li et al., 2014a), which has led to the suggestion that lipid 
droplets could even play a role in the coordination of nuclear events in some cell types 
(Welte, 2015).  Another hypothesised role for lipid droplets is the removal of 
unwanted or misfolded proteins from the endoplasmic reticulum (Ploegh, 2007).  
Accordingly, ancient ubiquitous protein 1 (AUP1), which is involved in ubiquitin-
mediated protein degradation, has been identified at the lipid droplet surface (Klemm 
et al., 2011; Spandl et al., 2011) and specific components of the proteasomal and 
autophagic pathways have been found to converge on the lipid droplet (Ohsaki et al., 
2006; Fujimoto and Ohsaki, 2006; Ohsaki et al., 2008; Hartman et al., 2010).  Future 
studies will likely further refine our growing appreciation of the lipid droplet as a 
dynamic and multi-functional organelle, which is positioned at the nexus of several 
important regulatory pathways.   
 
1.2.2.3 Lipid droplet formation and life cycle 
The prevailing model of lipid droplet biogenesis comprises four steps (Figure 
1.5; Walther et al., 2017).  First, neutral lipids are synthesised by enzymes that reside 
in the endoplasmic reticulum, with DGAT enzymes catalysing the final step in 
triacylglyceride synthesis (Harris et al., 2011; Wilfling et al., 2013; Li et al., 2015a) 
and sterol-O-acyltransferase (SOAT) enzymes catalysing the synthesis of sterol esters 
(Chang et al., 2009).  Second, newly-synthesised lipid accumulates within the bilayer 
of the endoplasmic reticulum, eventually driving the formation of an oil lens in the 
membrane.  The presence of lens-like structures during the early stages of lipid droplet 
biogenesis was recently demonstrated by electron microscopy (Choudhary et al., 
2015).  Third, enlargement of the oil lens ultimately results in the ‘budding off’ of a 
spherical nascent lipid droplet.  Fourth, a subset of nascent lipid droplets go on to 
acquire specific proteins that facilitate their expansion, such as triacylglyceride 
synthesis enzymes (Wilfling et al., 2013).  Proteins are thought to target to lipid 
droplets in one of two ways: first, by translocation through the endoplasmic reticulum 
during lipid droplet formation, or subsequently via membrane bridges; and second, 
from the cytoplasm via amphipathic helices or short, hydrophobic-rich sequences 
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Figure 1.5. Current model for lipid droplet formation and expansion.  Lipid 
droplets (LD) are formed in the endoplasmic reticulum (ER).  Triglycerides (TG) are 
synthesised within the ER, accumulate within ER membrane to form an oil lens, which 
then enlarges and buds off as a nascent LD.  The subsequent acquisition of specific 
proteins then defines sub-populations of initial LDs (iLDs) or expanding LD (eLDs). 
Abbreviations: DGAT1/2, diacylglycerol acyltransferase 1/2; FIT2, fat storage-
inducing transmembrane 2; GPAT4, glycerol-3-phosphate acyltransferase 4; 
ARF1/COPI, ADP-ribosylation factor 1 / coat protein complex I; CCT1, CTP: 
phosphocholine cytidylyltransferase 1.  Figure reproduced from Walther et al., 2017.  
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(Kory et al., 2016).  Depending on their associated proteins, a selection of these 
expanding lipid droplets are destined to become steady-state droplets and will persist 
in the cytosol until their lipid stores are required.  These may then be remobilised 
through the lipolysis pathway (section 1.2.1) or through lipophagy, that is, the 
autophagy of lipid droplets (Singh et al., 2009). 
Although this lipid droplet biogenesis model is supported by multiple lines of 
evidence, it must be noted that it is yet to be comprehensively validated.  An 
alternative model suggests that lipid droplets form in the cytoplasm in close apposition 
to the endoplasmic reticulum membrane, rather than within it, with electron 
microscopy revealing that the endoplasmic reticulum membrane partially encloses the 
growing lipid droplet like an egg cup (Robenek et al., 2006).  Other studies have 
suggested that lipid droplets can also bud from the luminal leaflet, as well as the 
cytosolic leaflet, of the endoplasmic reticulum (Choudhary et al., 2011).  Furthermore, 
many questions remain with respect to the precise mechanisms underlying the 
prevailing ‘budding off’ model described above.  For example, it is currently unclear 
whether the formation of oil lenses in the endoplasmic reticulum membrane occurs at 
specifically defined sites or stochastically, or both (Thiam and Beller, 2017).  
Additionally, when the nascent lipid droplet buds off it is presumed to be encapsulated 
in a phospholipid monolayer originating from the cytoplasmic leaflet of the 
endoplasmic reticulum membrane; however, the phospholipid composition of lipid 
droplet membranes has been shown to be different from that of the endoplasmic 
reticulum membrane (Tauchi-Sato et al., 2002; Zanghellini et al., 2010) and the 
processes responsible for these differences remain to be determined. 
 
1.2.2.4 Lipid droplet-associated proteins 
 The proteins that are found on lipid droplet surfaces are hugely important to 
their functioning and, as previously mentioned, can vary greatly depending on cell 
type and metabolic state. Several hundred proteins have now been identified as being 
associated with lipid droplets through proteomic screens in various cellular systems 
(for example: Brasaemle et al., 2004; Fujimoto et al., 2006; Liu et al., 2004; Beller et  
al., 2006; Cermelli et al., 2006; Krahmer et al., 2013; Khor et al., 2014).  Although the 
project of filtering out potential protein contaminants and false negatives is ongoing, 
many of these lipid droplet-associated proteins have been validated by biochemical 
and imaging studies, with several functional groups emerging as consistently and 
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reproducibly present on lipid droplets (reviewed in Hodges and Wu, 2010; Yang et al., 
2012).  These groups include lipid droplet structural and regulatory proteins, lipid 
metabolic enzymes, membrane trafficking proteins, signalling proteins, and 
cytoskeletal proteins.  For many of these proteins, further research is required to 
understand how and why these proteins are associated with lipid droplets.  
Lipid droplets are stabilised, and the mobilisation of their lipid stores regulated, 
by a family of lipid-droplet-associated proteins known as perilipins (PLIN; previously 
PAT proteins).  There are five members of the mammalian PLIN protein family: 
PLIN1, or perilipin; PLIN2, or adipophilin, or ADRP (for adipose differentiation-
related protein); PLIN3, or TIP47 (for mannose 6-phosphate receptor tail-interacting 
protein of 47 kDa); PLIN4, or S3-12; and PLIN5, or OXPAT (for oxidative protein of 
the PAT family), or MLDP (for myocardial lipid droplet protein).  Each of the PLIN 
proteins possess at their N-terminus a conserved hydrophobic PAT domain of 
approximately 100 amino acids, followed by a repeating 11-mer helical motif of 
varying lengths (Figure 1.6; Kimmel and Sztalryd, 2016).  The C-terminal regions of 
the PLIN proteins are more divergent but commonly possess a hydrophobic cleft, with 
the exception of some perilipin isoforms (Figure 1.6; Kimmel and Sztalryd, 2016).  
Furthermore, the C-terminal region of TIP47 has been shown by X-ray crystallography 
to fold into a 4-helix bundle, with homology analyses suggesting that a similar helix 
bundle is likely to be present in perilipin, adipophilin, and OXPAT (Hickenbottom et 
al., 2004).  Interactions with lipid droplets are currently thought to be facilitated by the 
highly-conserved 11-mer repeat regions, which are proposed to fold into amphipathic 
helices at the lipid droplet surface, with the 4-helix bundle potentially contributing to 
these associations by anchoring the protein to the lipid droplet (Rowe et al., 2016).  
However, the precise mechanisms underlying the association of PLIN proteins with 
the lipid droplet surface have yet to be fully elucidated. 
The different PLIN proteins each make unique contributions to lipid droplet 
regulation.  Perilipin is abundant in adipocytes, where it functions as a gatekeeper by 
regulating lipase recruitment and access to the neutral lipids stored within the lipid  
droplet (Subramanian et al., 2004; Miyoshi et al., 2006; Granneman et al., 2007). 
Similar lipolysis-modulating roles have been demonstrated for adipophilin, TIP47, and 
OXPAT, although the mechanisms are less well-defined (Listenberger et al., 2007; 
Bell et al., 2008; Pollak et al., 2015).  The expression patterns of the PLIN proteins  
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Figure 1.6. Structural features of the perilipin (Plin) proteins.  The five members 
of the Plin protein family are shown, including four Plin1 isoforms that are derived 
from alternative splicing events.  Shared structural features are colour-coded, with a 
lighter colour for the PAT domain in Plin4 indicating that this region has reduced 
sequence similarity compared to the other family members.  The 11-mer repeat region 
in Plin4 is extended, being approximately 900 amino acids longer than the 11-mer 
regions in the other family members. The positions of phosphorylation (P) sites for the 
mouse PLINs are indicated by vertical bars above the diagram.  Figure reproduced 
from Kimmel and Sztalryd, 2016.  
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differ across cell types: perilipin is mostly limited to adipocytes and steroidogenic 
cells; adipophilin and TIP47 are expressed in most non-adipocyte cell types, as well as 
in pre-adipocytes; S3-12 is limited to adipocytes, as well as heart and skeletal muscle; 
and OXPAT is limited to heart and skeletal muscle, as well as brown adipose tissue 
(Kimmel and Sztalryd, 2016).  Furthermore, perilipin and adipophilin are both 
constitutively associated with lipid droplets and are rapidly degraded when not 
attached, while TIP47, S3-12, and OXPAT demonstrate exchangeable lipid droplet 
binding and remain stable in the cytoplasm (Wolins et al., 2006).  The localisation of 
PLIN proteins within cells is also known to change depending on the maturity of the 
lipid droplet.  In cultured 3T3-L1 adipocytes, TIP47 and S3-12 were shown to 
preferentially localise to small lipid droplets, while intermediate-sized lipid droplets 
were predominantly coated with adipophilin, and the largest lipid droplets were 
exclusively coated with perilipin (Wolins et al., 2003; Wolins et al., 2005).  Whether 
this sequential targeting of the PLINs to expanding lipid droplets occurs in all non-
adipocyte cell types remains to be determined.  
Another group of proteins that have been consistently found at lipid droplets 
are membrane trafficking proteins.  These include Rab proteins, small GTPases that act 
as molecular switches to regulate membrane trafficking through vesicle budding, 
delivery, tethering, and fusion (Grosshans et al., 2006).  Although numerous different 
Rab proteins have been associated with lipid droplets via proteomic studies, Rab1, 
Rab5, Rab7, and Rab18 are considered to be of particular interest to lipid droplet 
function (reviewed in Kiss and Nilsson, 2014).  Substantial evidence now implicates 
Rab18 as a lipid droplet resident protein in both adipocytes and non-adipocytes, with 
Rab18 localisation on lipid droplets shown to increase following the stimulation of 
lipolysis (Martin et al., 2005; Pulido et al., 2011).  Rab18 overexpression also resulted 
in Rab18 replacing adipophilin on lipid droplets, which induced membrane apposition 
between the lipid droplets and the endoplasmic reticulum (Ozeki et al., 2005).  Rab5, 
on the other hand, has been shown to be involved in the recruiting of early endosomes 
to the lipid droplet (Liu et al., 2007a; Liu et al., 2008).  Additional proteins found at  
lipid droplets include motor proteins that move vesicles along the cytoskeleton, 
SNARE proteins that mediate membrane docking and fusion, and vesicular traffic 
proteins such as Arf1 (ADP ribosylation factor 1) (Zehmer et al., 2009).  
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1.2.3 Altered lipid metabolism and storage in cancer 
1.2.3.1 The lipogenic phenotype 
Under normal physiological conditions, lipogenesis is largely restricted to 
adipose tissue, the liver, or the lactating breast (Santos and Schulze, 2012). Several 
cancer types, however, switch on a metabolic programme, termed the ‘lipogenic 
phenotype’, in which de novo lipid synthesis pathways are highly active (Menendez 
and Lupu, 2007).  Furthermore, while normal cells predominantly use dietary lipid, 
some cancer cells have been shown to preferentially utilise newly-synthesised fatty 
acids (Kannan et al., 1980; Ookhtens et al., 1984; Vazquez-Martin et al., 2008).  This 
is supported by the overexpression in cancer cells of the key enzymes of de novo 
lipogenesis (section 1.2.1), such as ACLY (Bauer et al., 2005), ACC (Milgraum et al., 
1997), and FASN.  The most extensively studied of these enzymes is FASN, whose 
overexpression has been demonstrated in diverse cancer types, including prostate, 
breast, ovarian, endometrial, colorectal, oesophageal, gastric, bladder, lung, melanoma, 
and many others (reviewed in Menendez and Lupu, 2007).  Additionally, FASN was 
identified as the breast cancer prognostic marker OA-519 (Kuhajda et al., 1994), and 
FASN overexpression and hyperactivity has been frequently associated with higher 
risk of disease recurrence and death in several cancer types (Epstein et al., 1995; Alo 
et al., 1996; Sebastiani et al., 2004; Visca et al., 2004).  These studies suggest that the 
lipogenic phenotype may not only be advantageous during cancer development, but 
may also promote a more aggressive tumour phenotype.  Finally, some cancers have 
been shown to scavenge lipids from neighbouring adipocytes, including ovarian 
(Nieman et al., 2011) and breast (Blucher and Stadler, 2017) cancer cells. 
In accordance with the upregulation of lipid synthesis and/or uptake, many 
cancer cells exhibit lipid droplet accumulation and an enhanced capacity for lipid 
storage.  By staining for PLIN proteins, lipid droplet accumulation was demonstrated 
to varying extents in cancers of the breast, colon, kidney, liver, lung, oropharynx, 
pancreas, prostate, and skin (Straub et al., 2010).  These investigations suggested that  
the proportion of tumours with lipid droplets was much higher than previously 
discerned by light microscopy.  The PLIN proteins were also found to be differentially 
expressed across cancer types.  Adipophilin and TIP47-positive lipid droplets were 
observed almost ubiquitously, but were particularly prominent in tumours with a clear 
cell phenotype, while perilipin-positive lipid droplets were restricted to hepatocellular 
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carcinomas, sebaceous tumours, and mesenchymal tumours with adipogenic 
differentiation (Straub et al., 2010).  It was proposed that the identity of the 
predominant PLIN proteins found coating the lipid droplets might serve as a 
prognostic marker, since this likely indicates the ease with which the stored lipid may 
be remobilised (Straub et al., 2010).  Lipid droplet accumulation has also been 
demonstrated in cell lines, including those derived from colon adenocarcinoma 
(Accioly et al., 2008), breast cancer (Kourtidis et al., 2010), and lung cancer 
(Chowdhury et al., 2014). 
 
1.2.3.2 Oncogenes implicated in altered lipid metabolism  
As our understanding of the reprogramming of lipid metabolism during cancer 
development continues to grow, so too does our knowledge of its connections to 
oncogenic signalling.  One oncogene that has been consistently implicated in altered 
lipid metabolism is ERBB2, which encodes a receptor tyrosine kinase that transduces 
signals for cellular proliferation and survival via multiple pathways.  ERBB2 is a well-
established amplification target, as discussed previously (section 1.1.2), particularly in 
breast cancers where it is estimated to be amplified in 20-30% of breast cancers 
(Roskoski, 2014).  The oncogenic consequences of ERBB2 overexpression have been 
demonstrated in vitro, where it promoted cell motility, sensitivity to mitogenic stimuli, 
anchorage-independent growth, and cell transformation (Chazin et al., 1992; Brandt et 
al., 1999; Ignatoski et al., 1999; Spencer et al., 2000), and confirmed in vivo (Muller et 
al., 1988; Bouchard et al., 1989; Guy et al., 1996).  The amplification of ERBB2 in 
breast cancer is associated with poor prognosis, shorter relapse times, and low survival 
rate (Slamon et al., 1987).     
ERBB2-positive breast cancers frequently exhibit a lipogenic phenotype.  
ERBB2 overexpression was positively correlated with FASN expression and 
enzymatic activity in breast cancer cell lines (Kumar-Sinha et al., 2003; Menendez et 
al., 2004a), and FASN, along with other lipogenic genes, has been shown to be highly  
expressed in ERBB2-positive breast tumours (Porter et al., 2003; Zhang et al., 2005; 
Kim et al., 2015).  Furthermore, the ectopic expression of ERBB2 in breast epithelial 
cells, as well as in mouse 3T3 fibroblasts, resulted in significant upregulation of FASN 
transcript and protein levels (Kumar-Sinha et al., 2003; Menendez et al., 2004b).  
Conversely, the pharmacological inhibition of ERBB2, using targeted drugs such as 
Herceptin, was shown to decrease the expression of FASN (Kumar-Sinha et al., 2003; 
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Zhang et al., 2005).  ERBB2 is thought to affect the expression of FASN, and other 
lipogenic enzymes, via the downstream modulation of their transcription factor, sterol 
regulatory element-binding protein-1c (SREBP-1c) (Menendez and Lupu, 2007).  In 
ERBB2-positive cancer cells, dysregulation of the PI3K/Akt and MAPK/ERK1/2 
signalling pathways drives the expression and maturation of SREBP-1c (Menendez 
and Lupu, 2007).  Accordingly, treatment with PI3K and MAPK inhibitors has been 
shown to downregulate SREBP-1c and decrease the transcription of FASN in ERBB2-
overexpressing cancer cells (Yang et al., 2003).  However, a SREBP-independent 
mechanism has also been proposed, with FASN and ACC transcripts subject to 
selective translational induction mediated by mammalian target of rapamycin (mTOR), 
which is a downstream effector of Akt (Yoon et al., 2007).  Accordingly, the 
activation of mTOR significantly increased the synthetic rates of FASN and ACC, 
while treatment with the mTOR inhibitor rapamycin blocked the ERBB2-induced 
overexpression of FASN (Yoon et al., 2007).  Collectively, these studies suggest that 
the ERBB2-induced overexpression of lipogenic enzymes can be mediated in several 
ways. 
Additionally, a functional RNA interference (RNAi) screen of co-
overexpressed genes in the ERBB2-positive BT474 breast cancer cell line found the 
survival of these cells to be reliant upon the expression of several lipid-relevant genes: 
NR1D1 (nuclear receptor subfamily 1, group D, member 1), MED1 (mediator complex 
subunit 1), and MAP2K6 (mitogen-activated protein kinase kinase 6), and to a lesser 
extent, FASN, STARD3 (StAR-related lipid transfer domain containing 3), and FADS2 
(fatty acid desaturase 2) (Kourtidis et al., 2010).  NR1D1 and MED1 are both involved 
in the transcriptional regulation of fat synthesis and storage.  NR1D1 is a nuclear 
hormone receptor that plays a pivotal role in adipocyte differentiation (Fontaine et al., 
2003; Laitinen et al., 2005; Wang and Lazar, 2008), while MED1 is a coactivator of 
PPARg, which upregulates several genes that are related to metabolic homeostasis and 
adipogenesis, including NR1D1 (Zhu et al., 1997; Fontaine et al., 2003; Perera et al., 
2006).  Interestingly, several of the genes identified in the RNAi screen are co-located 
with ERBB2 on chromosome 17q, including NR1D1, MED1, STARD3, and more 
distally, FASN (Figure 1.7).  Furthermore, the genes encoding the lipogenic enzymes  
ACC and ACLY are also located on chromosome 17q, and are close enough (within 5 
 megabases) to be commonly included in ERBB2 amplicons in breast and other cancers 
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Figure 1.7. Lipid associated genes located on chromosome 17q.  Chromosome 17q 
genes involved in lipid metabolism are indicated by vertical arrows.  Their 
approximate positions, according to hg18 coordinates, are as follows: ACACA (acetyl-
CoA carboxylase alpha, referred to in the text as ACC), 32.7 MB; ACLY (ATP citrate 
lyase), 37.3 MB; MED1 (mediator complex subunit 1), 34.8 MB; STARD3 (StAR-
related lipid transfer domain containing 3) and ERBB2, 35.1 MB; N1RD1 (nuclear 
receptor subfamily 1, group D, member 1), 35.5 MB; and FASN (fatty acid synthase), 
77.6 MB.  Below this, the ideogram shows the corresponding cytogenetic bands.  
Figure reproduced from Kamili and Byrne, 2014.  
  
	 26 
(Kamili and Byrne, 2014).  This raises the possibility that ERBB2-amplified cancers 
may not simply feature activation of pathways leading to the overexpression of FASN, 
but may also be ‘hard-wired’ to produce de novo fatty acid through co-amplification of 
several lipogenic and lipid-relevant genes (Kourtidis et al., 2010; Kamili and Byrne, 
2014).  
Another oncogene that has been implicated in lipid metabolism is MYC.  Like 
ERBB2, MYC is a well-established amplification target, and MYC overexpression has 
been demonstrated in many different cancer types (section 1.1.2).  Cancers that are 
driven by MYC overexpression have been shown to be especially sensitive to the 
withdrawal of glutamine because the genes that are involved in glutamine metabolism 
are part of the transcription program regulated by MYC (Yuneva et al., 2007; Wise et 
al., 2008; Toyoshima et al., 2012).  Although research into the contributions of MYC 
to reprogrammed cancer cell metabolism has been primarily focused on its role in 
glutaminolysis, several links to lipid metabolism have begun to emerge.  Glutamine 
metabolism has been recognised as an important source of NADPH, which is required 
for the reactions involved in lipid synthesis (Carracedo et al., 2013).  Additionally, 
glutaminolysis supplies citrate, which is the precursor for acetyl-CoA (section 1.2.1).  
Myc knockdown in rat fibroblasts was found to reduce the amount of acetyl-CoA and 
decrease transcript levels of key enzymes for fatty acid synthesis (ACLY, ACC, and 
FASN) and cholesterol synthesis (HMGCR) (Edmunds et al., 2014).  Furthermore, 
these cells were found to preferentially use exogenous fatty acids for energy 
production through b-oxidation, or store them as neutral lipids, rather than direct them 
towards anabolic processes such as phospholipid production (Edmunds et al., 2014).  
The inhibition of MYC function has also been shown to lead to an accumulation of 
intracellular lipid droplets in neuroblastoma cells (Zirath et al., 2013).  
 
1.2.3.3 Contributions of altered lipid metabolism to cancer development 
Altered lipid metabolism contributes to cancer development in several ways 
(Figure 1.8).  The overall metabolic switch that is observed in most cancers, whilst 
being energetically wasteful, is thought to advantage cancer cells by providing the 
metabolic intermediates required for anabolic processes (Vander Heiden et al., 2009).  
Fatty acids, which are delivered via increased de novo lipogenesis, are the building 
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Figure 1.8. Altered lipid metabolism contributes to cancer development in a 
variety of ways.  Figure reproduced from Santos and Schulze, 2012.  
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blocks that are required for the generation of structural membrane lipids.  The demand 
for these lipids is intensified in cancer cells, when compared to quiescent cells, 
because their ability to continue proliferating rapidly is contingent upon having 
sufficient lipid for the synthesis of daughter cell membranes (Santos and Schulze, 
2012; Currie et al., 2013; Kamili and Byrne, 2014).  The significance of phospholipid 
availability to cancer cells is underlined by choline kinase, an enzyme that is required 
for the synthesis of the two major phospholipids, which is overexpressed in several 
cancer types and promotes cellular transformation (Ramirez de Molina et al., 2002; 
Ramirez de Molina et al., 2005; Iorio et al., 2010).  Furthermore, the composition of 
the plasma membrane can also be altered in lipogenic cancers, with a higher proportion 
of saturated lipids, which potentially protects cancer cells from oxidative damage by 
reducing susceptibility to lipid peroxidation (Rysman et al., 2010).  
Some cancers can also use fatty acid as an alternative energy source through b-
oxidation.  This has been particularly documented in prostate cancer, where fatty acid 
oxidation is thought to be the dominant bioenergetics pathway (Liu, 2006).  
Accordingly, prostate cancer cells have been found to have low glucose consumption 
(Effert et al., 1996), increased fatty acid uptake (Liu et al., 2010), and increased levels 
of enzymes involved in b-oxidation (Zha et al., 2005).  b-oxidation has also been 
shown to be essential for the proliferation and survival of leukaemia cells (Samudio et 
al., 2010) and of MYC-overexpressing triple-negative breast cancer (Camarda et al., 
2016), and has been described in ovarian cancer cells that scavenge lipids from 
neighbouring adipocytes (Nieman et al., 2011).  Furthermore, b-oxidation may also 
help cancer cells to survive periods of energy stress, such as when the availability of 
glucose is limited (Buzzai et al., 2005).  Additionally, it has been proposed that b-
oxidation promotes intracellular redox balance by supplying NADPH to counteract 
oxidative stress (Carracedo et al., 2013).  Finally, as well as being substrates for  
membrane synthesis and energy production, lipids can coordinate specific signalling 
pathways implicated in cancer development, and a subset of lipids function as 
bioactive signalling molecules themselves, including prostaglandins, leukotrienes, and 
lyophosphatidic acid (reviewed in Santos and Schulze, 2012). 
Although research attention has predominately been given to de novo 
lipogenesis, cholesterol biosynthesis is also known to be perturbed in cancer and 
dysregulation of the mevalonate pathway has been shown to drive transformation 
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(Clendening et al., 2010).  The accumulation of cholesterol esters has been 
demonstrated in prostate and breast cancer, where it has been associated with tumour 
aggressiveness (Yue et al., 2014; de Gonzalo-Calvo et al., 2015; Abramczyk et al., 
2015).  Cholesterol is also an important component of plasma membranes, where it 
modulates fluidity and forms detergent-resistant micro-domains known as lipid rafts 
that are involved in the coordinated activation of several signalling pathways 
(Lingwood and Simons, 2010; Gorin et al., 2012).  Cholesterol biosynthesis also 
generates intermediates that are required for the post-translational modification 
(farnesylation and geranylgeranylation) of certain proteins, such as the RAS 
superfamily of GTPases, which are themselves implicated in cancer development 
(Konstantinopoulos et al., 2007).  Finally, cholesterol is required for the production of 
steroid hormones, which are implicated in some cancer types (Capper et al., 2016).    
 
1.2.4 Therapeutic targeting of lipid metabolism in cancer  
There is now strong interest in translating our knowledge of altered lipid 
metabolism in cancer to the development of new cancer treatments.  Given its 
connection to oncogenic signalling, metabolic reprogramming may be conceptualised 
as one of the complementary adaptations upon which cancer cells critically rely 
(section 1.1.3).  Some cancers may even be addicted to lipogenesis, as highlighted by 
the dependence of ERBB2-positive breast cancer cells on lipid-relevant genes, 
including NR1D1 and MED1, for their survival (Kourtidis et al., 2010).  Therefore, 
disrupting these pathways is considered a promising avenue for controlling cancer 
proliferation and progression, especially since this dependence upon lipogenesis is not 
shared by most normal cells (Currie et al., 2013; Beloribi-Djefaflia et al., 2016).  A 
selection of drugs that are currently under investigation for the targeting of fatty acid 
and cholesterol dependencies in cancer cells are shown in Table 1.1.  From these, we 
can discern several broad strategies for therapeutic intervention.   
One strategy involves depriving cancer cells of fatty acids, and therefore the 
complex lipids built from them.  This may be achieved by blocking their synthesis 
with inhibitors of ACLY, ACC, and FASN, which has been shown to be effective in 
multiple preclinical studies (Table 1.1 and references within).  Adverse side effects for 
FASN-directed drugs, including anorexia and dramatic weight loss, have precluded  
their translation to the clinic (Loftus, 2000; Clegg et al., 2002; Tu et al., 2005), 
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Table 1.1. Examples of drugs that are currently under investigation for the 
therapeutic targeting of lipid dependencies in cancer cells.   
Target Drug Drug development stage,  evidence, and cancer types Selected references 
ACC 
TOFA Preclinical; X (ovarian) Li et al., 2013a 
Soraphen-A Preclinical; CCL (prostate) Beckers et al., 2007 
Metformin a Clinical trials (>100 completed, >100 active); FDA-approved anti-diabetic drug 
Pollack, 2012 (Review); 
clinicaltrials.gov (May 2018)  
ACLY SB-204990 Preclinical; CCL and X (lung, prostate, ovarian) Hatzivassiliou et al., 2005 
CPT1 
Etomoxir,  Preclinical; CCL (prostate, leukaemia, glioblastoma), X (prostate) 
Samudio et al., 2010; Pike et 
al., 2011; Schlaepfer et al., 
2014 
Ranolazine Preclinical; FDA-approved anti-angina drug; CCL (leukaemia) Samudio et al., 2010 
ST1326 Preclinical; CCL (leukaemia) Ricciardi et al., 2015 
FASN 
Cerulenin  
(and C75) 
Preclinical; CCL (breast), X (ovarian);  
MM (breast)  
Pizer et al., 1996a, b; Alli et 
al., 2005 
CC247 Preclinical; MM (breast) Alli et al., 2005 
C93  
(or FAS93) 
Preclinical; CCL and X (lung, ovarian);  
MM (lung) 
Orita et al., 2007, 2008; Zhou 
et al., 2007 
Orlistat 
Preclinical; FDA-approved anti-obesity 
drug; CCL (prostate, breast, melanoma),  
X (prostate) 
Kridel et al., 2004; Menendez 
et al., 2005; Carvalho et al., 
2008 
Triclosan Preclinical; antibiotic; CCL (breast) Liu et al., 2002 
EGCG Preclinical; naturally-occurring (green tea); CCL (prostate) Brusselmans et al., 2003 
Flavonoids  Preclinical; naturally-occurring;  CCL (breast, prostate)  Brusselmans et al., 2005 
HMGCR Statins 
Preclinical and clinical; FDA-approved for 
the lowering blood cholesterol levels; CCL 
and MM (multiple), epidemiological 
Clendening and Penn, 2012 
(Review) 
LXR 
T0901317 Preclinical; CCL and X (multiple) Bovenga et al., 2015 (Review) 
SR9243 Preclinical; CCL and X (colon) Flaveny et al., 2015 
MAGL JZL184 Preclinical; CCL and X (breast, ovarian, melanoma) Nomura et al., 2010 
OSC Ro 48-8071 Preclinical; MM (colon, pancreatic) Maione et al., 2015 
SCD1 
A939572 Preclinical; CCL and X (multiple) Roongta et al., 2011; von Roemeling et al., 2013, 2015 
CAY-10566 Preclinical; CCL (hepatocellular),  X (colon)  
Mason et al., 2012; Huang et 
al., 2015 
BZ36 Preclinical; CCL and X (prostate) Fritz et al., 2010 
MF-438 Preclinical; CCL and X (thyroid, lung) Noto et al., 2013; von Roemeling et al., 2015 
SOAT1 
Avasimibe Preclinical; CCL and X (prostate) Yue et al., 2014 
Sandoz-58-
035 
Preclinical; CCL (prostate, adrenocortical), 
X (prostate) 
Yue et al., 2014; Sbiera et al., 
2015 
SREBP Fatostatin Preclinical; CCL (glioma, prostate, pancreatic) 
Williams et al., 2013; Li et al., 
2014b; Shao et al., 2016; 
Siqingaowa et al., 2017 
a Indirect inhibitor; activates AMPK, which inactivates ACC by phosphorylation 
Evidence: CCL, cancer cell lines; X, xenografts; MM, mouse model 
Abbreviations: ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; CPT1, carnitine palmitoyltransferase 1; EGCG, 
epigallocatechin-3-gallate; FASN, fatty acid synthase; HMGCR, 3-hydroxy-3-methylglutaryl CoA reductase; LXR, liver 
X receptor; MAGL, monoacylglycerol lipase; OSC, 2,3-oxidosqualene cyclase; SCD1, stearoyl-CoA desaturase 1; 
SOAT1, sterol-O-acyltransferase 1; SREBP, sterol regulatory element-binding protein. 
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although newer more-promising compounds are under development (Flavin, 2010).  
Furthermore, inhibition of stearoyl-CoA desaturase 1 (SCD1), which catalyses the 
desaturation of long-chain fatty acids and is required for subsequent phospholipid 
production, has been reproducibly shown to inhibit cancer cell proliferation and induce 
apoptosis (Table 1.1 and references within).  Alternatively, cancer cells may be 
deprived of fatty acids by blocking their release from storage.  Inhibiting MAGL, 
which catalyses the final hydrolysis that releases fatty acid from the glycerol 
backbone, has been shown to lower fatty acid levels and reduce the pathogenicity of 
cancer cells in vitro and in vivo (Table 1.1; Nomura et al., 2010).  
A parallel approach involves depriving cancer cells of cholesterol.  Again, this 
may be achieved by inhibiting key enzymes required for cholesterol biosynthesis, such 
as 2,3-oxidosqualene cyclase (OSC) and HMGCR, with demonstrated efficacy in 
preclinical studies (Table 1.1 and references within).  Targeting HMGCR with statins 
is thought to be particularly promising, since these drugs are already widely used for 
the lowering of blood cholesterol levels; however, the results from clinical trials have 
so far been mixed (reviewed in Clendening and Penn, 2012).  Finally, since cholesterol 
can also be acquired from low-density lipoprotein (LDL) particles circulating in the 
bloodstream, cellular uptake pathways comprise additional targets for depriving cancer 
cells of cholesterol.  Accordingly, activation of the liver X receptors (LXRs), which 
are transcriptional regulators of cholesterol homeostasis, inhibits cholesterol uptake 
and synthesis, while promoting cholesterol efflux (Table 1.1; reviewed in Bovenga et 
al., 2015).  
Another strategy involves unbalancing lipid homeostasis to induce lipotoxicity.  
For example, inhibiting carnitine palmitoyltransferase 1 (CPT1), which catalyses the 
rate-limiting transport of fatty acids into the mitochondria for b-oxidation, appears to 
induce apoptosis by allowing the fatty acids to instead be converted to palmitate, 
which accumulates inside the cell and causes lipotoxicity (Table 1.1; Ricciardi et al., 
2015).  Similarly, inhibiting SOAT1, which catalyses cholesterol esterification for 
storage, produces an overwhelming increase in free cholesterol that triggers 
endoplasmic reticulum stress (Table 1.1; Sbiera et al., 2015). SOAT1 was recently 
found to be the molecular target of mitotane, a chemotherapeutic drug that, despite 
serious adverse side effects, has been employed clinically for decades (Sbiera et al.,  
2015).  Furthermore, the expression of numerous genes involved in lipid metabolism 
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pathways can be simultaneously altered by inhibiting their transcription factors, the 
sterol regulatory element-binding proteins (SREBPs).  Inhibiting the activity of 
SREBPs in glioma cells with heightened P13K/Akt signalling was shown to uncouple 
fatty acid synthesis from desaturation, creating a critical imbalance between saturated 
and monounsaturated fatty acid pools and producing lipotoxicity (Table 1.1; Williams 
et al., 2013).  Given the current momentum within the cancer metabolism field, we 
expect that novel therapeutics will continue to be derived for both existing and new 
lipid-relevant targets.  
 
1.3 Tumor Protein D52  
Tumor Protein D52 (TPD52) is an oncogene whose overexpression has been 
demonstrated in tumours of diverse cellular origins and associated with poorer 
outcomes.  The TPD52 gene is located on the frequently gained chromosome band 
8q21, where we propose that it is an important amplification target.  The following 
sections will review the breadth and clinical significance of TPD52 overexpression in 
cancer, the evidence for targeted amplification of the TPD52 locus in a subset of these 
cancers, the consequences of TPD52 overexpression in cell line models, and our 
current understanding of the molecular pathways in which TPD52 may operate, 
including preliminary evidence for its involvement in lipid metabolism and/or storage. 
 
1.3.1 Introduction to TPD52 and related proteins  
TPD52 is the founding member of the TPD52-like gene family.  Four human 
TPD52-like genes have now been identified: TPD52 (Byrne et al., 1995), TPD52L1 
(Byrne et al., 1996; Byrne et al., 1998a), TPD52L2 (Nourse et al., 1998), and the 
testis-specific TPD52L3 (Cao et al., 2006).  These genes encode small hydrophilic 
polypeptides that commonly possess N- and C-terminally located PEST sequences, 
which have been linked to the regulation of protein stability, and a coiled-coil motif, 
which is required for both homo- and heteromeric interactions between TPD52-like 
proteins (reviewed in Boutros et al., 2004).  TPD52L3 is slightly different to the other 
family members in that it is shorter, at 140 residues compared to 180-200 residues, and 
lacks the C-terminal PEST sequence (Cao et al., 2006).  The TPD52-like sequences 
are well-conserved both within and between species, but show little similarity with 
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those of other proteins (Byrne et al., 2014).  Several TPD52 isoforms have been 
identified, which are produced through alternatively-spliced transcripts and/or the use 
of an alternate first exon (Figure 1.9).  Isoforms that are characterised by a longer N-
terminal region are referred to as PrLZ (prostate leucine zipper) and have been shown 
to be elevated in prostate cancer (Wang et al., 2004; Shehata et al., 2008a).  TPD52 
orthologues have been identified in several species, including mouse (Tpd52; Byrne et 
al., 1996), rat (CRHSP-28; Groblewski et al., 1996), rabbit (CSPP28; Parente et al., 
1996), and Japanese quail (R10; Proux et al., 1996), while ancestral genes have been 
identified in Drosophila melanogaster (CG5174; Giot et al., 2003) and Caenorhabditis 
elegans (F13E6.1; Boutros et al., 2004). 
 
1.3.2 TPD52 overexpression in cancer 
1.3.2.1 TPD52 overexpression in breast and prostate cancer 
The TPD52 gene was first identified through its overexpression in a human 
breast carcinoma (Byrne et al., 1995).  It was subsequently estimated that TPD52 was 
overexpressed in approximately 60% of breast cancer cases, with amplification 
occurring in a proportion of these (Balleine et al., 2000).  Numerous studies have now 
established the importance of TPD52 overexpression in breast cancer (Shehata et al., 
2008a; Roslan et al., 2014) with this continuing to be reported in new cohorts (for 
example, Tennstedt et al., 2014).  TPD52 overexpression has been associated with 
certain molecular subtypes of breast cancer, including luminal B (Guedj et al., 2012; 
Cornen et al., 2014) and ERBB2-positive (Roslan et al., 2014) cancers.  TPD52 
overexpression has also been linked to poor outcomes in breast cancer patients, having 
been included in gene expression signatures of poor prognosis (Adler et al., 2006; Liu  
et al., 2007b) and shown to be an independent predictor of metastasis-free survival 
(Shehata et al., 2008b; Roslan et al., 2014).  This is consistent with earlier associations 
between gain of chromosome 8q21, which harbours the TPD52 gene, and poor 
outcome in breast cancer patients (Rennstam et al., 2003; Melchor et al., 2005; Han et 
al., 2006).   
The overexpression of TPD52 (or PrLZ) in prostate cancer is also well-
established (Rubin et al., 2004; Wang et al., 2004) and may even occur in the majority 
of prostate cancers (Tennstedt et al., 2014).  As for breast cancer, TPD52 
overexpression in prostate cancer has been linked to more aggressive cancers and 
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Figure 1.9. Exon and domain organisation of TPD52 isoforms.  The coiled-coil 
motif is indicated by a dotted line above the sequence representation, while the two 
PEST motifs are shown by solid lines below.  Exon 1a encodes a shorter N-terminal 
sequence that is found in most TPD52 isoforms, while exon 1b encodes a longer N-
terminal sequence that is characteristic of PrLZ isoforms.  Exons 5 and 6 are 
alternatively spliced in a cassette fashion, as indicated above and below the sequence 
representation; however, their encoded sequences are absent from most TPD52 and 
PrLZ isoforms.  The red dot indicates the location of a confirmed phosphorylation site 
at Ser136.  Figure reproduced from Byrne et al., 2014. 
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poorer patient outcomes.  TPD52 transcript levels were found to be increased in high- 
versus low-grade localised prostate cancers (Ross et al., 2011), suggesting a role for 
TPD52 in cancer progression.  TPD52 was also included in a panel of 12 genes whose 
expression was associated with prostate cancer progression and could be used to 
predict PSA failure following surgery (Bismar et al., 2006).  Similarly, TPD52 
transcript levels were increased in patients who developed systemic progression within 
5 years, compared to those who did not (Nakagawa et al., 2008). 
 
1.3.2.2 TPD52 overexpression in other adult cancers 
TPD52 overexpression has also been reported in a range of other cancer types. 
Increased TPD52 expression in lung cancer was first shown in cancer cell lines (Chen 
et al., 1996) and continues to be variably reported for cell lines and tissues from 
different lung cancer subtypes (reviewed in Byrne et al., 2014).  TPD52 
overexpression has also been demonstrated in ovarian cancer, where it was found in 
cancers of all histological subtypes and in tumours of different grades and surgical 
stages (Byrne et al., 2005), and in testicular germ cell tumours (Alagaratnam et al., 
2009).  Additionally, increased TPD52 expression has also been reported in melanoma 
(Roesch et al., 2007), which is consistent with TPD52 being ranked fifth, behind four 
established melanoma antigens, in a microarray meta-analysis of genes overexpressed 
in melanoma (Hoek, 2007).  Furthermore, TPD52 overexpression has been found in a 
range of haematological malignancies, including multiple myeloma (Tiacci et al., 
2005; Largo et al., 2006) and Burkitt’s lymphoma (Dave et al., 2006).  Accordingly, 
B-cell lymphomas result from the integration of avian leucosis virus into intron 1 of 
the chick TPD52 orthologue (Yang et al., 2007) and the integration site of the T-
lymphomagenic SL3-3 retrovirus is located in the upstream region of the mouse Tpd52 
orthologue (Sorensen et al., 1996; Martin-Hernandez et al., 2006).  Finally, a 
collection of independent studies has implicated TPD52 overexpression in additional 
cancer types, including colon (Malek et al., 2002), pancreatic (Loukopoulos et al., 
2007), hepatocellular (Ho et al., 2006), and gastric (Cheng et al., 2012; Aquino et al., 
2012) cancers.  An analysis of TPD52 expression patterns across solid tumour types 
supported several of these previous reports of TPD52 overexpression, as well as 
extending the list to include endometrial and cervical cancers (Tennstedt et al., 2014).  
Taken together, these studies emphasise the breadth of TPD52 overexpression in adult 
cancers. 
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1.3.2.3 TPD52 overexpression in paediatric cancers 
 Evidence of TPD52 overexpression in paediatric cancers is also beginning to 
emerge.  The frequent gain of chromosome 8q in osteosarcoma and Ewing sarcoma 
(Stock et al., 2000; Ozaki et al., 2001) suggested that TPD52 overexpression might be 
observed in these cancer types.  TPD52 immunostaining was subsequently detected in 
over one-third of Ewing sarcoma family tumours in a large cohort (Machado et al., 
2011).  TPD52 overexpression has also been reported in osteosarcoma cell lines (Li et 
al., 2007; Zou et al., 2012) and in small cell osteosarcoma tumours (Machado et al., 
2010).  TPD52 transcripts were also frequently detected in bone marrow samples of 
paediatric acute lymphoblastic leukemia (ALL) (Barbaric et al., 2006) and were found 
to be increased in samples that were associated with poorer event-free survival (Kang 
et al., 2012).  The relative paucity of studies demonstrating TPD52 overexpression in 
paediatric cancers, when compared to adult cancers, may be partly due to the 
comparative rarity of these cancers and further research is required to determine the 
full extent of TPD52 overexpression in this context.  
 
1.3.3 TPD52 as a candidate amplification target on chromosome 8q21 
The TPD52 gene is located on the frequently gained chromosome band 8q21, 
where we propose that it is an important amplification target.  Gain of chromosome 
8q21 has been reported for breast cancer (Kallioniemi et al., 1994), prostate cancer 
(Cher et al., 1994), osteosarcoma (Tarkkanen et al., 1995), and ovarian cancer  
(Suehiro et al., 2000; Partheen et al., 2004).  As outlined in section 1.1.4, high-
resolution mapping of the amplicons from large sample cohorts now allows 
researchers to define progressively smaller regions of overlap and thereby narrow the 
list of potential amplification target genes.  In 2012, a comprehensive review of the 
existing literature found 13 studies reporting genomic gains that were largely restricted 
to chromosome 8q21.13, with TPD52 identified as being in one of two minimal 
regions of overlap for the amplicons reported by each of these studies (Figure 1.10; 
Byrne et al., 2012).  TPD52 was subsequently reported as being focally amplified,  
along with five neighbouring chromosome 8q21.13 genes, on an amplicon found in 
breast cancer samples (Cancer Genome Atlas Network, 2012) and again on a similar 
amplicon found across 11 different cancer lineages (Zack et al., 2013).  
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Figure 1.10. Reported chromosome 8q21.13 amplicons in cancer tissues and cell 
lines.  Defined regions of copy number gain are indicated using horizontal lines, 
according to hg18 chromosome 8 coordinates below (in megabases), with gene 
locations labelled.  Below this, the ideogram shows the corresponding cytogenetic 
bands, with the arrow indicating that this band extends beyond this figure.  Each of the 
amplicons is labelled with the cancer type in which it was found and the study that 
reported it.  The two shaded regions (light blue) indicate the minimal regions of 
overlap between amplicons.  Figure reproduced from Byrne et al., 2012. 
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As well as mapping to the minimal region of overlap, TPD52 amplification 
results in overexpression in various cancer types.  Increased TPD52 copy number, with 
associated gene overexpression, has been demonstrated in breast cancer tissues and 
cell lines (Balleine et al., 2000; Pollack et al., 2002; Adelaide et al., 2007; Chin et al., 
2007; Jonsson et al., 2007; Rodriguez et al., 2007; Andre et al., 2009; Kao et al., 2009; 
Natrajan et al., 2010; Guedj et al., 2012) as well as in prostate cancer tissues, cell 
lines, and xenografts (Rubin et al., 2004; Wang et al., 2004; van Duin et al., 2005; 
Paris et al., 2006) and ovarian cancer tissues (Byrne et al., 2005).  Increased TPD52 
copy number has also been ascribed prognostic significance in breast cancer, where it 
was found to be associated with a higher risk of metastasis (Zhang et al., 2009), and in 
prostate cancer, where it was associated with early mortality (Liu et al., 2013).  Taken 
together, these studies support the targeting of TPD52 amplification in many cancers.  
However, increased TPD52 copy number has also been reported in the absence of 
associated gene overexpression, which suggests that TPD52 may occasionally 
represent a passenger alteration (Hyman et al., 2002; Yao et al., 2006; Holcomb et al., 
2009; Ramakrishna et al., 2010).  Other studies have reported increased TPD52 copy 
number in lung, breast, and colorectal cancers, but did not examine associated gene 
expression (Weir et al., 2007; Natrajan et al., 2009; Sayagués et al., 2010).  As 
additional studies continue to be published, we expect that a more complete picture 
will emerge showing the extent and significance of TPD52 amplification in cancer.  
 
1.3.4 Consequences of altered TPD52 expression in cell lines 
 In addition to clinical data supporting the prevalence and prognostic 
significance of TPD52 amplification and/or overexpression in cancer, the effects of 
increased TPD52 expression have also been investigated in cell line models (Figure 
1.11).  In mouse fibroblast cells, the stable exogenous expression of mouse or human 
TPD52 produced transformed phenotypes and increased the capacity for proliferation 
and anchorage-independent growth (Lewis et al., 2007; Shehata et al., 2008b).  
TPD52-expressing cells displayed dramatic morphological alterations, being smaller 
and rounder than their parental controls and possessing significantly poorer actin stress 
fibre organisation (Shehata et al., 2008b).  Changes in proliferative capacities were not 
observed with the exogenous expression of the family member TPD52L1, despite 
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Figure 1.11. Consequences of altered TPD52/PrLZ expression in cell line models.  
The effects of conferring (+) or increasing (­) human/mouse TPD52/PrLZ in mouse 
3T3 fibroblast or human LNCaP prostate cancer cells are summarised.  Phenotypes are 
shown as increased (­), decreased (¯), or unchanged («) when compared to parental 
cells, or conferred (+) if the phenotype was not present in parental cells.  
Abbreviations: AR, androgen receptor; MMP2, matrix metalloproteinase 2; PSA, 
prostate-specific antigen; pAKT, phospho-AKT.  Figure reproduced from Byrne et al., 
2014. 
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these cells showing similar morphological alterations (Shehata et al., 2008b). 
Furthermore, Tpd52-overexpressing fibroblast cells that were transplanted into 
syngenic Balb/c hosts demonstrated an ability to form both subcutaneous tumours and 
distant lung metastases (Lewis et al., 2007).  In human prostate cancer cell lines, 
increasing the expression of TPD52 (or the prostate-specific isoform PrLZ) resulted in 
enhanced proliferation, clonogenic growth, and invasiveness, as well as increased 
levels of active phospho-Akt, the androgen receptor, matrix metalloproteinase 2, and 
prostate-specific antigen (Ummanni et al., 2008; Zhang et al., 2007; Zhang et al., 
2011; Li et al., 2009; Li et al., 2013b). 
 The effects of reduced TPD52 expression have also been investigated in cell 
line models.  These studies have reproducibly established TPD52 as a survival factor 
for some, but not all, cancer cell lines.  The first indication that cells may become 
reliant upon sustained TPD52 expression for their survival came from studies in the 
prostate cancer cell lines LNCaP and C4-2 (Ummanni et al., 2008; Zhang et al., 2007; 
Zhang et al., 2011), and in the breast cancer cell line SKBR3 (Shehata et al., 2008b), 
which showed increased cell death following transient TPD52 or PrLZ knockdown.  
However, a subsequent study in a panel of breast cancer cell lines observed increased 
apoptotic cell death exclusively in the ERBB2-amplified cell lines SKBR3 and BT474, 
with the survival of non-ERBB2-amplified MCF7, MDAMB231, and MCF10A cells 
unaffected by TPD52 knockdown (Roslan et al., 2014).  Interestingly, the increases in  
cell death were similar for SKBR3 and BT474, despite these cell lines having 
significantly different TPD52 expression levels (Roslan et al., 2014).  Similar results 
were reported for SKBR3, BT474, and MCF7 in an independent functional RNA 
interference screen (Kourtidis et al., 2010).  Since both LNCaP and C4-2 cells also 
express ERBB2, the combined results of these studies suggest that TPD52 may be  
particularly important for the survival of ERBB2-positive cancer cells.  However, 
significant reductions in cell viability with TPD52 knockdown have also been reported 
for some ERBB2-negative cancer cell lines (Kourtidis et al., 2010), which suggests 
that there may be factors beyond ERBB2 that similarly sensitise cancer cells to the loss 
of TPD52.  Further research is required to better define the contexts in which cancer 
cells become reliant upon TPD52 and may highlight potential avenues for future 
therapeutic targeting.   
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1.3.5   Molecular functions of TPD52 
 Despite collective evidence from both tumour samples and cell line models, the 
molecular pathways through which TPD52 overexpression contributes to cancer 
development are yet to be elucidated.  TPD52, along with other members of the 
TPD52-like protein family, displays little sequence homology with proteins of known 
functions, which has been a major impediment for de novo functional predictions 
(Chen et al., 2016).  Nevertheless, a physiological role for TPD52 has been identified 
in secretory cells, where it is normally abundant (Groblewski et al., 1999; Chew et al., 
2008).  Whether the oncogenicity associated with TPD52 overexpression in other cell 
types is derived from a perturbation of this physiological function, or is related to the 
gain of a new function, remains an open question. 
 
1.3.5.1   Physiological function of TPD52 
Current evidence indicates that TPD52 plays a role in the regulation of 
digestive enzyme secretion and vesicular membrane trafficking.  Under non-
pathological conditions, TPD52/Tpd52 is predominantly expressed in polarised 
secretory cells of the gastrointestinal tract, as well in the kidney and in granule cells of 
the hippocampus (Byrne et al., 1995; Parente et al., 1996; Chen et al., 1996; Chen et 
al., 1997; Groblewski et al., 1999; Chew et al., 2008).  The rabbit and rat orthologues 
of TPD52 were shown to be phosphorylated in response to secretagogue stimulation of 
gastric parietal and pancreatic acinar, respectively (Parente et al., 1996; Groblewski et 
al., 1996).  Additionally, secretagogue stimulation of mucosal T84 and rat pancreatic 
acinar cells produced a rapid translocation of Tpd52 from supranuclear to subapical 
cytoplasmic compartments (Thomas et al., 2004), while the introduction of 
recombinant Tpd52 into rat pancreatic acinar cells stimulated the secretion of amylase 
(Thomas et al., 2001).  Tpd52 was subsequently shown to control membrane 
trafficking within the apical endolysosomal secretory pathway in pancreatic acinar 
cells (Messenger et al., 2013).  The involvement of TPD52 in these pathways is further 
supported by its associations with several membrane-associated trafficking proteins, 
including co-localisation with early endosomal antigen-1 (EEA-1) and lysosomal-
associated membrane protein (LAMP1), as well as binding to MAL2 and RAB5C in 
the yeast two-hybrid system, and to annexin VI in co-immunoprecipitation 
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experiments (Wilson et al., 2001; Thomas et al., 2002; Thomas et al., 2004; Thomas et 
al., 2010; Shahheydari et al., 2014).   
 
1.3.5.2   Preliminary evidence for TPD52 involvement in lipid metabolism 
Our laboratory recently demonstrated that TPD52 overexpression in mouse 
3T3 fibroblast cells is accompanied by increased neutral lipid storage (Kamili et al., 
2015).  A link between TPD52 and lipid metabolism is also supported by several 
indications within the literature, although the significance of these were not recognised 
until recently.  Knockdown of the ancestral TPD52 gene in C. elegans was shown to 
result in significantly decreased lipid storage (Ashrafi et al., 2003), while the ancestral 
TPD52 in D. melanogaster was identified in a study of the lipid droplet proteome 
(Cermelli et al., 2006).  Furthermore, the family member TPD52L2 has been reported 
as a lipid droplet-associated protein in numerous proteomic studies (Brasaemle et al., 
2004; Umlauf et al., 2004; Sato et al., 2006; Cho et al., 2007; Wan et al., 2007; 
Hodges and Wu, 2010).   Additionally, TPD52/Tpd52 transcript levels were found to 
be increased in human and mouse adipose tissue from obese versus lean subjects 
(Nadler et al., 2000; Clement et al., 2004; Keller et al., 2008) and TPD52 has been 
shown to be androgen-inducible in prostate cancer (Rubin et al., 2004; Wang et al., 
2004), which is consistent with androgen being a potent regulator of lipid metabolism 
and increasing cytoplasmic lipid droplets in prostate cancer cells (Swinnen and 
Verhoeven, 1998; Massie et al., 2011).  Moreover, TPD52 was predicted to associate 
with two important regulators of lipid storage, perilipin and TIP47, by two separate 
studies employing a yeast two-hybrid screen and co-immunoprecipitation experiments, 
respectively (Yamaguchi et al., 2006; Zhang et al., 2007).  Finally, TPD52 has been 
shown to be a survival factor in ERBB2-amplified breast cancer cell lines (Kourtidis et 
al., 2010; Roslan et al., 2014), which are known to frequently exhibit a lipogenic 
phenotype and be reliant upon the expression of several lipid-relevant genes (section 
1.2.3.2).  Collectively, this preliminary evidence suggests that TPD52 may be 
operating within lipid metabolic pathways and that it is perhaps this aspect of TPD52 
function that is targeted by its frequent amplification and overexpression in cancer.   
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1.4 Aims of the current study 
The current study addresses the long-standing deficit in our understanding of 
how TPD52 overexpression contributes to the development of cancer at a molecular 
level.  The discovery that TPD52 overexpression in mouse 3T3 fibroblast cells is 
accompanied by increased neutral lipid storage (Kamili et al., 2015), led us to 
hypothesise that increased lipid storage, or altered lipid metabolism, might also be a 
feature of TPD52-overexpressing cancer cells.  Furthermore, we hypothesised that if 
TPD52 overexpression is indeed associated with altered lipid metabolism, it could 
potentially signal cancers that are reliant upon high lipid levels for survival. TPD52 
amplification and/or overexpression could then be applied clinically as a predictive 
marker for cancers likely to respond to drugs that interfere with lipid pathways. 
 
The aims of the current study were: 
1. To explore the frequency, magnitude, and context of TPD52 amplification in 
995 cell lines from diverse cancer types, and assemble an experimental cohort 
of TPD52-amplified cell lines (Chapter 3) 
2. To ascertain whether TPD52 amplification and/or overexpression in cancer 
cells is broadly associated with increased lipid storage, and examine predicted 
interactions between TPD52 and lipid droplet-associated proteins (Chapter 4) 
3. To predict novel associations between TPD52 amplification and/or 
overexpression and altered sensitivity or resistance to drugs within publicly-
available pharmacogenomic datasets (Chapter 5) 
4. To investigate whether cancer cell line sensitivities to lipid-relevant drugs 
segregate according to TPD52 copy number and/or expression (Chapter 6) 
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Chapter 2 
 
Materials and Methods. 
 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
All general laboratory chemicals and reagents were of analytical grade and 
were sourced as indicated in Table 2.1. 
Table 2.1. Chemicals and reagents.  
Chemical / Reagent Manufacturer 
2-mercaptoethanol Sigma-Aldrich 
2-propanol Sigma-Aldrich 
Acetic acid, glacial BDH 
Acrylamide (30%) / Bis solution Bio-Rad 
Agar BD 
Agarose Amresco 
Alamar Blue Invitrogen 
Ammonium chloride Sigma-Aldrich 
APS (ammonium persulfate) Amresco 
BCA protein assay kit Thermo Fisher Scientific 
BFA (brefeldin A) Sigma-Aldrich 
BODIPY 493/503 Molecular Probes 
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Table 2.1. Continued… 
Chemical / Reagent Manufacturer 
Bromophenol blue BDH 
BSA (bovine serum albumin) Gibco 
Coomassie Brilliant Blue Sigma-Aldrich 
DAPI (4',6-diamidino-2-phenylindole dihydrochloride) Sigma-Aldrich 
Deoxycholate Sigma-Aldrich 
Dextrose BD 
Dimethyl pimelimidate-2-HCl Thermo Fisher Scientific 
DMSO (dimethylsulfoxide), sterile for cell culture Sigma-Aldrich 
DNase I Invitrogen 
DNase-free water Qiagen 
EDTA (ethylenediamine tetra-acetic acid) Amresco 
Ethanol, absolute (molecular grade) Merck 
Ethidium bromide Gibco 
Fatostatin hydrobromide Sigma-Aldrich 
FluorSave mounting medium Calbiochem 
Fuji X-ray film Fuji Film Corporation 
Glutaraldehyde Electron Microscopy Sciences 
Glutathione Sepharose 4B GE Healthcare 
Glycerol Amresco 
Glycine Amresco 
Hydrochloric acid (HCl) Lab-Scan 
Immobilon-P membrane, PVDF  Milipore 
IPTG (isopropyl-b-D-thiogalactopyranoside) Sigma-Aldrich 
Kanamycin Sulfate Sigma-Aldrich 
Lapatinib (GW-572016) Ditosylate Selleck Chemicals 
Leupeptin Sigma-Aldrich 
Lithium acetate (LiAc) Sigma-Aldrich 
Lysozyme Sigma-Aldrich 
Methanol Chem Supply 
PEG (polyethylene glycol) 4000 BDH 
Peptone BD 
PFA (paraformaldyhyde) Sigma-Aldrich 
PMSF (phenylmethanelsulfonyl fluoride) Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
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Table 2.1. Continued… 
Chemical / Reagent Manufacturer 
Potassium chloride (KCl) BDH 
Potassium dihydrogen orthophosphate (KH2PO4) BDH 
Pre-stained protein ladder (BenchMark) Invitrogen 
Pre-stained protein standard (Novex Sharp) Invitrogen 
Pronase Sigma-Aldrich 
Protease inhibitor cocktail tablets Roche 
QuantiFast SYBR Green PCR mastermix Qiagen 
Quickload 100 bp DNA ladder  New England BioLabs 
Reduced glutathione Sigma-Aldrich 
Salmon sperm carrier DNA  Sigma-Aldrich 
SDS (sodium dodecyl sulphate) Amresco 
siRNA buffer (5X) Dharmacon 
Skim milk powder Diploma 
Sodium chloride (NaCl) Amresco 
Sodium hydroxide (NaOH) Amresco 
Sodium phosphate dibasic anhydrous (Na2HPO4) BDH 
Synthetic dropout (SD) supplements Clontech 
TEA (triethanolamine) Sigma-Aldrich 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) Sigma-Aldrich 
TransIT-X2 dynamic delivery system  Mirus Bio 
Tris base Amresco 
Tris, 10mM, pH 8.5 Qiagen (from Miniprep Kit) 
Triton X-100 Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Trypsin Gibco 
Tween 20 Sigma-Aldrich 
Venor GeM mycoplasma detection kit Sigma-Aldrich 
Western Lightning Plus-ECL chemiluminescent reagent Perkin Elmer 
Xylene cyanol Progen 
Yeast extract BD 
Yeast nitrogen base without amino acids BD 
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2.1.2 Buffers and solutions 
All buffers and solutions were prepared as indicated in Table 2.2 and were 
stored at room temperature, unless otherwise stated. Aqueous solutions were prepared 
in Milli-Q water, unless otherwise stated. For some solutions, water was autoclaved 
(aH2O) prior to preparation. 
 
Table 2.2. Buffers and solutions. 
Solution Composition Preparation and storage 
Ammonium chloride 1X PBS 50 nM ammonium chloride Prepared fresh 
Antibody diluent 
(immunofluorescence) 
1X PBS  
3% (w/v) BSA Prepared fresh  
APS 10% (w/v) APS Prepared fresh 
BODIPY 493/503 stock 
solution, 1 mg/mL 
10 mg BODIPY 493/503  
10 mL 100% ethanol 
Stored in aliquots at -
20°C 
Dextrose, 40% 40% (w/v) dextrose Filter-sterilised (0.22 
µm)  
EDTA, pH 8.0 0.5 M EDTA Sterilised by autoclaving  
Ethanol, 70% 70% ethanol Prepared in aH2O 
LiAc, 10X 1 M LiAc Adjusted to pH 7.5 Sterilised by autoclaving 
Lysis buffer  
(genomic DNA 
extraction) 
50 mM Tris, pH 8 
20 mM EDTA, pH 8 
2% SDS 
Components pre-
autoclaved 
Prepared in aH2O 
Lysis buffer 
(total protein extraction)  
125 mM Tris, pH 8.8 
3% (w/v) SDS Autoclaving not required 
Lysis buffer  
(pull-downs) 
10 mM Tris, pH 7.5 
150 mM NaCl 
1 mM EDTA  
0.1% deoxycholate 
1% Triton X-100 
Autoclaving not required 
Lysis buffer  
(production of 
GST fusion proteins) 
20 mM Tris, pH 7.4 
250 mM NaCl  
1 mg/mL lysozyme 
1 mM PMSF  
20 µg/mL leu-peptin 
5 µg/mL DNase I,  
1% (v/v) Triton X-100 
Prepared fresh 
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Table 2.2. Continued… 
Solution Composition Preparation and storage 
Membrane blocking 
buffer (BSA) 
1X TBST 
3% (w/v) BSA Prepared fresh 
Membrane blocking 
buffer (skim milk) 
1X TBST 
5% (w/v) skim milk powder Prepared fresh 
PBS, 10X 
137 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.47 mM KH2PO4 
Adjusted to pH 7.4 
Sterilised by autoclaving 
PEG 4000 50% (w/v) PEG 4000 Sterilised by autoclaving 
PEG/LiAc 
1X TE 
1X LiAc 
40% PEG 4000 
Prepared fresh from pre-
autoclaved components 
PFA fixative 1X PBS 3% (w/v) PFA 
Prepared fresh 
Adjusted to pH 7.4 
Ponceau S stain 0.1% (v/v) Ponceau S 5% (v/v) acetic acid Autoclaving not required 
Pull-down beads storage 
buffer 
20 mM Tris 
50% glycerol Adjusted to pH 7.4 
Pull-down cross-linking 
wash buffer 
1.5 M NaCl 
25 mM Tris 
Adjusted to pH 7.6 
Sterilised by autoclaving 
Pull-down quenching 
buffer 1 M Tris Adjusted to pH 8.2 
Pull-down wash buffer 1 150 mM NaCl 20 mM Tris Adjusted to pH 7.4 
Pull-down wash buffer 2 25 mM Tris Adjusted to pH 7.4 
Running buffer, 10X 
250 mM Tris 
1.92 M glycine 
1% (v/v) SDS 
Autoclaving not required 
Sample loading buffer, 
4X (protein) 
0.5 M Tris, pH 6.8 
20% (v/v) glycerol 
2% (w/v) SDS  
20% (v/v) 2-mercaptoethanol 
0.01% (w/v) bromophenol 
blue 
Autoclaving not required 
Stored at -20°C 
Sample loading buffer, 
6X (DNA) 
30% (v/v) glycerol 
1 mM EDTA 
0.25% (w/v) bromophenol 
blue 
0.25% (w/v) xylene cyanol 
Autoclaving not required 
Stored at -20°C 
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Table 2.2. Continued… 
Solution Composition Preparation and storage 
SDS 10% (w/v) SDS 
Prepared in aH2O, with 
heating to 65°C to aid 
dissolution 
Sodium chloride  5 M NaCl Sterilised by autoclaving 
Synthetic dropout (SD) 
plates 
6.7 g/L yeast nitrogen base 
without amino acids 
SD powder of either: 
§ 0.64 g/L SD/-L-W 
§ 0.62 g/L SD/-H-L-W 
22 g/L agar 
2% dextrose 
Adjusted to pH 5.8 
Sterilised by autoclaving 
prior to addition of 
dextrose 
Plates stored at 4°C 
TAE, 50X 
242 g/L Tris 
37.2 g/L EDTA 
57 mL/L acetic acid 
Autoclaving not required 
TBS, 10X 1 M Tris, 1.5 M NaCl 
Adjusted to pH 7.5 
Autoclaving not required 
TBST 1X TBS 0.1% (v/v) Tween 20 Autoclaving not required 
TE, 10X 100 mM Tris 10 mM EDTA 
Adjusted to pH 7.5 
Sterilised by autoclaving 
TE/LiAc 1X TE 1X LiAc 
Prepared fresh from pre-
autoclaved components 
TEA 0.2 M TEA Adjusted to pH 8.3 Autoclaved 
Transfer buffer 
 
1X transfer buffer stock 
20% (v/v) methanol     
0.005% (w/v) SDS 
Prepared fresh  
Autoclaving not required 
Transfer buffer stock, 
10X 
 
25 mM Tris 
192 mM glycine Autoclaving not required 
Tris, pH 6.8 or 8.8 1 M Tris Adjusted to required pH Autoclaved  
Triton X-100 1X PBS 0.1% Triton X-100 Autoclaving not required 
YPD, liquid media 
20 g/L peptone 
10 g/L yeast extract 
2% dextrose 
Adjusted to pH 5.8 
Sterilised by autoclaving 
prior to addition of 
dextrose 
YPD, solid media As for YPD liquid media 18 g/L agar 
As for YPD liquid media 
Plates stored at 4°C 
 
 
	50 
2.1.3 Cell culture media and supplements 
The following cell culture media were used: ATCC-modified RPMI 1640, 
DMEM/F12 (Dulbecco’s Modified Eagle Medium with Nutrient Mixture F12), IMDM 
(Iscove’s modified Dulbecco’s Medium), MEM (Minimum Essential Medium), RPMI 
1640, and Waymouth’s Medium.  All media was manufactured by Gibco (Life 
Technologies) and stored at 4°C.  Media supplements were sourced and stored as 
indicated in Table 2.3.  
 
Table 2.3. Cell culture media supplements.  
Supplement Source Stock conc. Storage 
2-mercaptoethanol (for tissue culture) Gibco 55 mM 4°C 
Cholera toxin Sigma-Aldrich 1 mg/mL -20°C 
EGF (epidermal growth factor) Sigma-Aldrich 1 mg/mL -20°C 
FBS (fetal bovine serum) Gibco 100% -20°C 
Geneticin (G418) Gibco 50 mg/mL 4°C 
Horse serum Gibco 100% -20°C 
Human serum Sigma-Aldrich 100% -20°C 
Hydrocortisone Sigma-Aldrich 50 µg/mL -20°C 
Insulin Sigma-Aldrich 10 mg/mL 4°C 
L-glutamine Gibco 200 mM -20°C 
NEAA (non-essential amino acids) Gibco 100X 4°C 
Puromycin Sigma-Aldrich 10 mg/mL -20°C 
Sodium pyruvate Gibco 100 mM 4°C 
 
2.1.4 Primary antibodies 
 Primary antibodies were kept at either -20°C or -80°C for long-term storage, or 
at 4°C for short-term storage (up to 1 month).  Western blot and immunofluorescence 
are abbreviated to WB and IF, respectively. 
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Table 2.4. Primary antibodies. 
Antibody  
(Supplier / Reference) Species Reactivity Dilution 
Adipophilin  
(Gift from Dr Enoch Tay; 
Boulant et al., 2008) 
Sheep Human WB: 1:1000 
c-MYC [Y69] 
(Abcam #AB32072) Rabbit monoclonal Human, Mouse WB: 1:10,000 
ERBB2 [29D8]  
(Cell Signaling #2165) Rabbit monoclonal Human, Mouse WB: 1:1000 
FASN [A-5] 
(Santa Cruz #SC-55580) Mouse monoclonal Human, Mouse WB: 1:200 
GAPDH [6C5] 
(Ambion #AM4300) Mouse monoclonal Human, Mouse  WB: 1:5000 
HSP90 [AC-16] 
(Sigma-Aldrich #H1775) Mouse monoclonal Human WB: 1:5000 
RAB5  
(Sigma-Aldrich 
#HPA003426)  
Rabbit polyclonal Human WB: 1:300 
SREBP1 [2A4] 
(Abcam #AB3259) Mouse monoclonal Human WB: 1:200 
TIP47 
(Progen Biotechnik 
#GP30) 
Guinea-pig 
polyclonal Human WB: 1:2000 
TPD52  
(Tiacci et al., 2005) Mouse monoclonal Human, Mouse IF: 1:10 
TPD52 (747)  
(Balleine et al., 2000) Rabbit polyclonal Human  
WB: 1:100 
IF: 1:100 
TPD52 (748)  
(Shehata et al., 2008b) Rabbit polyclonal Human, Mouse  WB: 1:100 
 
2.1.5 Secondary antibodies 
Secondary antibodies were received lyophilised and reconstituted according to 
the manufacturers’ instructions.  These were kept at -80ºC for long-term storage, or at 
4ºC for short-term storage (up to 1 month).  Secondary antibodies for WB were 
conjugated to horse radish peroxidase (HRP), while secondary antibodies for IF were 
conjugated to cyanine 3 (Cy3). 
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Table 2.5. Secondary antibodies.  
Antibody (Supplier) Application and dilution 
Donkey anti-mouse, Cy3-linked  
(Jackson Immunoresearch Laboratories #715-165-150) IF: 1:1000 
Donkey anti-rabbit, Cy3-linked 
(Jackson Immunoresearch Laboratories #711-165-152) IF: 1:1000 
Donkey anti-rabbit, HRP-linked 
(GE Healthcare #NA934) WB: 1:10,000 
Donkey anti-sheep, HRP-linked 
(Jackson Immunoresearch Laboratories #713-035-147) WB: 1:5000 
Rabbit anti-guinea pig, HRP-linked  
(Invitrogen #61-4620) WB: 1:2000 
Sheep anti-mouse, HRP-linked 
(GE Healthcare #NA931) WB: 1:5000 
 
2.2 Methods 
2.2.1 Mammalian cell culture 
2.2.1.1 Human cancer cell line panel 
143B, BT474, HCC827, HOS, MCF7, MCF10A, MDAMB231, MG63, 
NCIH1734, SKBR3, and SUPB15 were obtained from the American Type Culture 
Collection (Manassas, VA, USA).  BHT101, CORL23, EFM192A, EVSAT, HMC18, 
and PSN1 were obtained from Creative Bioarray (Shirley, NY, USA).  TE4 was 
obtained from the RIKEN Cell Bank (Tsukuba, Ibaraki, Japan).  DMS454 was 
obtained from Sigma-Aldrich.  AU565, and ZR7530 were kindly provided by 
Professor Roger Daly from the Garvan Institute (Sydney, NSW, Australia).  U2OS was 
obtained from CellBank (Westmead, NSW, Australia).  The cancer type represented by 
each of these cell lines, as well as other pertinent information, is summarised in Table 
2.6.  MCF10A is a non-tumorigenic breast cell line and was included in our panel as a 
control.  The identities of all cell lines were confirmed either by their respective 
repositories or by short tandem repeat profiling at CellBank.  Cell lines were 
periodically tested for mycoplasma detection using a Venor GeM mycoplasma 
detection kit, according to the manufacturer’s instructions.  Cell lines were cultured in 
the appropriate growth media, as indicated in Table 2.6.   
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Table 2.6. Human cancer cell line panel. 
Cell line Cancer type Growth media 
143B Osteosarcoma (metastatic cell line derived from HOS) 
MEM + 1X NEAA + 1 mM 
sodium pyruvate + 10% FBS  
AU565 Breast adenocarcinoma (derived from the same patient as SKBR3) 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS  
BHT101 Anaplastic papillary thyroid carcinoma 
DMEM + 20% FBS + 0.5% 
human serum 
BT474 Invasive ductal carcinoma of the breast 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS 
CORL23 Large cell lung carcinoma ATCC-modified RPMI 1640  + 10% FBS  
DMS454 Small cell lung carcinoma Waymouth’s medium + 10% FBS  
EFM192A Breast adenocarcinoma RPMI 1640 + 2 mM L-glutamine + 20% FBS  
EVSAT Breast carcinoma MEM + 1X NEAA + 1 mM sodium pyruvate + 10% FBS 
HCC827 Non-small cell lung adenocarcinoma 
ATCC-modified RPMI 1640  
+ 10% FBS  
HMC18 Infiltrating scirrhous carcinoma of the breast 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS 
HOS Osteosarcoma MEM + 1X NEAA + 1 mM sodium pyruvate + 10% FBS 
MCF7 Breast adenocarcinoma 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS + 10 
µg/ml insulin  
MCF10A Non-tumorigenic breast cell line 
DMEM/F12 + 5% horse 
serum + 20 ng/mL EGF  
+ 0.5 µg/mL hydrocortisone  
+ 100 ng/mL cholera toxin  
+ 10 µg/ml insulin  
MDAMB231 Breast adenocarcinoma RPMI 1640 + 6 mM L-glutamine + 10% FBS 
MG63 Osteosarcoma MEM + 1X NEAA + 1 mM sodium pyruvate + 10% FBS 
NCIH1734 Non-small cell lung adenocarcinoma 
ATCC-modified RPMI  
+ 10% FBS 
PSN1 Pancreatic adenocarcinoma  ATCC-modified RPMI  + 10% FBS  
SKBR3 Breast adenocarcinoma (derived from the same patient as AU565) 
RPMI 1640 + 6 mM  
L-glutamine + 10% FBS 
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Table 2.6. Continued… 
Cell line Cancer type Growth media 
SUPB15 Acute lymphoblastic leukaemia   
IMDM + 20% FBS + 0.05 
mM 2-mercaptoethanol 
(supplemented daily) 
TE4 
Oesophageal cancer (lymph node 
metastasis from a highly 
differentiated squamous carcinoma) 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS 
U2OS Osteosarcoma DMEM + 10% FBS  
ZR7530 Infiltrating ductal carcinoma of the breast 
RPMI 1640 + 6 mM L-
glutamine + 10% FBS 
 
2.2.1.2 Stably TPD52-overexpressing MDAMB231 human cancer cell lines  
Stably-transfected MDAMB231 cells, including two TPD52-overexpressing 
cell lines (H1, H2) and two vector control cell lines (PG-10, PG-13), were derived as 
described previously (Boutros et al., 2003).  The cell lines were cultured in RPMI 
1640 supplemented with 10% FBS and 6 mM L-glutamine, as well as 1mg/mL 
geneticin (G418) for plasmid retention.  
 
2.2.1.3 Stably TPD52-depleted SKBR3 human cancer cell lines  
Stably-transfected SKBR3 cells, including four TPD52-depleted cell lines (9B, 
4B, 7C, and 7D) and one non-targeted control cell line (8C), were derived as described 
previously (Roslan et al., 2014).  The cell lines were cultured in RPMI 1640 
supplemented with 10% FBS and 6 mM L-glutamine, as well as 1µg/mL puromycin 
for plasmid retention.  
 
2.2.1.4 Stably TPD52-expressing 3T3 mouse fibroblast cell lines  
The mouse Balb/c 3T3 fibroblast cell line was kindly provided by Robert K 
Bright (Department of Microbiology and Immunology, Texas Tech University, Health 
Sciences Center, Lubbock, Texas, USA).  Stably-transfected 3T3 fibroblasts, 
expressing either TPD52 or vector, were derived as described previously (Shehata et 
al., 2008b).  The cell lines were cultured in RPMI 1640 supplemented with 10% FBS 
and 6 mM L-glutamine, as well as 1mg/mL geneticin (G418) for plasmid retention.  
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2.2.1.5 Passaging, freezing, and harvesting cells  
All cell lines were cultured at 37oC in a humidified incubator with 5% CO2 and 
allowed to grow until approximately 70% confluent before being passaged for 
propagation, frozen as stocks, or harvested for analysis.  Cells were washed in PBS, 
trypsinised for 5 minutes at 37oC, resuspended in 5 times this volume of media, and 
centrifuged at 1100 rpm for 5 minutes. For propagation, pelleted cells were 
resuspended in an appropriate volume of growth media.  If seeding at a known cell 
number was required, a small volume of this suspension was mixed with an equal 
volume of trypan blue and counted using a hemacytometer.  Otherwise, cells were split 
according to an established splitting schedule to ensure approximately 70% confluence 
after 3-4 days growth.  For frozen stocks, pelleted cells were resuspended in the 
appropriate growth media supplemented with 5-10% DMSO and frozen to -80oC at a 
rate of 1oC/minute (using a Mr Frosty freezing container) before long-term storage in 
the vapour phase of liquid nitrogen.  For cells harvested but not required immediately, 
cell pellets were washed twice in ice-cold PBS, snap-frozen on dry ice, and stored at -
80oC until use. 
 
2.2.2 Determination of gene copy number 
2.2.2.1 Genomic DNA extraction from cultured cells 
 Cell pellets were washed and resuspended in 50-100 µL of PBS prior to the 
addition of 3.5 mL of DNA lysis buffer (50 mM Tris-HCl pH 8, 20 mM EDTA, 2% 
SDS), supplemented with 0.2 mg/mL pronase.  Lysis was allowed to proceed at 37oC 
for 12-16 hours.  Next, 1.3 mL of 5 M NaCl was added and the lysates were incubated 
on ice for at least 2 hours to precipitate salt/SDS/protein.  Samples were then 
centrifuged at 4oC at 4700 rpm for 15 minutes and the clear supernatant decanted into 
fresh tubes.  This centrifugation step was repeated three to four times, taking care to 
transfer as much as possible of the supernatant adjacent to the precipitate to enhance 
DNA yield.  Next, absolute ethanol was added at 2.5 times the volume of the 
supernatant and the tubes inverted to mix.  Samples were incubated for 12-16 hours at 
4oC.  Samples were centrifuged at 4oC at 4700 rpm for 30 minutes and the resultant 
DNA pellet washed with 70% ethanol and centrifuged again for 15 minutes.  After 
carefully decanting the supernatant, the DNA pellet was allowed to air dry for 10-20 
minutes.  The DNA was then resuspended in 10 mM Tris (pH 8.5) for 12-16 hours and 
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quantitated using a QUBIT fluorometer (Thermo Fisher Scientific).  DNA was stored 
at 4oC in the short-term and kept at -20oC for long-term storage. 
 
2.2.2.2 Primer design 
Primers were designed in Primer3 (http://frodo.wi.mit.edu/primer3/) and their 
specificity for the template sequence confirmed by a BLASTN search.  All primers 
were then manufactured by Sigma-Aldrich, reconstituted in 10 mM Tris (pH 8.5), and 
stored at -20°C.  The TPD52 PCR primer set was comprised of sense sequence 5’-
CAG TTT AGA GCC CAG GGA AA-3’ and antisense sequence 5’-CGA TCA TCC 
AAC GTA GCA TG-3’.  These primers target a 225 bp TPD52 fragment that includes 
exon 5, as well as some of the preceding and following intronic sequences 
(ENST00000518937, NM_001025253).  The MYC PCR primer set was comprised of 
sense sequence 5’-TAG GGG ATA GCT CTG CAA GG-3’ and antisense sequence 
5’-GGG AGG CAG TCT TGA GTT AAA G-3’.  These primers target a 102 bp MYC 
fragment that includes the intronic sequence preceding exon 2 (ENST00000621592, 
NM_002467). The ERBB2 PCR primer set was comprised of sense sequence 5’-AAG 
GGG TCC GTG GTA AGG T-3’ and antisense sequence 5’-CGA AGC AGA GGT 
GGG TGT TA-3’.  These primers target a 154 bp ERBB2 fragment that includes part 
of exon 12, as well as preceding intronic sequence (ENST00000269571, NM_004448).  
A qBiomarker Multicopy Reference (MRef) Assay (Qiagen) was used for the 
normalisation of input DNA.  This assay detects a unique repetitive sequence that is 
located at multiple loci and is therefore less influenced by chromosomal amplifications 
or deletions than single gene normalisation.  
 
2.2.2.3 Quantitative PCR 
 A mastermix was prepared using QuantiFast SYBR Green PCR mastermix, the 
appropriate forward and reverse primers at final concentrations of 10 µM each, and 
DNase-free water.  Each PCR reaction used 20µL of this mastermix and 5µL of either 
standard or test DNA.  Ten standards were prepared by serial dilution using genomic 
DNA extracted from SKBR3 and ranged from 0.015625 to 8 ng/µL.  Test DNA 
samples were diluted to 1 ng/µL, ensuring that there was sufficient volume for target 
and reference sequences to be assessed from the same preparation (thereby minimising 
the potential variation introduced by separate dilutions).  PCR reactions were 
performed using the Corbett Rotor-Gene 6000 (Qiagen) and the following thermal 
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cycling conditions: an initial denaturation step of 95°C for 5 minutes, and 33-37 cycles 
of 95°C for 15 seconds, 61°C for 30 seconds, and 72°C for 20 seconds.  The TPD52 
primer set required 35 cycles, while the MYC and ERBB2 primer sets required 37 
cycles, and MRef required 33 cycles.  Each run included: the relevant test samples, in 
triplicate; a set of standards, in duplicate; a no template control, in duplicate, for the 
detection of PCR contamination; and a TaqMan human genomic DNA control 
(Applied Biosystems), in triplicate, for the comparison of relative copy numbers across 
test samples.   
 
2.2.2.4 Validation 
Melting curve analysis was performed at the conclusion of each run, with a 
single peak indicative of the amplification of a specific PCR product.  Furthermore, 
agarose gel electrophoresis was performed for each primer set to confirm the 
amplification of a single PCR product of the anticipated size.  Following PCR, samples 
were mixed with DNA loading buffer and loaded onto a 3% agarose gel, which was 
prepared in TAE buffer and contained 0.4 µg/mL ethidium bromide.  A Quickload 100 
bp DNA ladder was also included to allow for the determination of PCR product size.  
The samples were resolved by electrophoresis at 80-100 V in a horizontal submarine 
electrophoresis tank (Bio-Rad) filled with TAE buffer and then visualised under UV 
transillumination (Alpha Imager).  
 
2.2.2.5 Data analysis 
Data analysis was completed using Rotor-Gene (version 6.1) software 
(Qiagen).  The concentration of the target (TPD52, MYC, or ERBB2) and MRef 
sequences were first determined from their respective standard curves.  The 
concentration of the target gene was then normalised with respect to the MRef 
concentration to control for differences in the amount of input DNA.  Finally, relative 
gene copy numbers for TPD52, MYC, and ERBB2 were calculated by comparing the 
results for each of the cell lines to those for the human genomic DNA control.  These 
analyses were completed for three separate biological replicates and the mean values 
calculated.   
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2.2.3 Determination of cellular protein levels  
2.2.3.1 Total protein extraction from cultured cells 
 Protein lysates were obtained by washing cells twice in ice-cold PBS and then 
scraping cells from the surface of the plates in the presence of protein lysis buffer (3% 
SDS in 125 mM Tris-HCl, pH 8.8) supplemented with 1 mM PMSF and 1X protease 
inhibitor.  Lysates were then sonicated to reduce viscosity and centrifuged at 13,000 
rpm for 20 minutes at 4oC.  The supernatant was transferred to a fresh tube and either 
used immediately or snap-frozen on dry ice and kept at -80oC until use.  Total protein 
concentration of the lysates was quantitated using a BCA protein assay kit, as per the 
manufacturer’s instructions. 
 
2.2.3.2 SDS-PAGE  
 Lysates (typically 15-20 µg/well) were mixed with sample buffer, incubated at 
95oC for 5 minutes, and resolved on either 12.5% polyacrylamide gels (Table 2.7) or 
on pre-cast 4-12% gradient polyacrylamide gels (Life Technologies).  Gels were run at 
80 V for the first 30 minutes, or until the samples had traversed the stacking gel, and 
then at 120 V for 1.5 to 2 hours, depending on the required degree of separation.  
Sample progress was monitored using a BenchMark pre-stained protein ladder (10-200 
kDa) for 12.5% gels, or a Novex Sharp pre-stained protein standard (3.5-260 kDa) for 
4-12% gradient gels. 
 
Table 2.7. Composition of 12.5% polyacrylamide gel.  Volumes are indicative of 
requirements for a single gel and were scaled as needed.  
Gel constituent Resolving gel Stacking gel 
1 M Tris, pH 6.8  - 250 µL 
1 M Tris, pH 8.8 1.875 mL - 
Milli-Q water 0.95 mL 1.45 mL 
10% SDS 50 µL 20 µL 
30% Acrylamide/Bis-Acrylamide solution 2.075 mL 266 µL 
10% APS 37.5 µL 15 µL 
TEMED 2 µL 2 µL 
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2.2.3.3 Western blot transfer 
 Following electrophoresis, proteins in the gel were electro-transferred onto an 
Immobilon-P PVDF membrane.  The membrane was first rehydrated in 100% 
methanol for 1-2 minutes and then equilibrated in transfer buffer.  A sponge followed 
by two pieces of Whatman filter paper, all pre-soaked in transfer buffer, were placed 
on the red (positive) side of an open electrode cassette.  The membrane was then 
placed on top.  The gel was removed from the running apparatus, the stacking gel 
detached and discarded, and the remaining resolving gel placed on top of the 
membrane.  This was followed by another two pieces of filter paper and a second 
sponge.  Care was taken throughout this stacking process to exclude air bubbles.  The 
cassette was closed and placed inside a transfer tank, which was filled with ice-cold 
transfer buffer and housed within an ice bucket.  The transfer was run at 80 V for 2 
hours, or 30 V overnight in a cold room (4°C).  Once completed, the membrane was 
removed from the cassette, noting the side that was in contact with the gel, and then 
rinsed in 100% methanol before air drying for 15 minutes.  The membrane was then 
rehydrated in 100% methanol, rinsed in Milli-Q water, and stained with Ponceau S to 
visualise protein bands and confirm the efficacy of the transfer process.  Excess stain 
was removed by washing in TBST prior to immunostaining. 
 
2.2.3.4 Immunostaining of Western blots 
 Membranes were blocked overnight at 4°C or for 60 minutes at room 
temperature to prevent non-specific background binding of the antibodies.  Blocking 
buffer was either 5% skim milk powder in TBST or 3% BSA in TBST, depending on 
the antibodies to be used.  Membranes were then washed three times with TBST prior 
to incubation with the appropriate primary antibody, prepared at an optimised dilution 
in the appropriate diluent (section 2.1.4).  Incubation conditions varied from 1 to 2 
hours at room temperature or overnight at 4°C, depending on the antibody used.  
Membranes were then washed three times with TBST prior to incubation for 1 hour at 
room temperature with the appropriate horseradish peroxidase-conjugated secondary 
antibody, prepared at an optimised dilution in the appropriate diluent (section 2.1.5).  
Membranes were then washed three times with TBST and washed a final time in TBS.  
All preceding steps were performed with shaking to ensure even distribution of the 
liquid across the membrane.  To reveal the protein(s) of interest, membranes were 
incubated for 5 minutes at room temperature with Western Lightning Plus-ECL 
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chemiluminescent reagent and placed into a film cassette (Kodak).  In a dark room, X-
ray film was placed on top of the membranes and exposed for between 30 seconds to 1 
hour, depending on signal strength.  The film was developed using an automatic X-ray 
processor (Konica SRX-101A).  
 
2.2.3.5 Densitometry analyses 
 Densitometry analyses were completed in ImageJ (1.48v) to quantitate fold 
changes in protein levels, relative to loading controls.  One lane of each gel was 
reserved for the same lysate to enable normalisation across multiple gels.  The data 
were then plotted and the relevant statistical tests performed in GraphPad Prism 
(version 7).   
 
2.2.4 In situ staining of cultured cells 
2.2.4.1 Neutral lipid staining 
 Cells were cultured on glass coverslips until 70-80% confluent, typically by 
24-48 hours after seeding.  The cells were washed twice with PBS prior to fixation 
with 3% PFA in PBS for 30 minutes.  They were then washed three times with PBS 
prior to neutral lipid staining with BODIPY 493/503, diluted to 1 µg/mL in 150 mM 
NaCl, for 30 minutes.  For this, and all subsequent steps, coverslips were protected 
from light as much as possible to preserve fluorescence.  The cells were again washed 
three times with PBS before nuclear counter-staining with 100 ng/mL DAPI for 5 
minutes.  Finally, the cells were washed three times with PBS and the coverslips were 
mounted onto glass slides using FluorSave mounting medium.  Slides were allowed to 
dry for at least 48 hours at 4°C before viewing, to ensure proper adhesion of the 
coverslip.  
 
2.2.4.2 Co-staining of neutral lipid and proteins 
Cells were cultured on glass coverslips until 70-80% confluent, typically by 
24-48 hours after seeding.  The cells were washed twice with PBS prior to fixation 
with 3% PFA and 0.025% glutaraldehyde in PBS for 10 minutes.  They were then 
treated with 50 nM ammonium chloride in PBS for 10 minutes, followed by 
permeabilisation with 0.1% Triton X-100 in PBS for 10 minutes.  Next, the cells were 
incubated with the appropriate primary antibody, prepared at an optimised dilution in 
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3% BSA in PBS, at 4°C overnight (section 2.1.4).  This was followed by incubation 
with the appropriate fluorescence-conjugated secondary antibody, prepared at an 
optimised dilution in 3% BSA in PBS, for 1 hour at room temperature (section 2.1.5).  
For this, and all subsequent steps, coverslips were protected from light as much as 
possible to preserve fluorescence.  The cells were then incubated for 30 minutes with 
BODIPY 493/503, diluted to 1 µg/mL in 150 mM NaCl, for neutral lipid staining.  
Finally, the cells were incubated for 5 minutes with 100 ng/mL DAPI for nuclear 
counter-staining.  Between each of the steps above, cells were washed three times with 
PBS.  The coverslips were then mounted onto glass slides using FluorSave mounting 
medium.  Slides were allowed to dry for at least 48 hours at 4°C before viewing, to 
ensure proper adhesion of the coverslip.  
 
2.2.4.3 Image capture  
The stained cells were imaged using a Leica TCS SP2 or TCS SP5 confocal 
laser scanning microscope (Leica Technologies), with a Plan 63X oil objective.  The 
405, 488, and 543 nm lasers were used to excite DAPI, BODIPY 493/503, and Cy3, 
respectively.  All image data intended for quantitative comparison were acquired at the 
same sub-saturating exposure time.  Semi-quantitative profiling of neutral lipid content 
in our cancer cell line panel was carried out using AU565 cells to set the intensity 
range.  
 
2.2.4.4 Lipid droplet quantitation 
Lipid droplet quantitation was performed using Image ProPlus 7.0 (Media 
Cybernetics).  The number of lipid droplets and their areas were recorded for each 
image, with the same calibration thresholds applied to those images intended for 
quantitative comparison.  To reduce non-specific background noise, objects with 
diameters smaller than 0.3 µm were excluded, based on expected lipid droplet 
diameters of 0.2 to 1 µm in non-adipocytes (Suzuki et al., 2011, Walther and Farese, 
2012).  The number of nuclei in each image was also recorded and used as a surrogate 
for cell number when calculating mean lipid droplet numbers per cell.  This process 
was repeated for 15-20 images per condition per biological replicate.  These data were 
then plotted and the relevant statistical tests performed in GraphPad Prism (version 7).   
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2.2.5 Transient cell line transfections  
2.2.5.1 Transient knockdown 
 AU565 and HMC18 cells were transfected with either TPD52 or non-targeting 
ON-TARGETplus SMART pools (Dharmacon) (Table 2.8).  Parental cells, and cells 
treated with the transfection reagent only, were included as additional controls.  Cells 
were seeded at pre-optimised numbers onto glass coverslips for in situ staining, and 
into 24-well plates for Western blot analyses.  For HMC18, transfections were 
performed 24 hours after seeding, while for AU565, 48 hours were required for 
adhesion and expected morphology to be present.  Transfections were performed using 
the TransIT-X2 dynamic delivery system (Mirus Bio), according to the manufacturer’s 
instructions.  Media were replaced 24 hours after transfection.  At 72 hours after 
transfection, cells were either prepared for in situ staining (section 2.2.4) or harvested 
for the corresponding Western blot analyses (section 2.2.3).   
 
Table 2.8. ON-TARGETplus SMART siRNA pools (Dharmacon). siRNA pools 
were reconstituted in siRNA buffer (Dharmacon) at stock concentrations of 10 µM and 
stored in aliquots at -80°C until required. 
Target gene siRNA sequences 
Experimental 
concentration for 
siRNA pool 
TPD52  
5’-GCG GAA ACU UGG AAU CAA U-3’ 
5’-GGA GAA GUC UUG AAU UCG G-3’ 
5’-GAA GAA ACA UUU GGC CAU U-3’ 
5’-GGU GAU AAC UCU UGA GGA U-3’  
100 nM 
Non-targeting  
5’-UGG UUU ACA UGU CGA CUA A-3’ 
5’-UGG UUU ACA UGU UGU GUG A-3’ 
5’-UGG UUU ACA UGU UUU CUG A-3’ 
5’-UGG UUU ACA UGU UUU CCU A-3’ 
100 nM 
 
2.2.5.2 Transient overexpression  
 MDAMB231 cells were transfected with either a pHM6 control or HA-tagged 
TPD52 vector.  The derivation of these expression vectors has been described 
previously (Thomas et al., 2010).  Parental cells, and cells treated with the transfection 
reagent only, were included as additional controls.  Cells were seeded at pre-optimised 
numbers onto glass coverslips, for in situ staining, and into 24-well plates, for Western 
blot analyses.  Transfections were performed 24 hours after seeding, using the 
TransIT-X2 dynamic delivery system (Mirus Bio) at a ratio of 1:4 (DNA:reagent), 
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according to the manufacturer’s instructions.  Media were replaced 24 hours after 
transfection.  At 72 hours after transfection, cells were either prepared for in situ 
staining (section 2.2.4) or harvested for the corresponding Western blot analyses 
(section 2.2.3). 
 
2.2.6 Yeast two-hybrid system  
2.2.6.1 Derivation of bait and prey constructs 
 Plasmids encoding bait (pAS2.1) TPD52 and prey (pACT2) TPD52 or 
TPD52L1 have been described previously (Byrne et al., 1998b).  Bait constructs 
encoding human TIP47 (Genbank NM_005817.4) and ADRP (Genbank 
NM_001122.3) were generated by subcloning the respective EcoRI–XhoI fragments 
from pVP16-TIP47 and pVP16-ADRP, which were kind gifts from Paul D. Bieniasz 
(The Rockefeller University, New York, NY) (Eastman et al., 2009), into the EcoRI 
and SalI sites of pAS2.1 (Kamili et al., 2015).  Sanger sequencing confirmed that the 
pAS2.1-TIP47 construct encodes full-length TIP47 (434 amino acids), whereas 
pAS2.1-ADRP encodes ADRP residues 1–415 (of 437 residues) due to a C>T 
mutation at nucleotide 1456 (NM_001122.3) that produces a stop codon (Kamili et al., 
2015). 
 
2.2.6.2 Transformation of competent yeast cells 
We used the Saccharomyces cerevisiae strain Hf7c (MATa, ura3-52, his3-200, 
ade2-101, lys2-801, trp1-901, leu2-3, 112, gal4-542, gal80-538, LYS2::GAL1UAS-
GAL1TATA-HIS3, URA3::GAL417-mers(x3)-CYC1TATA-lacZ) (Feilotter et al., 1994).  
Aseptic technique was maintained during all yeast manipulations.  An overnight 
culture containing 50 mL of YPD was inoculated with several yeast colonies and 
incubated at 30°C for 18-21 hours with orbital shaking at 250 rpm.  This culture was 
then transferred into 300 mL of YPD and incubated for a further 3 hours with shaking 
at 230 rpm.  A cell pellet was obtained by centrifugation at 2500 rpm for 5 minutes at 
room temperature and washed with 25 mL of autoclaved water.  The yeast cells were 
then resuspended in 1.5 mL of sterile TE/LiAc and stored on ice during 
transformation.  400 ng of bait DNA (pAS2.1 constructs) and 200 ng of prey DNA 
(pACT2 constructs) were combined with 100 µg of salmon sperm carrier DNA and 
kept on ice.  100 µL of competent yeast cells and 600 µL of sterile PEG/LiAc solution 
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were added and the tubes incubated at 30°C for 30 minutes with shaking at 200 rpm.  
70 µL of DMSO was added and the yeast cells subjected to heat-shock at 42°C for 15 
minutes.  The cells were then immediately chilled on ice and centrifuged at 13,000 rpm 
for 5 seconds.  The resultant pellet was resuspended in 100 µL of sterile TE and plated 
onto solid synthetic drop-out (SD) medium lacking leucine and tryptophan (SD/-L-W).  
These plates were incubated at 30°C for 3 to 5 days to allow for the growth of 
cotransformants. 
 
2.2.6.3 Interaction testing 
For interaction testing, cotransformant yeast colonies were streaked onto solid 
SD medium lacking leucine, tryptophan, and histidine (SD/-H-L-W).  Growth at 30°C 
was assessed in triplicate for at least 7 days, with bait-prey interactions scored 
according to the time taken for colony growth to be visible.  Bait or prey constructs 
that were paired with the opposing empty vectors served as negative controls, to 
ensure that the constructs did not autoactivate the HIS3 reporter gene.  The established 
interaction between TPD52 bait and TPD52L1 prey (Byrne et al., 1998b) was used as 
a positive control. 
 
2.2.7 Pull-down assays  
2.2.7.1 Production of fusion proteins 
Pulldown assays employed GST-tagged recombinant mouse Tpd52 expressed 
from pGEX3X (Byrne et al., 1998; Sathasivam et al., 2001), and GST-tagged 
recombinant human TPD52 expressed from pGEX6P-1 (Chen et al., 2013; 
Shahheydari et al., 2014).  Mouse or human TPD52 fusion proteins, and their 
respective controls, were produced in log-phase cultures of the E. coli strain BL21 
following induction with 100 µM IPTG for 3 hours at 29°C.  Bacterial cultures were 
lysed by the addition of lysis buffer (20 mM Tris-HCl pH 7.4, 250 mM NaCl, 1 
mg/mL lysozyme, 1 mM PMSF, 20 µg/mL leu-peptin, 5 µg/mL DNase I, 1% Triton 
X-100) and the recombinant proteins then bound to GSH beads (glutathione sepharose 
4B).  The sizes of the purified proteins in pre- and post-induction samples were 
verified by SDS-PAGE (section 2.2.3.2), with Coomassie Brilliant Blue staining. 
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2.2.7.2 Cross-linking of GST-fusion proteins to GSH beads 
 Since GST-tagged TPD52 has a molecular mass similar to adipophilin 
(approximately 50 kDa), the GST-fusion proteins were cross-linked to the GSH beads 
prior to performing the pull-down assay.  First, the GST-fusion protein beads were 
transferred to BioSpin columns (Bio-Rad), centrifuged at 500 x g for 5 minutes at 4°C, 
and washed four times with 0.2 M TEA.  The beads were then resuspended in 500 µL 
TEA supplemented with 30 mM dimethyl pimelimidate-2-HCl, followed by incubation 
with rotation for 1 hour at room temperature.  Next, 2 mL of quenching buffer (1 M 
Tris-HCl pH 8.2) was added, the columns rotated for 10 minutes, and then centrifuged 
at 500 x g for 5 minutes.  The columns were then washed four times with pull-down 
wash buffer 1 (150 mM NaCl, 20 mM Tris-HCl pH 7.4), supplemented with 50 mM 
reduced glutathione, followed by the addition of ice-cold wash buffer 1.  The columns 
were washed twice with ice-cold cross-linking wash buffer (1.5 M NaCl, 25 mM Tris-
HCl pH 7.6), and then twice with ice-cold pull-down wash buffer 1.  Beads storage 
buffer (20 mM Tris-HCl pH 7.4, 50% glycerol) was used for storage. 
 
2.2.7.3 GST pull-down  
TPD52-expressing 3T3 cells were lysed by the addition of lysis buffer (150 
mM NaCl, 1 mM EDTA, 10 mM Tris-HCl pH 7.5, 0.1% deoxycholate, 1% Triton X-
100) (Lopez-Verges et al., 2006).  These cell lysates were pre-cleared three times with 
washed GSH beads and then incubated with 150 µL of the cross-linked mouse or 
human TPD52 fusion proteins, and their respective controls, for 1 hour with rotation at 
4°C.  This was followed by centrifugation at 500 x g for 5 minutes at 4°C.  The bead 
pellets were transferred to pre-chilled MicroSpin columns (Bio-Rad) and washed six 
times with pull-down wash buffer 1, and then 3 three times with pull-down wash 
buffer 2 (25 mM Tris-HCl pH 7.4).  The bound proteins were eluted in 20 µL of 
sample loading buffer for 5 minutes at 85°C and then analysed by SDS-PAGE and 
Western blot (section 2.2.3.2-4). 
 
 
 
 
	66 
2.2.8 Bioinformatic analyses 
 Bioinformatic analyses were conducted in collaboration with Dr Erdahl Teber 
at the Children’s Medical Research Institute (Westmead, NSW, Australia), using R 
software.  The following files were downloaded from the Cancer Cell Line 
Encylopedia (CCLE), which was accessed via the online portal 
(https://portals.broadinstitute.org/ccle) established by the Broad Institute and Novartis, 
and the Cancer Therapeutics Response Portal (CTRP), which was accessed via the 
Cancer Target Discovery and Development (CTD2) Network 
(https://ocg.cancer.gov/programs/ctd2/data-portal) established by the National Cancer 
Institute’s Office of Cancer Genomics: 
§ CCLE_copynumber_byGene_2012-09-29.txt (Affymetrix SNP6.0 arrays) 
§ CCLE_Expression_Entrez_2012-09-29.gct (Affymetrix U133+2 arrays) 
§ CCLE_NP24.2009_Drug_data_2012.02.20.csv 
§ CTRPv1.0_2013_pub_Cell_154_1151.zip 
 
2.2.9 Drug treatment of cultured cells 
2.2.9.1 96-well plate set-up for dose-response curves 
Drug treatments were set up identically, regardless of the drug to be tested 
(Figure 2.1).  Cells were seeded at pre-optimised numbers into 96-well plates (one 
plate per cell line), omitting one column to allow for the measurement of background 
media fluorescence during the Alamar Blue assay.  Each experiment included six 
technical replicates per treatment group.  No data were collected from the outside 
border of wells to avoid edge-effects.     
 
2.2.9.2 Drug treatments for dose-response curves 
For HMC18 and MDAMB231, drug treatments were begun 24 hours after 
seeding, while for AU565 and SKBR3, 48 hours were required for adhesion and 
expected morphology to be present.  Cells were cultured in the appropriate growth 
media, supplemented either with drug (at seven serially-diluted concentrations) or 
DMSO (vehicle control).  Cells with no treatment were included as an additional 
control (parental control).  For lapatinib, the concentrations were: 15 µM, 3 µM, 0.6 
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Figure 2.1. 96-well plate set-up for dose-response curves.  Shading indicates the 
presence of cells. 
 
µM, 120 nM, 24 nM, 4.8 nM, and 0.96 nM.  DMSO content in these treatments was 
kept constant at 0.15% by supplementation and 0.15% DMSO was used for the vehicle 
control.  For fatostatin, the concentrations were: 150 µM, 37.5 µM, 9.38 µM, 2.34 µM, 
0.59 µM, 0.15 µM, and 37 nM.  DMSO content in these treatments was kept constant 
at 0.3% by supplementation and 0.3% DMSO was used for the vehicle-control.  
During optimisation, it was determined that fatostatin was best replaced daily to ensure 
its continued activity.  For BFA, the concentrations were 10 µM, 2 µM, 0.4 µM, 80 
nM, 16 nM, 3.2 nM, and 0.64 nM.  DMSO content in these treatments was kept 
constant at 0.03% by supplementation and 0.03% DMSO was used for the vehicle-
control.  After 72 hours of treatment, cells were subjected to the Alamar Blue assay to 
determine cell viability, relative to vehicle-treated cells (section 2.2.9.5).   
 
2.2.9.3 96-well plate set-up for proliferation curves 
Cells were seeded at pre-optimised numbers into 96-well plates.  Multiple cell 
lines were seeded into the same plate, with one to two plates required for each of the 5 
days after drug treatment, plus another one to two plates for the baseline reading on the 
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day of drug treatment (Figure 2.2).  Each experiment included six technical replicates 
per treatment group.  As for the dose-response set-up, several wells were omitted to 
allow for the measurement of background media fluorescence and no data were 
collected from the outside border of wells to avoid edge-effects. 
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Figure 2.2. 96-well plate set-up for proliferation curves.  Shading indicates the 
presence of cells.  An additional plate per day was required for fatostatin since three 
different drug dosages were tested, instead of the single dosage for BFA shown above. 
 
2.2.9.4 Drug treatments for proliferation curves 
For HMC18 and MDAMB231, drug treatments were begun 24 hours after 
seeding, while for AU565 and SKBR3, 48 hours were required for adhesion and 
expected morphology to be present.  Cells were cultured in the appropriate growth 
media, supplemented either with drug (10, 20, or 40 µM fatostatin, or 50 nM BFA) or 
DMSO (vehicle control).  For fatostatin, DMSO content was kept constant at 0.08% by 
supplementation and 0.08% DMSO was used for the vehicle control.  For BFA, 0.01% 
DMSO was used for the vehicle control.  On the day of drug treatment and on each of 
the subsequent 5 days, cells were subjected to the Alamar Blue assay to determine cell 
viability, relative to vehicle-treated cells (section 2.2.9.5). 
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2.2.9.5 Alamar Blue assay 
 The Alamar Blue reagent was first removed from storage at 4°C and allowed to 
equilibrate to room temperature. To begin the assay, 11 µL of Alamar Blue reagent 
was added to each well, for a final concentration of 10% when mixed with the existing 
media.  Plates were gently rocked back and forth to distribute the reagent and then 
returned to the 37°C incubator.  After 4 hours, the fluorescence was read on an enSpire 
plate reader (Perkin Elmer), using an excitation wavelength of 535 nm and an emission 
wavelength of 587 nm. 
 
2.2.9.6 Data analysis 
Data analysis was conducted using Excel (Microsoft).  For each treatment 
group, the mean of six technical replicates was calculated.  All readings were then 
normalised by subtracting the mean background fluorescence of the media-only wells 
(Figure 2.1 and 2.2).  The relative viabilities of all drug-treated cells were then 
calculated as a percentage of the corresponding vehicle-treated cells.  GraphPad Prism 
(version 7) was used to interpolate dose-response curves and calculate the IC50 for the 
drugs in each of the cell lines. 
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Chapter 3 
 
Characterising TPD52 amplification 
in cancer cell lines.  
 
 
3.1 Introduction  
 TPD52 is an oncogene whose overexpression has been demonstrated in 
tumours of diverse cellular origins.  These include breast, prostate, lung, ovarian, and 
haematological cancers, as well as melanoma, and the paediatric cancers, 
osteosarcoma and Ewing sarcoma (section 1.3.2; reviewed in Shehata et al., 2008a; 
Byrne et al., 2014).  TPD52 overexpression has been predominantly studied in breast 
and prostate cancer, where it has been persistently associated with poorer outcomes 
(Shehata et al., 2008b; Nakagawa et al., 2008; Ross et al., 2011; Roslan et al., 2014).  
Further evidence for the oncogenicity of TPD52, when expressed at levels beyond 
those in normal tissues, has been garnered from cell line models.  In mouse fibroblast 
cells, the stable exogenous expression of mouse or human TPD52 produced 
transformed phenotypes and increased the capacity for proliferation and anchorage-
independent growth (Lewis et al., 2007; Shehata et al., 2008b).  Furthermore, Tpd52-
overexpressing fibroblast cells that were transplanted into syngenic Balb/c hosts 
demonstrated an ability to form both subcutaneous tumours and distant lung 
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metastases (Lewis et al., 2007).  In human prostate cancer cell lines, increasing the 
expression of TPD52 (or the prostate-specific isoform PrLZ) resulted in enhanced 
proliferation, clonogenic growth, and invasiveness (Ummanni et al., 2008; Zhang et 
al., 2007; Zhang et al., 2011; Li et al., 2009; Li et al., 2013b).  Taken together, 
evidence from both tumour samples and cell line models support a role for TPD52 
overexpression in tumour initiation and/or progression. 
 The TPD52 gene is located on the frequently gained chromosome band 8q21, 
where we propose that it is an important amplification target.  For a gene to qualify as 
a cancer amplification target, its oncogenic overexpression must be derived, at least in 
some cases, from the increased copy number of a restricted genomic region that 
includes the gene locus (Santarius et al., 2010).  TPD52 overexpression in association 
with gain of the corresponding locus at 8q21.13 has been demonstrated in breast, 
prostate, and ovarian cancers (Balleine et al., 2000; Rubin et al., 2004; Wang et al., 
2004; Byrne et al., 2005).  A comprehensive review found 13 studies reporting 
genomic gains that were largely restricted to chromosome 8q21.13, with TPD52 
identified as being in one of two minimal regions of overlap for the amplicons reported 
by each of these studies (Figure 1.10; Byrne et al., 2012).  TPD52 was subsequently 
reported as being focally amplified, along with five neighbouring chromosome 
8q21.13 genes, on an amplicon found in breast cancer samples (Cancer Genome Atlas 
Network, 2012) and again on a similar amplicon found across 11 different cancer 
lineages (Zack et al., 2013).  Furthermore, TPD52 was highlighted as a potential driver 
gene in breast cancer that was highly associated with regeneration, based on 
integrative analyses of copy number and expression networks (Aure et al., 2013).  
 The chromosome 8q arm is also the location of the well-established oncogene 
and amplification target MYC.  Gene amplification and subsequent overexpression of 
MYC has been demonstrated in breast, colorectal, gastric, lung, and prostate cancers as 
well as in medulloblastoma (reviewed in Santarius et al., 2010).  It is therefore likely 
that MYC is a driver gene for the gain of chromosome 8q, or portions thereof, in at 
least some cancers.  However, TPD52 and MYC are located on distinct chromosomal 
bands (8q21 and 8q24, respectively) and while it is apparent that these chromosomal 
regions can be gained together, they can also be gained separately (Kallioniemi et al., 
1994; Cher et al., 1994; Kallioniemi et al., 1995; Zhu et al., 2007; Rodriguez et al., 
2007; Choschzick et al., 2010).  To date, limited data exist concerning the nature of 
TPD52 and MYC co-amplification across multiple cancer types, and whether this is 
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driven primarily by gain of the whole chromosome 8q arm or by focal targeting of 
these two genes within separate amplicons.  The current study will help to answer this 
unresolved question. 
Finally, TPD52 has been repeatedly reported as being co-expressed in breast 
cancer with another well-established oncogene and amplification target ERBB2.  The 
TPD52 gene was originally identified from an ERBB2-expressing breast tumour and 
TPD52 transcript levels were later shown to be increased in ERBB2-positive breast 
cancer cell lines (Byrne et al., 1995; Wilson et al., 2002).  Tpd52 transcript and/or 
proteins levels were also found to be increased in the mammary tissues of Erbb2 
transgenic animals (Chen et al., 2010; Landis et al. 2005; Landis et al., 2006; 
Whiteaker et al., 2007).  A meta-analysis of 22 expression studies identified increased 
TPD52 levels in ERBB2-positive breast tumours and cancer cell lines (Kourtidis et al., 
2010).  More recently, TPD52 was shown to be a survival factor in ERBB2-amplified 
breast cancer cell lines (Roslan et al., 2014).  We hypothesised that TPD52 and ERBB2 
co-overexpression might, in at least some cases, result from co-amplification of these 
two genes.  Chromosome 8q21 amplification, as determined by a FISH probe located 6 
Mb proximal to TPD52, has been shown to be significantly associated with ERBB2 
amplification in breast cancer (Choschzick et al., 2010).  However, the literature 
surrounding TPD52 and ERBB2 co-amplification is otherwise limited.  The current 
study will explore TPD52 and ERBB2 co-amplification in cancer cell lines, including 
those derived from tumour types beyond breast cancer. 
  
3.1.1 Aims of this chapter 
The specific aims of this chapter were as follows: 
1. To determine the frequency and magnitude of TPD52 amplification in 995 cell 
lines from diverse cancer types, using data from the Cancer Cell Line 
Encylopedia 
2. To determine the degree to which TPD52 was co-amplified with the 
oncogenes, MYC and/or ERBB2, in these 995 cell lines 
3. To assemble a cohort of TPD52-amplified cell lines, with and without MYC- 
and/or ERBB2-amplification, from a range of different cancer types  
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3.2 Results 
3.2.1 TPD52 amplification in cancer cell lines 
 We first sought to determine the frequency of TPD52 amplification across a 
range of cancer types by analysing existing gene copy number data from the Cancer 
Cell Line Encylopedia (CCLE) (Barretina et al., 2012).  At the time of analysis, this 
publicly-accessible resource held genome-wide copy number data for 995 cancer cell 
lines, from 24 different tumour types.  We defined as amplified genes that had log2 
copy number ratios greater than or equal to 0.848.  This threshold is approximately 
equivalent to a 1.8-fold increase in copy number and has been previously reported to 
selectively exclude copy number gains spanning an entire chromosomal arm (Weir et 
al., 2007; Mermel et al., 2011).  TPD52 was found to be amplified in 4.0% (40/995) of 
all cancer cell lines, compared to 15.6% (155/995) for MYC and 4.4% (44/995) for 
ERBB2 (Table 3.2.1).   
TPD52 amplifications were most frequent in breast and prostate cancer cell 
lines, at 22% (13/59) and 25% (2/8) respectively (Table 3.2.1).  TPD52 amplification 
also occurred at lower frequencies in 12 of the remaining 22 tumour types, including 
cell lines derived from cancers of the biliary tract, bone, central nervous system, 
endometrium, haematopoietic and lymphoid tissue, kidney, large intestine, lung, 
oesophagus, pleura, stomach, and thyroid (Table 3.2.1).  By comparison, MYC 
amplification was present in 19 of the 24 tumour types and occurred at frequencies of 
25% or greater in cell lines derived from biliary tract, breast, oesophagus, pleura, 
prostate, stomach, and thyroid cancers (Table 3.2.1).  ERBB2 amplification was 
restricted to 11 of the 24 tumour types and occurred most frequently in breast and 
oesophageal cancer cell lines, at 25% (15/59) and 23% (6/26) respectively (Table 
3.2.1). 
We then investigated the magnitude of TPD52 copy number change in those 
cell lines that were found to be TPD52-amplified.  TPD52 log2 copy number ratios in 
these cell lines ranged from 0.848 to 2.471, which is approximately equivalent to a 
1.8- to 5.5-fold increase in copy number (Figure 3.2.1).  The top five cell lines 
according to TPD52 log2 copy number ratio were the breast cancer cell lines SKBR3 
(2.471), EFM192A (2.446), and AU565 (2.382), the thyroid cancer cell line BHT101 
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Table 3.2.1 Frequency of TPD52, MYC and ERBB2 amplification in the Cancer 
Cell Line Encyclopedia (CCLE).  The number of cell lines harbouring amplification 
at TPD52, MYC or ERBB2 are shown, with their frequencies indicated as percentages.  
Copy number data were accessed for 995 cancer cell lines, from 24 different tumour 
types, and genes were defined as amplified if their log2 copy number ratios were 
greater than or equal to 0.848. 
Tumour type 
Number (percentage) of cell lines  
with gene amplification 
TPD52 MYC ERBB2 
Upper aerodigestive tract (n=31) 0 (0%) 1 (3%) 3 (10%) 
Autonomic ganglia (n=17) 0 (0%) 0 (0%) 1 (6%) 
Biliary tract (n=7) 1 (14%) 2 (29%) 0 (0%) 
Bone (n=28) 2 (7%) 5 (18%) 0 (0%) 
Breast (n=59) 13 (22%) 25 (42%) 15 (25%) 
Central nervous system (n=55) 1 (2%) 4 (7%) 0 (0%) 
Endometrium (n=28) 1 (4%) 4 (14%) 2 (7%) 
Haematopoietic and lymphoid tissue 
(n=178) 5 (3%) 17 (10%) 0 (0%) 
Kidney (n=33) 1 (3%) 0 (0%) 0 (0%) 
Large intestine (n=58) 1 (2%) 7 (12%) 1 (2%) 
Liver (n=27) 0 (0%) 1 (4%) 1 (4%) 
Lung (n=177) 7 (4%) 40 (23%) 6 (3%) 
Oesophagus (n=26) 1 (4%) 8 (31%) 6 (23%) 
Ovary (n=51) 0 (0%) 10 (20%) 2 (4%) 
Pancreas (n=44) 0 (0%) 6 (14%) 2 (5%) 
Pleura (n=10) 1 (10%) 4 (40%) 0 (0%) 
Prostate (n=8) 2 (25%) 3 (37.5%) 0 (0%) 
Salivary gland (n=2) 0 (0%) 0 (0%) 0 (0%) 
Skin (n=61) 0 (0%) 1 (2%) 0 (0%) 
Small intestine (n=1) 0 (0%) 0 (0%) 0 (0%) 
Soft tissue (n=20) 0 (0%) 0 (0%) 0 (0%) 
Stomach (n=38) 3 (8%) 13 (34%) 5 (13%) 
Thyroid (n=12) 1 (8%) 3 (25%) 0 (0%) 
Urinary tract (n=24) 0 (0%) 1 (4%) 0 (0%) 
TOTAL (n=995) 40 (4.0%) 155 (15.6%) 44 (4.4%) 
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(2.015), and the lung cancer cell line HCC827 (1.719).  By comparison, log2 copy 
number ratios for MYC in cell lines defined as MYC-amplified ranged from 0.860 to 
3.592, which is approximately equivalent to a 1.8- to 12-fold increase in copy number, 
and log2 copy number ratios for ERBB2 in cell lines defined as ERBB2-amplified 
ranged from 0.852 to 5.355, which is approximately equivalent to a 1.8- to 41-fold 
increase in copy number (Figure 3.2.1).  The median log2 copy number ratio was 
higher for MYC-amplified cell lines (1.245, approximately equivalent to a 2.4-fold 
increase in copy number) when compared to TPD52-amplified cell lines (1.040, 
approximately equivalent to a 2-fold increase in copy number), which was statistically 
significant as determined by the Mann-Whitney u test (p = 0.0004, n = 195) (Figure 
3.2.1).  The median log2 copy number ratio was higher again for ERBB2-amplified cell 
lines (2.368, approximately equivalent to a 5.2-fold increase in copy number), which 
was significantly different to both TPD52-amplified cell lines (p < 0.0001, n = 84) and 
MYC-amplified cell lines (p = 0.0001, n = 199) (Figure 3.2.1). 
Next, we explored TPD52 amplification in the context of neighbouring genes 
on the chromosome 8q arm.  Since both arm-level and focal gain of chromosome 8q 
genes have been reported in cancer (section 1.3.3), we sought to further understand the 
landscape of chromosome 8q copy number changes in CCLE cell lines.  We therefore 
generated plots showing the overall frequency of amplification at the first 400 genes 
on chromosome 8q by first re-coding their log2 copy number ratios to binary data, 
with ‘0’ representing no amplification and ‘1’ representing amplification (i.e. log2 
copy number ratios ³ 0.848), and then summing the data at each gene for all 995 
cancer cell lines (Figure 3.2.2A).  The selected chromosome 8q region encompasses 
approximately 97 Mb, from KIAA0146 (48.3 Mb) to SPATC1 (145.2 Mb), and 
includes TPD52 (81.1 Mb) and MYC (128.8 Mb).  For comparison, we generated a 
similar plot for the first 400 genes on chromosome 17q (Figure 3.2.2B).  This region 
encompasses approximately 18 Mb, from LGALS9 (23.0 Mb) to IMP5 (41.3 Mb), and 
includes ERBB2 (35.1 Mb).  All genomic coordinates provided are measured from the 
chromosome p terminus, according to the hg18 assembly, since this was the version 
used by the CCLE. 
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Figure 3.2.1. Magnitude of TPD52, MYC and ERBB2 amplification in the Cancer 
Cell Line Encyclopedia (CCLE).  The graph compares the distribution of log2 copy 
number ratio (y-axis) in cell lines harbouring amplification of TPD52 (pink circle), 
MYC (orange square) or ERBB2 (purple triangle) (x-axis).  Genes were defined as 
amplified if their log2 copy number ratios were greater than or equal to 0.848.  The 
horizontal bars represent the median log2 copy number ratios for each gene, which 
were 1.040, 1.245, and 2.368 for TPD52, MYC, and ERBB2, respectively.  Mann-
Whitney u test: *** p £ 0.001, **** p £ 0.0001. 
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Figure 3.2.2. Frequency of amplification for genes neighbouring TPD52, MYC 
and ERBB2 in the Cancer Cell Line Encyclopedia (CCLE).  The plots show the 
frequency of amplification (y-axis) across 995 cancer cell lines for (A) 400 adjacent 
genes on chromosome 8q, from KIAA0146 (gene 1, 48.3 Mb) to SPATC1 (gene 400, 
145.2 Mb), and (B) 400 adjacent genes on chromosome 17q, from LGALS9 (gene 1, 
23.0 Mb) to IMP5 (gene 400, 41.3 Mb).  Genes are presented on the x-axis, from left 
to right, in the order that they occur on the relevant chromosome.  CPA6 (gene 79, 
68.5 Mb), TPD52 (gene 117, 81.1 Mb), RALYL (gene 131, 85.3 Mb), MYC (gene 304, 
128.8 Mb), and ERBB2 (gene 196, 35.1 Mb) are indicated by arrows.  Genomic 
locations are from p terminus, according to the hg18 assembly.  
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Genes that are more frequently amplified amongst the CCLE cell lines emerge 
as peaks on the cumulative plots (Figure 3.2.2).  The chromosome 8q plot confirms 
MYC as the primary amplification target on this chromosome, with an overall 
amplification frequency of 155, which is unsurprising given its status as a well-known 
oncogene.  TPD52 is a much smaller peak, both in terms of its overall frequency of 
amplification (40) as well as its height above neighbouring genes.  The latter suggests 
that, in at least some cell lines, TPD52 is gained as part of an amplicon that comprises 
nearby genes and that some of these neighbouring genes may also be targeted by 
amplification events.  Additionally, the presence of two sharp peaks on either side of 
TPD52 indicates that there are other genes in this region that have higher overall 
amplification frequencies than TPD52. These peaks represent CPA6 (carboxypeptidase 
A6), which is located at 8q13.2, 12.6 Mb before TPD52, and has an overall 
amplification frequency of 46, and RALYL (RALY RNA binding protein-like), which is 
located at 8q21.2, 4.2 Mb after TPD52, and has an overall amplification frequency of 
56.  By comparison, ERBB2 emerges as a clear peak on chromosome 17q, despite 
having a similar overall frequency of amplification (44) as TPD52.  
 
3.2.2 TPD52 co-amplification with MYC in cancer cell lines  
We next examined the co-amplification of TPD52 and MYC in both cancer cell 
lines and breast tumour samples.  TPD52 and MYC co-amplification occurred in 3.2% 
(32/995) of the cell lines within the CCLE (Figure 3.2.3A and B).  We found that 80% 
(32/40) of TPD52-amplified cell lines were co-amplified for MYC, while TPD52 was 
co-amplified in 20.65% (32/155) of MYC-amplified cell lines (Figure 3.2.3A and B).  
The association between TPD52 and MYC amplification was found to be highly 
statistically significant using Fisher’s exact test (p < 0.0001, n = 995).  Since breast 
was the tumour type with the highest number of TPD52-amplified cell lines (Table 
3.2.1) and the highest proportion (12/32) of TPD52 and MYC co-amplified cell lines 
(Table 3.2.2), we then investigated the frequency of TPD52 and MYC co-amplification 
amongst breast cancer cell lines specifically.  Co-amplification occurred in 20.34% 
(12/59) of the breast cancer cell lines within the CCLE (data not shown).  TPD52 and 
MYC amplification were significantly associated, with 92.31% (12/13) of TPD52-
amplified cell lines co-amplified for MYC, and 48% (12/25) of MYC-amplified cell 
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Figure 3.2.3. Co-amplification of TPD52 and MYC and/or ERBB2 in cell lines 
from the Cancer Cell Line Encyclopedia (CCLE).  The number of cancer cell lines 
that are amplified at TPD52, MYC and/or ERBB2 are shown by (A) Venn diagram and 
(B, C) cross-tabulations.  Fisher’s exact test showed statistically significant 
associations between (B) TPD52 and MYC amplification (p < 0.0001, n = 995) and (C) 
TPD52 and ERBB2 amplification (p = 0.0002, n = 995).    
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Table 3.2.2. TPD52 and MYC co-amplification in the Cancer Cell Line 
Encyclopedia (CCLE).  The 32 cell lines with co-amplification of TPD52 and MYC 
are ranked according to their TPD52 log2 copy number ratio.  TPD52 and MYC gene 
amplifications were deemed to be independent (i.e. occurring on separate amplicons) if 
any of the genes in the chromosomal region between them were non-amplified (i.e. 
log2 copy number ratio < 0.848).  Abbreviations: H&L, haematopoietic and lymphoid 
tissue; CNS, central nervous system. 
Cell line Tumour type TPD52  log2 ratio 
MYC  
log2 ratio 
Independent 
amplification?  
SKBR3 Breast 2.471 2.470 Yes 
EFM192A Breast 2.446 2.235 Yes 
AU565 Breast 2.382 2.280 Yes 
BHT101 Thyroid 2.015 2.414 Yes 
HCC827 Lung 1.719 1.688 Yes 
EVSAT Breast 1.622 1.446 Yes 
HCC1428 Breast 1.390 1.354 No 
SKMM2 H&L 1.287 1.223 Yes 
HCC38 Breast 1.280 0.867 Yes 
D283MED CNS 1.226 1.491 No 
BV173 H&L 1.223 1.201 No 
KG1 H&L 1.208 1.177 No 
TE4 Oesophagus 1.184 1.080 Yes 
LU99 Lung 1.147 1.082 No 
NCIH660 Prostate 1.140 1.086 No 
LMSU Stomach 1.103 1.430 Yes 
NCIH2052 Pleura 1.068 1.039 Yes 
HCC2157 Breast 1.060 1.503 No 
KE39 Stomach 1.036 1.136 Yes 
MOLM13 H&L 0.993 0.993 No 
JHUEM3 Endometrium 0.991 1.166 Yes 
HCC2218 Breast 0.972 0.959 No 
PC3 Prostate 0.965 0.953 Yes 
SKNMC Bone 0.944 0.982 No 
CADOES1 Bone 0.919 0.901 No 
SNU668 Stomach 0.901 1.022 Yes 
HS578T Breast 0.883 0.894 No 
BT483 Breast 0.874 0.907 No 
SNU1196 Biliary tract 0.871 0.871 No 
HCC1954 Breast 0.868 0.906 Yes 
HCC1569 Breast 0.849 1.387 No 
NCIH1437 Lung 0.848 0.948 No 
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lines co-amplified for TPD52 (Fisher’s exact test, p < 0.0001, n = 59).  Finally, to 
ascertain whether similar co-amplification frequencies would be observed in breast 
tumour samples, we examined the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) cohort (Pereira et al., 2016). TPD52 and MYC co-
amplification occurred in 16% (347/2173) of the tumour samples (Figure 3.2.4A and 
B).  Once again, the amplification of these genes was significantly associated, with 
86.53% (347/401) of TPD52-amplified tumours co-amplified for MYC, and 62.64% 
(347/554) of MYC-amplified tumours co-amplified for TPD52 (Fisher’s exact test, p < 
0.0001, n = 2173).   
We had anticipated that low level gain of the whole chromosome 8q arm would 
underpin a proportion of TPD52 and MYC co-amplification and endeavoured to 
exclude such cell lines by selecting a high amplitude threshold (i.e. log2 copy number 
ratios ³ 0.848) (Weir et al., 2007; Mermel et al., 2011).  However, this does not 
preclude cell lines with high level gain of the chromosome 8q arm and, although such 
events are expected to be rare, our approach does not allow us to distinguish between 
this and the occurrence of multiple focal amplifications along the chromosome.  
Therefore, to view MYC co-amplification with TPD52 in context, we generated a plot 
showing the overall frequency of amplifications at the first 400 genes on chromosome 
8q for all TPD52 and MYC co-amplified cancer cell lines (n = 32) (Figure 3.2.5).  The 
peaks on this plot confirm TPD52 (with the two following genes ZBTB10 and 
ZNF704) and MYC (with the two preceding genes LOC727677 and POU5F1B) as the 
most frequently amplified genes in these cell lines.  It is also worth mentioning that the 
two sharp peaks seen on either side of TPD52 in the plot for the overall amplification 
frequency of chromosome 8q genes in all 995 cell lines (Figure 3.2.2A) are no longer 
prominent when focusing on TPD52 and MYC co-amplified cell lines (Figure 3.2.5).  
This suggests that they are not relevant to TPD52 amplification and were therefore not 
studied further. 
Importantly, the plot revealed that the frequency of amplification was not 
uniform across the region between TPD52 and MYC.  This indicates that, in at least 
some of these cell lines, TPD52 and MYC were not co-amplified simply through gain 
of the whole chromosome arm.  There was, however, a significant positive correlation 
between the log2 copy number ratios for TPD52 and MYC in these co-amplified cell 
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Figure 3.2.4 Co-amplification of TPD52 and MYC and/or ERBB2 in tumour 
samples from the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC).  The number of samples that are amplified at TPD52, 
MYC and/or ERBB2 are shown by (A) Venn diagram and (B, C) cross-tabulations.  
Fisher’s exact test showed statistically significant associations between (B) TPD52 and 
MYC amplification (p < 0.0001, n = 2173) and (C) TPD52 and ERBB2 amplification  
(p < 0.0001, n = 2173).    
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Figure 3.2.5. Frequency of amplification for chromosome 8q genes in TPD52 and 
MYC co-amplified cancer cell lines from the Cancer Cell Line Encyclopedia 
(CCLE).  The plot shows the frequency of amplification across 32 TPD52 and MYC 
co-amplified cancer cell lines for 400 adjacent genes on chromosome 8q, from 
KIAA0146 (gene 1 at 48.3 Mb) to SPATC1 (gene 400 at 145.2 Mb).  Genes are 
presented on the x-axis, from left to right, in the order that they occur on the 
chromosome.  CPA6 (gene 79 at 68.5 Mb), TPD52 (gene 117 at 81.1 Mb), RALYL 
(gene 131 at 85.3 Mb), and MYC (gene 304 at 128.8 Mb) are indicated by arrows.  
Genomic locations are from p terminus, according to the hg18 assembly. 
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lines (Spearman’s test, rs = 0.7357, p < 0.0001, n = 32) (Figure 3.2.6).  We then 
generated individual chromosome 8q copy number plots for each of the 32 cell lines 
that had TPD52 and MYC co-amplification (Figure 3.2.7 and data not shown) and 
found that 50% (16/32) of these cell lines had independent amplification of TPD52 and 
MYC (Table 3.2.2).  The amplifications were deemed to be independent if any of the 
genes located in the 48 Mb chromosomal region between TPD52 and MYC were non-
amplified (i.e. had log2 copy number ratios < 0.848), indicating that TPD52 and MYC 
were on separate amplicons.  
 
3.2.3 TPD52 co-amplification with ERBB2 in cancer cell lines  
Our analyses also revealed recurrent co-amplification of TPD52 and ERBB2 in 
both cancer cell lines and breast tumour samples, albeit less frequently than TPD52 
and MYC co-amplification.  TPD52 and ERBB2 co-amplification occurred in 0.8% 
(8/995) of the cell lines within the CCLE (Figure 3.2.3A and C).  We found that 20% 
(8/40) of TPD52-amplified cell lines were co-amplified for ERBB2, while TPD52 was 
co-amplified in 18.18% (8/44) of ERBB2-amplified cell lines (Figure 3.2.3A and C).  
The association between TPD52 and ERBB2 amplification was found to be statistically 
significant using Fisher’s exact test (p = 0.0002, n = 995).  We were also interested to 
discover that ERBB2 co-amplification with TPD52 within cancer cell lines only 
occurred in combination with MYC co-amplification (Figure 3.2.3A).  Breast was 
again the tumour type with the highest proportion (6/8 or 75%) of TPD52 and ERBB2 
co-amplified cell lines (Table 3.2.3).  We therefore investigated the frequency of 
TPD52 and ERBB2 co-amplification amongst breast cancer cell lines specifically, 
finding that co-amplification occurred in 10.17% (6/59) of the breast cancer cell lines 
within the CCLE (data not shown).  The association between TPD52 and ERBB2 
amplification was not statistically significantly associated, with 46.15% (6/13) of 
TPD52-amplified cell lines co-amplified for ERBB2, and 40% (6/15) of ERBB2-
amplified cell lines co-amplified for TPD52 (Fisher’s exact test, p = 0.0733, n = 59).  
Finally, we examined the METABRIC cohort to ascertain whether these co-
amplification frequencies were reflective of those in breast tumour samples.  TPD52 
and ERBB2 co-amplification occurred in 4.8% (104/2173) of the METABRIC samples 
(Figure 3.2.4A and C).  The amplification of these genes was significantly associated,  
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Figure 3.2.6. Correlation between TPD52 and MYC log2 copy number in co-
amplified cell lines from the Cancer Cell Line Encyclopedia (CCLE).  Scatterplot 
showing a significant positive correlation (Spearman’s test) between TPD52 log2 copy 
number ratio (x-axis) and MYC log2 copy number ratio (y-axis) in 32 co-amplified cell 
lines (Table 3.2.2).  
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Figure 3.2.7: (legend on the following page) 
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Figure 3.2.7: (legend on the following page) 
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Figure 3.2.7:  
 
 
 
 
Figure 3.2.7. Chromosome 8q gene copy numbers in selected TPD52-amplified 
cancer cell lines.  Plots (A) to (K) show individual copy number profiles for each of 
the 11 TPD52-amplified cancer cell lines that were selected for our experimental 
cohort.  These are presented in order of decreasing TPD52 log2 copy number ratio.  
400 adjacent genes, from KIAA0146 (48.3 Mb) to SPATC1 (145.2 Mb), appear along 
the x-axis, in the order that they appear on chromosome 8q.  TPD52 (81.1 MB) and 
MYC (128.8 MB) are indicated by arrows.  Genomic locations are from p terminus, 
according to the hg18 assembly.  A dotted line indicates a log2 copy number ratio of 
0.848, which was used as a threshold for determining gene amplification.  
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Table 3.2.3. TPD52 and ERBB2 co-amplification in the Cancer Cell Line 
Encyclopedia (CCLE).  The 8 cell lines with co-amplification of TPD52 and ERBB2 
are ranked according to their TPD52 log2 copy number ratio.   
 
Cell line Tumour type TPD52  log2 ratio 
ERBB2  
log2 ratio 
SKBR3 Breast 2.471 2.781 
EFM192A Breast 2.446 2.725 
AU565 Breast 2.382 2.706 
TE4 Oesophagus 1.184 3.346 
KE39 Stomach 1.036 0.852 
HCC2218 Breast 0.972 2.709 
HCC1954 Breast 0.868 3.463 
HCC1569 Breast 0.849 3.241 
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with 25.94% (104/401) of TPD52-amplified cell lines co-amplified for ERBB2, while 
TPD52 was co-amplified in 30.41% (104/342) of ERBB2-amplified cell lines (Fisher’s 
exact test, p < 0.0001, n = 2173). In breast tumours, 81.73% (85/104) of samples that 
were co-amplified for TPD52 and ERBB2 were also co-amplified for MYC (Figure 
3.2.4).   
 
3.2.4 Selecting a cohort of TPD52-amplified cancer cell lines  
Based on the analyses above, we selected a subset of TPD52-amplified cancer 
cell lines with co-amplification of MYC and/or ERBB2 for our experiments.  We 
applied the following selection criteria.  First, we selected only those cell lines in 
which TPD52 and MYC were independently amplified, as determined from the 
individual chromosome 8q copy number plots described in section 3.2.2.  Second, we 
selected those cell lines with the highest magnitudes of amplification.  These included 
the top six cell lines, which were, in order of decreasing TPD52 log2 copy number 
ratios, SKBR3, EFM192A, AU565, BHT101, HCC827, and EVSAT (Figure 3.2.7A-
F).  We also included TE4, which despite being ranked below the above cell lines, 
featured high-level TPD52 amplification (i.e. log2 copy number ratio > 1) and co-
amplification of a relatively small number of neighbouring genes (Figure 3.2.7G).  Of 
these TPD52-amplified cell lines, BHT101, HCC827, and EVSAT were co-amplified 
for MYC, while SKBR3, EFM192A, AU565, and TE4 were co-amplified for both 
MYC and ERBB2 (Table 3.2.2 and 3.2.3).  Including both SKBR3 and AU565 in our 
cohort served as a valuable control since these cell lines were derived from the same 
patient and, as such, share many molecular features (Neve et al., 2006).   
We also sought to include several cell lines that were amplified for TPD52, 
without co-amplification of MYC and/or ERBB2.  This necessitated the inclusion of 
cell lines with more modest TPD52 amplification (i.e. log2 copy number ratio < 1), 
since those with higher-level TPD52 amplification were co-amplified for MYC 
(Appendix 1).  The selected cell lines included DMS454, HMC18, and SUPB15, as 
well as NCIH1734, with its TPD52 log2 copy number ratio of 0.843 being just below 
our amplification threshold of 0.848 (Figure 3.2.7H-K).  Finally, we selected a range 
of comparator cell lines including: cell lines that were amplified for MYC only 
(CORL23, PSN1, MG63, and MCF7); cell lines that were amplified for ERBB2 only 
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(BT474); cell lines that were amplified for both MYC and ERBB2 but not TPD52 
(ZR7530); cell lines that were not amplified for TPD52, MYC, or ERBB2 
(MDAMB231, U2OS, HOS, and 143B); and the non-cancer breast epithelial cell line 
MCF10A (Soule et al., 1990) (Appendix 1 and data not shown).  In total, our newly-
assembled cohort comprised 22 cell lines, including 10 cell lines that were predicted to 
be TPD52-amplified based upon CCLE data.  These cell lines were derived from seven 
different tumour types: breast (EVSAT, SKBR3, EFM192A, AU565, HMC18, MCF7, 
BT474, ZR7530, and MDAMB231), lung (HCC827, DMS454, NCIH1734, and 
CORL23), thyroid (BHT101), oesophagus (TE4), haematopoietic and lymphoid tissue 
(SUPB15), pancreas (PSN1), and bone (MG63, U2OS, HOS, and 143B). 
 
3.2.5 Confirming gene copy number and protein levels in cell line 
cohort  
 We next confirmed the amplification status at TPD52, MYC and ERBB2 for 
each cell line in our cohort.  Genomic DNA was extracted from cell lines and 
subjected to quantitative PCR (qPCR). Copy numbers for each target gene were 
normalised using the qBiomarker Multicopy Reference (MRef) Assay (Qiagen), which 
controls for differences in the amount of input DNA in the assay.  Copy numbers were 
then reported relative to those in the TaqMan human genomic DNA control (Applied 
Biosystems).  All calculations were carried out as described in section 2.2.2.5.  
Relative copy numbers greater than or equal to 3 were considered copy number gain, 
while those greater than or equal to 5 were considered gene amplification.  We 
selected a more stringent threshold when determining amplified cell lines from our 
qPCR analyses, with a relative copy number of 5 being approximately equal to a log2 
copy number ratio of 1.322, to allow us to differentiate those cell lines with gain of 1-2 
gene copies from those with high-level amplification in subsequent phenotypic 
analyses.  We then performed Western blot and densitometry analyses on total cell 
lysates from each cell line to determine corresponding protein levels, relative to the 
GAPDH loading control and normalised to the ratio for MCF10A, which was set at 1.  
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3.2.5.1 TPD52 copy number and protein levels in cell line cohort 
Our qPCR analyses demonstrated that relative TPD52 gene copy number was 
increased (by gain or amplification) in 9 of 22 cell lines (Figure 3.2.8A, Table 3.2.4).  
Of these cell lines, five were amplified for TPD52 (SKBR3, AU565, EFM192A, 
HCC827, and BHT101), while four showed TPD52 copy number gain (TE4, 
NCIH1734, SUPB15, and HMC18).  There was a strong positive correlation between 
the TPD52 relative gene copy number, determined by qPCR, and the TPD52 log2 copy 
number ratio, reported by the CCLE (Spearman’s test, rs = 0.7957, p < 0.0001, n = 21) 
(Figure 3.2.8D).  All five of the cell lines shown by qPCR to be TPD52-amplified 
were similarly predicted by the CCLE and were the same five cell lines that emerged 
when CCLE analyses were ranked by TPD52 log2 copy number ratios, albeit in a 
different order (Figure 3.2.8D, Table 3.2.2).  Furthermore, all four of the cell lines 
shown by qPCR to feature TPD52 copy number gain had TPD52 log2 copy number 
ratios in a lower tier when compared to the first group.  Surprisingly, however, 
EVSAT displayed no TPD52 gain in our qPCR analyses, despite being ranked the 
sixth-highest cell line in the CCLE and having a TPD52 log2 copy number ratio 
(1.622) consistent with the other TPD52-amplified cell lines (Table 3.2.2).  
Western blot analyses revealed that relative TPD52 protein levels were high in 
4 of 22 cell lines (SKBR3, AU565, EFM192A, and DMS454), moderate in another 6 
cell lines (TE4, EVSAT, BT474, ZR7530, HCC827, and NCIH1734), and low in the 
remaining 12 cell lines (Figure 3.2.8B, Table 3.2.4).  There was an incomplete overlap 
between those cell lines with increased relative TPD52 gene copy number (i.e. gained 
or amplified) and those with increased relative TPD52 protein levels (i.e. moderate or 
high).  Of the five TPD52-amplified cell lines, relative TPD52 protein levels varied 
considerably, with SKBR3, AU565, and EFM192A expressing high levels, HCC827 
expressing moderate levels, and BHT101 expressing very low levels.  This observation 
for BHT101 is particularly surprising given that it had the third-highest relative TPD52 
copy number in our qPCR analyses and was the fourth-highest cell line for TPD52 
log2 copy number ratios in the CCLE dataset (Figure 3.2.8D).  Relative TPD52 protein 
levels also varied considerably between the four cell lines with TPD52 gain, and 
between the 13 cell lines with neither gain nor amplification of TPD52 (Figure 3.2.8A 
and B).  Of the latter category, DMS454 is noteworthy since it displayed high relative 
TPD52 protein levels despite being diploid for TPD52 (Figure 3.2.8A and B). 
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Figure 3.2.8: (legend on the following page) 
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Figure 3.2.8. TPD52 copy number and protein detection in human cancer cell line 
cohort.  (A) Genomic DNA extracted from 22 cell lines (x-axis) was subjected to 
quantitative PCR to determine TPD52 gene copy numbers relative to those in a 
genomic DNA control (y-axis).  The results are graphed, showing mean ± SEM from 3 
independent experiments, performed in triplicate.  Cell lines that were predicted to be 
amplified according to log2 copy number ratios derived from the Cancer Cell Line 
Encylopedia are indicated by an asterisk (*).  Dotted lines indicate a relative copy 
number of 3 and 5, which were used as thresholds for determining gene gain and 
amplification, respectively.  (B) Total cell lysates were subjected to Western blot 
analyses to determine TPD52 protein levels, with GAPDH used as a loading control.  
Densitometry analyses were then performed to quantitate the intensity of TPD52 
protein bands, relative to GAPDH and normalised to the ratio for MCF10A (set at 1.0).  
The results are graphed, showing mean ± SEM (y-axis) for each of the cell lines  
(x-axis), from 3 independent experiments.  A representative image is shown, with the 
proteins analysed and the molecular weights of the detected species labelled to the left 
and right, respectively.  (C) The graph compares the distribution of mean relative 
TPD52 protein levels (y-axis) between cell lines found by qPCR to have no TPD52 
gain (relative copy number < 3), TPD52 gain (3 ≤ relative copy number < 5), or 
TPD52 amplification (relative copy number ³ 5) (x-axis).  The horizontal bars 
represent the median values for the mean relative intensities of the TPD52 protein 
bands in each category, which were 1.654, 2.443, and 8.192 for cell lines with no 
TPD52 gain, TPD52 gain, and TPD52 amplification, respectively.  Mann-Whitney u 
test: N.S. p > 0.05, ** p £ 0.01.  (D) Scatterplot showing the correlations (Spearman’s 
test) between log2 copy number ratios reported by the CCLE (x-axis) and mean 
relative copy numbers determined by qPCR (y-axis) for TPD52 in 21 cell lines.  The 
vertical dotted line indicates a log2 copy number ratio of 0.848, which was used as a 
threshold for determining amplified cell lines in the CCLE.  The horizontal dotted line 
indicates a relative copy number of 3.6, which is approximately equivalent to a log2 
copy number ratio of 0.848.  Labelled cell lines are those with relative copy numbers ³ 
5, which was used as a more stringent threshold for determining amplified cell lines 
after qPCR.  MCF10A was not included in these analyses since, as a non-cancer cell 
line, it was not present in the CCLE.  
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Table 3.2.4. Summary of new experimental cell line cohort.  Cell lines were 
subjected to quantitative PCR to determine copy number (CN) of the target gene, 
relative to normal DNA, and Western blot analyses to determine protein levels (P).  
For copy number: A = amplified (relative copy number ³ 5), G = gained (3 ≤ relative 
copy number < 5), and N = not gained (relative copy number < 3).  For protein level: 
H = high, M = moderate, L = low. 
 
Cell line 
TPD52 MYC ERBB2 
CN P CN P CN P 
1 
SKBR3 A H A M A H 
AU565 A H A M A H 
2 
TE4 G M A M A H 
EVSAT N M A M A H 
BT474 N M A M A H 
ZR7530 N M A L A H 
3 
EFM192A A H A H N M 
HCC827 A M A M N L 
BHT101 A L A M N L 
4 
NCIH1734 G M G L N L 
SUPB15 G L A L N L 
HMC18 G L A M N L 
5 
DMS454 N H A M N L 
CORL23 N L A H N L 
PSN1 N L A H N L 
MG63 N L A M N L 
MCF7 N L A L N L 
MDAMB231 N L A H N L 
U2OS N L A M G L 
HOS N L G H N L 
143B N L G H N L 
MCF10A N L A M N L 
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Nevertheless, the median relative TPD52 protein level was significantly higher in 
TPD52-amplified cell lines, when compared to cell lines with no TPD52 gain (Mann-
Whitney u test, p = 0.0068, n = 18) (Figure 3.2.8C).   
 
3.2.5.2 MYC copy number and protein levels in cell line cohort 
 Compared to TPD52, MYC gene amplification and protein expression was 
more common in our cell line cohort.  In fact, qPCR analyses demonstrated that MYC 
gene copy number was increased (by gain or amplification) in all 22 cell lines, 
including the non-cancer cell line MCF10A, when compared to the genomic DNA 
control (Figure 3.2.9A).  Of these cell lines, only NCIH1734, HOS, and 143B were 
found to show MYC gain, while the rest were MYC-amplified.  MYC amplification has 
been previously reported for the breast cancer cell lines SKBR3, EFM192A, and 
ZR7530 (Kao et al., 2009).  MYC amplification also occurred with much higher 
relative copy numbers than TPD52 amplification.  The highest relative MYC copy 
number was 226.21, which was approximately 20-times the highest relative TPD52 
copy number of 11.80 (Figure 3.2.8A and 3.2.9A).  This was in keeping with the 
CCLE data, which reported much higher log2 copy number ratios for MYC when 
amplified, than for TPD52 (Figure 3.2.1).  
Our qPCR findings for MYC showed an overall concordance with the CCLE 
data.  There was a very strong positive correlation between the MYC relative gene 
copy number, determined by qPCR, and the MYC log2 copy number ratio, reported by 
the CCLE (Spearman’s test, rs = 0.9312, p < 0.0001, n = 21) (Figure 3.2.9D).  The two 
cell lines that were shown by qPCR to have the highest relative MYC copy numbers 
were PSN1 and CORL23, which were also the highest-ranking of the CCLE cell lines 
included in our cell line cohort (Figure 3.2.9D and data not shown).  With a few 
exceptions, the ranking of the other cell lines agreed with those generated from CCLE 
data.  EVSAT, for example, was shown by qPCR to have the third-highest relative 
MYC copy number of the cell lines in our cohort, but was ranked eighth according to 
CCLE data (Figure 3.2.9D and data not shown).   
Western blot analyses also revealed more frequent detection of moderate to 
high MYC protein levels in these cell lines, when compared to TPD52 protein 
detection (Figure 3.2.8B and 9B).  Even the non-cancer cell line MCF10A features 
moderate MYC protein levels.  Six cell lines (EFM192A, CORL23, PSN1, 
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Figure 3.2.9: (legend on the following page) 
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Figure 3.2.9. MYC copy number and protein detection in human cancer cell line 
cohort.  (A) Genomic DNA extracted from 22 cell lines (x-axis) was subjected to 
quantitative PCR to determine MYC gene copy numbers relative to those in a genomic 
DNA control (y-axis, log-scale).  The results are graphed, showing mean ± SEM from 
3 independent experiments, performed in triplicate.  Cell lines that were predicted to 
be amplified according to log2 copy number ratios derived from the Cancer Cell Line 
Encylopedia are indicated by an asterisk (*).  Dotted lines indicate a relative copy 
number of 3 and 5, which were used as thresholds for determining gene gain and 
amplification, respectively.  (B) Total cell lysates were subjected to Western blot 
analyses to determine MYC protein levels, with GAPDH used as a loading control.  
Densitometry analyses were then performed to quantitate the intensity of MYC protein 
bands, relative to GAPDH and normalised to the ratio for MCF10A (set at 1.0).  The 
results are graphed, showing mean ± SEM (y-axis) for each of the cell lines (x-axis), 
from 3 independent experiments.  A representative image is shown, with the proteins 
analysed and the molecular weights of the detected species labelled to the left and 
right, respectively.  (C) The graph compares the distribution of relative MYC protein 
levels (y-axis) between cell lines found by qPCR to have MYC gain (3 ≤ relative copy 
number < 5) or MYC amplification (relative copy number ³ 5) (x-axis).  The horizontal 
bars represent the median values for the mean relative intensities of the TPD52 protein 
bands in each category, which were 1.447 and 0.8638 for cell lines with MYC gain and 
MYC amplification, respectively.  Mann-Whitney u test: N.S. p > 0.05, n = 22.  (D) 
Scatterplot showing the correlations (Spearman’s test) between log2 copy number 
ratios reported by the CCLE (x-axis) and mean relative copy numbers determined by 
qPCR (y-axis, log-scale) for MYC in 21 cell lines.  The vertical dotted line indicates a 
log2 copy number ratio of 0.848, which was used as a threshold for determining 
amplified cell lines in the CCLE.  The horizontal dotted line indicates a relative copy 
number of 3.6, which is approximately equivalent to a log2 copy number ratio of 
0.848.  MCF10A was not included in these analyses since, as a non-cancer cell line, it 
was not present in the CCLE.  
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MDAMB231, HOS, and 143B) had higher MYC protein levels than MCF10A and 
were therefore classified as high (Figure 3.2.9B, Table 3.2.4).  Of these, it should be 
noted that CORL23 and PSN1 had such high relative MYC protein levels that the 
densitometry analyses were saturated (Figure 3.2.9B).  Four cell lines (ZR7530, 
NCIH1734, SUPB15, and MCF7) had approximately half the MYC protein levels of 
MCF10A and were therefore classified as low (Figure 3.2.9B, Table 3.2.4).  The 
remaining 12 cell lines were classified as moderate (Figure 3.2.9B, Table 3.2.4).  Apart 
from CORL23 and PSN1, there was no overall relationship between relative MYC 
copy number and protein levels (Figure 3.2.9A and B).  This was reflected in there 
being no significant difference between the median MYC protein level between MYC-
amplified and MYC-gained cell lines (Mann-Whitney u test, p = 0.3558, n = 22) 
(Figure 3.2.9C) and no significant correlation between relative MYC protein level and 
MYC copy number (Spearman’s test, rs = 0.0209, p = 0.9265, n =22) (data not shown).  
 
3.2.5.3 ERBB2 copy number and protein levels in cell line cohort 
Our qPCR analyses demonstrated that ERBB2 was amplified in 6 of 22 cell 
lines, when compared to the genomic DNA control (Figure 3.2.10A, Table 3.2.4).  
These cell lines were SKBR3, AU565, TE4, EVSAT, BT474, and ZR7530.  An 
additional cell line, U2OS, showed ERBB2 gain (Table 3.2.4).  ERBB2 amplification 
has been extensively studied in breast cancer cell lines, since these have been used to 
evaluate response to ERBB2-targeted drugs (Neve et al., 2006; Jernstrom et al., 2017).  
Our results are consistent with those of published array CGH data demonstrating 
ERBB2 amplification in SKBR3, AU565, BT474, and ZR7530 (Neve et al., 2006; Kao 
et al., 2009).  As for MYC, ERBB2 amplification involved much higher relative copy 
numbers than TPD52 amplification.  The highest relative ERBB2 copy number was 
111.56, which was approximately 10-times the highest relative TPD52 copy number of 
11.80 (Figure 3.2.8A and 10A).  Again, this was in keeping with the CCLE data, 
which reported much higher log2 copy number ratios for ERBB2 when amplified, than 
for TPD52 (Figure 3.2.1).  
There was a moderate positive correlation between the ERBB2 relative gene 
copy number, determined by qPCR, and the ERBB2 log2 copy number ratio, reported 
by the CCLE (Spearman’s test, rs = 0.5705, p = 0.0069, n = 21) (Figure 3.2.10D).  Five 
of the cell lines shown by qPCR to be ERBB2-amplified were also predicted by the 
 
		 100 
Figure 3.2.10: (legend on the following page) 
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Figure 3.2.10. ERBB2 copy number and protein detection in human cancer cell 
line cohort.  (A) Genomic DNA extracted from 22 cell lines (x-axis) was subjected to 
quantitative PCR to determine ERBB2 gene copy numbers relative to those in a 
genomic DNA control (y-axis, log-scale).  The results are graphed, showing mean ± 
SEM from 3 independent experiments, performed in triplicate.  Cell lines that were 
predicted to be amplified according to log2 copy number ratios derived from the 
Cancer Cell Line Encylopedia are indicated by an asterisk (*).  Dotted lines indicate a 
relative copy number of 3 and 5, which were used as thresholds for determining gene 
gain and amplification, respectively.  (B) Total cell lysates were subjected to Western 
blot analyses to determine ERBB2 protein levels, with GAPDH used as a loading 
control.  Densitometry analyses were then performed to quantitate the intensity of 
ERBB2 protein bands, relative to GAPDH and normalised to the ratio for MCF10A 
(set at 1.0).  The results are graphed, showing mean ± SEM (y-axis) for each of the cell 
lines (x-axis), from 3 independent experiments.  A representative image is shown, with 
the proteins analysed and the molecular weights of the detected species labelled to the 
left and right, respectively.  (C) The graph compares the distribution of mean relative 
ERBB2 protein levels (y-axis) between cell lines found by qPCR to have no ERBB2 
gain (relative copy number < 3), ERBB2 gain (3 ≤ relative copy number < 5), or 
ERBB2 amplification (relative copy number ³ 5) (x-axis).  The horizontal bars 
represent the median values for the mean relative intensities of the TPD52 protein 
bands in each category, which were 0.8502 and 110 for cell lines with no ERBB2 gain 
and ERBB2 amplification, respectively.  Note that no comparisons were made with cell 
lines that had ERBB2 gain, since this category comprised a single cell line.  Mann-
Whitney u test: **** p £ 0.0001, n = 21.  (D) Scatterplot showing the correlations 
(Spearman’s test) between log2 copy number ratios reported by the CCLE (x-axis) and 
mean relative copy numbers determined by qPCR (y-axis, log-scale) for ERBB2 in 21 
cell lines.  The vertical dotted line indicates a log2 copy number ratio of 0.848, which 
was used as a threshold for determining amplified cell lines in the CCLE.  The 
horizontal dotted line indicates a relative copy number of 3.6, which is approximately 
equivalent to a log2 copy number ratio of 0.848.  Labelled cell lines are those with 
relative copy numbers ³ 5, which was used as a more stringent threshold for 
determining amplified cell lines after qPCR.  MCF10A was not included in these 
analyses since, as a non-cancer cell line, it was not present in the CCLE.    
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CCLE data, although there were some discrepancies in their ranking.  However, there 
were striking disagreements between qPCR and CCLE results for EVSAT and 
EFM192A.  EVSAT was shown by qPCR to harbour the second-highest relative 
ERBB2 copy number, but was not ERBB2-amplified according to the CCLE data 
(Figure 3.2.10A, Appendix 1).  Conversely, EFM192A showed a diploid relative 
ERBB2 copy number, despite CCLE data indicating a ERBB2 log2 copy number ratio 
(2.725) consistent with ERBB2 amplification (Figure 3.2.10A, Table 3.2.3).  
Western blot analyses revealed moderate to high relative ERBB2 protein levels 
in seven cell lines (Figure 3.2.10B, Table 3.2.4).  Of these, six cell lines (SKBR3, 
AU565, TE4, EVSAT, BT474, and ZR7530) showed high ERBB2 protein levels, 
while EFM192A showed moderately increased ERBB2 protein levels (Figure 3.2.10B, 
Table 3.2.4).  The remaining 15 cell lines showed low ERBB2 protein levels (Figure 
3.2.10B, Table 3.2.4).  These results were again consistent with previous reports for 
SKBR3, AU565, BT474, and ZR7530 (Neve et al., 2006), as well as for EFM192A 
(Kao et al., 2009).  There was strong agreement between relative ERBB2 copy number 
and ERBB2 protein levels, with all six of the cell lines found to be ERBB2-amplified 
by qPCR expressing ERBB2 protein at high levels (Figure 3.2.10 A and B).  Only 
EFM192A showed moderate relative ERBB2 protein levels, despite being diploid 
according to the qPCR results (Figure 3.2.10 A and B).  This was reflected in the 
median ERBB2 protein level being significantly higher in ERBB2-amplified cell lines, 
when compared to cell lines with no ERBB2 gain (Mann-Whitney u test, p < 0.0001, n 
= 21) (Figure 3.2.10C).   
 
3.2.6 A novel experimental cell line cohort  
We set out to assemble a cohort of TPD52-amplified cell lines, with and 
without MYC- and/or ERBB2-amplification, from a range of different cancer types.  
Following validation of gene copy number and protein levels, we divided this cohort 
into five groups (Table 3.2.4).  Group 1 is comprised of SKBR3 and AU565, which are 
TPD52-amplified cell lines featuring co-amplification of MYC and ERBB2.  Group 2 is 
comprised of TE4, EVSAT, BT474, and ZR7530, which feature co-amplification of 
MYC and ERBB2 but not of TPD52.  These cell lines, however, do express moderate 
levels of TPD52 protein.  Group 3 is comprised of EFM192A, HCC827, and BHT101, 
which are TPD52-amplified cell lines featuring co-amplification of MYC, but not 
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ERBB2.  It is important to note, however, that TPD52 protein levels in HCC827 and 
BHT101 are lower than their amplification status would suggest.  Group 4 is 
comprised of NCIH1734, SUPB15, and HMC18, which feature copy number gain of 
TPD52 and amplification or gain of MYC, but not ERBB2.  Protein levels for both 
TPD52 and MYC in these cell lines, however, are not well correlated with their 
amplification status.  Finally, Group 5 is comprised of the remaining ten cell lines, 
which feature MYC amplification (n = 8) or gain (n = 2), without co-amplification of 
either TPD52 or ERBB2.  Accordingly, TPD52 proteins levels are low in these cell 
lines (with the exception of DMS454), as are ERBB2 protein levels.  MYC protein 
levels for the cell lines in this group show little correlation with their amplification 
status.  
 
3.3 Discussion  
In this chapter, we explored the frequency, magnitude, and context of TPD52 
amplification in 995 cancer cell lines from diverse tumour types.  We then investigated 
the degree to which TPD52 was co-amplified with the oncogenes MYC and ERBB2 in 
these cancer cell lines.  Finally, we confirmed gene amplification status for TPD52, 
MYC, and ERBB2 in a subset of 22 cell lines and examined associations between gene 
copy number and protein levels.  
 
3.3.1 TPD52 as an amplification target gene 
 We propose that TPD52 is an amplification target gene and, as such, drives the 
frequent gain of chromosome band 8q21. TPD52 amplification characterised 4.0% 
(40/995) of all cancer cell lines in the CCLE, with copy number increases of 
approximately 1.8 to 5.5-fold.  Our results identify cancer cell line correlates for 
several cancer types that have been previously associated with TPD52 amplification 
and/or overexpression, including breast, prostate, lung, haematological, bone, and 
stomach cancers (reviewed in Shehata et al., 2008a; Byrne et al., 2014).  Our results 
also expand the list of cancer types for which TPD52 amplification is implicated to 
include several cancer types that have not been previously or extensively reported.  
These include cancers derived from the biliary tract, central nervous system, 
endometrium, kidney, large intestine, oesophagus, pleura, and thyroid.  Further study 
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will be required to ascertain whether TPD52 amplification in these cancer cell lines is 
accompanied by increased TPD52 expression, and whether this is recapitulated in 
tumour samples.   
One of the challenges we faced in our analyses was how to distinguish between 
amplified and non-amplified genes given a dataset comprised of log2 copy number 
ratios.  The cytogenetics literature has historically drawn a distinction between ‘gains’, 
as small copy number increases affecting a large genomic region, and ‘amplifications’, 
as large copy number increases affecting a small genomic region (Beroukhim et al., 
2010).  For array-based studies, the distinction is less clear, since absolute copy 
numbers cannot be definitively determined from the log2 copy number ratios 
(Beroukhim et al., 2010).  We therefore followed the rationale used by previous 
investigators who re-interpreted ‘gains’ as referring to arm-level events and 
‘amplifications’ as referring to more focal events, due to their restricted nature and 
tendency to be higher in amplitude (Beroukhim et al., 2010).  We then employed a 
high amplitude threshold of 0.848, which has been previously reported to selectively 
exclude arm-level copy number gains (Weir et al., 2007; Mermel et al., 2011).  This 
means that our analyses may conservatively estimate amplification (and co-
amplification) frequencies.  It is important to note that, where we have reported 
approximate copy number fold-changes, these are estimates only, derived from the 
log2 copy number ratios by assuming a pure, homogenous, diploid genome.   
Another more general challenge, which is encountered by any study that seeks 
to map the genomic landscapes of cancer, is how to distinguish those alterations that 
drive cancer development from passenger alterations that confer little to no fitness 
change.  This challenge is further complicated in the study of gene amplification 
because amplicons are frequently comprised of multiple neighbouring genes (Santarius 
et al., 2010).  A common solution is to assume that genomic regions containing driver 
genes will be amplified more frequently within a cohort of cancer cell lines or samples.  
However, this approach risks overlooking the target genes that are infrequently 
amplified (‘hills’), but nonetheless are highly significant in those cancers in which they 
occur (Byrne et al., 2012).  Additionally, when the driver gene is also an amplification 
target, it is often assumed that its amplification will occur at a higher amplitude than 
passenger genes (Mermel et al., 2011).  This approach similarly risks overlooking 
genes that are targeted by focal amplification at low to moderate amplitudes (Mermel 
et al., 2011).  We chose to use a high amplitude threshold to define amplification 
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because it was more important for our analyses to exclude low amplitude arm-level 
gains than it was to accommodate rarer instances of low amplitude focal TPD52 
amplification.     
Once a candidate amplification target gene has been identified, a foundational 
requirement is that its amplification be accompanied by overexpression (Santarius et 
al., 2010).  In the cancer cell lines that we selected for experimental validation, the 
median TPD52 protein level was significantly higher in TPD52-amplified cell lines, 
when compared to cell lines without TPD52 copy number gain.  Only BHT101 
showed unexpectedly low TPD52 protein levels, despite having the third-highest 
relative TPD52 copy number in our cohort.  This could indicate that TPD52 is a 
passenger gene in this cell line, and that the focally-restricted copy number gain of the 
genomic region surrounding TPD52 is in fact driven by a neighbouring gene.  It is 
important to note that the same amplicon can have different driver genes in different 
cancer types, or even within different subtypes of a given cancer (Santarius et al., 
2010).  Alternatively, it must be remembered that the structural variations 
accompanying copy number change can have multifarious, and sometimes unexpected, 
effects on gene expression, for example, by modifying chromatin structure or more 
distal regulatory mechanisms (Gamazon and Stranger, 2015).  Finally, amplification is 
just one mechanism through which oncogenes may be overexpressed.  This is 
evidenced within our cell line cohort by the high TPD52 protein levels in DMS454, 
which lacks increased TPD52 copy number.   
 
3.3.2 TPD52 and MYC co-amplification 
 TPD52 and MYC are located on distinct chromosomal bands (8q21 and 8q24, 
respectively) and while it is apparent that these chromosomal regions can be gained 
together, they can also be gained separately (section 3.1).  Our analyses confirmed that 
TPD52 and MYC are frequently co-amplified in both cancer cell lines and breast 
tumour samples.  TPD52 and MYC amplification were significantly associated in 
CCLE cancer cell lines, with 80% (32/40) of TPD52-amplified cell lines co-amplified 
for MYC.  The inverse situation was less frequent, with TPD52 co-amplified in 20.65% 
(32/155) of MYC-amplified cell lines. TPD52 and MYC amplification was also 
significantly associated when considering only the breast cancer cell lines within the 
CCLE.  In breast cancer cell lines, MYC was co-amplified in 92.31% (12/13) of 
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TPD52-amplified cell lines, while TPD52 was co-amplified in 48% (12/25) of MYC-
amplified cell lines.  These observations were recapitulated in breast tumour samples 
from the METABRIC cohort, where TPD52 and MYC amplification was again 
significantly associated.  In breast tumour samples, MYC was co-amplified in 86.53% 
(347/401) of TPD52-amplified tumours, while TPD52 was co-amplified in 62.64% 
(347/554) of MYC-amplified tumours.  Interestingly, while the percentage of MYC co-
amplification in TPD52-amplified tumours was only marginally higher for both breast 
cell lines and tumour samples, when compared to the pan-cancer cell line cohort, the 
percentage of TPD52 co-amplification in MYC-amplified tumours was 2- to 3-fold 
higher.  This enrichment suggests that the co-amplification of TPD52 in MYC-
amplified cancers may be particularly important to breast cancer.  Furthermore, the 
lower frequency of co-amplification in MYC-amplified versus TPD52-amplified cell 
lines in all sets of analyses, suggests that if these genes do cooperate functionally, 
TPD52 is likely to play a supporting role rather than being essential for MYC-driven 
oncogenesis. 
Since TPD52 and MYC are co-located on chromosome 8q, we sought to further 
explore the context of their co-amplification in cancer cell lines.  In particular, we were 
interested in whether or not they were independently gained as part of separate 
amplicons, which we determined based upon whether any of the genes located in the 
intervening chromosomal region were also amplified (i.e. had log2 copy number ratios  
³ 0.848).  This approach was guided by amplicon mapping methods (Beroukhim et al., 
2010); however, it is important to note that true amplicon mapping, which also 
considers the non-coding sequence between genes, was not possible using the gene-
based dataset we accessed from the CCLE.  We found that 50% (16/32) of TPD52 and 
MYC co-amplifications were independent.  This included the breast cancer cell line 
SKBR3, which has been previously shown to have independent amplification at 8q21 
and 8q24 (Rodriguez et al., 2007; Navin et al., 2011).   
Independent amplification of TPD52 and MYC has also been reported in a 
breast tumour sample (Hicks et al., 2006).  This same study describes these 
amplifications as occurring within a complex amplification pattern that is comprised of 
clustered narrow peaks of elevated copy number along a chromosomal segment.  
Chromosomal plots of these so-called ‘firestorms’ are very reminiscent of the 
individual copy number profiles that we generated for our co-amplified cell lines 
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(Figure 3.2.7).  Interestingly, both chromosome 8q and 17q, which features ERBB2, 
were found to be among the most frequent genomic regions to be affected by 
‘firestorms’ of amplification (Hicks et al., 2006).  In addition to these breast cancer 
studies, TPD52 and MYC have been reported as independently amplified in prostate 
cancer, where they were significantly correlated with prostate cancer-specific mortality 
(Liu et al., 2013).  Finally, it is worth noting that although amplified DNA often occurs 
as repeats within a given chromosome, as we have presented in chromosomal plots, it 
can also be organised as extrachromosomal copies or distributed to various locations in 
the genome (Albertson, 2006). 
 It is perhaps surprising that only half of the co-amplified cell lines were 
deemed to feature independent amplification of TPD52 and MYC.  As discussed 
above, we deliberately selected a high amplitude threshold to eliminate low amplitude 
arm-level gain of 8q and anticipated that high amplitude arm-level gain would be a 
relatively rare event based on analyses performed by other investigators (Mermel et 
al., 2011).  However, many of the co-amplified cell lines that were deemed to have 
non-independent amplification of TPD52 and MYC had arm-level, or nearly arm-level, 
amplification (data not shown).  It is possible that a one-size-fits-all amplitude-based 
threshold is less effective when applied to certain chromosomes due to their 
disproportionate background amplification rates.  For example, chromosome 8q is 
approximately half the length of chromosome 17q and approximately 5-fold less gene-
dense (with 400 genes spread over 97 Mb versus 18 Mb, respectively) (Figure 3.2.2 
and data not shown).  This might render chromosome 8q more permissive of high level 
whole arm gain and explain why this was observed more frequently than expected.  
Finally, although it made sense to exclude low amplitude arm-level gains from our 
analyses, it must be noted that these should not be overlooked biologically.  These still 
have the potential to alter gene dosage and have been shown to occur far more 
frequently than amplicons of larger or smaller lengths (Mermel et al., 2011).  Whether 
by default or design, our results show that MYC amplification is a feature of most 
TPD52-amplified cells and therefore the potential exists for functional cooperation 
between these oncogenes.   
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3.3.3 TPD52 and ERBB2 co-amplification 
Multiple studies report TPD52 and ERBB2 co-overexpression, and in some 
cases co-amplification, in breast cancer (section 3.1).  Our analyses confirmed that 
TPD52 and ERBB2 are recurrently co-amplified in both cancer cell lines and breast 
tumour samples.  TPD52 and ERBB2 amplification was significantly associated in 
cancer cell lines, with 20% (8/40) of TPD52-amplified cell lines co-amplified for 
ERBB2, and 18.18% (8/44) of ERBB2-amplified cell lines co-amplified for TPD52.  
Interestingly, six out of the eight co-amplified cell lines were derived from breast 
cancers.  This may reflect the fact that breast cancer cell lines comprised 
approximately one-third of all TPD52- or ERBB2-amplified cell lines (13/40 or 15/44, 
respectively).  However, TPD52 and ERBB2 were also individually amplified in 
several other cancer types and, of these, only one stomach cancer cell line and one 
oesophageal cancer cell line were co-amplified.  This suggests that TPD52 and ERBB2 
co-amplification may be particularly important for breast cancers.  Although the 
association between TPD52 and ERBB2 amplification was not statistically significant 
in breast cancer cell lines, this association was significant in breast tumour samples 
from the METABRIC cohort, where 25.94% (104/401) of TPD52-amplified cell lines 
co-amplified for ERBB2, and 30.41% (104/342) of ERBB2-amplified cell lines co-
amplified for TPD52.  Furthermore, the overall TPD52 and ERBB2 co-amplification 
frequency was much higher in the breast-specific METABRIC cohort, when compared 
to the pan-cancer CCLE cohort (4.8% or 104/2173 versus 0.8% or 8/995, 
respectively), suggesting enrichment in the former dataset.  Further study, using larger 
sample sizes, will be required to ascertain whether an analogous situation pertains to 
cancer types beyond breast cancer.  
An unexpected finding of our study was that ERBB2 co-amplification with 
TPD52 within cancer cell lines only occurred in combination with MYC co-
amplification.  In breast tumours, 81.73% (85/104) of samples that were co-amplified 
for TPD52 and ERBB2 were also co-amplified for MYC.  There are several possible 
explanations for this.  On the one hand, this might simply reflect the high frequency of 
TPD52 and MYC co-amplification, that is, the co-amplification of MYC in 80% 
(32/40) of TPD52-amplified cancer cell lines (CCLE) and 86.53% (347/401) of 
TPD52-amplified breast tumours (METABRIC).  However, as we discussed above, 
TPD52 and MYC can be independently amplified and their co-amplification, when it 
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does occur, does not necessarily result from whole arm gain but also from more 
restricted gains of the genomic regions surrounding each gene.  Another possibility 
could be that breast cancers with TPD52 amplification belong to a subset of cancers 
with high genomic instability, which consequently possess frequent amplifications at 
multiple loci.  This so-called ‘amplifier’ phenotype was proposed as a potential 
explanation for the observation that tumours with 8q21 amplification had a twofold 
increased likelihood of featuring additional amplifications (Choschzick et al., 2010) 
and has been previously observed for several breast cancers (Courjal et al., 1997a; 
Courjal et al., 1997b; Al-Kuraya et al., 2004; Melchor et al., 2005; Albertson et al., 
2006).  On the other hand, the high frequency of co-amplification for TPD52, MYC, 
and ERBB2 in breast cancer could indicate a functional cooperation between these 
genes.  The evidence for TPD52 as a survival factor in ERBB2-amplified cancers gives 
weight to the argument that the co-amplification of TPD52 and ERBB2, at least, is 
driven by more than simply genomic instability (Roslan et al., 2014).  The significance 
of this potential functional cooperation will be explored in the following chapter.  
 
3.3.4 Utility and reproducibility of large-scale studies  
 Large-scale studies, such as the CCLE, commonly cite hypothesis generation 
as an important application of their results (Barretina et al., 2012).  We recognised the 
potential of this data for investigating TPD52 amplification in an unprecedented 
number of cancer cell lines, including cancer types that had not been previously or 
extensively explored.  We anticipate that a similar approach could be taken to 
investigate many of the other ‘hills’ in the amplification landscape of cancers.  
However, there are several caveats to consider when using data generated by such 
large-scale studies.  Their high-throughput nature renders them particularly susceptible 
to the inclusion of erroneous data, which may affect their reproducibility.  
Furthermore, cell lines are subject to ‘drift’, by which their genomic characteristics 
may alter over time due to continuous passaging, and this could contribute to different 
results being reported for a single cell line.  These reproducibility concerns are 
exemplified in the clear disagreement between CCLE data and our qPCR results for 
the ERBB2 amplification status of EVSAT and EFM192A, which underlines the 
importance of conducting initial validation experiments before pursuing any 
hypotheses generated through analysis of CCLE data.  Finally, although cancer cell 
		 110 
lines are widely used as preclinical models, they do not completely recapitulate the 
primary tumours from which they are derived.  Therefore, any observations made in 
cancer cell lines should ideally be followed up in cancer specimens, as we have done 
by examining TPD52 and MYC or ERBB2 co-amplification amongst breast tumour 
samples of the METABRIC cohort.    
 
3.4 Summary and conclusions  
We have investigated the amplification of TPD52, MYC, and ERBB2 in 995 
cell lines from diverse tumour types, using gene copy number data generated by CCLE 
array-based studies.  Our analyses have confirmed that TPD52 is frequently amplified 
in cancer cell lines derived from diverse cancer types, particularly breast, as well as 
expanding this list to include several new cancer types.  We have also demonstrated 
that TPD52 amplification is accompanied by overexpression in the majority of cell 
lines that we validated experimentally.  Importantly, we have also contributed to the 
previously limited literature regarding the nature of TPD52 and MYC co-amplification 
in cancer, by demonstrating that half of the co-amplified cell lines in the CCLE have 
independent amplification of these genes and that high amplitude gains of the 
chromosome 8q arm also occur more frequently than might have been expected from 
background arm-level amplification rates reported in the literature.  We have shown 
that MYC amplification is a feature of most TPD52-amplified cells and therefore the 
potential exists for functional cooperation between these oncogenes, although TPD52 
is likely to play a supporting role rather than being essential for MYC-driven 
oncogenesis.  We have also shown that TPD52 and ERBB2 are recurrently co-
amplified in breast cancer, and frequently with co-amplification of MYC.  Finally, we 
have assembled a cohort of 22 cancer cell lines with validated TPD52, MYC, and 
ERBB2 amplification status and protein levels.  This generated a resource, which was 
then used to perform the novel investigations that will be presented in the following 
chapter.  
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Chapter 4 
 
Lipid storage and metabolism in cell 
lines with TPD52 amplification 
and/or overexpression. 
 
 
4.1 Introduction  
 In the previous chapter, we explored TPD52 amplification in cancer cell lines 
from diverse tumour types.  TPD52 overexpression, both with and without underlying 
gene amplification, has now been demonstrated in various cancer types and associated 
with poor prognosis and unfavourable outcomes (reviewed in Shehata et al., 2008a; 
Byrne et al., 2014).  Despite this, very little is known about how TPD52 
overexpression might promote the development of cancer on a molecular level.  An 
important advance in this respect was our recent discovery that TPD52 overexpression 
in mouse 3T3 fibroblast cells is accompanied by increased neutral lipid storage 
(Kamili et al., 2015).  This led us to consider whether increased lipid storage, or 
altered lipid metabolism, might also be a feature of TPD52-overexpressing cancer cells 
and, if so, whether this phenotype would be broadly observed across several different 
cancer types.   
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A possible role for TPD52 in the regulation of lipid metabolism is supported by 
several lines of evidence within the literature.  First, knockdown of the TPD52 
orthologue in C. elegans was shown to result in significantly decreased lipid storage 
(Ashrafi et al., 2003).  Second, TPD52/Tpd52 transcript levels were found to be 
increased in human and mouse adipose tissue from obese versus lean subjects (Nadler 
et al., 2000; Clement et al., 2004; Keller et al., 2008).  Third, TPD52 has been shown 
to be androgen-inducible in prostate cancer (Rubin et al., 2004; Wang et al., 2004), 
which is consistent with androgen being a potent regulator of lipid metabolism and 
increasing cytoplasmic lipid droplets in prostate cancer cells (Swinnen and Verhoeven, 
1998; Massie et al., 2011).  Fourth, the TPD52 paralogue TPD52L2 was reported as a 
lipid droplet-associated protein in numerous proteomic studies (Brasaemle et al., 2004; 
Umlauf et al., 2004; Sato et al., 2006; Cho et al., 2007; Wan et al., 2007; Hodges and 
Wu, 2010).  Finally, TPD52 was predicted to associate with two important regulators 
of lipid storage, perilipin and TIP47, by two separate studies employing a yeast two-
hybrid screen and co-immunoprecipitation experiments, respectively (Yamaguchi et 
al., 2006; Zhang et al., 2007).  Taken together, this evidence suggests that TPD52 may 
be operating within lipid metabolic pathways and that it is perhaps this aspect of 
TPD52 function that is targeted by its frequent amplification and overexpression in 
cancer.   
Furthermore, as explored in the previous chapter, TPD52 has been repeatedly 
reported as being co-expressed with ERBB2 in breast cancer.  This is significant 
because breast cancers that overexpress ERBB2 frequently exhibit a lipogenic 
phenotype.  We, among others, have speculated that this phenotype may even be ‘hard-
wired’ into cancers that feature ERBB2 amplification due to the frequent co-
amplification of nearby genes, including ACLY (ATP citrate lyase) and ACC (acetyl-
CoA carboxylase), which encode key lipogenic enzymes, as well as NR1D1 (nuclear 
receptor subfamily 1, group D, member 1) and MED1 (mediator complex subunit 1), 
which are involved in the transcriptional regulation of fat synthesis and storage 
(section 1.2.3.2; Kourtidis et al., 2010; Kamili and Byrne, 2014).  ERBB2-positive 
breast cancer cell lines commonly feature increased lipid droplet staining (Kourtidis et 
al., 2010), while ERBB2-positive breast cancers more frequently express proteins that 
are associated with lipogenesis or lipid storage (Kim et al., 2015).  ERBB2 has also 
been found to regulate the function of fatty acid synthase (FASN), a key enzyme in the 
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de novo synthesis of fatty acids (section 1.2.3.2; Kumar-Sinha et al., 2003; Menendez 
and Lupu, 2007).  In addition, a functional RNA interference (RNAi) screen of co-
overexpressed genes in the ERBB2-positive BT474 breast cancer cell line found the 
survival of these cells to be particularly reliant upon the expression of the lipid-
relevant genes, NR1D1, MED1, and MAP2K6 (mitogen-activated protein kinase kinase 
6), and to a lesser extent, FASN, STARD3 (StAR-related lipid transfer domain 
containing 3), and FADS2 (fatty acid desaturase 2) (Kourtidis et al., 2010).  
Interestingly, this same screen identified TPD52 as one of ten genes whose knockdown 
decreased proliferation by more than 50% (Kourtidis et al., 2010).  This is consistent 
with findings from our laboratory, which indicated that TPD52 is a survival factor in 
ERBB2-amplified breast cancer cell lines (Roslan et al., 2014).   
We therefore hypothesised that the recurrent co-expression of TPD52 and 
ERBB2 in breast cancer may be partially attributable to their complementary effects on 
lipid metabolic pathways, involving concomitant increases in the synthesis and storage 
of lipid.  The demand for lipid is intensified in cancer cells, when compared to 
quiescent cells, because their ability to continue proliferating is contingent upon 
having enough lipids to produce daughter cell membranes, lipid cofactors and lipid-
modified proteins (Kamili and Byrne, 2014).  An important corollary of this is an 
increased requirement for lipid storage, which enables the cell to avoid the toxicity 
associated with excess intracellular free fatty acids (Kamili and Byrne, 2014).  If 
TPD52 indeed promotes lipid storage, its overexpression may complement the 
lipogenic phenotype of ERBB2-positive cells by allowing them to rely upon high 
levels of intracellular lipid without the associated risk of lipotoxicity.  The current 
study will test, for the first time, whether increased levels of stored lipid are a shared 
feature of cancer cell lines with TPD52 amplification and/or overexpression, or 
whether this phenotype is uniquely present in a subset of cell lines, such as those that 
also feature ERBB2 amplification and/or overexpression. 
 
4.1.1 Aims of this chapter 
The specific aims of this chapter were as follows: 
1. To ascertain whether TPD52 amplification and/or overexpression in cancer 
cells is broadly associated with increased lipid storage, or altered expression of 
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lipid droplet-associated proteins and key metabolic enzymes 
2. To investigate whether there were any significant differences for those cell 
lines featuring TPD52 and ERBB2 co-amplification and/or overexpression 
3. To examine predicted interactions between TPD52 and lipid droplet-associated 
proteins 
 
4.2 Results 
4.2.1 Lipid droplet phenotypes in cancer cell line cohort 
 We began by visualising lipid droplets within the cancer cell line cohort 
assembled in the previous chapter.  Lipid droplets are specialised organelles for the 
storage of neutral lipid within cells and are known to exhibit a diverse range of 
phenotypes (Figure 4.2.1; Thiam and Beller, 2017).  We observed a variety of these 
phenotypes within our cohort, with lipid droplets varying not just between different 
cell lines but also within some cell lines (Table 4.2.1, Figure 4.2.2).  In particular, we 
noted differences in the number and size of lipid droplets, as well as in their spatial 
organisation (dispersed or clustered) and their subcellular localisation (cytoplasmic, 
perinuclear, or peripheral). Of these parameters, the numbers and size of lipid droplets 
varied most between cell lines.  All cell lines in which lipid droplets were observed 
had these dispersed throughout the cytoplasm; however, some cell lines also featured 
sub-populations of clustered lipid droplets.  In AU565, BT474, and EVSAT, these 
clusters were particularly localised to perinuclear regions.  All images intended for 
comparison were acquired with the same confocal settings and lipid droplet sizes were 
scaled relative to the extremes observed within these images.  The cell line SUPB15 
was not included in these investigations because it grows in suspension and therefore 
could not be cultured on coverslips for microscopy. 
To facilitate comparison, we assigned each cell line a semi-quantitative score 
based on a visual assessment of the amount of neutral lipid staining (Table 4.2.1, 
Figure 4.2.2).  If there was considerable heterogeneity within any given cell line, we 
considered the lipid droplet phenotype that was displayed by the majority (greater than 
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Figure 4.2.1. Diversity of lipid droplet phenotypes within cells.  Lipid droplet 
diversity manifests in several ways: number and size (A-C); spatial organisation and 
subcellular localisation (D-E); and identity and function (F-H).  Within a given cell, 
lipid droplets may be predominantly uniform in size (A), show considerable size 
variation (B), or be present as a single, very large lipid droplet (C).  The latter occurs 
exclusively in mammalian white adipocytes, for which lipid storage is the primary 
function.  In addition to being dispersed, as shown in (A) and (B), lipid droplets can 
also be clustered in various subcellular locations (D), or even polarised (E).  
Furthermore, individual lipid droplets can vary with respect to the proteins found on 
their surfaces (F), and whether they are prone to diminishing (-) or growing (+) under 
different metabolic conditions (G).  Finally, lipid droplets may be composed of a 
variety of different lipids, in varying proportions (H).  Figure reproduced from Thiam 
and Beller, 2017. 
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Table 4.2.1. Lipid droplet phenotypes in cancer cell line cohort.  Intracellular lipid 
droplets were stained with BODIPY and visualised using confocal microscopy, in 3 
independent experiments.  Lipid staining was assessed visually and each cell line given 
an overall score.  
Cell line 
Lipid 
droplet  
score 
Number and 
size of lipid 
droplets 
Spatial organisation  
and subcellular 
localisation 
Intra- cell line 
heterogeneity  
DMS454 Negligible N/A N/A No 
HOS Negligible N/A N/A No 
MCF10A Negligible N/A N/A No 
MDAMB231 Negligible N/A N/A No 
PSN1 Negligible N/A N/A No 
TE4 Negligible N/A N/A No 
U2OS Negligible N/A N/A No 
143B Low Few, uniformly small Dispersed, cytoplasmic No 
BHT101 Low Few, small Dispersed, cytoplasmic Yes 
CORL23 Low Few, small  Dispersed, cytoplasmic Yes 
MG63 Low Few, small to medium Dispersed, cytoplasmic Yes 
AU565 Moderate Numerous, small to medium 
Dispersed with some 
clusters, often 
perinuclear  
Yes 
BT474 Moderate Numerous, small to medium 
Dispersed with some 
clusters, often 
perinuclear 
Yes 
EFM192A Moderate Numerous, small to medium 
Dispersed with some 
clusters, cytoplasmic Yes 
EVSAT Moderate Numerous, small to medium 
Dispersed with some 
clusters, often 
perinuclear 
Yes 
HCC827 Moderate Numerous, small to medium Dispersed, cytoplasmic Yes 
MCF7 Moderate Numerous, small Dispersed, cytoplasmic Yes 
NCIH1734 Moderate Numerous, small to medium 
Dispersed with some 
clusters, cytoplasmic Yes 
SKBR3 Moderate Numerous, small to medium Dispersed, cytoplasmic Yes 
HMC18 High Saturated, large Dispersed, cytoplasmic No 
ZR7530 High Saturated, large Dispersed with some clusters, cytoplasmic Yes 
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Figure 4.2.2: (legend on the following page) 
 
A. Negligible lipid droplet score    
 
B. Low lipid droplet score 
 
C. Moderate lipid droplet score 
 
D. High lipid droplet score 
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Figure 4.2.2. Examples of cancer cell lines with different lipid droplet scores.  
Each cell line was assigned a semi-quantitative score based on visual assessment of the 
amount of lipid staining: (A) a negligible lipid droplet score indicates that lipid 
droplets were rarely observed; (B) a low lipid droplet score indicates the presence of a 
few lipid droplets that were small in size; (C) a moderate lipid droplet score indicates 
the presence of numerous lipid droplets, ranging from small to medium in size; and 
(D) a high lipid droplet score indicates that cells were nearly saturated with large lipid 
droplets.  Enlarged images of the white-boxed regions for AU565 and BT474 indicate 
clustered perinuclear lipid droplets and dispersed cytoplasmic lipid droplets, 
respectively.  All cells were stained with BODIPY 493/503 (green) for lipid droplets 
and DAPI (blue) for nuclei and visualised using the same confocal settings.  The 
images are representative of results from three independent experiments.  Scale bar = 
25µm 
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50%) of cells and assigned a score accordingly.  Negligible lipid staining was observed 
for 7/21 (33%) cell lines.  A low lipid droplet score was assigned to 4/21 (19%) cell 
lines, which featured fewer lipid droplets that tended to be uniformly small in size.  A 
moderate lipid droplet score was assigned to 8/21 (38%) cells lines, which featured 
numerous lipid droplets of various sizes, ranging from small to medium.  Finally, a 
high lipid droplet score was assigned to just 2/21 (10%) cell lines.  These cell lines 
were distinguished from the rest of the cohort by their cytoplasm being nearly 
saturated with large lipid droplets.  For all subsequent analyses, we divided the cell 
lines into two roughly-equal groups: those displaying negligible or low lipid staining 
(11/21, 52%); and those with moderate or high lipid staining (10/21, 48%). 
We then examined whether the two lipid staining groups segregated according 
to TPD52 or ERBB2 gene amplification status (Table 4.2.2, Figure 4.2.3A).  For these 
analyses, we used the gene amplification status established for each cell line in the 
previous chapter by quantitative PCR (Figure 3.2.8, Figure 3.2.10, Table 3.2.4).  We 
found that 80% (4/5) of TPD52-amplified cell lines had moderate to high lipid 
staining, compared to only 37.5% (6/16) of the non-amplified cell lines.  However, the 
difference in lipid staining according to TPD52 amplification status was not 
statistically significant (Fisher’s Exact test, p = 0.1486, n = 21).  Similarly, we found 
that 83.33% (5/6) of ERBB2-amplified cell lines had moderate to high lipid staining, 
compared to only 33.33% (5/15) of non-amplified cell lines, which was again not 
statistically significant (Fisher’s Exact test, p = 0.0635, n = 21).   
We next examined whether lipid droplet staining segregated according to 
TPD52 or ERBB2 protein level (Table 4.2.2, Figure 4.2.3B).  For these analyses, we 
used the protein level established for each cell line in the previous chapter by Western 
blot and densitometry (Figure 3.2.8, Figure 3.2.10, Table 3.2.4).  We found that 80% 
(8/10) of cell lines with moderate to high TPD52 protein levels displayed moderate to 
high lipid staining, compared to only 18.18% (2/11) of the cell lines with low TPD52 
protein levels.  This difference was statistically significant (Fisher’s Exact test,  
p = 0.0089, n = 21).  Similarly, we found that 85.71% (6/7) of cell lines with moderate 
to high ERBB2 protein levels displayed moderate to high lipid staining, compared to 
only 28.57% (4/14) of the cell lines with low ERBB2 protein levels.  This difference 
was also statistically significant (Fisher’s Exact test, p = 0.0237, n = 21). 
  
 
		 120 
 
Table 4.2.2. Summary of lipid droplet scores, TPD52 and ERBB2 amplification 
status and protein levels, and tumour type for cancer cell line cohort. 
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A.  
 
B.  
 
 
 
Figure 4.2.3. Lipid droplet staining according to TPD52 and ERBB2 status.  The 
graphs compare the percentage of cell lines with moderate/high lipid droplet scores 
(patterned) versus those with negligible/low lipid droplet scores (not patterned), 
according to (A) gene amplification status, or (B) protein expression level.  Lipid 
droplets were visualised by microscopy, with BODIPY staining, and scored semi-
quantitatively from three independent experiments.  Gene amplification status was 
determined by quantitative PCR, while protein levels were determined according to 
detection by Western blot and quantitation by densitometry.  Fisher’s exact test: N.S.  
p > 0.05, * p £ 0.05, ** p £ 0.01, n = 21.  
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Finally, we considered whether lipid droplet staining was significantly 
associated with tumour type.  Approximately half of our cohort (10/21) is comprised 
of cell lines derived from breast tissue, including the non-cancer breast epithelial cell 
line, MCF10A.  However, breast cell lines were significantly enriched in the moderate 
to high lipid staining category, representing 80% (8/10) of these cell lines, compared to 
only 18.8% (2/11) of the cell lines that displayed negligible or low lipid staining 
(Table 4.2.2).  Accordingly, there was a significant positive association between breast 
cell lines and increased lipid staining (Fisher’s Exact test, p = 0.0089, n = 21).  The 
only other tumour type to display moderate to high lipid staining within our cohort was 
lung cancer, representing 50% (2/4) of the lung cancer cell lines (HCC827 and 
NCIH1734, but not CORL23 or DMS454) (Table 4.2.2). 
 
4.2.2 Expression of key lipid droplet-associated proteins in cancer cell 
line cohort 
 In addition to differences in their appearance, lipid droplets display immense 
diversity in terms of the proteins that are found on their surfaces.  These proteins can 
define subpopulations of lipid droplets with differential responses to altered metabolic 
conditions, or indicate whether a lipid droplet is in a transient or persistent state 
(Figure 4.2.1).  Since adipophilin is the predominant PLIN protein found coating lipid 
droplets in non-adipocytes (Brasaemle et al., 1997; Kimmel and Sztalryd, 2016), we 
investigated its expression across our cancer cell line cohort.  Adipophilin was 
detectable by Western blot in the majority of cell lines, although relative adipophilin 
protein levels varied considerably (Figure 4.2.4A).  There was no obvious association 
between relative adipophilin and TPD52 protein levels (Figure 4.2.4B), with no 
statistically significant difference between median adipophilin levels in cell lines with 
moderate to high TPD52 versus low TPD52 levels (Mann-Whitney u test, p = 0.1402, 
n = 22).  ERBB2 protein levels, on the other hand, showed a significant inverse 
association with relative adipophilin protein levels (Figure 4.2.4B).  The median 
adipophilin level in cell lines with moderate to high ERBB2 levels was approximately 
one-third of that in cell lines with low ERBB2 levels (Mann-Whitney u test,  
p = 0.0029, n = 22).   
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A. 
 
B. 
 
 
 
Figure 4.2.4. Expression of the lipid droplet-associated protein adipophilin in 
cancer cell line cohort.  (A) Total cell lysates were subjected to Western blot analyses 
and densitometry was performed to quantitate the intensity of adipophilin protein 
bands, relative to the GAPDH loading control and normalised to the ratio measured in 
MCF10A cells (set at 1.0).  The graph displays quantitation results (y-axis) for each of 
the cell lines (x-axis) in the image shown, which was representative of 3 independent 
experiments.  The proteins analysed and the molecular weights of the detected species 
are labelled to the left and right, respectively. (B) The graph compares the distribution 
of relative adipophilin protein levels (y-axis) between cell lines with moderate to high 
TPD52 or ERBB2 protein levels and those with low TPD52 or ERBB2 levels (x-axis).  
The horizontal bars represent the median values for each category, which were 1.74 
and 3.33 for cell lines with moderate to high and low TPD52 levels, respectively, and 
1.23 and 3.68 for cell lines with moderate to high and low ERBB2 levels, respectively.  
Mann-Whitney u test: N.S. p > 0.05, ** p £ 0.01, n = 22.    
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We also investigated the expression of TIP47, another PLIN protein, which is 
thought to help stabilise nascent lipid droplets during their biogenesis (Bulankina et 
al., 2009) and is therefore found on smaller lipid droplets (Wolins et al., 2005).  
Relative TIP47 protein levels were less variable than relative adipophilin protein 
levels, but still showed differences between cell lines (Figure 4.2.5A).  There was no 
obvious association between relative TIP47 and TPD52 protein levels (Figure 4.2.5B), 
with no statistically significant difference between median TIP47 levels in cell lines 
with moderate to high TPD52 levels versus low TPD52 levels (Mann-Whitney u test,  
p = 0.5824, n = 22).  There was also no obvious association between relative TIP47 
and ERBB2 protein levels (Figure 4.2.5B), with no statistically significant difference 
between median TIP47 levels in cell lines with moderate to high ERBB2 versus low 
ERBB2 levels (Mann-Whitney u test, p = 0.4902, n = 22).   
 
4.2.3 Expression of key lipid metabolism proteins in cancer cell line 
cohort 
To gain a broader context for the diverse lipid droplet phenotypes that we 
observed in our cell line cohort, we next considered the expression of the key lipogenic 
enzyme FASN, whose overexpression and hyperactivity has been demonstrated in 
numerous cancer types (reviewed in Menendez and Lupu, 2007).  Relative FASN 
protein levels varied considerably between cell lines, with clear overexpression in six 
of the 22 cell lines, namely SKBR3, AU565, EVSAT, BT474, ZR7530, and EFM192A 
(Figure 4.2.6A).  Each of these FASN-overexpressing cell lines also featured moderate 
to high TPD52 levels (Table 4.2.2).  There was a significant positive association 
between relative FASN and TPD52 levels (Figure 4.2.6B), with the median FASN 
level approximately 3-fold higher in cell lines with moderate to high TPD52 levels 
than those with low TPD52 levels (Mann-Whitney u test, p = 0.0112, n = 22).  Each of 
the FASN-overexpressing cell lines also featured moderate to high ERBB2 levels.  
Accordingly, there was a positive association between relative FASN and ERBB2 
levels (Figure 4.2.6B).  This result was highly significant, with the median FASN level 
in cell lines with moderate to high ERBB2 levels being approximately 5-fold higher 
than that in cell lines with low ERBB2 levels (Mann-Whitney u test, p < 0.0001,  
n = 22).   
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A. 
 
B. 
 
 
Figure 4.2.5. Expression of the lipid droplet-associated protein TIP47 in cancer 
cell line cohort.  (A) Total cell lysates were subjected to Western blot analyses and 
densitometry was performed to quantitate the intensity of TIP47 protein bands, relative 
to the GAPDH loading control and normalised to the ratio measured in MCF10A cells 
(set at 1.0).  The graph displays quantitation results (y-axis) for each of the cell lines 
(x-axis) in the image shown, which was representative of 3 independent experiments.  
The proteins analysed and the molecular weights of the detected species are labelled to 
the left and right, respectively.  (B) The graph compares the distribution of relative 
TIP47 protein levels (y-axis) between cell lines with moderate to high TPD52 or 
ERBB2 protein levels and those with low TPD52 or ERBB2 levels (x-axis).  The 
horizontal bars represent the median values for each category, which were 0.88 and 
0.95 for cell lines with moderate to high and low TPD52 levels, respectively, and 1.00 
and 0.93 for cell lines with moderate to high and low ERBB2 levels, respectively.  
Mann-Whitney u test: N.S. p > 0.05, n = 22.  
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Figure 4.2.6. Expression of fatty acid synthase (FASN) in cancer cell line cohort.  
(A) Total cell lysates were subjected to Western blot analyses and densitometry was 
performed to quantitate the intensity of FASN protein bands, relative to the GAPDH 
loading control and normalised to the ratio measured in MCF10A cells (set at 1.0).  
The graph displays quantitation results (y-axis) for each of the cell lines (x-axis) in the 
image shown, which was representative of 3 independent experiments.  The proteins 
analysed and the molecular weights of the detected species are labelled to the left and 
right, respectively.  (B) The graph compares the distribution of relative FASN protein 
levels (y-axis) between cell lines with moderate to high TPD52 or ERBB2 protein 
levels and those with low TPD52 or ERBB2 levels (x-axis).  The horizontal bars 
represent the median values for each category, which were 3.26 and 1.01 for cell lines 
with moderate to high and low TPD52 levels, respectively, and 5.44 and 1.01 for cell 
lines with moderate to high and low ERBB2 levels, respectively.  Mann-Whitney u 
test: * p £ 0.05, **** p £ 0.0001, n = 22.   
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We also examined SREBP1 (sterol regulatory element-binding protein 1), a 
transcription factor that regulates the expression of genes involved in de novo 
lipogenesis (Bengoechea-Alonso and Ericsson, 2007).  We specifically considered 
levels of cleaved SREBP1 (70 kDa) because this corresponds to the active form of the 
transcription factor (Kamisuki et al., 2009; Li et al., 2014b).  Cleaved SREBP1 was 
detected in all cell lines (Figure 4.2.7A).  Accordingly, there was no obvious 
association between the relative protein levels of cleaved SREBP1 and either TPD52 
or ERBB2 levels (Figure 4.2.7B).  We found no statistically significant difference 
between median cleaved SREBP1 levels in cell lines with moderate to high TPD52 
versus low TPD52 levels (Mann-Whitney u test, p = 0.0503, n = 22) or in cell lines 
with moderate to high ERBB2 versus low ERBB2 levels (Mann-Whitney u test,  
p = 0.1229, n = 22).   
 
4.2.4 Lipid droplet phenotypes following TPD52 overexpression  
We next conducted transient TPD52 overexpression experiments in 
MDAMB231 cells to ascertain whether the observed lipid droplet phenotypes would 
be altered by the gain of TPD52 expression.  This cell line was chosen because the 
TPD52 gene is not amplified, TPD52 protein levels are low and cells display low lipid 
staining (Table 4.2.2).  MDAMB231 cells were transiently transfected with TPD52 for 
72 hours prior to the visualisation of lipid droplets by confocal microscopy (Figure 
4.2.8).  Quantitation of the images was then performed to facilitate the comparison of 
lipid droplet number and size between experimental conditions (Figure 4.2.9).  TPD52 
overexpression in MDAMB231 cells resulted in a striking increase in both parameters, 
when compared to control cells (Figure 4.2.8, Figure 4.2.9).  Specifically, the median 
lipid droplet number per cell in TPD52-overexpressing cells was 13.56, compared to 
zero in cells subjected to transfection reagent only or cells transfected with the control 
vector (Mann-Whitney u test, p < 0.0001, n = 50 or 49, respectively).  The median 
value for mean lipid droplet areas in TPD52-overexpressing cells was 4.5-fold higher 
than that in cells transfected with the control vector (Mann-Whitney u test, p < 0.0001, 
n = 38).     
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Figure 4.2.7. Levels of cleaved sterol regulatory element-binding protein 1 
(SREBP1) in cancer cell line cohort.  (A) Total cell lysates were subjected to 
Western blot analyses and densitometry was performed to quantitate the intensity of 
cleaved SREBP1 protein bands, relative to the HSP90 loading control and normalised 
to the ratio measured in MCF10A cells (set at 1.0).  The graph displays quantitation 
results (y-axis) for each of the cell lines (x-axis) in the image shown, which was 
representative of 3 independent experiments.  The proteins analysed and the molecular 
weights of the detected species are labelled to the left and right, respectively.  (B) The 
graph compares the distribution of relative cleaved SREBP1 protein levels (y-axis) 
between cell lines with moderate to high TPD52 or ERBB2 protein levels and those 
with low TPD52 or ERBB2 levels (x-axis).  The horizontal bars represent the median 
values for each category, which were 0.46 and 0.64 for cell lines with moderate to high 
and low TPD52 levels, respectively, and 0.44 and 0.59 for cell lines with moderate to 
high and low ERBB2 levels, respectively.  Mann-Whitney u test: N.S. p > 0.05, n = 22.   
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Figure 4.2.8. Visualisation of lipid droplets in MDAMB231 cells with and without 
transient TPD52 overexpression.  (A) MDAMB231 cells were subjected to the 
following conditions for 72 hours: parental (no treatment); transfection reagent (TR) 
only; transfection with a control vector; and transfection with a vector encoding HA-
tagged TPD52.  Cells were stained with BODIPY 493/503 for lipid droplets (green), 
antisera for TPD52 (red), and DAPI for nuclei (blue), and then visualised using 
confocal microscopy.  At least 20 images (equating to a total of approximately 300 
cells) were captured per condition, from randomly-selected fields of view.  The images 
are representative of results from one experiment.  Scale bar = 10 µm.  (B) TPD52 
overexpression was confirmed by Western blot, with HSP90 used as a loading control.   
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Figure 4.2.9. Quantitation of lipid droplets in MDAMB231 cells with and without 
transient overexpression of TPD52.  Images were analysed using Image-Pro Plus 7.0 
software to determine (A) lipid droplet numbers per cell (y-axis) and (B) mean lipid 
droplet area (µm2) (y-axis).  Each data point represents the quantitation results for a 
single image, with the number of images per condition indicated on the x-axes.  The 
images were captured from randomly-selected fields of view in one experiment.  
Horizontal lines indicate median values, bounded by interquartile ranges.  If an image 
showed zero lipid droplets (A), it was excluded from quantitation of mean lipid droplet 
area (B).  P values, Mann-Whitney u test. 
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We then sought to determine whether the changes observed in response to 
transient gain of TPD52 expression would be borne out in stable models.  We therefore 
visualised lipid droplets within MDAMB231 cell lines stably expressing either TPD52 
(H1 and H2) or vector (PG10 and PG13) (Figure 4.2.10).  Lipid droplet number and 
size were visibly increased in cells that stably expressed TPD52, compared to vector 
controls (Figure 4.2.10), with quantitation of TPD52-H2 and PG13 cell lines 
confirming a significant positive association between TPD52 overexpression and both 
lipid droplet parameters (Figure 4.2.11).  The images for TPD52-H1 and PG10 were 
not quantitated.  The median lipid droplet number per cell was approximately 3-fold 
higher in the TPD52-H2 cell line than in the PG13 vector control cell line (Mann-
Whitney u test, p < 0.0001, n = 40), while the median value for mean lipid droplet 
areas was approximately 2-fold higher in the TPD52-H2 cell line than in the PG13 cell 
line (Mann-Whitney u test, p < 0.0001, n = 40).   
 
4.2.5 Lipid droplet phenotypes following TPD52 knockdown  
Since lipid droplet number and size increased with TPD52 overexpression in 
MDAMB231 cells, we next queried whether a reduction in TPD52 expression would 
produce the opposing effect.  We conducted transient knockdown experiments in two 
breast cancer cell lines.  AU565 was chosen because it features TPD52 amplification 
and the equal highest levels of TPD52 protein of all cell lines in our cohort, as well as 
displaying moderate lipid staining (Table 4.2.2, Figure 3.2.8).  HMC18 was chosen 
because it has the highest lipid droplet staining of all cell lines in our cohort (Table 
4.2.1, Figure 4.2.2).  This cell line features gain of the TPD52 gene and low levels of 
TPD52 protein (Table 3.2.4, Table 4.2.2).  Both cell lines were subjected to transient 
knockdown with TPD52 siRNA for 72 hours prior to the visualisation and quantitation 
of lipid droplets. 
A moderate TPD52 knockdown of approximately 50% was achieved for 
AU565, with lipid droplets observed in all experimental conditions (Figure 4.2.12).  
Lipid droplet phenotypes in AU565 display a considerable degree of intra-cell line 
heterogeneity, even without treatment, which renders the selection of representative 
images problematic.  We therefore chose images in which lipid droplet numbers and 
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Figure 4.2.10. Visualisation of lipid droplets in MDAMB231 cells with and 
without stable overexpression of TPD52.  The derivation of MDAMB231 cell lines 
featuring stable TPD52 overexpression has been described previously (Boutros et al., 
2003).  (A) Cells were stained with BODIPY 493/503 for lipid droplets (green), 
antisera for TPD52 (red), and DAPI for nuclei (blue), and then visualised using 
confocal microscopy.  At least 20 images (equating to a total of approximately 200 
cells) were captured per condition, from randomly-selected fields of view.  The images 
are representative of results from one experiment.  Scale bar = 10 µm.  (B) TPD52 
protein levels were confirmed by Western blot, with HSP90 used as a loading control.  
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Figure 4.2.11. Quantitation of lipid droplets in MDAMB231 cells with and 
without stable TPD52 overexpression.  Images were analysed using Image-Pro Plus 
7.0 software to determine (A) lipid droplet numbers per cell (y-axis) and (B) mean 
lipid droplet area (µm2) (y-axis).  Each data point represents the quantitation results for 
a single image, with the number of images per condition indicated on the x-axes.  The 
images were captured from randomly-selected fields of view in one experiment.  
Horizontal lines indicate median values, bounded by interquartile ranges.  P values, 
Mann-Whitney u test. 
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Figure 4.2.12. Visualisation of lipid droplets in AU565 cells with and without 
transient knockdown of TPD52.  (A) AU565 cells were subjected to the following 
conditions for 72 hours: parental (no treatment); transfection reagent (TR) only; 
transfection with a non-targeting (NT) siRNA pool; and transfection with a TPD52 
siRNA pool.  Cells were stained with BODIPY 493/503 for lipid droplets (green), 
antisera for TPD52 (red), and DAPI for nuclei (blue), and then visualised using 
confocal microscopy.  At least 20 images (equating to a total of 300-350 cells) were 
captured per condition, from randomly-selected fields of view.  The images are 
representative of results from two independent experiments.  Scale bar = 10 µm.  (B) 
TPD52 knockdown was confirmed by Western blot analysis, with HSP90 used as a 
loading control.   
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sizes were closest to the medians calculated for each experimental condition (Figure 
4.2.13).  Quantitation revealed that TPD52 knockdown in AU565 cells was associated 
with fewer lipid droplet numbers per cell when compared to cells subjected to 
transfection reagent only (Mann-Whitney u test, p < 0.0001, n = 88).  There was no 
significant difference between median values for mean lipid droplet area between 
AU565 cells with TPD52 knockdown and those subjected to the transfection reagent 
only (Mann-Whitney u test, p = 0.2658, n = 83).  Importantly, however, a significant 
decrease in both lipid droplet number and size were observed for cells treated with the 
non-targeting siRNA pool, when compared to cells subjected to transfection reagent 
only (Mann-Whitney u test, p < 0.0001, n = 86 for lipid droplet number, and n = 79 for 
lipid droplet area).  This precludes the conclusive interpretation of the observed lipid 
droplet changes following TPD52 knockdown. 
A moderate TPD52 knockdown of approximately 50% was also achieved for 
HMC18, with lipid droplets again observed in all experimental conditions (Figure 
4.2.14).  Quantitation revealed that TPD52 knockdown was associated with reduced 
lipid droplet numbers, while lipid droplet size was not significantly affected (Figure 
4.2.15).  TPD52 knockdown in HMC18 cells was associated with fewer lipid droplet 
numbers per cell when compared to cells subjected to transfection reagent only (Mann-
Whitney u test, p = 0.0466, n = 67).  TPD52 knockdown was also associated with 
fewer lipid droplet numbers per cell when compared to cells transfected with non-
targeted siRNA (Mann-Whitney u test, p = 0.0020, n = 67).  There was no significant 
difference between median values for mean lipid droplet area between HMC18 cells 
with TPD52 knockdown and those subjected to the transfection reagent only (Mann-
Whitney u test, p = 0.3972, n = 67) or those transfected with non-targeting siRNA 
(Mann-Whitney u test, p = 0.5944, n = 67).  Unlike AU565 cells, there was no 
significant change in either lipid droplet number or size in cells treated with the non-
targeting siRNA pool, when compared to cells subjected to transfection reagent only 
(Mann-Whitney u test, p = 0.0935, n = 60 for lipid droplet number, and p = 0.0699,  
n = 60 for lipid droplet area).   
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Figure 4.2.13. Quantitation of lipid droplets in AU565 cells with and without 
transient knockdown (KD) of TPD52. Images were analysed using Image-Pro Plus 
7.0 software to determine (A) lipid droplet numbers per cell, normalised to the median 
for parental cells (y-axis) and (B) mean lipid droplet area (µm2), normalised to the 
median for parental cells (y-axis).  Each data point represents the quantitation results 
for a single image, with the number of images per condition indicated on the x-axes.  
The images were captured from randomly-selected fields of view in two independent 
experiments.  Horizontal lines indicate median values, bounded by interquartile ranges.  
If an image showed zero lipid droplets (A), it was excluded from quantitation of mean 
lipid droplet area (B).  P values, Mann-Whitney u test.  
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Figure 4.2.14. Visualisation of lipid droplets in HMC18 cells with and without 
transient knockdown of TPD52.  (A) HMC18 cells were subjected to the following 
conditions for 72 hours: parental (no treatment); transfection reagent (TR) only; 
transfection with a non-targeting (NT) siRNA pool; and transfection with a TPD52 
siRNA pool.  Cells were stained with BODIPY 493/503 for lipid droplets (green), 
antisera for TPD52 (red), and DAPI for nuclei (blue), and then visualised using 
confocal microscopy.  At least 15 images (equating to a total of 350-400 cells) were 
captured per condition, from randomly-selected fields of view.  The images are 
representative of results from two independent experiments.  Scale bar = 10 µm.  (B) 
TPD52 knockdowns were confirmed by Western blot, with HSP90 used as a loading 
control.   
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Figure 4.2.15. Quantitation of lipid droplets in HMC18 cells with and without 
transient knockdown (KD) of TPD52.  Images were analysed using Image-Pro Plus 
7.0 software to determine (A) lipid droplet numbers per cell, normalised to the median 
for parental cells (y-axis) and (B) mean lipid droplet area (µm2), normalised to the 
median for parental cells (y-axis).  Each data point represents a single image, with the 
number of images per condition indicated on the x-axes.  The images were captured 
from randomly-selected fields of view in two independent experiments.  Horizontal 
lines indicate median values, bounded by interquartile ranges.  P values, Mann-
Whitney u test.  
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4.2.6 Protein interactions between TPD52 and lipid droplet-associated 
proteins 
Finally, we explored the possibility that TPD52 could interact directly with 
lipid droplet-associated proteins.  TPD52 has been previously predicted to interact 
with perilipin and TIP47, two members of the PLIN protein family of lipid droplet-
associated proteins, which function as important regulators of lipid storage 
(Yamaguchi et al., 2006; Zhang et al., 2007).  Since perilipin is predominantly 
expressed in adipocytes (Kimmel and Sztalryd, 2016), we focused on validating the 
predicted interaction with TIP47 and investigating whether an interaction might also 
occur with adipophilin, which is commonly found on lipid droplets in non-adipocytes.  
We began our investigations in the yeast two-hybrid system, with interaction strengths 
assessed qualitatively by monitoring the time taken for co-transformed yeast cells to 
grow on synthetic dropout (SD) media lacking the amino acids histidine, leucine, and 
tryptophan.  Yeast cells co-transformed with TPD52 prey and either TIP47 or 
adipophilin bait constructs demonstrated growth after 3 days and 5 days, respectively 
(Figure 4.2.16A).  Interestingly, there was no detectable growth after 9 days when the 
TIP47 or adipopilin bait constructs were co-transformed with a prey construct 
encoding TPD52L1, another member of the TPD52-like protein family.  Bait or prey 
constructs co-transformed with the opposing empty vector (pACT2 or pAS2.1, 
respectively) served as negative controls, while the known interaction between TPD52 
and TPD52L1 was used as a positive control (Byrne et al., 1998b). 
To further validate the interaction between TPD52 and adipophilin, we then 
performed GST pulldown assays.  The GST-tagged TPD52 was first immobilised by 
cross-linking to the GSH beads and then incubated with lysates from two stably 
TPD52-expressing 3T3 fibroblast cell lines (D52-1-12 and D52-2-7).  Adipophilin 
interacted with both GST-tagged mouse and human TPD52, but not with the GST tag 
alone (Figure 4.2.16B).  The previously established interaction between TPD52 and 
Rab5 was used as a positive control (Shahheydari et al., 2014).   Taken together, the 
results of the yeast two-hybrid and GST pulldown assays indicate that TPD52 is able 
to directly interact with the lipid droplet-associated proteins adipophilin and TIP47, 
and that these interactions are specific to TPD52 and not the related TPD52L1.   
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Figure 4.2.16. Protein interactions between TPD52 and adipophilin (ADRP) or 
TIP47.  (A) Direct interactions between TPD52 or TPD52L1 and ADRP or TIP47 
were tested in the yeast two-hybrid system.  Interaction strength was assessed 
qualitatively according to the time taken for co-transformant growth on SD/-His-Leu-
Trp media at 30°C: ‘+++’ indicates growth after 1-2 days; ‘++’ indicates growth after 
3-4 days; ‘+’ indicates growth after 5-6 days; and ‘-’ indicates no growth after at least 
7 days.  ‘ND’ indicates that the interaction was not determined.  The table summarises 
results from three independent experiments, where each interaction was assessed in 
triplicate.  (B) The interaction between TPD52 and ADRP was further tested using a 
GST pulldown assay.  GST-tagged full-length mouse Tpd52 or human TPD52 was 
incubated with lysates from two stably TPD52-expressing 3T3 mouse fibroblast cell 
lines (D52-1-12 and D52-2-7).  The upper and middle panels show the results of 
Western blot analyses using Adrp and Rab5 antisera, respectively.  The lower panel 
shows Ponceau S staining, revealing GST-Tpd52, GST-TPD52, and the GST tag 
before cross-linking.  The images are representative of results from three independent 
experiments. 
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4.3 Discussion 
In this chapter, we investigated whether TPD52 amplification and/or 
overexpression in cancer cells is broadly associated with increased lipid storage, or 
altered expression of lipid droplet-associated proteins and key metabolic enzymes.  We 
then considered whether there were any significant differences for those cell lines 
featuring TPD52 and ERBB2 co-amplification and/or overexpression.  Next, we 
examined whether the reduction or gain of TPD52 expression altered these 
observations for a subset of cell lines.  Finally, we validated predicted interactions 
between TPD52 and the lipid droplet-associated proteins, TIP47 and adipophilin. 
 
4.3.1 TPD52 association with increased lipid droplets in cancer cell 
lines 
A possible role for TPD52 in the modulation of lipid storage and/or 
metabolism was hypothesised following the discovery that TPD52 overexpression in 
mouse 3T3 fibroblast cells is accompanied by increased neutral lipid storage (Kamili 
et al., 2015).  This raised the interesting possibility that TPD52 may be operating 
within lipid metabolic pathways and that it is perhaps this aspect of TPD52 function 
that is targeted by its frequent amplification and overexpression in cancer.  We 
therefore aimed to ascertain whether TPD52 amplification and/or overexpression in 
cancer cells is broadly associated with altered lipid storage and/or metabolism, and 
whether these phenotypes would be altered by the reduction or gain of TPD52 
expression. 
Although there was incomplete concordance between TPD52 status and lipid 
droplet score for the 21 cell lines investigated, we found that moderate to high lipid 
staining was significantly more frequent among cell lines with moderate to high 
TPD52 protein levels (8/10, 80%) than those with low TPD52 levels (2/11, 18.18%).  
The same proportion (4/5, 80%) of TPD52-amplified cell lines was found to have 
moderate to high lipid staining, however, this was not statistically significant when 
compared to TPD52 non-amplified cell lines.  This is likely due to the higher 
proportion (6/16, 37.5%) of moderate to high lipid staining cell lines in the TPD52 
non-amplified category, which reflects the inclusion of cell lines that overexpress 
TPD52 via an alternative mechanism.  These data suggest that there is an association 
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between TPD52 overexpression and increased neutral lipid storage, while the 
incomplete nature of this association provides two important insights.  First, it supports 
the existence of multiple mechanisms leading to lipid droplet accumulation.  Second, it 
reveals that TPD52 overexpression does not necessarily lead to increased lipid droplets 
in all cells, suggesting that this phenotype may be uniquely present in a subset of cell 
lines that have complementary genomic alterations or were derived from a specific 
cancer type (to be discussed further in section 4.3.2).  Taken together, these results 
suggest that TPD52 plays a supporting role in the pathways that regulate lipid droplets. 
An important caveat for interpretation of the association between TPD52 lipid 
droplet scores within these cell lines is the relatively small cohort examined.  The 
current study represents the first analysis of its type and, as such, was intended as an 
exploratory pilot study.  The number of cell lines examined was restricted due to the 
time-consuming nature of the profiling experiments required.  We did, however, 
endeavour to select the most appropriate cell lines by pre-profiling a larger cohort of 
cell lines in silico using existing data from the Cancer Cell Line Encylopedia (as 
described in Chapter 3).  Additionally, whilst categorical scoring of lipid staining was 
appropriate for these preliminary screening experiments, this methodology 
oversimplifies what we have shown to be a highly variable phenotype.  The moderate 
lipid droplet category, for example, spans a range of lipid staining that includes both 
MCF7 and BT474, with the former identified by a previous study as having less than 
half the amount of fatty acids as BT474 (Kourtidis et al., 2010).  We observed that 
variation in lipid droplets is even present within a given cell line: between cells of the 
same image; between different images of the same slide; and between experimental 
replicates.  This level of variation has been consistently reported in the lipid droplet 
field and is therefore not surprising (reviewed in Thiam and Beller, 2017).  Our 
experiments have laid the technical groundwork for the translation of these 
investigations to a high-content microscopy platform, which will generate continuous 
quantitative data that is expected to more accurately capture subtle variations in lipid 
staining.  Future experiments will also involve biochemical quantification of 
intracellular triacylglyceride levels.  That a significant association between TPD52 and 
intracellular lipid storage was observed even with categorical scoring in a small cell 
line cohort, argues strongly for the value of these future studies.   
To further understand the nature of the association between TPD52 and 
intracellular lipid storage, we investigated the effect of either increasing or reducing 
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TPD52 expression.  Both the transient and stable overexpression of TPD52 in 
MDAMB231 cells, which otherwise feature low levels of endogenous TPD52, resulted 
in a dramatic increase in lipid droplet number and size.  These increases in lipid 
droplets with exogenous TPD52 expression are consistent with the phenotypes 
previously observed for TPD52-expressing 3T3 cells (Kamili et al., 2015).  The 
current results are particularly striking given the size of the effect observed, with the 
median lipid droplet number per cell in TPD52-overexpressing cells being 
approximately 14, compared to zero in cells transfected with the control vector.  The 
results of transient TPD52 knockdown, however, were more ambiguous.  In AU565 
cells, which feature TPD52 amplification and overexpression, reduced TPD52 
expression resulted in a decrease in lipid droplet number, but not size, when compared 
to cells treated with the transfection reagent alone.  Importantly, however, significant 
changes in both lipid droplet number and size were also observed for cells treated with 
the non-targeting siRNA pool, when compared to cells treated with transfection 
reagent alone, which precludes the interpretation of these results.  In HMC18 cells, 
which feature low TPD52 expression, reducing TPD52 expression produced a subtle 
decrease in lipid droplet number, but not size, when compared to cells treated with the 
transfection reagent alone or the non-targeting siRNA control.  
The difference between the striking results of TPD52 overexpression and the 
ambiguous results of TPD52 knockdown could be attributable to several experimental 
factors.  Firstly, there was significant disparity in protein fold-change achieved in 
overexpression versus knockdown experiments, with the large increases in TPD52 
expression, particularly for the transiently transfected cells, representing a much more 
dramatic deviation from control than the more moderate reductions achieved in the 
knockdown cells.  Secondly, TPD52 knockdown also reduced cell viability for AU565 
(data not shown), which has potential ramifications for dysregulated cellular 
metabolism.  This is consistent with previous reports of TPD52 as a survival factor in 
SKBR3 cells (Roslan et al., 2014), which were derived from the same patient as 
AU565, and in other ERBB2-overexpressing breast cancer cell lines more generally 
(Kourtidis et al., 2010).  Finally, it must be noted that treatment with the transfection 
reagent alone in the knockdown experiments increased both the median lipid droplet 
numbers per cell as well as the interquartile range for the data. The presence of 
transfection reagent could therefore have introduced an opposing inf
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droplet numbers, as well as increasing data noise, which may have masked the effect 
of TPD52 knockdown.  
In addition to these technical explanations, it is also possible that the difference 
between the effect of increasing versus decreasing TPD52 expression reflects a true 
biologically-relevant difference in the way that altered TPD52 expression impacts lipid 
droplet phenotypes.  For instance, while the 72-hour timeframe of these transient 
transfections might be sufficient for an increase in TPD52 to result in new or larger 
lipid droplets, it could be too brief for a reduction in TPD52 to significantly alter 
existing lipid droplets.  This would depend on the mechanism by which TPD52 
promotes an increase in lipid droplets and would reflect the different dynamics of 
processes such as lipid synthesis, trafficking, storage, and breakdown, which 
collectively regulate lipid droplet number and size.  Modest decreases in fat stores 
have been previously reported with ERBB2 knockdown in BT474 after 48 hours, 
indicating that this timeframe can be sufficient to observe changes, as well as revealing 
that the effects of reductions in lipogenic genes can be relatively small (Kourtidis et 
al., 2010).  Furthermore, it is possible that compensation by other proteins may 
account for the modest phenotypes observed.  Future knockdown and overexpression 
studies will be performed using a high-content microscopy platform.  These 
experiments are expected to resolve the ambiguities associated with the current TPD52 
knockdown results, as well as more accurately quantify the fold-change observed with 
TPD52 overexpression in MDAMB231 cells.  In the future it would also be 
worthwhile to extend these investigations to include more cell lines, as well as to 
derive a stable knockdown model, overcoming some of the technical issues associated 
with transient knockdown. 
 
4.3.2 Potential cooperation between TPD52 and ERBB2 
overexpression and/or tumour type in altering lipid droplet 
phenotypes  
As discussed above, we have shown an incomplete concordance between 
increased TPD52 expression and increased lipid droplets, which indicates that this 
phenotype is uniquely present in a subset of cell lines.  We hypothesised that this 
subset might be characterised by complementary genomic alterations, such as ERBB2 
amplification and/or overexpression, or be derived from a specific cancer type, such as 
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breast cancer.  This is because a lipogenic phenotype has been consistently reported for 
ERBB2-positive breast cancers and cell lines (section 1.2.3.2; Kumar-Sinha et al., 
2003; Menendez and Lupu, 2007; Kourtidis et al., 2010; Kim et al., 2015).  We 
reasoned that, if TPD52 promotes lipid storage, its overexpression may complement 
the lipogenic phenotype of ERBB2-positive cells by allowing them to rely upon high 
levels of intracellular lipid without the associated risk of lipotoxicity. 
Our results support the anticipated positive association between ERBB2 status 
and lipid droplet score, with moderate to high lipid staining significantly more frequent 
among cell lines with moderate to high ERBB2 protein levels (6/7, 85.71%) than those 
with low ERBB2 levels (4/14, 28.57%).  When considering the association between 
lipid droplet score and ERBB2 co-overexpression with TPD52, we observed the same 
proportions.  This is because all seven of the ERBB2-overexpressing cell lines were 
found to have either moderate or high TPD52 levels.  We had originally selected 
several cell lines that we expected to feature ERBB2 overexpression only, based upon 
their amplification status; however, we subsequently found TPD52 to also be 
expressed at moderate to high levels in these cell lines (Figure 3.2.8, Figure 3.2.10, 
Table 3.2.4).  Without an ERBB2-only group, we cannot analyse whether lipid droplet 
phenotypes are significantly different in ERBB2 and TPD52 co-overexpressing cells 
when compared to those overexpressing ERBB2 alone.  Our results do, however, 
demonstrate that the subset of TPD52-overexpressing cell lines with increased lipid 
droplets is not exclusively comprised of cell lines with ERBB2 co-overexpression, as 
evidenced by HCC827 and NCIH1734.  Whether or not the increased expression of 
TPD52 is directly contributing to this phenotype in these cell lines remains to be 
determined.  Clearly further studies are required to elucidate the potential functional 
cooperation between TPD52 and ERBB2 in the pathways regulating lipid droplets. 
It is also important to consider the potential influence of tumour type on lipid 
metabolism and/or storage, as well as the effect that this may have had on our 
analyses.  We have shown a significant association between lipid staining and the 
breast cell lines within our cohort.  However, TPD52 (and ERBB2) overexpression is 
also associated with breast cancer.  Of the ten cell lines with moderate to high lipid 
staining, six were both TPD52 (and ERBB2) overexpressing and derived from breast 
cancer (SKBR3, AU565, EVSAT, BT474, ZR7530, and EFM192A).  This makes it 
difficult to infer the direction, if any, of the observed associations.  On the one hand, 
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the association between TPD52 and lipid staining in our cohort might be driven by its 
frequent overexpression in a cancer type that is independently susceptible to lipid 
droplet accumulation.  Breast cancer, in particular, may be characterised by a lipogenic 
phenotype given the physiological function of breast epithelial cells in the uptake, 
synthesis, and secretion of lipid during late pregnancy and lactation (Kamili and 
Byrne, 2014).  The breast cancer cell line HMC18, for example, displays the highest 
lipid staining of the cohort but has low protein levels of both TPD52 and ERBB2.  On 
the other hand, it might be the increased expression of TPD52 in breast cancer cell 
lines that is responsible for their frequently reported lipid droplet accumulation.  
Importantly, we revealed that lipid droplets were increased in two lung cell lines 
(HCC827 and NCIH1734) that overexpress TPD52.  Yet another option is that lipid 
droplet accumulation occurs via a combination of increased TPD52 expression in a 
‘permissive’ cancer type.  It should be noted that of the seven cell lines with TPD52 
and ERBB2 co-overexpression, the six that displayed moderate to high lipid staining 
were all breast cancer cell lines, while the one cell with low to negligible lipid staining 
was an oesophageal cancer cell line (TE4).  Since low cell line numbers preclude 
statistical testing of the association between TPD52 expression and lipid droplet score 
in breast cancer cells only, further studies with a larger cell line cohort will be required 
to resolve this issue.   
 Finally, we were also interested in whether TPD52 and MYC might also 
cooperate in the pathways regulating lipid droplets.  However, the unexpectedly high 
level of MYC overexpression in our cohort rendered it unsuitable for making these 
comparisons (Figure 3.2.9, Table 3.2.4).  Myc knockdown in rat fibroblasts reduced 
the amount of acetyl-CoA available for de novo lipid synthetic pathways, decreased 
transcript levels of key synthetic enzymes ACLY, ACC, FASN (fatty acid) and 
HMGCR (cholesterol), and preferentially directed exogenous fatty acids into energy 
production or storage rather than anabolic processes such as phospholipid production 
(Edmunds et al., 2014).  The inhibition of MYC function has also been shown to lead 
to an accumulation of intracellular lipid droplets in neuroblastoma cells due to 
mitochondrial dysfunction (Zirath et al., 2013).  In the previous chapter, we 
demonstrated that MYC amplification is a feature of most TPD52-amplified cells, and 
therefore the potential exists for functional cooperation between these oncogenes.  If 
MYC is involved in the regulation of enzymes involved in lipid metabolism, or their 
substrates, then a potential role for TPD52 in modulating lipid storage could 
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complement these activities.  Pursuing this hypothesis represents another possible 
avenue for future study. 
 
4.3.3 Potential roles for TPD52 in lipid storage and/or metabolism  
With evidence of a positive association between TPD52 expression and lipid 
staining within our cell line cohort, and a dramatic increase in lipid droplet number and 
size with exogenous TPD52 overexpression, we next considered the potential 
mechanisms by which TPD52 might operate.  Since TPD52 was predicted by two 
separate studies to interact with two important regulators of lipid storage, perilipin and 
TIP47 (Yamaguchi et al., 2006; Zhang et al., 2007), we began our investigations there.  
We found that TPD52 is able to bind both adipophilin and TIP47 in the yeast two-
hybrid system, with the adipophilin interaction validated by GST pulldown assays.  
There was no significant association between TPD52 and either adipophilin or TIP47 
protein levels among our cell line cohort.  Furthermore, adipophilin expression was 
unchanged by the exogenous expression of TPD52 in 3T3 fibroblast cells (Nuruliza 
Roslan, unpublished data).  The ability of TPD52 to interact directly with adipophilin 
and TIP47 suggests that it could function with these proteins at the lipid droplet 
surface to promote lipid storage and/or trafficking. 
 It is appropriate to be cautious when interpreting the results of yeast two-hybrid 
and GST pulldown interaction studies, since these approaches can identify false 
positive interactions between proteins that are either segregated spatially (through 
localisation in different subcellular compartments) or temporally (with their expression 
differentially regulated throughout the cell cycle or in response to active signalling 
pathways).  However, mounting evidence from our laboratory now supports the 
targeting of TPD52 to lipid droplets, which would place it in close proximity to 
adipophilin and TIP47.  TPD52 has been detected in the lipid droplet fraction of 
TPD52-expressing 3T3 fibroblast cells (Kamili et al., 2015), which is consistent with 
detection of the Drosophila orthologue CG5174 in the lipid droplet proteome 
(Cermelli et al., 2006).  A small proportion of TPD52 has been shown to co-localise 
with adipophilin-coated lipid droplets in TPD52-expressing 3T3 fibroblast cells, with 
this co-localisation increasing significantly upon supplementation with oleic acid 
(Kamili et al., 2015).  TPD52 expression was also associated with a redistribution of 
adipophilin-coated lipid droplets from the perinuclear regions of vector control cells to 
		 148 
the periphery of TPD52-expressing cells (Kamili et al., 2015).  
Importantly, interactions with adipophilin and TIP47 were not observed for 
another member of the TPD52-like protein family, TPD52L1.  Unlike TPD52, 
TPD52L1 is not overexpressed in breast cancer and its stable expression in 3T3 cells 
did not increase proliferation or anchorage-independent growth (Shehata et al., 2008b).  
This suggests the existence of isoform-specific functions for TPD52 that are not shared 
by TPD52L1, which are likely to underpin the oncogenicity of TPD52 overexpression. 
However, previous investigations have failed to identify these isoform-specific 
functions.  TPD52 and TPD52L1 exhibit functional redundancy in terms of their 
ability to bind to each other and other members of the TPD52-like protein family, as 
well as to previously-identified protein partners (Byrne et al., 1998b; Wilson et al., 
2001; Proux-Gillardeaux et al., 2003; Shahheydari et al., 2014).  The current study 
represents the first time that protein partners specific to TPD52 have been identified.  
It is not presently known why TPD52 but not TPD52L1 is able to bind adipophilin and 
TIP47.  We have hypothesised that a 14-3-3-binding site, which is encoded on an 
alternatively-spliced exon that is commonly included in TPD52L1 transcripts but less 
frequently in TPD52 transcripts, may act as a molecular switch to render interactions 
with 14-3-3 proteins and PLIN proteins mutually exclusive (Kamili et al., 2015).  This 
hypothesis is supported by the less frequent inclusion of a 14-3-3-binding site in 
isoforms of another TPD52-like protein, TPD52L2, which has been reported as a lipid 
droplet-associated protein in numerous proteomic studies (Brasaemle et al., 2004; 
Umlauf et al., 2004; Sato et al., 2006; Cho et al., 2007; Wan et al., 2007; Hodges and 
Wu, 2010).   
To further explore the molecular mechanisms contributing to increased lipid 
droplets in TPD52-overexpressing cells, we also examined the levels of two key lipid 
metabolic proteins, FASN and SREBP1.  FASN is a key enzyme in the de novo 
synthesis of fatty acids, which has been previously associated with ERBB2-expression 
in breast cancers (Kumar-Sinha et al., 2003; Menendez and Lupu, 2007).  We found a 
significant positive association between TPD52 and FASN levels; however, since the 
majority (7/10) of cell lines with moderate to high TPD52 levels also had moderate to 
high ERBB2 levels, it is unclear whether this association could be partially driven by 
the strong positive association between ERBB2 and FASN levels in our cell line 
cohort.  FASN expression was not altered by transient TPD52 knockdown, nor was it 
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increased in MDAMB231 cells that transiently or stably overexpress exogenous 
TPD52 (data not shown), even though we found these cells to have significant 
increases in lipid droplets.  This suggests that the role of TPD52 in promoting lipid 
droplet accumulation is independent of FASN.  Furthermore, we found no significant 
association between TPD52 and cleaved SREBP1 levels.  Similarly, we observed no 
change in cleaved SREBP1 levels in response to TPD52 knockdown or overexpression 
(data not shown).  This suggests that there is no change to the transcriptional activation 
of SREBP1-regulated genes in the de novo lipogenesis pathway in these cells.  
 
4.4 Summary and conclusions 
We have investigated lipid storage and metabolism in cancer cell lines with and 
without TPD52 amplification and/or overexpression.  This first systematic analysis of 
its type demonstrates that there is a significant positive association between TPD52 
expression and lipid droplet staining.  Our results also substantiate previous reports of 
increased lipid droplets in ERBB2-overexpressing breast cancer cell lines, while 
indicating that increased TPD52 expression and lipid droplets can also occur in cell 
lines that are not ERBB2-overexpressing or derived from breast cancers.  The 
exogenous overexpression of TPD52 in MDAMB231 cells produced a dramatic 
increase in lipid droplet number and size.  TPD52, but not TPD52L1, is able to interact 
directly with the lipid droplet-associated proteins, adipophilin and TIP47; however, 
there was no significant association between the expression levels of TPD52 and 
adipophilin or TIP47.  The incomplete concordance between TPD52 status and lipid 
droplets or key lipid metabolic proteins indicates that there are multiple mechanisms 
responsible for the accumulation of lipid droplets in cancer cell lines.  A better 
understanding of these mechanisms will not only expand our knowledge within the 
important and rapidly-growing field of cancer metabolism research, but may also help 
us to identify new ways to target lipogenic cancers.  If TPD52 overexpression is 
indeed associated with altered lipid metabolism in a defined subset of cancers, it may 
represent a valuable marker for predicting cancers that are reliant upon high lipid 
levels for survival.  These cancers could then be treated with increased efficacy by 
designing combinatorial treatment regimens that include drugs to interfere with lipid 
pathways.  
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Chapter 5 
 
Novel associations between TPD52 
amplification and/or overexpression 
and cancer cell line chemo-sensitivity. 
 
 
5.1 Introduction  
Substantial international research effort has been directed towards identifying 
gene amplification events during cancer development, with the view that these 
represent promising therapeutic targets or otherwise highlight pathways for therapeutic 
intervention (Harris and McCormick, 2010).  The movement towards molecularly 
targeted treatment is premised on the idea that cancer cells are particularly vulnerable 
to the disruption of key oncogenic pathways, in ways that normal cells are not.  
Interestingly, despite the extensive genomic alterations that are found in cancer cells, 
many tumours have been shown to be reliant upon the activity of a single dominant 
oncogene for their growth and survival (reviewed in Weinstein and Joe, 2006; Sharma 
and Settleman, 2007; Torti and Trusolino, 2011).  The amplification targets, MYC and 
ERBB2, were both early examples of this phenomenon, which has come to be known 
as ‘oncogene addiction’ (Weinstein, 2000; 2002).  Oncogenes that are activated 
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through amplification (or mutation), rather than overexpression, are thought to be more 
closely aligned with oncogene addiction because they likely reflect the ‘hard-wiring’ 
of cancer cells (Weinstein and Joe, 2008).  The concept of ‘non-oncogene addiction’ 
has also been developed to describe the heightened dependence of cancer cells on 
genes and pathways that support oncogenic phenotypes (Solimini et al., 2007; Luo et 
al., 2009; Nagel et al., 2016).  This recognises that oncogene-addicted cancers often 
rely on extensive complementary adaptations, which therefore become vulnerabilities 
that may be exploited therapeutically. 
As a candidate amplification target, TPD52 warrants investigation as a 
therapeutic target.  In Chapter 3, we found that TPD52 amplification characterised 
4.0% (40/995) of cancer cell lines in the Cancer Cell Line Encyclopedia (CCLE) and 
occurred across a range of tumour types.  TPD52 overexpression in association with 
gain of the corresponding locus at 8q21.13 has been demonstrated in breast, prostate, 
and ovarian cancers (Balleine et al., 2000; Rubin et al., 2004; Wang et al., 2004; 
Byrne et al., 2005). TPD52 amplification and/or overexpression has also been 
persistently associated with poorer outcomes in breast and prostate cancer (Shehata et 
al., 2008b; Nakagawa et al., 2008; Zhang et al., 2009; Ross et al., 2011; Roslan et al., 
2014; Liu et al., 2013).  However, although the breadth and clinical significance of 
TPD52 overexpression in cancer is now well-established, this knowledge has not yet 
been translated into treatment.  The transient depletion of TPD52 in ERBB2-positive 
breast cancer cell lines has been shown to result in significantly increased apoptotic 
cell death, suggesting that therapeutic targeting of TPD52 could be effective in some 
cancers (Roslan et al., 2014).  Furthermore, in addition to TPD52’s promise as a 
therapeutic target in its own right, we hypothesise that TPD52 amplification and/or 
overexpression could represent a biomarker of drug sensitivity or resistance in 
different cancers.  For example, if TPD52 overexpression is indeed associated with 
altered lipid metabolism in a defined subset of cancers, as we explored in Chapter 4, it 
may represent a valuable marker for predicting cancers that are reliant upon high lipid 
levels for survival.  In this way, TPD52 amplification and/or overexpression could be 
applied clinically as a predictive marker for cancers likely to respond to drugs that 
interfere with lipid pathways. 
The repurposing of existing drugs has emerged as an important avenue for new 
cancer treatments and opportunities for the identification of new drug applications 
have been greatly enhanced by recent large-scale pharmacogenomic studies. Drug 
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repurposing, or repositioning, refers to the use of existing drugs outside of their 
original scope or indication (Ashburn and Thor, 2004).  In the context of cancer 
treatment, this may involve the repositioning of a drug currently used for one type of 
cancer to another type of cancer (Kim et al., 2017), or it may involve the use of a drug 
from another disease altogether, as for metformin (Chae et al., 2016).  Drug 
repurposing carries the advantages of faster translation to the clinic and reduced risks, 
since many of the drugs have passed clinical trials and consequently already have 
described safety and pharmacokinetic profiles (Ashburn and Thor, 2004). In 2012, two 
landmark pharmacogenomic studies were published side by side: the Cancer Genome 
Project (CGP), out of the United Kingdom (Garnett et al., 2012), and the Cancer Cell 
Line Encyclopedia (CCLE), out of the United States (Barretina et al., 2012). The latter 
study was extended in the following year with the release of the Cancer Therapeutics 
Response Portal (CTRP; Basu et al., 2013). The datasets generated by each of these 
studies were made publicly-available resources, providing an unprecedented 
opportunity for identifying new associations between existing drugs and genomic 
alterations in cancer. 
We therefore considered whether we could mine these pharmacogenomic 
datasets to uncover novel associations between TPD52 amplification or overexpression 
and cancer cell line chemo-sensitivity or -resistance. We also examined the known 
amplification targets, ERBB2 and MYC, since these have been associated with both 
TPD52 amplification and/or overexpression (Byrne et al., 1995; Wilson et al., 2002; 
Kallioniemi et al., 1994; Kourtidis et al., 2010; Cher et al., 1994; Kallioniemi et al., 
1995; Zhu et al., 2007; Rodriguez et al., 2007; Choschzick et al., 2010).  These 
investigations test, for the first time, whether TPD52 amplification and/or 
overexpression represents a biomarker of drug sensitivity or resistance in different 
cancers.  
 
5.1.1 Aims of this chapter 
The specific aims of this chapter were as follows: 
1. To design a predictive modelling approach that facilitates the identification of 
novel drug-gene associations 
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2. To predict novel associations between TPD52 amplification and/or 
overexpression and altered sensitivity or resistance to drugs within the CCLE 
and CTRP databases 
3. To predict novel associations between MYC or ERBB2 amplification and/or 
overexpression and altered sensitivity or resistance to drugs within the CCLE 
and CTRP databases 
 
5.2 Results 
5.2.1 Dataset selection, filtering, and curation  
We first evaluated each of the large pharmacogenomic studies (Garnett et al., 
2012; Barretina et al., 2012; Basu et al., 2013) to determine which of these would be 
the most useful for our purposes.  These comparisons are summarised in Table 5.2.1.  
We restricted our evaluation to these landmark studies because their predecessors 
tended to favour either a large number of drugs or a large panel of cell lines, but not 
both (for example: Shoemaker et al., 1988; Weinstein et al., 1997; Staunton et al., 
2001; Shoemaker et al., 2006; McDermott et al., 2007; Sos et al., 2009; Greshock et 
al., 2010; Heiser et al., 2012).  We then reasoned that combining the CCLE and the 
CTRP would provide the largest pool of drugs, while maintaining a sufficient number 
and diversity of cancer cell lines.  Furthermore, the CTRP widens the pool of drugs 
beyond anticancer therapeutics to incorporate small molecules that target numerous 
cellular processes, including but not limited to the DNA damage response, apoptosis, 
and metabolism (Basu et al., 2013).  Such drugs potentially act within the pathways 
upon which cancer cells are highly dependent, including those in which TPD52 could 
operate.  This approach therefore maximises the opportunity for the identification of 
novel compounds associated with TPD52 amplification and/or overexpression.  
We accessed datasets containing gene copy number and gene expression for 
each cancer cell line from the CCLE.  We then filtered these datasets to include only 
those cell lines with accompanying drug response data from either the CCLE or the 
CTRP.  Finally, we cleaned the datasets to exclude any cell lines with missing copy 
number or expression data for TPD52, MYC, or ERBB2.  Overall, predictive modelling 
was possible for 24 drugs in up to 487 cell lines from the CCLE, and for 323 drugs in
		
Table 5.2.1. Summary of large pharmacogenomic studies in cancer cell lines.  
Study 
Cancer cell lines Genomic annotation Pharmacological annotation 
Number of cell lines 
screened per drug a 
Tumour 
types 
Gene copy 
number 
Gene 
expression 
Gene 
mutations 
Number 
of drugs Drug types 
Cancer Genome 
Project (CGP) 
 
Garnett et al., 2012 
 275 – 507  
(mean = 368)  16 
Genome-wide 
(i.e. all genes)  
> 14,500 
genes 
64 
commonly 
mutated 
cancer 
genes 
130 
§ Mixture of targeted 
and cytotoxic drugs 
§ Drugs approved for 
clinical practice 
§ Drugs in clinical and 
preclinical testing  
§ Experimental tools  
 
Cancer Cell Line 
Encylopedia (CCLE) 
 
Barretina et al., 2012 
 
303 – 487 b 
(mean = 469)  23 
Genome-wide 
(i.e. all genes)  
> 38,500 
genes 
> 1600 
cancer 
genes 
24 
§ Mixture of targeted 
and cytotoxic drugs 
§ Drugs approved for 
clinical practice 
§ Drugs in clinical and 
preclinical testing  
Cancer Therapeutics 
Response Portal 
(CTRP) 
 
Basu et al., 2013 
23 – 230 b, c 
(mean = 128) 19 323 
§ Small molecules 
(probes) with specific 
targets  
§ FDA-approved drugs 
and clinical candidates 
a Cell lines with accompanying drug data are presented as ranges because not every drug was tested in the same number of cell lines.  These numbers were 
obtained from the first data release and will not necessarily match the numbers in currently available datasets, since these are continually evolving resources. 
b These numbers have been modified from the raw dataset to match the outcome of our data cleaning, which excluded several cell lines due to missing data.   
c CTRP cell lines partially overlap with the CCLE cell lines. 
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up to 230 cell lines from the CTRP (Table 5.2.1).  The cell lines screened as part of the 
CTRP partially overlap with those screened for the CCLE.  During the filtering 
process, we discovered that the datasets were incomplete in the sense that not every 
drug was tested in the same number of cell lines, and not every cell line was tested 
with the same number of drugs.  The number of cell lines screened per drug ranged 
from 303 to 487, with a mean of 469, for the 24 drugs in the CCLE, and from 23 to 
230, with a mean of 128, for the 323 drugs in the CTRP (Table 5.2.1, Appendix 2 and 
3).  This generated a total of 11,263 drug-cell line combinations for the CCLE and 
41,334 drug-cell line combinations for the CTRP, compared to the 48,178 drug-cell 
line combinations reported in the CGP at the time of publication (Appendix 2 and 3; 
Garnett et al., 2012).  
Drug sensitivity metrics in both the CCLE and CTRP were derived from dose-
response curves, which were generated by exposing cancer cell lines to eight drug 
concentrations and then measuring cellular ATP levels, as a surrogate for cell number, 
after 72 to 84 hours (Barretina et al., 2012; Basu et al., 2013).  Of the numerous 
metrics that can be read off these dose-response curves, including the commonly-
reported IC50, the CCLE and CTRP favour activity area (AA) and area under the curve 
(AUC), respectively, because these metrics simultaneously capture both the potency 
and the efficacy of the drug (Figure 5.2.1; Barretina et al., 2012; Basu et al., 2013).  
Activity area describes the area between the response curve and a fixed reference line 
where relative growth inhibition is zero across all drug concentrations. The larger the 
activity area, the greater the response to a given drug; these range from 0 for inactive 
compounds to 8 for drugs that are highly efficacious at low doses (Barretina et al., 
2012).  The AUC metric is essentially the inverse of activity area; it is the area 
between the response curve and a fixed reference line where relative growth inhibition 
is 100% across all drug concentrations.  The smaller an activity area, the greater the 
response to a given drug; these range from 1 for the most cytotoxic drugs to 6 for the 
inactive compounds (Basu et al., 2013).  To facilitate comparison between these 
studies, we flipped CCLE activity areas so that lower values for both metrics denote a 
greater response to the drug.  Linking of these response metrics to gene copy number 
and gene expression measures for the relevant cancer cell lines produced the final 
curated datasets, which we used for all subsequent analyses. 
 
 
		156 
 
 
 
 
 
 
 
 
 
Figure 5.2.1. A canonical dose-response curve and associated drug sensitivity 
metrics.  A dose-response curve is generated by plotting the percentage growth 
inhibition relative to vehicle-treated control cells (y-axis), at increasing concentrations 
of a given drug (x-axis). IC50 reports the drug concentration at which 50% growth 
inhibition is reached, indicating the drug’s potency. EC50 reports the drug 
concentration at which 50% of the maximal effect occurs.  Amax reports the distance 
between zero and maximal growth inhibition, indicating the drug’s efficacy.  However, 
the potency and efficacy of a given drug may be captured simultaneously by 
measuring either the area above or below the response curve.  The shaded area above 
the curve is designated the activity area (AA) and used by the Cancer Cell Line 
Encylopedia (Barretina et al., 2012) in their modelling analyses, while the unshaded 
area under the curve (AUC) is used by the Cancer Therapeutics Response Portal (Basu 
et al., 2013).  The dose-response curve above is reproduced from Barretina et al., 
2012.   
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5.2.2 Visualising drug-gene relationships  
To begin exploring the associations between gene amplification and cancer cell 
line chemo-sensitivity or -resistance, we generated a series of scatter plots to visualise 
drug-gene relationships within our curated datasets. For each of the 347 drugs (i.e. 24 
CCLE compounds and 323 CTRP compounds), we created separate plots for our three 
genes of interest (TPD52, MYC, and ERBB2), producing a total of 1041 plots (data not 
shown).  The data points on each scatter plot represent cancer cell lines that have been 
plotted according to their copy numbers at either TPD52, MYC, or ERBB2, and their 
drug responses (AUC or flipped activity area).  We then converted these scatter plots 
into box-and-whisker plots at intervals along the x-axis and joined these to represent 
overall trends.  We repeated this process using gene expression levels, instead of copy 
number, for our three genes of interest.  This produced another 1041 plots (data not 
shown), which allowed us to compare how closely (or not) the drug-gene relationships 
predicted for gene copy numbers resembled those for gene expression levels.  As an 
example, Figure 5.2.2 shows our visualisation of the drug-gene relationship between 
ERBB2 and the ERBB2-targeted drug, lapatinib, which was an expected intra-dataset 
positive control.   
 We next discretised drug responses into three categories: resistant, 
intermediate, and sensitive.  Given the large pool of drugs in our dataset, we 
anticipated an array of activity profiles ranging from cytotoxic drugs, to which most 
cell lines would respond, to targeted drugs and small molecules inhibiting specific 
pathways, to which fewer cell lines (such as those harbouring the relevant alterations) 
would respond, and then ineffective drugs, to which very few cell lines would respond.  
We therefore reasoned that ‘one-size-fits-all’ cut-offs designating sensitivity and 
resistance would be inappropriate.  To address this, we produced drug-specific cut-offs 
using a modified version of the waterfall method described in the CCLE study 
(Barretina et al., 2012).  Briefly, we sorted the cell lines from least to most responsive 
and used the inflection point of the resulting distribution as an indicator of the point at 
which ‘responsiveness’ begins to change.  Cell lines with AUCs falling within 1.2-fold 
of this inflection point were defined as showing an intermediate response, while those 
with AUCs outside this range were defined as either sensitive (lower) or resistant 
(higher).  As anticipated, the shapes of the waterfall distributions for broadly active 
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Figure 5.2.2: (legend on the following page) 
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Figure 5.2.2. Visualising the relationship between ERBB2 copy number or 
expression and the ERBB2-targeting drug lapatinib.  The series of plots visualises 
the relationship between response to lapatinib and (A) ERBB2 copy number, reported 
as log2 copy number ratio, or (B) ERBB2 expression, reported as log2 intensity.  (i) 
Data points represent cancer cell lines that have been plotted according to their ERBB2 
copy number or expression (x-axis) and their responses to lapatinib, reported as 
maximum activity area (AA) minus the observed activity area (y-axis).  (ii) Data points 
represent the median responses observed at copy number or expression increments 
(obtained by rounding to the nearest integer), within each of the 5 colour-coded global 
gene expression clusters.  (iii) Box and whisker plots represent the distribution of 
responses observed at copy number or expression increments, for all cancer cell lines, 
with a line connecting the medians to show the overall trend.  (C) The waterfall plot 
shows cancer cell lines (x-axis) sorted from least to most responsive to lapatinib  
(y-axis), with the inflection point marked.  Cell lines with responses falling within 1.2-
fold of this inflection point were classified as having an intermediate response (blue), 
while those with responses lower or higher than this range were classified as sensitive 
(green) or resistant (red), respectively.  These classifications were then used to 
discretise drug response and correspond to the green and red dashed lines on (A), (B) 
and (D).  (D) The plot shows the distribution of responses to lapatinib within each of 
the global gene expression clusters.  Cancer cell lines were sorted into 1 of 5 clusters 
based on the expression of the 500 most highly varying genes, and the data points in 
(A) and (B) were colour-coded accordingly.  There were 129, 64, 140, 70, and 84 cell 
lines in clusters 1, 2, 3, 4, and 5, respectively.  
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drugs were clearly different from those for targeted drugs (Figure 5.2.3).  Furthermore, 
the waterfall distributions were often similar between drugs with similar targets or 
mechanisms of action (Figure 5.2.3).  These waterfall distributions allowed us to 
ground the predictions made by subsequent modelling within the broader context of 
each drug’s activity profile.  
 
5.2.3 Considering the influence of cell lineage  
The CCLE dataset encompassed cancer cell lines derived from 23 different cell 
lineages (Table 5.2.2), compared with 19 cell lineages in the CTRP dataset (Table 
5.2.3).  Lung was the largest cell lineage group in the CCLE, comprising 18.48% 
(90/487) of cell lines, followed by haematopoietic and lymphoid tissue in 14.58% 
(71/487) of cell lines.  The remaining cell lineages individually comprised less than 
10% of the CCLE data, with four cell lineages represented by 5 or fewer cell lines.  In 
the CTRP, lung was again the largest group, comprising 36.09% (83/230) of cell lines, 
followed by large intestine in 15.22% (35/230) of cell lines, and ovary in 11.3% 
(26/230) of cell lines.  All other cell lineages individually comprised 10% or less of the 
CCLE data, with 11 cell lineages represented by 5 or fewer cell lines.  Of the cell lines 
that were included from the CCLE cohort, 3.5% (17/487) were TPD52-amplified, 
15.2% (74/487) were MYC-amplified, and 5.1% (25/487) were ERBB2-amplified, 
according to the thresholding approach described in Chapter 3 (data not shown).  In 
those from the CTRP cohort, 3% (7/230) were TPD52-amplified, 18.3% (42/230) were 
MYC-amplified, and 3% (7/230) were ERBB2-amplified (data not shown). 
The diverse range of cancer types encompassed by our datasets is valuable in 
broadening the scope of our analyses but it also necessitates the consideration of cell 
lineage as a potential confounder.  Ideally, each cell lineage or cancer type would be 
considered a separate category; however, the limited number of cell lines with 
accompanying drug response data meant that grouping the cell lines in this way would 
result in many categories with five or fewer cases (Table 5.2.2 and 5.2.3). This 
imbalance in size between categories could provide misleading results in subsequent 
predictive modelling.  We therefore performed agglomerative hierarchical clustering of 
the cell lines into five groups based on the 500 most highly varying genes.  We then 
colour-coded the cell lines according to their cluster in plots visualising drug-gene 
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Figure 5.2.3. Waterfall distributions of cell line sensitivity vary between drugs.  
The waterfall plots show cancer cell lines (x-axis) sorted from least to most responsive 
to (A) lapatinib, (B) erlotinib, (C) topotecan, or (D) paclitaxel.  Drug responsiveness is 
reported as maximum activity area (AA) minus the observed activity area (y-axis).  
The inflection point is marked on each plot.  Cell lines with responses falling within 
1.2-fold of this inflection point were classified as having an intermediate response 
(blue), while those with responses lower or higher than this were classified as sensitive 
(green) or resistant (red), respectively.  Both (A) lapatinib and (B) erlotinib are 
receptor tyrosine kinase inhibitors and as such are examples of targeted drugs.  
Accordingly, the shape of their waterfall distributions are similar to each other, with a 
restricted number of cell lines that are classed as sensitive. These waterfall plots are 
clearly different to those for (C) topotecan and (D) paclitaxel, which are broadly 
cytotoxic compounds.  
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Table 5.2.2. Clustering of Cancer Cell Line Encylopedia (CCLE) cell lines into 
five groups based on global gene expression.  Agglomerative hierarchical clustering 
was performed using the 500 most highly varying genes within the CCLE cohort of 
487 cell lines from 23 different cell lineages.  
 
Cell lineage 
(number of cell lines) 
Global gene expression cluster 
(number of cell lines) 
1 2 3 4 5 
Autonomic ganglia (n=10) 4 6 0 0 0 
Biliary tract (n=1) 0 0 1 0 0 
Bone (n=10) 6 4 0 0 0 
Breast (n=29) 5 3 20 0 1 
Central nervous system (n=29) 29 0 0 0 0 
Endometrium (n=20) 1 4 1 0 14 
Haematopoietic and lymphoid tissue (n=71) 1 0 0 70 0 
Kidney (n=9) 1 0 0 0 8 
Large intestine (n=22) 0 2 19 0 1 
Liver (n=19) 6 1 0 0 12 
Lung (n=90) 12 22 36 0 20 
Oesophagus (n=15) 0 0 15 0 0 
Ovary (n=27) 4 3 2 0 18 
Pancreas (n=28) 0 3 18 0 7 
Pleura (n=7) 6 0 0 0 1 
Prostate (n=3) 0 1 2 0 0 
Salivary gland (n=1) 0 0 1 0 0 
Skin (n=40) 38 2 0 0 0 
Soft tissue (n=12) 6 6 0 0 0 
Stomach (n=18) 1 5 11 0 1 
Thyroid (n=5) 5 0 0 0 0 
Upper aerodigestive tract (n=7) 1 0 6 0 0 
Urinary tract (n=14) 3 2 8 0 1 
Total number of cell lines 129 64 140 70 84 
Total number of cell lineages represented 17 14 13 1 11 
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Table 5.2.3. Clustering of Cancer Therapeutics Response Portal (CTRP) cell lines 
into five groups based on global gene expression. Agglomerative hierarchical 
clustering was performed using the 500 most highly varying genes within the CTRP 
cohort of 230 cell lines from 19 different cell lineages. 
 
Cell lineage 
(number of cell lines) 
Global gene expression cluster 
(number of cell lines) 
1 2 3 4 5 
Bone (n=1) 1 0 0 0 0 
Breast (n=1) 0 1 0 0 0 
Central nervous system (n=3) 3 0 0 0 0 
Endometrium (n=11) 1 10 0 0 0 
Haematopoietic and lymphoid tissue (n=23) 0 0 23 0 0 
Kidney (n=2) 2 0 0 0 0 
Large intestine (n=35) 0 11 0 23 1 
Liver (n=4) 3 1 0 0 0 
Lung (n=83) 27 35 0 1 20 
Oesophagus (n=3) 0 3 0 0 0 
Ovary (n=26) 9 17 0 0 0 
Pancreas (n=10) 2 7 0 0 1 
Pleura (n=3) 3 0 0 0 0 
Prostate (n=1) 0 1 0 0 0 
Skin (n=9) 9 0 0 0 0 
Soft tissue (n=2) 2 0 0 0 0 
Stomach (n=6) 1 4 0 1 0 
Upper aerodigestive tract (n=2) 0 2 0 0 0 
Urinary tract (n=5) 1 4 0 0 0 
Total number of cell lines 64 96 23 25 22 
Total number of cell lineages represented 13 12 1 3 3 
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relationships (Figure 5.2.2Aii and Bii).  For each drug, we also generated a box-and-
whisker plot to compare the distribution of drug responses between global gene 
expression clusters (Figure 5.2.2D).  This facilitated the identification of clusters 
and/or cell lineages that might be particularly responsive to a given drug, regardless of 
their gene copy number or expression for our genes of interest. 
For analyses using the 487 CCLE cell lines, the cell lineage compositions of 
the five global gene expression clusters are summarised in Table 5.2.2 (see Appendix 4 
for a full list of the cell lines assigned to each cluster).  Clusters 1 and 3 were the 
largest (with 129 and 140 cell lines, respectively) and encompassed a broad range of 
cell lineages (17 and 13, respectively, out of the 23 cell lineages represented in our 
curated dataset).  Clusters 2 and 5 were much smaller (with 64 and 84 cell lines, 
respectively) yet still encompassed a broad range of cell lineages (14 and 11, 
respectively).  Cluster 4 was also smaller (with 70 cell lines), but was comprised 
entirely of cell lines derived from haematopoietic and lymphatic cancers.  The median 
log2 copy number ratios for TPD52 were similar between the global gene expression 
clusters, with the only statistically significant difference being between cluster 3 and 5 
(0.2316 versus 0.1168) (Figure 5.2.4Ai).  Similarly, median log2 copy number ratios 
for ERBB2 were comparable between most clusters, with a significant difference 
occurring between cluster 1 and 3 (0.0267 versus 0.1169) (Figure 5.2.4Aiii).  Median 
MYC log2 copy number ratios, on the other hand, varied considerably between clusters 
(Figure 5.2.4Aii).   The median MYC log2 copy number ratio was highest in cluster 3 
(0.5333), which was significantly different to each of the other clusters.  The median 
for cluster 1 was also significantly less than that for cluster 5 (0.2158 versus 0.2852). 
For analyses using the 230 CTRP cell lines, the cell lineage compositions of the 
five global gene expression clusters are summarised in Table 5.2.3 (see Appendix 5 for 
a full list of the cell lines assigned to each cluster).  Clusters 1 and 2 were the largest 
(with 64 and 96 cell lines, respectively) and encompassed a broad range of cell 
lineages (13 and 12, respectively, out of the 19 cell lineages represented in the CTRP-
derived subset).  Clusters 3, 4 and 5 were much smaller (with 23, 25, and 22 cell lines, 
respectively) and were comprised of fewer cell lineages (1, 3, and 3, respectively).  
Cluster 3 was comprised entirely of cell lines derived from haematopoietic and 
lymphatic cancers, while clusters 4 and 5 were comprised almost entirely of cell lines 
derived from cancers of the large intestine and lung, respectively.  The median log2 
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Figure 5.2.4: (legend on the following page) 
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Figure 5.2.4. TPD52, MYC, and ERBB2 gene copy number within each global 
gene expression cluster. Agglomerative hierarchical clustering was performed using 
the 500 most highly varying genes within (A) the Cancer Cell Line Encylopedia and 
(B) the Cancer Therapeutics Response Portal.  The distribution of log2 copy number 
values (y-axis) for (i) TPD52, (ii) MYC, and (iii) ERBB2 is shown for each of the five 
global gene expression clusters (x-axis).  Horizontal lines indicate median values, 
bounded by interquartile ranges.  Only significant p values are shown on the plots, 
Mann-Whitney u test. 
  
		167 
copy number ratios for TPD52 were similar between the global gene expression 
clusters, with the only statistically significant difference being between cluster 1 and 4 
(0.1992 versus 0.0040) (Figure 5.2.BAi).  Median log2 copy number ratios for ERBB2 
were comparable between all clusters, with no significant differences shown (Figure 
5.2.4Biii).  As observed for the CCLE cell lines, median MYC log2 copy number ratios 
varied considerably between clusters (Figure 5.2.4Bii).    
 
5.2.4 Designing a predictive modelling approach 
Predictive modelling allows us to capture the drug-gene relationships in a high-
throughput manner and ascertain whether the gene made a statistically significant 
contribution in predicting drug response.  Multivariate linear regression showed the 
best overall performance of the modelling approaches trialled (data not shown).  The 
models used for each drug-gene relationship were as follows.  
For gene copy number: Y = b0 + b1GCNi + b2GGECi 
For gene expression: Y = b0 + b1GEi + b2GGECi 
Where,  
Y = drug sensitivity, reported as either AUC or flipped AA (i.e. maximum AA 
minus observed AA) 
GCN = copy number for gene of interest in cell line i,  
GE = expression for gene of interest in cell line i,  
GGEC = global gene expression cluster for cell line i = {1, 2, 3, 4, 5} 
b0 = intercept 
b1 = regression coefficient (effect size) for gene copy number or expression  
b2 = regression coefficient (effect size) for global gene expression cluster 
These models consider both gene copy number or expression and global gene 
expression cluster (as a surrogate for cell lineage) as predictor variables with the 
potential to explain variation in the response variable AUC.  When applied to each 
drug-gene combination, the model describes a line that best fits the data points on the 
corresponding scatter plot.  The regression coefficient b1 of this line indicates effect 
size, that is, the mean change in drug sensitivity for each unit change in gene copy 
number/expression, when global gene expression cluster is fixed.  In other words, b1 is 
the influence of gene copy number or expression on drug sensitivity, adjusted for cell 
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lineage.  We then estimated the relative contribution of either gene copy number or 
expression to the total variation in drug sensitivity captured by each model, using the 
method proposed by Lindeman et al., 1980.  Through regression modelling, we also 
derived p values to determine whether the association between gene copy number or 
expression and drug response was statistically significant. We then derived adjusted  
p values to account for multiple testing, using the false discovery rate method 
(Benjamini and Hochberg, 1995).  
Furthermore, we considered a range of additional statistics pertaining to these 
predictions.  We calculated the relative contribution of global gene expression cluster 
to the total variation in drug sensitivity captured by each model (Appendix 6).  We also 
reported the number of global gene expression clusters for which the drug response 
was found to be significantly different to that displayed by the reference cluster 1, 
which would indicate that cell lineage may significantly affect response patterns for 
that particular drug (Appendix 6).  We then investigated whether any significant 
interactions were detected between the predictor variables, gene copy number or 
expression and global gene expression cluster, for each drug; that is, whether the 
regression coefficients (effect sizes) differed significantly across the five global gene 
expression clusters (Appendix 6).  Finally, we examined statistics pertaining to each 
drug-gene model as a whole, including the full model p value, F statistic, adjusted R 
squared, and AIC metric (Appendix 6 and data not shown).  
 
5.2.5 Predicting novel drug-gene associations  
Multivariate linear regression yielded a total of 84 significant associations  
(p < 0.05) between drug response and copy number at TPD52 (n = 9), MYC (n = 22), 
or ERBB2 (n = 53) (Table 5.2.4).  Modelling also yielded 101 significant associations 
(p < 0.05) between drug response and gene expression of TPD52 (n = 31), MYC (n = 
44), or ERBB2 (n = 26) (Table 5.2.4).  When adjusting p values to account for multiple 
testing, the total number of significant associations for copy number and gene 
expression was substantially reduced to 7 and 10, respectively (Table 5.2.4).  Since the 
current study is a preliminary investigation, we therefore considered all drug-gene 
models with a non-adjusted p value of less than 0.05 in subsequent analyses.  These 
drug-gene models are explored further in the following sections.  Where possible, the 
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Table 5.2.4. Summary of significant drug-gene associations identified by 
predictive modelling.  Multivariate linear regression was undertaken to predict novel 
associations between drug response and either copy number or gene expression for 
TPD52, MYC, and ERBB2.  This yielded a total of 84 significant associations between 
drug response and copy number and 101 significant associations between drug 
response and gene expression (p < 0.05). 
 
 
Number of Drugs 
Copy Number Gene Expression 
TPD52 MYC ERBB2 TPD52 MYC ERBB2 
Significantly 
associated (p < 0.05) 9 22 53 31 44 26 
Adjusted for multiple 
testing 0 0 7 4 5 1 
Associated with 
chemo-sensitivity 9 4 2 3 14 11 
Associated with 
chemo-resistance 0 18 51 28 30 15 
Also identified in 
copy number / gene 
expression models 
0 
(0%) 
6 
(27.3%) 
13 
(24.5%) 
0 
(0%) 
6 
(13.6%) 
13 
(50%) 
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compound identifiers used within the CTRP (Basu et al., 2013) have been replaced 
with more informative drug names and have been functionally annotated with target 
proteins or pathways.  In some cases, this information has only recently become 
available with the publication of version 2 of the CTRP online interface 
(https://portals.broadinstitute.org/ctrp/).  We have incorporated these updates into the 
tables that report the outcomes of predictive modelling as this provides a more 
complete picture of the drugs found to be associated with our genes of interest.  
 
5.2.5.1 Drugs associated with TPD52 copy number and/or expression 
There were nine drugs significantly associated with TPD52 copy number and 
31 drugs significantly associated with TPD52 expression (p < 0.05, Tables 5.2.4, 5.2.5, 
and 5.2.6).  Of these, only four drugs (selumetinib, TTNBP, BRD-K90072296, and 
TKI258) remained significant following p value adjustment (Tables 5.2.4 and 5.2.6).  
There was zero concordance between the drugs associated with copy number and those 
identified through gene expression models (Table 5.2.4).  Overall, chemo-sensitivity 
with increasing TPD52 copy number or expression was predicted for 30% (12/40) of 
drug associations, as indicated by a negative effect size, while chemo-resistance was 
predicted for the remaining 70% (28/40) of drug associations, as indicated by a 
positive effect size (Table 5.2.4).  The functions and/or molecular target(s) of the drugs 
predicted to be associated with TPD52 copy number or expression are summarised in 
Table 5.2.7.     
Effect sizes for chemo-sensitivity ranged from -1.74 to -0.16 for drugs 
significantly associated with TPD52 copy number, and from -0.29 to -0.08 for drugs 
significantly associated with TPD52 expression, while effect sizes for chemo-
resistance ranged from 0.62 to 0.04 for drugs significantly associated with TPD52 
expression (Tables 5.2.5 and 5.2.6, Figure 5.2.5).  The estimated relative contributions 
of TPD52 status to the variations in drug response ranged from 0.01 to 0.24 for drugs 
significantly associated with TPD52 copy number, and from 0.01 to 0.16 for drugs 
significantly associated with TPD52 expression (Tables 5.2.5 and 5.2.6). Cell lineage, 
as represented by global gene expression cluster, was also shown to influence the 
majority of drug-gene models for TPD52.  The estimated relative contributions of 
global gene expression cluster to the variations in drug response ranged from 0.02 to 
0.39 for drugs significantly associated with TPD52 copy number or expression 
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Table 5.2.5. Drugs predicted by multivariate linear regression to be associated 
with TPD52 copy number.  Drugs are separated into two categories based on whether 
increased TPD52 copy number was significantly associated with chemo-sensitivity or  
-resistance (non-adjusted p < 0.05), and are ranked according to effect size.  Note that 
increased TPD52 copy number was not significantly associated with resistance to any 
of the drugs.  
 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
ns
iti
ve
 
PL-DI CTRP -1.74 0.24 0.010 0.998 
KU 0060648 CTRP -1.01 0.09 0.016 0.998 
Importazole CTRP -0.84 0.08 0.041 0.998 
MLN2238 CTRP -0.80 0.10 0.028 0.998 
Ubistatin CTRP -0.72 0.04 0.037 0.998 
Kinetin riboside CTRP -0.62 0.03 0.008 0.998 
Brefeldin A CTRP -0.43 0.02 0.045 0.998 
Nilotinib CCLE -0.18 0.01 0.041 0.490 
Lapatinib CCLE -0.16 0.01 0.018 0.439 
 
a  Effect size is the mean change in drug sensitivity for each unit change in TPD52 copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by TPD52 copy number to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant 
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.6. Drugs predicted by multivariate linear regression to be associated 
with TPD52 expression.  Drugs are separated into two categories based on whether 
increased TPD52 expression was significantly associated with chemo-sensitivity or  
-resistance (non-adjusted p < 0.05), and are ranked according to effect size.  
Associations that remained significant following p value adjustment are shown in bold. 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
n.
 BEC CTRP -0.29 0.08 0.002 0.149 
BRD-K78716413 CTRP -0.26 0.14 0.004 0.208 
SN-38 CTRP -0.08 0.01 0.030 0.180 
R
es
is
ta
nt
 
Selumetinib CTRP 0.62 0.10 < 0.001 0.034 
Tanespimycin CTRP 0.25 0.03 0.042 0.548 
All-trans retinoic acid CTRP 0.23 0.02 0.042 0.548 
BRD-K11853856 CTRP 0.22 0.16 0.005 0.208 
TTNBP CTRP 0.21 0.08 < 0.001 0.043 
NSC 74859 CTRP 0.21 0.07 0.006 0.208 
GW-405833 CTRP 0.20 0.03 0.021 0.447 
AC55649 CTRP 0.19 0.03 0.002 0.157 
PDMP CTRP 0.19 0.06 0.012 0.297 
Sildenafil CTRP 0.18 0.06 0.009 0.264 
B02 CTRP 0.18 0.07 0.027 0.484 
CCT036477 CTRP 0.17 0.02 0.016 0.368 
SNX-2112 CTRP 0.17 0.03 0.030 0.484 
7-nitroindazole CTRP 0.16 0.08 0.006 0.208 
Sonidegib CTRP 0.16 0.12 0.010 0.264 
CAY10594 CTRP 0.16 0.05 0.039 0.544 
BRD-K90072296 CTRP 0.15 0.15 < 0.001 0.034 
Fatostatin CTRP 0.13 0.02 0.029 0.484 
BRD-A12409803 CTRP 0.13 0.04 0.047 0.556 
BRD-K22014046 CTRP 0.11 0.07 0.006 0.208 
GSK-2334470 CTRP 0.11 0.06 0.035 0.514 
BRD-K40758391 CTRP 0.10 0.05 0.044 0.551 
16,16-dimethyl 
prostaglandin-E2 CTRP 0.09 0.01 0.025 0.484 
BRD-K52904470 CTRP 0.09 0.08 0.030 0.484 
BRD-K28506825 CTRP 0.09 0.05 0.034 0.514 
TAE684 CCLE 0.08 0.01 0.005 0.059 
TKI258 CCLE 0.07 0.03 < 0.001 0.003 
PF2341066 CCLE 0.04 0.01 0.017 0.136 
 
a  Effect size is the mean change in drug sensitivity for each unit change in TPD52 copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by TPD52 expression to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant 
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.7. Activities and/or target(s) of the drugs predicted to be associated with 
TPD52 copy number or expression.  The activity and/or target(s) of each drug are 
shown as reported in the Cancer Cell Line Encylopedia or Cancer Therapeutics 
Response Portal, with additional references provided if these were insufficient.  ‘S’ 
and ‘R’ indicate that chemo-sensitivity and -resistance, respectively, were predicted in 
association with increasing TPD52 copy number (CN) or expression (expn), while ‘-’ 
indicates that there was no statistically significant association with drug response (non-
adjusted p > 0.05).  Associations that remained significant following p value 
adjustment are shown in bold.  Drugs with the prefix BRD- have been omitted since 
information regarding the activity and/or target(s) of these compounds is not publicly-
available. 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing TPD52 
CN expn 
16,16-dimethyl 
prostaglandin-E2 Activator of prostaglandin E receptor - R 
7-nitroindazole Inhibitor of neuronal nitric oxide synthase - R 
AC55649 Agonist of retinoic acid receptor beta - R 
All-trans retinoic 
acid Agonist of retinoic acid receptors - R 
B02 Inhibitor of RAD51 recombinase  - R 
BEC Inhibitor of arginase I and II  - S 
Brefeldin A 
Modulator of ADP-ribosylation factor 1 and 
inhibitor of protein translocation from the 
endoplasmic reticulum to the Golgi 
S - 
CAY10594 Inhibitor of phospholipase D2 - R 
CCT036477 Inhibitor of WNT signalling by blocking beta-catenin transcription - R 
Fatostatin Inhibitor of sterol regulatory element binding transcription factor 1 and 2 signalling - R 
GSK-2334470 Inhibitor of pyruvate dehydrogenase kinase - R 
GW-405833 Partial agonist of cannabinoid receptor 2  - R 
Importazole Inhibitor of importin S - 
Kinetin riboside 
Natural compound (plant hormone) that 
produces cell cycle arrest and promotes 
apoptosis (Siveen et al., 2017) 
S - 
KU 0060648 Inhibitor of DNA-dependent protein kinase  S - 
Lapatinib Inhibitor of epidermal growth factor receptor and ERBB2 (kinases) S - 
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Table 5.2.7. Continued… 
 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing TPD52 
CN expn 
MLN2238 Inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site  S - 
Nilotinib Inhibitor of BCR-ABL and c-KIT tyrosine kinases S - 
NSC 74859 Inhibitor of STAT3 (signal transducer and activator of transcription 3) - R 
PDMP Inhibitor of ceramide glucosyltransferase  - R 
PF2341066 Inhibitor of c-MET and ALK receptor tyrosine kinases - R 
PL-DI Dimer of piperlongumine, which modulates levels of reactive oxygen species S - 
Selumetinib Inhibitor of MEK1 and MEK2, members of the mitogen-activated protein kinase kinase family - R 
Sildenafil Inhibitor of phosphodiesterase 5A - R 
SN-38 Inhibitor of topoisomerase I  - S 
SNX-2112 Inhibitor of heat shock protein 90  - R 
Sonidegib 
Inhibitor of smoothened (SMO), a protein 
involved in the hedgehog signalling pathway 
(Sekulic and Von Hoff, 2016) 
- R 
TAE684 Inhibitor of ALK receptor tyrosine kinase - R 
Tanespimycin Inhibitor of heat shock protein 90 - R 
TKI258 Multi-kinase inhibitor - R 
TTNBP Analog of retinoic acid that acts as an agonist of retinoic acid receptors - R 
Ubistatin 
Blocks cell cycle progression by inhibiting 
cyclin B proteolysis and blocks the binding of 
ubiquitinated substrates to the proteasome for 
degradation (Verma et al., 2004) 
S - 
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Figure 5.2.5. Effect sizes for drugs predicted to be associated with TPD52 copy 
number or expression.  The graphs compare effect sizes (x-axis) for drugs predicted 
to be significantly associated (non-adjusted p < 0.05) with either (A) TPD52 copy 
number (n = 9) or (B) TPD52 expression (n = 31).  Effect size is the gene coefficient 
generated by multivariate linear regression and indicates the mean change in drug 
sensitivity for each unit change in TPD52 copy number or expression, when the global 
gene expression cluster was fixed.  A negative effect size indicates chemo-sensitivity, 
while a positive effect size indicates chemo-resistance.  Associations that remained 
significant following p value adjustment are shown in bold. 
  
		176 
(Appendix Tables 6.1 and 6.2).  The differential response of at least one global gene 
expression cluster (when compared to reference cluster 1) was found for 77.8% (7/9) 
of drugs associated with TPD52 copy number and 64.5% (20/31) of drugs associated 
with TPD52 expression (Appendix Tables 6.1 and 6.2).  A significant interaction 
between TPD52 status and global gene expression cluster was detected for 11.1% (1/9) 
of drugs associated with TPD52 copy number and 12.9% (4/31) of drugs associated 
with TPD52 expression (Appendix Tables 6.1 and 6.2).   
 
5.2.5.2 Drugs associated with MYC copy number and/or expression 
There were 22 drugs significantly associated with MYC copy number and 44 
drugs significantly associated with MYC expression (p < 0.05, Tables 5.2.4, 5.2.8, and 
5.2.9).  Of these, five drugs (itraconazole, RAF265, sorafenib, BRD-K88560311, and 
veliparib) remained significant following p value adjustment (Tables 5.2.4 and 5.2.9).  
Six drugs were predicted by both sets of analyses, comprising 27.3% of the 22 drugs 
associated with MYC copy number and 13.6% of the 44 drugs associated with MYC 
expression (Table 5.2.4).  These six drugs were: itraconazole, nilotinib, KU 0060648, 
batimatstat, ABT-737, and SNX-2112 (Tables 5.2.8 and 5.2.9).  Importantly, the 
predicted response to these drugs was in the same direction (either chemo-sensitivity 
or -resistance) in all cases.  Overall, chemo-sensitivity with increasing MYC copy 
number or expression was predicted for 27.3% (18/66) of drug associations, as 
indicated by a negative effect size, while chemo-resistance was predicted for the 
remaining 72.7% (48/66) of drug associations, as indicated by a positive effect size 
(Table 5.2.4).  The functions and/or molecular target(s) of the drugs predicted to be 
associated with MYC copy number or expression are summarised in Table 5.2.10.    
Effect sizes for chemo-sensitivity ranged from -0.32 to -0.11 for drugs 
associated with MYC copy number, and from -0.18 to -0.04 for drugs associated with 
MYC expression, while effect sizes for chemo-resistance ranged from 0.85 to 0.06 for 
drugs associated with MYC copy number, and from 0.42 to 0.05 for drugs associated 
with MYC expression (Tables 5.2.8 and 5.2.9, Figure 5.2.6).  The estimated relative 
contributions of MYC status to the reported variations in drug response ranged from 
0.00 to 0.26 for drugs associated with MYC copy number, and from 0.01 to 0.28 for 
drugs associated with MYC expression (Tables 5.2.8 and 5.2.9).  The potential of cell 
lineage as a confounder was again shown in drug-gene models for MYC.  The 
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Table 5.2.8. Drugs predicted by multivariate linear regression to be associated 
with MYC copy number.  Drugs are separated into two categories based on whether 
increased MYC copy number was significantly associated with chemo-sensitivity or  
-resistance (non-adjusted p < 0.05), and are ranked according to effect size.  Asterisks 
(*) indicate that the drug was also predicted in association with MYC expression. 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
ns
iti
ve
 Linsitinib CTRP -0.32 0.05 0.012 0.654 
Itraconazole* CTRP -0.24 0.02 0.015 0.657 
Paclitaxel CCLE -0.19 0.01 0.032 0.209 
Nilotinib* CCLE -0.11 0.01 0.045 0.209 
R
es
is
ta
nt
 
PL-DI CTRP 0.85 0.26 0.003 0.654 
Etoposide CTRP 0.49 0.04 0.010 0.654 
KU 0060648* CTRP 0.49 0.05 0.045 0.858 
BRD-K78867378 CTRP 0.44 0.04 0.008 0.654 
Tyrphostin CTRP 0.42 0.05 0.011 0.654 
PX-12 CTRP 0.42 0.03 0.019 0.657 
Teniposide CTRP 0.42 0.03 0.042 0.858 
Batimatstat* CTRP 0.39 0.04 0.020 0.657 
Parthenolide CTRP 0.36 0.02 0.025 0.668 
RITA CTRP 0.34 0.02 0.017 0.657 
Navitoclax CTRP 0.30 0.01 0.044 0.858 
ABT-737* CTRP 0.29 0.01 0.024 0.668 
SNX-2112* CTRP 0.23 0.04 0.037 0.858 
16-beta-
bromoandrosterone CTRP 0.20 0.02 0.009 0.654 
BRD-K73261812 CTRP 0.19 0.02 0.045 0.858 
Erlotinib CCLE 0.09 0.00 0.041 0.209 
PHA-665752 CCLE 0.08 0.01 0.031 0.209 
Nutlin-3 CCLE 0.06 0.01 0.034 0.209 
 
a  Effect size is the mean change in drug sensitivity for each unit change in MYC copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by MYC copy number to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant 
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.9. Drugs predicted by multivariate linear regression to be associated 
with MYC expression.  Drugs are separated into two categories based on whether 
increased MYC expression was significantly associated with chemo-sensitivity or  
-resistance (non-adjusted p < 0.05), and are ranked according to effect size.  Asterisks 
(*) indicate that the drug was also predicted in association with MYC copy number.  
Associations that remained significant following p value adjustment are shown in bold. 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
ns
iti
ve
 
BRD-K93725829 CTRP -0.18 0.10 0.007 0.219 
Itraconazole* CTRP -0.17 0.04 < 0.001 0.049 
Kinetin riboside CTRP -0.15 0.03 0.021 0.299 
Simvastatin CTRP -0.12 0.02 0.010 0.279 
PD-0325901 CCLE -0.12 0.01 0.011 0.064 
RAF265 CCLE -0.09 0.02 < 0.001 0.003 
17-AAG CCLE -0.09 0.01 0.008 0.064 
BRD-K50650713 CTRP -0.09 0.07 0.021 0.299 
Selumetinib CCLE -0.08 0.01 0.036 0.122 
Nilotinib* CCLE -0.06 0.03 0.015 0.070 
Alda-1 CTRP -0.06 0.07 0.035 0.346 
Gly-Gly-PALO CTRP -0.06 0.02 0.049 0.418 
Sorafenib CCLE -0.05 0.04 < 0.001 0.003 
TKI258 CCLE -0.04 0.01 0.020 0.079 
R
es
is
ta
nt
 
BRD-K88560311 CTRP 0.42 0.28 < 0.001 0.009 
BRD-K00615600 CTRP 0.35 0.07 0.002 0.131 
MK-2206 CTRP 0.30 0.04 0.032 0.346 
Veliparib CTRP 0.27 0.16 < 0.001 0.049 
Importazole CTRP 0.27 0.04 0.033 0.346 
KU 0060648* CTRP 0.26 0.04 0.048 0.418 
Ursolic acid CTRP 0.22 0.05 0.033 0.346 
Olaparib CTRP 0.21 0.05 0.004 0.131 
ABT-737* CTRP 0.19 0.04 0.003 0.131 
Manumycin A CTRP 0.19 0.04 0.004 0.131 
BRD-K11853856 CTRP 0.19 0.07 0.016 0.299 
PRIMA-1 CTRP 0.19 0.03 0.016 0.299 
AA-COCF3 CTRP 0.17 0.03 0.027 0.342 
Batimatstat* CTRP 0.17 0.02 0.035 0.346 
SNX-2112* CTRP 0.16 0.03 0.003 0.131 
JTT-705 CTRP 0.16 0.08 0.012 0.287 
QW-BI-011 CTRP 0.16 0.04 0.019 0.299 
PRIMA-1-Met CTRP 0.15 0.02 0.019 0.299 
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Table 5.2.9. Continued… 
 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
 CCT036477 CTRP 0.14 0.06 0.002 0.131 
Necrostatin-1 CTRP 0.14 0.07 0.007 0.219 
Cerulenin CTRP 0.14 0.04 0.032 0.346 
Tacrolimus CTRP 0.11 0.06 0.011 0.285 
PF-04217903 CTRP 0.09 0.04 0.017 0.299 
ML050 CTRP 0.09 0.04 0.027 0.342 
Quinoclamine CTRP 0.09 0.03 0.043 0.398 
LFM-A13 CTRP 0.08 0.06 0.019 0.299 
Lonidamine CTRP 0.08 0.06 0.041 0.388 
BRD-K61053657 CTRP 0.07 0.04 0.021 0.299 
Losartan CTRP 0.06 0.04 0.03 0.346 
ML083 CTRP 0.05 0.02 0.025 0.342 
 
a  Effect size is the mean change in drug sensitivity for each unit change in MYC copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by MYC expression to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant  
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.10. Activities and/or target(s) of the drugs predicted to be associated 
with MYC copy number and/or expression.  The activity and/or target(s) of each 
drug are shown as reported in the Cancer Cell Line Encylopedia or Cancer 
Therapeutics Response Portal, with additional references provided if these were 
insufficient.  ‘S’ and ‘R’ indicate that chemo-sensitivity and -resistance, respectively, 
were predicted in association with increasing MYC copy number (CN) or expression 
(expn), while ‘-’ indicates that there was no statistically significant association with 
drug response (non-adjusted p > 0.05).  Associations that remained significant 
following p value adjustment are shown in bold.  Drugs with the prefix BRD- have 
been omitted since information regarding the activity and/or target(s) of these 
compounds is not publicly-available.   
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing MYC 
CN expn 
16-beta-
bromoandrosterone 
Analog of dehydroepiandrosterone (DHEA), 
an endogenous steroid hormone R - 
17-AAG Inhibitor of heat shock protein 90 - S 
AA-COCF3 Inhibitor of cytosolic phospholipase A2 and fatty acid amide hydrolase  - R 
ABT-737 Inhibitor of BCL2 family members, which are regulators of apoptosis  R R 
Alda-1 Activator of aldehyde dehydrogenase 2 - S 
Batimatstat Inhibitor of matrix metalloproteinases (Wojtowicz-Praga et al., 1997) R R 
CCT036477 Inhibitor of WNT signalling by blocking beta-catenin transcription - R 
Cerulenin Inhibitor of fatty acid synthase and HMG-CoA synthase - R 
Erlotinib Inhibitor of epidermal growth factor receptor (EGFR) and ERBB2 (kinases) R  
Etoposide Inhibitor of topoisomerase II  R - 
Gly-Gly-PALO Inhibitor of ornithine carbamoyltransferase  S 
Importazole Inhibitor of importin - R 
Itraconazole Anti-fungal agent and inhibitor of the hedgehog signalling pathway S S 
JTT-705 
(dalcetrapib) 
Inhibitor of cholesteryl ester transfer protein 
(Niesor et al., 2010) - R 
Kinetin riboside 
Natural compound (plant hormone) that 
produces cell cycle arrest and promotes 
apoptosis (Siveen et al., 2017) 
- S 
KU 0060648 Inhibitor of DNA-dependent protein kinase R R 
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Table 5.2.10. Continued… 
 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing MYC 
CN expn 
LFM-A13 Inhibitor of Bruton tyrosine kinase and polo-like kinase 1 - R 
Linsitinib Inhibitor of insulin-like growth factor 1 receptor and insulin receptor (kinases) S - 
Lonidamine Inhibitor of hexokinase - R 
Losartan Inhibitor of angiotensin II receptor - R 
Manumycin A Inhibitor of RAS farnesyltransferase  - R 
MK-2206 Inhibitor of AKT1, AKT2, and AKT3, which are serine/threonine protein kinases - R 
ML050 Inhibitor of G protein-coupled estrogen receptor 1 - R 
ML083 Activator of muscle pyruvate kinase - R 
Navitoclax Inhibitor of BCL2 family members, which are regulators of apoptosis R - 
Necrostatin-1 
Inhibitor of receptor-interacting protein 
kinase 1 and the necroptosis cell death 
pathway 
- R 
Nilotinib Inhibitor of BCR-ABL and c-KIT tyrosine kinases S S 
Nutlin-3 Inhibitor of p53-MDM2 interaction R - 
Olaparib Inhibitor of poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) - R 
Paclitaxel Inhibitor of microtubule assembly S - 
Parthenolide 
Natural product, which modulates levels of 
reactive oxygen species and NF-kappa-B-
signalling 
R - 
PD-0325901 
Inhibitor of MEK1 and MEK2, members of 
the mitogen-activated protein kinase kinase 
family 
- S 
PF-04217903 Inhibitor of c-MET receptor tyrosine kinase - R 
PHA-665752 Inhibitor of c-MET receptor tyrosine kinase R - 
PL-DI Dimer of piperlongumine, which modulates levels of reactive oxygen species R - 
PRIMA-1 Re-activator of the pro-apoptotic activity of mutant p53 - R 
PRIMA-1-Met Re-activator of the pro-apoptotic activity of mutant p53 - R 
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Table 5.2.10. Continued… 
 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing MYC 
CN expn 
PX-12 Inhibitor of thioredoxin-1 R - 
Quinoclamine Modulator of NF-kappa-B signalling - R 
QW-BI-011 Inhibitor of G9a histone methyltransferase - R 
RAF265 
Inhibitor of B-Raf proto-oncogene, 
serine/threonine kinase (BRAF) and 
vascular endothelial growth factor receptor 2 
(VEGFR2) 
- S 
RITA Inhibitor of p53-MDM2 interaction R - 
Selumetinib 
Inhibitor of MEK1 and MEK2, members of 
the mitogen-activated protein kinase kinase 
family 
- S 
Simvastatin Inhibitor of HMG-CoA reductase - S 
SNX-2112 Inhibitor of heat shock protein 90 R R 
Sorafenib Multi-kinase inhibitor - S 
Tacrolimus Inhibitor of calcineurin - R 
Teniposide Inhibitor of topoisomerase II  R - 
TKI258 Multi-kinase inhibitor - S 
Tyrphostin Inhibitor of epidermal growth factor receptor (EGFR) (kinase) R - 
Ursolic acid Inhibitor of signal transducer and activator of transcription 3 (STAT3) signalling - R 
Veliparib Inhibitor of poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) - R 
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Figure 5.2.6. Effect sizes for drugs predicted to be associated with MYC copy 
number and/or expression.  The graphs compare effect sizes (x-axis) for drugs 
predicted to be significantly associated (non-adjusted p < 0.05) with either (A) MYC 
copy number (n = 22) or (B) MYC expression (n = 44).  Effect size is the gene 
coefficient generated by multivariate linear regression and indicates the mean change 
in drug sensitivities for each unit change in MYC copy number or expression, when the 
global gene expression cluster was fixed.  A negative effect size indicates chemo-
sensitivity, while a positive effect size indicates chemo-resistance.  Associations that 
remained significant following p value adjustment are shown in bold.  Asterisks (*) 
indicate drugs that were predicted in association with both copy number and 
expression. 
		184 
estimated relative contributions of global gene expression cluster to the variations in 
drug response ranged from 0.01 to 0.46 for drugs significantly associated with MYC 
copy number and/or expression (Appendix Tables 6.3 and 6.4).  The differential 
response of at least one global gene expression cluster (when compared to reference 
cluster 1) was found for 90.9% (20/22) of drugs associated with MYC copy number 
and 70.5% (31/44) of drugs associated with MYC expression (Appendix Tables 6.3 and 
6.4).  A significant interaction between MYC status and global gene expression cluster 
was detected for 18.2% (4/22) of drugs associated with MYC copy number and 18.2% 
(8/44) of drugs associated with MYC expression (Appendix Tables 6.3 and 6.4).   
 
5.2.5.3 Drugs associated with ERBB2 copy number and/or expression 
There were 53 drugs significantly associated with ERBB2 copy number and 26 
drugs significantly associated with ERBB2 expression (p < 0.05, Tables 5.2.4, 5.2.11, 
and 5.2.12).  Of these, seven drugs (lapatinib, PD-0325901, paclitaxel, selumetinib, 
TAE684, AEW541, and TKI258) remained significant following p value adjustment 
(Tables 5.2.4, 5.2.11 and 5.2.12).  Thirteen drugs were predicted by both sets of 
analyses, comprising 24.5% of the 53 drugs associated with ERBB2 copy number and 
50% of the 26 drugs associated with ERBB2 expression (Table 5.2.4).  These 13 drugs 
were: lapatinib, panobinostat, MLN2238, SB-225002, PNU-74654, ML006, PI-103, 
BX-795, AZD1775, PD-0325901, paclitaxel, selumetinib, AEW541 (Tables 5.2.11 and 
5.2.12).  Importantly, the predicted response to these drugs was in the same direction 
(either chemo-sensitivity or -resistance) in all but one case (with the exception being 
ML006).  Overall, chemo-sensitivity with increasing ERBB2 copy number or 
expression was predicted for 16.5% (13/79) of drug associations, as indicated by a 
negative effect size, while chemo-resistance was predicted for the remaining 83.5% 
(66/79) of drug associations, as indicated by a positive effect size (Table 5.2.4).  The 
functions and/or molecular target(s) of the drugs predicted to be associated with 
ERBB2 copy number or expression are summarised in Table 5.2.13.    
Effect sizes for chemo-sensitivity ranged from -0.36 to -0.11 for drugs 
associated with ERBB2 copy number, and from -0.84 to -0.06 for drugs associated with 
ERBB2 expression, while effect sizes for chemo-resistance ranged from 1.55 to 0.05 
for drugs associated with ERBB2 copy number, and from 0.59 to 0.06 for drugs 
associated with ERBB2 expression (Tables 5.2.11 and 5.2.12, Figure 5.2.7).  The 
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Table 5.2.11. Drugs predicted by multivariate linear regression to be associated 
with ERBB2 copy number.  Drugs are separated into two categories based on 
whether increased ERBB2 copy number was significantly associated with chemo-
sensitivity or -resistance (non-adjusted p < 0.05), and are ranked according to effect 
size.  Asterisks (*) indicate that the drug was also predicted in association with ERBB2 
expression.  Associations that remained significant following p value adjustment are 
shown in bold. 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
n.
 Lapatinib* CCLE -0.36 0.14 < 0.001 < 0.001 
Panobinostat* CCLE -0.11 0.01 0.021 0.062 
R
es
is
ta
nt
 
MLN2238* CTRP 1.55 0.24 < 0.001 0.062 
Dactolisib CTRP 0.95 0.09 0.001 0.080 
Blebbistatin CTRP 0.91 0.09 0.001 0.080 
CHM-1 CTRP 0.89 0.04 0.017 0.326 
TW-37 CTRP 0.85 0.05 0.028 0.326 
Epigallocatechin-3-
gallate CTRP 0.76 0.04 0.048 0.358 
Parbendazole CTRP 0.69 0.03 0.036 0.336 
Olaparib CTRP 0.67 0.04 0.038 0.336 
BMS-754807 CTRP 0.65 0.03 0.048 0.358 
BRD-K03618428 CTRP 0.60 0.05 0.02 0.326 
4-methylfasudil CTRP 0.59 0.03 0.046 0.358 
SB-225002* CTRP 0.58 0.04 0.001 0.080 
PNU-74654* CTRP 0.58 0.04 0.033 0.331 
ML006* CTRP 0.57 0.04 0.046 0.358 
PI-103* CTRP 0.53 0.04 0.002 0.132 
BX-795* CTRP 0.51 0.04 0.027 0.326 
CCT036477 CTRP 0.50 0.05 0.007 0.231 
Triazolothiadiazine CTRP 0.49 0.04 0.016 0.326 
Fedratinib CTRP 0.47 0.05 < 0.001 0.062 
RITA CTRP 0.47 0.03 0.019 0.326 
PF-750 CTRP 0.47 0.04 0.048 0.358 
BMS-536924 CTRP 0.46 0.03 0.005 0.209 
CD-437 CTRP 0.41 0.02 0.03 0.331 
AZD1775* CTRP 0.40 0.03 0.013 0.310 
m-3M3-FBS CTRP 0.40 0.03 0.049 0.358 
ML050 CTRP 0.38 0.05 0.022 0.326 
Myriocin CTRP 0.38 0.03 0.045 0.358 
BRD-K74761218 CTRP 0.37 0.03 0.007 0.231 
LY-2183240 CTRP 0.36 0.03 0.013 0.310 
BRD-A60366732 CTRP 0.35 0.11 0.038 0.336 
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Table 5.2.11. Continued… 
 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
 NSC95397 CTRP 0.33 0.02 0.024 0.326 
Tipifarnib-P1 CTRP 0.30 0.04 0.003 0.142 
Gossypol CTRP 0.30 0.02 0.025 0.326 
PD-0325901* CCLE 0.29 0.01 0.008 0.033 
Tipifarnib-P2 CTRP 0.29 0.02 0.027 0.326 
Piperlongumine CTRP 0.29 0.02 0.027 0.326 
Quinoclamine CTRP 0.27 0.02 0.034 0.331 
Paclitaxel* CCLE 0.26 0.02 0.004 0.033 
SCH-79797 CTRP 0.26 0.02 0.033 0.331 
DL-TBOA CTRP 0.23 0.04 0.033 0.331 
AGK-2 CTRP 0.23 0.02 0.038 0.336 
Selumetinib* CCLE 0.22 0.01 0.008 0.033 
XAV-939 CTRP 0.21 0.02 0.015 0.321 
JZL184 CTRP 0.17 0.03 0.008 0.231 
TAE684 CCLE 0.16 0.02 0.007 0.033 
BRD-K40892394 CTRP 0.15 0.02 0.021 0.326 
Glibenclamide CTRP 0.13 0.03 0.009 0.231 
AEW541* CCLE 0.12 0.01 0.005 0.033 
GDC-0449 CTRP 0.11 0.02 0.028 0.326 
TKI258 CCLE 0.10 0.02 0.014 0.049 
Nutlin-3 CCLE 0.05 0.01 0.049 0.130 
 
a  Effect size is the mean change in drug sensitivity for each unit change in ERBB2 copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by ERBB2 copy number to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant  
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.12. Drugs predicted by multivariate linear regression to be associated 
with ERBB2 expression.  Drugs are separated into two categories based on whether 
increased ERBB2 expression was significantly associated with chemo-sensitivity or  
-resistance (non-adjusted p < 0.05), and are ranked according to effect size.  Asterisks 
(*) indicate that the drug was also predicted in association with ERBB2 copy number.  
Associations that remained significant following p value adjustment are shown in bold. 
 Drug Dataset Effect size a 
Relative 
contribution b p value 
Adjusted 
p value 
Se
ns
iti
ve
 
Ursolic acid CTRP -0.84 0.05 0.001 0.097 
Tyrphostin CTRP -0.61 0.15 0.001 0.097 
BRD-K78867378 CTRP -0.43 0.02 0.011 0.413 
Parthenolide CTRP -0.42 0.03 0.010 0.413 
ML006* CTRP -0.36 0.02 0.022 0.584 
BRD-K43620258 CTRP -0.32 0.03 0.012 0.413 
Lapatinib* CCLE -0.27 0.24 < 0.001 < 0.001 
Navitoclax CTRP -0.27 0.01 0.038 0.77 
BRD-K33218418 CTRP -0.16 0.02 0.047 0.789 
BRD-K52904470 CTRP -0.14 0.06 0.044 0.789 
Panobinostat* CCLE -0.06 0.01 0.037 0.149 
R
es
is
ta
nt
 
MLN2238* CTRP 0.59 0.18 0.001 0.160 
Rotenone CTRP 0.51 0.09 0.021 0.584 
Pevonedistat CTRP 0.40 0.06 0.005 0.305 
SB-225002* CTRP 0.33 0.10 0.004 0.305 
BX-795* CTRP 0.31 0.12 0.010 0.413 
Tozasertib CTRP 0.30 0.04 0.015 0.493 
PNU-74654* CTRP 0.29 0.06 0.050 0.789 
ABT-751 CTRP 0.26 0.06 0.036 0.770 
MST-312 CTRP 0.25 0.06 0.033 0.766 
AZD1775* CTRP 0.24 0.04 0.026 0.637 
PI-103* CTRP 0.23 0.04 0.041 0.770 
PD-0325901* CCLE 0.19 0.01 0.006 0.064 
Paclitaxel* CCLE 0.15 0.03 0.008 0.064 
Selumetinib* CCLE 0.13 0.01 0.013 0.077 
AEW541* CCLE 0.06 0.01 0.016 0.077 
 
a  Effect size is the mean change in drug sensitivity for each unit change in ERBB2 copy 
number, when the global gene expression cluster was fixed 
b  Relative contribution made by ERBB2 expression to the variation in drug sensitivity 
c  P value indicates whether the association was statistically significant 
d  Adjusted p value accounts for multiple testing, using the false discovery rate method 
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Table 5.2.13. Activities and/or target(s) of the drugs predicted to be associated 
with ERBB2 copy number and/or expression.  The activity and/or target(s) of each 
drug are shown as reported in the Cancer Cell Line Encylopedia or Cancer 
Therapeutics Response Portal, with additional references provided if these were 
insufficient.  ‘S’ and ‘R’ indicate that chemo-sensitivity and -resistance, respectively, 
were predicted in association with increasing ERBB2 copy number (CN) or expression 
(expn), while ‘-’ indicates that there was no statistically significant association with 
drug response (non-adjusted p > 0.05).  Associations that remained significant 
following p value adjustment are shown in bold.  Drugs with the prefix BRD- have 
been omitted since information regarding the activity and/or target(s) of these 
compounds is not publicly-available.   
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing ERBB2 
CN expn 
4-methylfasudil Inhibitor of serine/threonine kinase 33 and Rho-associated kinases (ROCK) R - 
ABT-751 Inhibitor of beta-tubulin - R 
AEW541 Inhibitor of insulin-like growth factor 1 receptor (kinase) R R 
AGK-2 Inhibitor of sirtuin 2  R - 
AZD1775 Inhibitor of WEE1 G2 checkpoint kinase R R 
Blebbistatin Inhibitor of myosin II ATPases R - 
BMS-536924 Inhibitor of insulin-like growth factor 1 receptor and insulin receptor (kinases) R - 
BMS-754807 Inhibitor of insulin-like growth factor 1 receptor and insulin receptor (kinases) R - 
BX-795 
Inhibitor of TANK-binding kinase 1, 
inhibitor of nuclear factor kappa B kinase 
subunit epsilon, and pyruvate 
dehydrogenase kinase 1  
R R 
CCT036477 Inhibitor of WNT signalling by blocking beta-catenin transcription R - 
CD-437 Agonist of retinoic acid receptor gamma R - 
CHM-1 Inhibitor of tubulin polymerisation R - 
Dactolisib 
Inhibitor of PI3K (phosphatidylinositol-4,5-
bisphospate 3-kinase) and mTOR 
(mechanistic target of rapamycin kinase)  
R - 
DL-TBOA Inhibitor of excitatory amino acid transporters R - 
Epigallocatechin-3-
gallate 
Natural product (found in tea) with targets 
including glutamate dehydrogenase 1,  
ELANE (elastase, neutrophil expressed), 
E1A binding protein p300, fatty acid 
synthase, lysine acetyltransferase 2B, and 
matrix metallopeptidases 2 and 14 
R - 
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Table 5.2.13. Continued… 
 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing ERBB2 
CN expn 
Fedratinib Inhibitor of Janus kinase 2 R - 
GDC-0449 
(vismodegib) 
Inhibitor of smoothened (SMO), a protein 
involved in the hedgehog signalling 
pathway (Khatra et al., 2017) 
R - 
Glibenclamide 
inhibitor of ATP-dependent K+ channel 
and cystic fibrosis transmembrane 
conductance regulator 
R - 
Gossypol 
Inhibitor of BCL2 family members, which 
are regulators of apoptosis, and lactate 
dehydrogenase 
R - 
JZL184 Inhibitor of monoacylglycerol lipase  R - 
Lapatinib Inhibitor of epidermal growth factor receptor and ERBB2 (kinases) S S 
LY-2183240 Inhibitor of fatty acid amide hydrolase and anadamide uptake R - 
m-3M3-FBS Activator of phospholipase C R - 
ML006 Agonist of sphingosine 1-phosphate receptor 3 R S 
ML050 Inhibitor of G protein-coupled estrogen receptor 1 R - 
MLN2238 Inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site R R 
MST-312 Inhibitor of telomerase reverse transcriptase - R 
Myriocin Inhibitor of serine palmitoyltransferases  R - 
Navitoclax Inhibitor of BCL2 family members, which are regulators of apoptosis - S 
NSC95397 Inhibitor of cell division cycle 25 phosphatase R - 
Nutlin-3 Inhibitor of p53-MDM2 interaction R - 
Olaparib Inhibitor of poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) R - 
Paclitaxel Inhibitor of microtubule assembly R R 
Panobinostat Inhibitor of histone deacetylases S S 
Parbendazole Inhibitor of microtubule assembly R - 
Parthenolide 
Natural product, which modulates levels of 
reactive oxygen species and NF-kappa-B-
signalling 
- S 
PD-0325901 
Inhibitor of MEK1 and MEK2, members of 
the mitogen-activated protein kinase 
kinase family 
R R 
Pevonedistat Inhibitor of Nedd-8 activating enzyme  - R 
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Table 5.2.13. Continued… 
 
Drug Activity and/or target(s) 
Drug response 
predicted with 
increasing ERBB2 
CN expn 
PF-750 Inhibitor of fatty acid amide hydrolase R - 
PI-103 
Inhibitor of PI3K (phosphatidylinositol-4,5-
bisphospate 3-kinase) and mTOR 
(mechanistic target of rapamycin kinase) 
R R 
Piperlongumine Natural product, which modulates levels of reactive oxygen species R - 
PNU-74654 Inhibitor of the interaction between beta-catenin and transcription factor 4 R R 
Quinoclamine Modulator of NF-kappa-B signalling R - 
RITA Inhibitor of p53-MDM2 interaction R - 
Rotenone Inhibitor of mitochondrial electron transport chain at complex I - R 
SB-225002 Inhibitor of chemokine receptor 2  R R 
SCH-79797 Antagonist of proteinase-activated receptor 1 R - 
Selumetinib 
Inhibitor of MEK1 and MEK2, members of 
the mitogen-activated protein kinase 
kinase family 
R R 
TAE684 Inhibitor of ALK receptor tyrosine kinase R - 
Tipifarnib-P1 Inhibitor of farnesyltransferase R - 
Tipifarnib-P2 Inhibitor of farnesyltransferase R - 
TKI258 Multi-kinase inhibitor R - 
Tozasertib Inhibitor of aurora kinases - R 
Triazolothiadiazine Inhibitor of phosphodiesterase 4 R - 
TW-37 Inhibitor of BCL2 family members, which are regulators of apoptosis R - 
Tyrphostin Inhibitor of epidermal growth factor receptor (EGFR) (kinase) - S 
Ursolic acid Inhibitor of signal transducer and activator of transcription 3 (STAT3) signalling - S 
XAV-939 Inhibitor of tankyrase 1 and 2 R - 
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Figure 5.2.7. Effect sizes for drugs predicted to be associated with ERBB2 copy 
number and/or expression.  The graphs compare effect sizes (x-axis) for drugs 
predicted to be significantly associated (non-adjusted p < 0.05) with either (A) ERBB2 
copy number (n = 53) or (B) ERBB2 expression (n = 26).  Effect size is the gene 
coefficient generated by multivariate linear regression and indicates the mean change 
in drug sensitivities for each unit change in ERBB2 copy number or expression, when 
the global gene expression cluster was fixed.  A negative effect size indicates chemo-
sensitivity, while a positive effect size indicates chemo-resistance.  Associations that 
remained significant following p value adjustment are shown in bold.  Asterisks (*) 
indicate drugs that were predicted in association with both copy number and 
expression. 
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estimated relative contributions of ERBB2 status to the reported variations in drug 
response ranged from 0.01 to 0.24 for drugs associated with ERBB2 copy number, and 
from 0.01 to 0.24 for drugs associated with ERBB2 expression (Tables 5.2.11 and 
5.2.12).  As previously, cell lineage was shown to influence the majority of drug-gene 
models for ERBB2.  The estimated relative contributions of global gene expression 
cluster to the variations in drug response ranged from 0.02 to 0.43 for drugs 
significantly associated with ERBB2 copy number and/or expression (Appendix Tables 
6.5 and 6.6).  The differential response of at least one global gene expression cluster 
(when compared to reference cluster 1) was found for 64.2% (34/53) of drugs 
associated with ERBB2 copy number and 76.9% (20/26) of drugs associated with 
ERBB2 expression (Appendix Tables 6.5 and 6.6).  A significant interaction between 
ERBB2 status and global gene expression cluster was detected for 9.4% (5/53) of drugs 
associated with ERBB2 copy number and 11.5% (3/26) of drugs associated with 
ERBB2 expression (Appendix Tables 6.5 and 6.6).   
Importantly, our predictive modelling approach identified the known 
sensitisation of ERBB2-overexpressing cell lines to lapatinib.  Indeed, lapatinib was 
the compound most significantly associated with both copy number and gene 
expression of ERBB2 (p < 0.001 in both cases) (Tables 5.2.11 and 5.2.12).  The 
scatterplots for this drug-gene relationship were presented in a previous section (Figure 
5.2.2).  As part of the CCLE dataset, lapatinib was tested in 487 cell lines (Appendix 
2).  The effect sizes for lapatinib were similar in both copy number and expression 
models (-0.36 and -0.27, respectively), and were moderate when compared to the range 
of effect sizes for ERBB2 expression models (Tables 5.2.11 and 5.2.12, Figure 5.2.7).  
However, the estimated relative contributions for lapatinib in copy number and 
expression models were the second-highest (0.14) and highest (0.24), respectively, of 
all the ERBB2 models in each category (Tables 5.2.11 and 5.2.12).  This association 
was a crucial intra-dataset control for our predictive modelling approach because 
lapatinib is an inhibitor of ERBB2, whose efficacy against ERBB2-positive cancers 
has been well-demonstrated in both in vitro and clinical studies (Jernstrom et al., 
2017).  Treatment with lapatinib was subsequently used as a positive control in our 
own in vitro experiments (which will be presented in Chapter 6).   
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5.2.5.4 Drugs associated with more than one gene 
Finally, it is worth noting that several drugs were identified through predictive 
modelling in association with the copy number and/or expression of more than one of 
the three genes TPD52, MYC, and ERBB2 (Table 5.2.14).  There were three drugs 
(CCT036477, selumetinib, and TKI258) that were identified in association with all 
three genes, and it was only for CCT036477 that the predicted direction of these 
associations (that is, chemo-sensitivity versus -resistance) were consistent for all three 
genes.  There were 10 drugs that were identified in association with both TPD52 and 
MYC (either gene copy number or expression), seven drugs that were identified in 
association with both TPD52 and ERBB2, and 15 drugs that were identified in 
association with both MYC and ERBB2.  While some of the drugs may have been 
identified through the targeting of common pathways for TPD52, MYC, and/or ERBB2, 
it is also possible that they represent false positives, particularly where the p value did 
not achieve statistical significance following adjustment for multiple testing. 
 
5.3 Discussion   
In this chapter, we explored whether TPD52 amplification and/or 
overexpression is broadly associated with altered sensitivity or resistance to 
chemotherapeutic and experimental drugs.  Multivariate linear regression modelling 
was performed to determine whether cell lines from diverse cancer types displayed 
differential responses to the same compound according to their gene copy number at 
TPD52, MYC, and ERBB2.  For each drug, chemo-sensitivity measures were 
discretised into three categories (resistant, intermediate and sensitive).  We also 
modelled the associations between drug response and gene expression of TPD52, 
MYC, and ERBB2 to ascertain whether these recapitulated the gene-drug associations 
predicted by copy number.  Both models were adjusted for cell lineage as a potential 
confounder by performing agglomerative hierarchical clustering of cell lines into five 
groups based on the 500 most highly varying genes.  Finally, we considered the 
activities and/or molecular targets of the drugs that were significantly associated with 
TPD52, MYC, or ERBB2 copy number and/or expression to identify candidates for 
subsequent in vitro testing.  
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Table 5.2.14. Drugs predicted by multivariate linear regression to be associated 
with more than one of the three genes TPD52, MYC, and ERBB2. ‘S’ and ‘R’ 
indicate that chemo-sensitivity and -resistance, respectively, were predicted in 
association with increasing gene copy number (CN) or expression (expn), while ‘-’ 
indicates that there was no statistically significant association with drug response (non-
adjusted p < 0.05). 
 
Drug 
Drug response 
predicted with 
increasing TPD52 
Drug response 
predicted with 
increasing MYC 
Drug response 
predicted with 
increasing ERBB2 
CN expn CN expn CN expn 
BRD-K11853856 - R - R - - 
BRD-K52904470 - R - - - S 
BRD-K78867378 - - R - - S 
CCT036477 - R - R R - 
Importazole S - - R - - 
Kinetin riboside S - - S - - 
KU 0060648 S - R R - - 
Lapatinib S - - - S S 
ML050 - - - R R - 
MLN2238 S - - - R R 
Navitoclax - - R - - S 
Nilotinib S - S S - - 
Nutlin-3 - - R - R - 
Olaparib - - - R R - 
Paclitaxel - - S - R R 
Parthenolide - - R - - S 
PD-0325901 - - - S R R 
PL-DI S - R - - - 
Quinoclamine - - - R R - 
RITA - - R - R - 
Selumetinib - R - S R R 
SNX-2112 - R R R - - 
TAE684 - R - - R - 
TKI258 - R - S R - 
Tyrphostin - - R - - S 
Ursolic acid - - - R - S 
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5.3.1 Drugs associated with TPD52 copy number and/or expression 
Predictive modelling identified nine drugs that were significantly associated 
with TPD52 copy number and 31 drugs that were significantly associated with TPD52 
expression, targeting an array of proteins and pathways.  Of the four drugs that 
remained significant following p value adjustment for multiple testing, two were 
kinase inhibitors (selumetinib and TKI258), one was an agonist of retinoic acid 
receptors (TTNBP), and the other was not functionally annotated (BRD-K90072296).  
Retinoic acid receptor agonists and kinase inhibitors were also featured among the 
drugs with significant non-adjusted p values.  Resistance to agonists of retinoic acid 
receptors with increasing TPD52 expression was predicted through the association of 
three different compounds (AC55649, all-trans retinoic acid, and TTNBP).  
Interestingly, retinoic acid is known to suppress adipogenesis in mouse 3T3-L1 pre-
adipocytes (Kawada et al., 1990; Schwarz et al., 1997) and has been shown to 
modulate lipid accumulation via altered expression of sterol regulatory element-
binding protein 1 (SREBP1) and fatty acid synthase (FASN) (Abd Eldaim et al., 
2017).  Treatment of keratinocytes with retinoic acid has also been shown to suppress 
several enzymes involved in lipid biosynthesis including FASN and HMG-CoA 
reductase (HMGCR) (Lee et al., 2009).  Sensitivity to the kinase inhibitors KU 
0060648, lapatinib, and nilotinib was predicted with increasing TPD52 copy number, 
while resistance to the kinase inhibitors PF2341066, selumetinib, TAE684, and 
TKI258 was predicted with increasing TPD52 expression.  An important recent 
publication identified TPD52 as one of 20 genes on a 3.67 Mb chromosomal segment 
(labelled PANCAN86) that was recurrently gained across multiple cancer cell lines 
and predicted to be associated with sensitivity to the ERBB2-targeting drug CP724714 
(Iorio et al., 2016).  Interestingly, although CP724714 was not included in our dataset, 
our analyses did predict a similar association between increased TPD52 copy number 
and sensitivity to the ERBB2-targeting drug lapatinib.  Finally, we noted two drugs 
with potential relevance to lipid metabolism (brefeldin A and fatostatin). These will be 
addressed in more detail in Chapter 6.  
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5.3.2 Drugs associated with MYC copy number and/or expression 
Predictive modelling for drugs that were significantly associated with MYC 
copy number and/or expression also identified a range of compounds with diverse 
molecular targets. Of the five drugs that remained significant following p value 
adjustment for multiple testing, two were kinase inhibitors (RAF265 and sorafenib), 
one was an inhibitor of the hedgehog signalling pathway (itraconazole), another was 
an inhibitor of PARP1 and PARP2 (veliparib), and the remaining drug was not 
functionally annotated (BRD-K88560311).  Of the drugs with significant non-adjusted 
p values, kinase inhibitors were a major drug class associated with MYC status, with 
6/22 and 12/44 drugs of this type identified through copy number and expression 
analyses, respectively.  Several pathways and/or targets were implicated through the 
identification of two or more drugs.  These include the induction and modulation of 
reactive oxygen species (PL-DI and parthenolide), topoisomerase II inhibition 
(etoposide and teniposide), BCL2 inhibition (ABT-737 and navitoclax), and PARP 
inhibition (veliparib and olaparib).  Notably, increased MYC copy number was 
predicted to be associated with resistance to drugs RITA and nutlin-3, which both 
inhibit the interaction between p53 and MDM2 (to reactivate p53).  Increased MYC 
expression was similarly predicted to be associated with increased resistance to drugs 
PRIMA-1 and PRIMA-1-Met, which are both re-activators of p53.   
In line with our hypotheses, several drugs that act within metabolic pathways 
were also identified through MYC expression analyses.  Increased MYC expression was 
associated with sensitivity to simvastatin, which inhibits HMGCR, the rate-limiting 
enzyme in de novo cholesterol synthesis (section 1.2.1).  Increased MYC expression 
was predicted to be associated with resistance to cerulenin, which inhibits fatty acid 
synthase (FASN) and thereby blocks the de novo fatty acid (section 1.2.1).  
Interestingly, both HMGCR and FASN transcript levels have been shown to be reduced 
in fibroblasts with myc knockout, but increased with the stable re-expression of MYC 
in these cells (Edmunds et al., 2014).  Both of these synthetic pathways also begin with 
acetyl-CoA, whose levels have been shown to be critically low in myc knockout cells 
(Edmunds et al., 2014).  Additionally, our analyses predicted resistance to AA-
COCF3, which inhibits cytosolic phospholipase A2 and fatty acid amide hydrolase 
(FAAH).  Finally, our analyses also predicted resistance to JTT-705 (dalcetrapib), 
which inhibits cholesteryl ester transfer protein to modulate the transfer of cholesterol 
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esters between different lipoproteins (Niesor et al., 2010).  These drug predictions, 
although interesting, were not pursued further as the current study was focused 
primarily on finding new associations for TPD52. 
 
5.3.3 Drugs associated with ERBB2 copy number and/or expression 
As for TPD52 and MYC, predictive modelling for drugs that were significantly 
associated with ERBB2 copy number and/or expression again identified a range of 
compounds with diverse molecular targets.  Of the seven drugs that remained 
significant following p value adjustment for multiple testing, six were kinase inhibitors 
(AEW541, lapatinib, PD-0325901, selumetinib, TAE684, and TKI258) while the other 
was an inhibitor of microtubule assembly (paclitaxel).  Accordingly, kinase inhibitors 
were a major drug class associated with ERBB2 status among drugs with significant 
non-adjusted p values, with 14/53 and 9/26 drugs of this type identified through copy 
number and expression analyses, respectively.  Kinase inhibitors also represented 7 of 
the 13 drugs that were identified through both copy number and expression analyses. 
ERBB2 has been identified on a recurrently-gained chromosomal segment (labelled 
PANCAN301) in cancer cell lines that was predicted to be associated with sensitivity 
to three different ERBB2-targeting drugs (afatinib, CP724714, and lapatinib) and 
resistance to five drugs with various targets (681640, BMS-536924, camptothecin, 
CEP-701, and PD-173074) (Iorio et al., 2016).  Of these, only lapatinib and BMS-
536924 were also in our dataset and, encouragingly, both associations were similarly 
identified through our analyses. BMS-536924 inhibits insulin-like growth factor 
receptor, which is also the target of two additional drugs predicted by our modelling 
(AEW541 and BMS-754807). 
In line with our hypotheses, several drugs that act within metabolic pathways 
were also identified through ERBB2 copy number analyses.  Increased ERBB2 copy 
number was predicted to be associated with resistance to epigallocatechin-3-gallate 
(EGCG), a naturally-occurring polyphenol found in green tea, which has been shown 
to inhibit FASN in a similar way to the FASN-targeted drugs cerulenin and C75 (Table 
1.1; Wang and Tian, 2001; Brusselmans et al., 2005).  This is particularly interesting 
given the strong correlation between ERBB2 and FASN expression in cancer (Kumar-
Sinha et al., 2003; Menendez and Lupu, 2007).  Increased ERBB2 copy number was 
also predicted to be associated with resistance to JZL184, which is an inhibitor of 
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monoacylglycerol lipase (MAGL), an enzyme that hydrolyses monoacylglyceride into 
fatty acid and glycerol (Table 1.1; Nomura et al., 2010).  Furthermore, our analyses 
also predicted resistance to two drugs, PF-750 and LY-2183240, which inhibit FAAH.  
MAGL and FAAH are the major enzymes involved in the degradation of 
endocannabinoids (Schwarz et al., 2018).  Additionally, increased ERBB2 copy 
number was predicted to be associated with resistance to two drugs, tipifarnib-P1 and 
tipifarnib-P2, which target farneyltransferase.  This enzyme adds a farnesyl group to 
proteins, which is an important post-translational modification for several cancer-
relevant proteins, including the Ras superfamily of GTPases (Konstantinopoulos et al., 
2007).  Interestingly, this farnesyl group is an intermediate product derived from 
cholesterol biosynthesis through the mevalonate pathway, which is known to be 
dysregulated in some cancers (section 1.2.3.3; Konstantinopoulos et al., 2007; 
Clendening et al., 2010).  Finally, our analyses also predicted resistance to myriocin, 
which inhibits serine palmitoyltransferase, the rate-limiting enzyme of sphingolipid 
metabolism (Miyake et al., 1995).  These drug predictions were not pursued further as 
this was beyond the scope of the current study.  
 
5.3.4 Predictive modelling approach 
In addition to identifying candidate drugs for further study, our predictive 
modelling approach provided several general insights.  Importantly, we found that 
there was limited concordance between drugs identified through copy number and 
gene expression models. Although gene amplification usually results in gene 
overexpression, it is not the case that overexpression always results from 
amplification, as there are many other mechanisms by which overexpression can 
occur.  This was evident for TPD52, MYC, and ERBB2 within the cohort of 22 cell 
lines characterised in Chapter 3 (Table 3.2.4).  Gene expression datasets therefore tell a 
much broader story than copy number datasets.  On the other hand, oncogenes that are 
activated through amplification rather than overexpression, are thought to be more 
closely aligned with oncogene addiction because they likely reflect the ‘hard-wiring’ 
of cancer cells (Weinstein and Joe, 2008).  It was for these reasons that we elected to 
perform both sets of analyses, with the expectation that those drugs identified by both 
analyses would be more likely to reflect true associations.  While we anticipated 
additional drugs to be identified through expression models, it is surprising that so few 
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drugs identified through copy number models were recapitulated in expression models.  
While there were no drugs that were identified through both sets of analyses for 
TPD52, there were only 6 drugs associated with MYC in both copy number and 
expression models (out of 22 and 44, respectively), and 13 drugs associated with 
ERBB2 in copy number and expression models (out of 53 and 26, respectively). 
One possible explanation for this discordance is that a proportion of the drugs 
predicted by these models were false positives, or otherwise represent very weak 
associations.  It is important to note that only 7 of the drugs identified for gene copy 
number, and 10 of the drugs identified for gene expression, achieved statistical 
significance following p value adjustment for multiple testing.  This explanation would 
be supported by the fact that the strong association between ERBB2 and lapatinib was 
indeed identified through both sets of analyses, where it remained significant after p 
value adjustment.  ERBB2 expression was also the top predictor of lapatinib response 
in the regression-based analyses performed by the CCLE (Barretina et al., 2012) and 
was one of the most highly-significant genomic biomarkers of drug response identified 
through elastic net regression in an independent dataset (Garnett et al., 2012).  
However, it might be unreasonable to expect that the kind of association seen for 
ERBB2 and lapatinib would be recapitulated for drugs associated with TPD52 (or 
MYC), since none of these drugs were designed to target these oncogenes in the way 
that lapatinib was designed to inhibit ERBB2.  Thus, although the lapatinib-ERBB2 
association served as a valuable positive control for our analyses, we could realistically 
expect other associations to be weaker without necessarily being false positives.   
Another caveat that should be considered when interpreting the results of our 
predictive modelling is that the gene copy number and expression models were 
unequally impacted by the presence of cell lines in the dataset that harbour mutations 
in the given gene.  Such cell lines might show the associated drug response, either 
increased sensitivity or resistance, despite not being considered to have amplification 
and/or overexpression of the gene.  This would more likely affect drugs predicted to be 
associated with ERBB2 (or MYC), since TPD52 is rarely mutated in human cancer cell 
lines (www.cbioportal.org).   
Our predictive modelling was also subject to several limitations, which stem 
primarily from the large pharmacogenomic datasets that were used.  As with all high-
throughput studies, there is the potential for these datasets to contain some erroneous 
data or for technical or methodological factors to influence the reproducibility of these 
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results.  Specifically, variability could be introduced with cell line growth conditions, 
including seeding densities and growth media, as well as the choice of assay for 
determining cell viability (Hatzis et al., 2014).  Using metabolic activity (ATP 
quantitation) as a read-out for cell viability has the potential to distort the results for 
drugs that act within these pathways.  The continuous passaging of cell lines may also 
lead to a ‘drift’ in both genomic characteristics and drug sensitivities over time.  In 
2013, the reproducibility of large-scale pharmacogenomic studies was called into 
question by a study that found substantial disagreement between drug response data 
from the CCLE and a similar endeavour called the Cancer Genome Project (Haibe-
Kains et al., 2013).  This remains a point of contention, with one study asserting that 
these large-scale studies do exhibit a reasonable level of consistency when 
“biologically-grounded analytical considerations are incorporated” (Stransky et al., 
2015), while another study asserts that, even when these considerations are made, a 
large number of inconsistencies remain (Safikhani et al., 2016).  Finally, it must be 
noted that human cancer cell lines are a model system and as such will not completely 
recapitulate the primary tumours from which they are derived.  However, for copy 
number and gene expression at least, comparisons undertaken by the CCLE showed a 
strong positive correlation between cell lines and primary tumours, according to 
lineage (Barretina et al., 2012).  
Our investigations were also limited by the discovery that the CCLE and CTRP 
datasets were largely incomplete, in the sense that not every drug was tested in the 
same number of cell lines, and not every cell line was tested with the same number of 
drugs.  These restricted testing combinations precluded early attempts to derive 
categorical models – that is, comparing drug responses in amplified versus non-
amplified cell lines – since very few of the TPD52-amplified cell lines were screened 
with a sufficient number of drugs.  Such gaps in the data disproportionately affect 
oncogenes that are less-frequently amplified, including TPD52 as well as many other 
oncogenes for which these analyses might otherwise uncover novel and actionable 
associations with drug response.  Such oncogenes are not necessarily less worthy of 
study, particularly with the urgent need to counteract the development of resistance to 
drugs targeted against canonical oncogenes such as ERBB2 (Jernstrom et al., 2017).      
Given the paucity of TPD52-amplified cell lines with associated drug response 
data, we decided to pursue a continuous modelling approach instead.  This has the 
advantage of taking into account the magnitude of amplification, which may influence 
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the magnitude of any corresponding change in drug response.  For example, if 
sensitivity to a particular drug were to increase with increasing TPD52 copy number, 
this could be captured by continuous models, whereas a categorical model would 
consider only the differences in drug response between cell lines that harbour TPD52 
amplification, above a set threshold, and those that did not.  The disadvantage of these 
continuous models is that their results may be less clear-cut than the categorical 
models.  We found multivariate linear regression to perform best for the majority of 
drug-gene models; however, it must be noted that this is a high-throughput method and 
linear regression may not necessarily be the ideal modelling approach for each 
individual drug-gene association.  Finally, the missing data in the CCLE and CTRP 
datasets appear to be randomly distributed and therefore unlikely to disproportionately 
affect those cell lines with TPD52 amplification or overexpression.   
A corollary of these limited datasets was the need to modify the way in which 
cell lineage was accounted for in our predictive modelling.  Cell lineage was 
confirmed to be a major predictor for response to several drugs within both the CCLE 
and CTRP (Barretina et al., 2012, Basu et al., 2013).  However, due to the limited 
number of cell lines with accompanying drug response data, grouping cell lines by cell 
lineage or cancer type would result in many categories with five or fewer cases.  This 
imbalance in size between categories could then provide misleading results in 
predictive modelling.  We therefore used gene expression cluster as a proxy for cell 
lineage and this was determined by agglomerative hierarchical clustering of the cell 
lines into five groups based on the 500 most highly varying genes.  However, if 
TPD52, MYC, or ERBB2 status were to significantly affect global gene expression, this 
could lead to problems associated with multi-collinearity, which occurs when two of 
the predictor variables in a multiple regression model are highly correlated with each 
other.  Comparing the median copy number for each of the three genes across global 
gene expression clusters found that this was predominantly similar between clusters 
for TPD52 and ERBB2, but not for MYC.  It is unsurprising that MYC would alter 
global gene expression given its function as a transcription factor.  To help ameliorate 
the potential problem of multicollinearity, we reported whether or not a significant 
interaction was detected between TPD52, MYC, or ERBB2 status and global gene 
expression cluster for each drug-gene association. 
 One final limitation of our investigations was that there was sometimes very 
little information available about the drugs identified through predictive modelling.  In 
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some cases, this was because the compound was given a database identifier only and 
therefore could not be searched in the literature or functionally annotated.  In other 
cases, compounds were linked to a searchable drug name, however, the drug targets or 
pathways were unknown.  Furthermore, many of these experimental drugs were not 
readily available, which precluded us from following up these findings within our own 
cell line cohort.  As mentioned in the results section, the recent publication of version 
2 of the CTRP online interface has provided a much more complete labelling and 
functional annotation of the compounds within this dataset 
(https://portals.broadinstitute.org/ctrp/).  Since much of this information was 
unavailable when we were selecting drugs to be carried forward into in vitro testing, 
there are several drugs that were originally identified through predictive modelling that 
would be worthy of further investigation in the future.   
 Despite these limitations, our study affirms the potential of using large-scale 
pharmacogenomic datasets to seek out novel associations between existing drugs and 
oncogenes that are amplified and/or overexpressed.  Such approaches capitalise upon 
substantial international research efforts, with the potential to fast-track translation 
since many drugs will already have well-described safety and pharmacokinetic 
profiles.  Furthermore, datasets such as the CTRP have been designed as living 
resources, constantly evolving as more combinations of drugs and cell lines are tested 
and as more in-depth information about these drugs’ molecular targets become known. 
As early consumers of these resources, we have shown how valuable such data can be 
and anticipate that the utility of these databases will continue to increase as they 
become more complete.  Efforts to expand these pharmacogenomic datasets are well 
underway, as evidenced by a recent publication that screened a median of 878 cell 
lines per drug (Iorio et al., 2016), representing a substantial improvement on the 
median of 128 CTRP cell lines that had corresponding drug response data at the time 
of our analyses.  With such rapid development, it may soon be possible to extend our 
search for drugs associated with TPD52 amplification in larger cohorts, allowing for 
the generation of categorical models as well as the consideration of drug sensitivities 
that might occur in a lineage-restricted manner.  
 
 
 
		203 
5.4 Summary and Conclusion 
We have applied predictive models to data from large-scale pharmacogenomic 
studies to detect both known and novel associations between gene copy number or 
expression and cell line chemo-sensitivity or -resistance.  Taken together, these 
analyses have identified several lead compounds for future experimental validation, 
two of which will be investigated in Chapter 6.  This study represents the first time that 
TPD52 amplification and/or overexpression has been investigated as a potential 
biomarker of drug sensitivity or resistance in different cancers.  Furthermore, our study 
provides a framework for the utilisation of large-scale pharmacogenomic datasets to 
seek out similar associations in other lesser-studied oncogenes.  Such analyses have 
the potential to link existing anti-cancer drugs with specific gene amplifications, which 
may then be applied as new biomarkers to predict efficacy or to reposition existing 
drugs for cancers which harbour amplifications in sensitising genes. 
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Chapter 6 
 
Lipid-modulating drugs in cancer cell 
lines with TPD52 amplification 
and/or overexpression. 
 
 
6.1 Introduction  
In the previous chapter, we investigated whether the amplification and 
subsequent overexpression of TPD52 might be broadly associated with altered 
sensitivity or resistance to chemotherapeutic and experimental drugs.  We were 
particularly interested in whether any of the lead compounds identified through 
predictive modelling could potentially modulate lipid metabolic pathways, since 
TPD52 has been implicated in these processes (Kamili et al., 2015).  Our knowledge 
of this aspect of TPD52 function was expanded in Chapter 4, where we found that 
increased lipid droplets were observed in most, but not all, cancer cell lines with 
moderate to high TPD52 levels, and demonstrated that lipid droplet numbers and size 
were dramatically increased following the exogenous overexpression of TPD52 in 
MDAMB231 cancer cells.  We therefore hypothesised that if TPD52 overexpression is 
indeed associated with altered lipid metabolism in a subset of cancers, it could 
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potentially signal cancers that are hard-wired to rely upon high lipid levels for their 
survival.  In this way, TPD52 overexpression could be applied clinically as a 
predictive marker for cancers likely to respond to drugs that interfere with lipid 
pathways.  This application of TPD52 is particularly promising in terms of fast-
tracking the translation of our research, since existing drugs could be repurposed to 
improve treatment outcomes.  
Of the lead compounds identified in association with TPD52 copy number 
and/or expression, there were two drugs that either operate directly within lipid 
pathways or impact lipid droplet accumulation.  The first of these, fatostatin, is a small 
molecule that inhibits the activation of SREBPs (sterol regulatory element-binding 
proteins) and thereby prevents these transcription factors from initiating the 
transcription of genes involved in fatty acid and cholesterol biosynthesis (Kamisuki et 
al., 2009).  The activation of SREBPs is tightly-regulated to preserve lipid 
homeostasis.  In the presence of sterols, precursor SREBPs are bound to SCAP 
(SREBP cleavage activating protein) and retained in the membrane of the endoplasmic 
reticulum (Goldstein et al., 2006).  When sterol levels drop, a conformational change 
in SCAP allows the SREBP-SCAP complex to be transported to the Golgi apparatus, 
where SREBP is activated through sequential cleavage by site-1 and site-2 proteases 
(Goldstein et al., 2006).  Active SREBPs are then able to translocate to the nucleus and 
initiate transcription of their target genes (Goldstein et al., 2006).  Fatostatin blocks the 
transport of SREBP to the Golgi apparatus, and therefore its activation, by binding to 
SCAP (Kamisuki et al., 2009).  Fatostatin has been shown to inhibit the insulin-
induced adipogenesis of 3T3-L1 cells (Choi et al., 2003), and to prevent body weight 
increases and hepatic fat accumulation in obese mice (Kamisuki et al., 2009).  
Fatostatin has also been shown to suppress cell proliferation in glioma (Williams et al., 
2013), prostate cancer (Li et al., 2014b), and pancreatic cancer (Shao et al., 2016; 
Siqingaowa et al., 2017) cell lines.             
The second drug was brefeldin A (BFA), a fungal metabolite that induces 
disassembly of the Golgi apparatus and retrograde transport of Golgi proteins to the 
endoplasmic reticulum, thereby critically disrupting intracellular membrane trafficking 
(Sciaky et al., 1997).  BFA acts by inhibiting the activation of the ARF (ADP-
ribosylation factor) family of small GTPases, which results in dissociation of cytosolic 
coat protein complexes, such as COPI (coat protein complex I), from Golgi 
membranes (Presley et al., 2002).  The vesicular trafficking machinery ARF1/COPI 
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that acts in the retrograde transport of proteins and vesicles from the Golgi to the 
endoplasmic reticulum is now recognised as an important regulator of lipid 
homeostasis (Beller et al., 2008; Guo et al., 2008).  Knockdown of components of the 
COPI complex produced a dramatic increase in lipid storage, which was partially 
attributable to the defective delivery of ATGL (adipocyte triglyceride lipase), an 
enzyme that remobilises stored lipid, to the lipid droplet surface (Beller et al., 2008).  
The ARF1/COPI machinery has also been shown to act directly on lipid droplets, 
enabling their connection to the endoplasmic reticulum for the targeting of specific 
triacylglyceride synthesis enzymes to lipid droplet surfaces (Wilfling et al., 2013; 
Wilfling et al., 2014).  Furthermore, phenotyping of mutant mice lacking ARFRP1 
(ARF-related protein 1) suggested that this protein plays an essential role in lipid 
droplet growth and the regulation of lipolysis (Hommel et al., 2010; Hesse et al., 
2013).  Finally, it is interesting to note that BFA treatment also impacts SREBP 
signalling, since the retrograde translocation of site-1 protease from the Golgi to the 
endoplasmic reticulum allows SREBPs to be constitutively activated in the 
endoplasmic reticulum (DeBose-Boyd et al., 1999).  This renders the levels of active 
cleaved SREBP unresponsive to both sterols and fatostatin, following treatment with 
BFA (Kamisuki et al., 2009).  
We therefore sought to validate in vitro the predicted associations between 
TPD52 copy number and/or expression and cancer cell line responses to fatostatin or 
BFA treatment.  
 
6.1.1 Aims of this chapter 
The specific aims of this chapter were as follows: 
1. To investigate whether cancer cell line sensitivities to fatostatin or BFA 
segregated according to TPD52 copy number and/or expression, as predicted 
2. To investigate whether TPD52 knockdown or overexpression altered the 
observed drug sensitivity or resistance 
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6.2 Results 
6.2.1 Lapatinib treatment in cancer cell lines 
We first investigated the known relationship between ERBB2 overexpression 
and sensitivity to lapatinib, as a positive control for our in vitro experiments.  We used 
four cell lines: AU565 and SKBR3, which feature ERBB2 amplification and 
overexpression, and HMC18 and MDAMB231, which feature low ERBB2 expression 
(Figure 3.2.11).  All cell lines were derived from breast cancers, to eliminate the 
potentially confounding influence of cell lineage on drug response.  Cell lines were 
seeded 24 or 48 hours prior to drug treatment (for HMC18 and MDAMB231, or 
AU565 and SKBR3, respectively) at densities optimised during assay development.  
During optimisation, we selected a lapatinib concentration range of 0.96 nM to 15 µM, 
with the DMSO vehicle content kept constant at 0.15%.  We were unable to test higher 
lapatinib concentrations due to insolubility of the drug; however, the concentration 
range tested was sufficient to demonstrate the selective response to lapatinib.  After 72 
hours, the viability of treated cells was assessed using Alamar Blue fluorescence as a 
surrogate for viable cell number and expressed relative to that of vehicle-treated cells.  
GraphPad was then used to interpolate dose-response curves, from which IC50 values 
were calculated.     
The dose-response curves demonstrate that lapatinib was more potent in the 
ERBB2-overexpressing cell lines, AU565 and SKBR3, compared to the non-ERBB2-
overexpressing cell lines, HMC18 and MDAMB231 (Figure 6.2.1).  This is reflected 
in the IC50 values for each cell line: 2 µM for both AU565 and SKBR3 versus 10 µM 
for HMC18.  The IC50 for MDAMB231 could not be derived, since 50% growth 
inhibition was not observed within the concentration range tested, and is therefore 
greater than the maximum dose of 15 µM.  Lapatinib treatment also varied in efficacy 
across the different cell lines (Figure 6.2.1).  Exposure to the maximum lapatinib dose 
(15 µM) for 72 hours produced decreases in cell viability to approximately 40% of 
vehicle-treated cells for AU565 and SKBR3, and approximately 25% for HMC18.  At 
this concentration, the viability of lapatinib-treated MDAMB231 cells decreased only 
to approximately 80% of vehicle-treated control cells.  Importantly, the dose-response 
curves for AU565 and SKBR3 are closely aligned, which is significant given that these 
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Figure 6.2.1. Viability of cancer cell lines following lapatinib treatment.  Dose-
response curves are presented for AU565, SKBR3, HMC18, and MDAMB231 cells 
treated with lapatinib. Cell viability relative to vehicle-treated cells (y-axis) was 
assayed 72 hours after treatment with 0.96 nM to 15 µM lapatinib (x-axis, log-scale), 
using Alamar Blue fluorescence as a surrogate for viable cell number. Data are 
represented as mean ± SEM from three independent experiments, performed in 
triplicate, with GraphPad used to interpolate the curves and calculate IC50 values.   
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cell lines were derived from the same patient and thereby feature very similar levels of  
ERBB2 expression (Neve et al., 2006; Figure 3.2.11).  These results validate our in 
vitro testing method and provide a benchmark of drug response to which other drugs 
may be compared.  
 
6.2.2 Fatostatin treatment in cancer cell lines 
6.2.2.1 Predicted drug-gene relationship between fatostatin and TPD52 expression   
Predictive modelling suggested that increased TPD52 expression was 
significantly associated with resistance to fatostatin (Table 5.2.6).  This relationship is 
visualised in Figure 6.2.2.   The waterfall plot for fatostatin assigns 80% (183/230) of 
cancer cell lines to the intermediate response category, with 13% (30/230) cell lines 
displaying sensitivity and 7% (17/230) displaying resistance (Figure 6.2.2B).  All five 
global gene expression clusters are represented by at least one cell line below the 
threshold for sensitivity and above the threshold for resistance (Figure 6.2.2Ai and C).  
The median area under the curve (AUC), which is a metric used to describe drug 
response, was similar between each of the global gene expression clusters, with cluster 
3 being the only cluster that was found to be significantly different to reference cluster 
1 (Figure 6.2.2C and data not shown).  Cluster 3 was comprised entirely of cell lines 
derived from haematopoietic and lymphatic cancers (Table 5.2.3).  There was no 
significant interaction detected between TPD52 expression and global gene expression 
cluster (Appendix Table 6.2).  
 
6.2.2.2 Viability of cancer cell lines following fatostatin treatment  
We therefore investigated whether TPD52-overexpressing cell lines displayed 
increased resistance to fatostatin, as predicted by our modelling approach.  We used 
the same four cell lines as for lapatinib: AU565 and SKBR3, which feature TPD52 
amplification and high TPD52 protein levels; HMC18, which features TPD52 gain and 
low TPD52 protein levels; and MDAMB231, which is diploid for TPD52 and features 
low TPD52 protein levels (Figure 3.2.8).  During optimisation, we selected a fatostatin 
concentration range of 37 nM to 150 µM, with the DMSO vehicle content kept 
constant at 0.3%, and determined that fatostatin was best replaced daily to ensure its 
continued activity over the 72 hours of treatment (data not shown).  The dose-response 
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Figure 6.2.2: (legend on the following page) 
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Figure 6.2.2. Visualisation of the predicted drug-gene relationship between 
fatostatin and TPD52 expression.  (A) The series of plots visualises the relationship 
between TPD52 expression, reported as log2 intensity, and response to fatostatin 
(BRD-K99696746).  (i) Data points represent cancer cell lines that have been plotted 
according to their TPD52 expression (x-axis) and their responses to fatostatin, reported 
as area under the dose response curve (AUC; y-axis).  (ii) Data points represent the 
median responses observed at expression increments (obtained by rounding to the 
nearest integer), within each of the 5 colour-coded global gene expression clusters.  
(iii) Box and whisker plots represent the distribution of responses observed at 
expression increments, for all cancer cell lines, with a line connecting the medians to 
show the overall trend.  (B) The waterfall plot shows cancer cell lines (x-axis) sorted 
from least to most responsive to fatostatin (y-axis), with the inflection point marked.  
Cell lines with responses falling within 1.2-fold of this inflection point were classified 
as having an intermediate response (blue), while those with responses lower or higher 
than this range were classified as sensitive (green) or resistant (red), respectively.  
These classifications were then used to discretise drug response and correspond to the 
green and red dashed lines on (A) and (C).  (C) The plot shows the distribution of 
responses to fatostatin within each of the global gene expression clusters.  Cancer cell 
lines were sorted into 1 of 5 clusters based on the expression of the 500 most highly 
varying genes, and the data points in (A) were colour-coded accordingly.  There were 
64, 96, 23, 25, and 22 cell lines in clusters 1, 2, 3, 4, and 5, respectively.    
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curves reveal that treatment with fatostatin had varied effects on the four cell lines 
tested, with both potency and efficacy ranging considerably (Figure 6.2.3A).  In 
agreement with the modelling prediction, fatostatin was most potent in the cell lines 
with low TPD52 expression, with IC50 values of 5.2 µM and 23 µM for MDAMB231 
and HMC18, respectively, while it was less potent in the TPD52-amplified and  
-overexpressing SKBR3, with an IC50 of 72 µM.  However, AU565 also features 
amplification and overexpression of TPD52, but the potency of fatostatin was closer to 
HMC18 and MDAMB231, with an IC50 of 13 µM.  The marked difference between 
SKBR3 and AU565 IC50 values was surprising given that they share many molecular 
features, including very similar TPD52 copy numbers and protein levels (Neve et al., 
2006; Figure 3.2.8).  Fatostatin treatment also displayed a range of efficacies across the 
cell lines.  For AU565 and SKBR3, exposure to the maximum fatostatin dose (150 
µM) for 72 hours reduced cell viabilities to approximately 40% and 30% of vehicle-
treated cells, respectively.  The same treatment of HMC18 and MDAMB231 reduced 
cell viabilities to approximately 8% and 20% of vehicle-treated cells, respectively. 
 We then tracked cell viability, relative to vehicle-treated cells, for 5 days 
following treatment with 10, 20, or 40 µM fatostatin (Figure 6.2.3B).  Cell viability 
initially increased for all four cell lines within the first 24 hours.  For AU565, cell 
viability decreased to below 50% of vehicle-treated cells by 72 hours after treatment 
with 20 and 40 µM, but not 10 µM, fatostatin (Figure 6.2.3Bi).  Reductions in cell 
viability continued beyond 72 hours for all fatostatin doses and were beginning to 
plateau by 5 days, reaching approximately 20% of vehicle-treated cells for 20 and 40 
µM fatostatin, and approximately 60% of vehicle-treated cells for 10 µM fatostatin.  
For SKBR3, reductions in cell viability were also beginning to plateau by 5 days but 
did not reach below 50% of vehicle-treated cells for any of the fatostatin doses (Figure 
6.2.3Bii).  For HMC18, cell viability decreased to below 50% of vehicle-treated cells 
by 48 hours after treatment with 40 µM fatostatin and by 72 hours after treatment with 
20 µM fatostatin (Figure 6.2.3Biii).  Reductions in cell viability continued beyond 72 
hours for fatostatin doses of 20 and 40 µM and plateaued by 5 days, reaching 
approximately 16% and 8% of vehicle-treated cells, respectively.  The viability of cells 
treated with 10 µM, on the other hand, increased slightly between days 4 and 5 to 
reach approximately 60% of vehicle-treated cells.  Finally, for MDAMB231, cell 
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Figure 6.2.3: (legend on the following page) 
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Figure 6.2.3. Viability of cancer cell lines following fatostatin treatment.  (A) 
Dose-response curves are presented for AU565, SKBR3, HMC18, and MDAMB231 
cells treated with fatostatin.  Cell viability relative to vehicle-treated cells (y-axis) was 
assayed 72 hours after treatment with 37 nM to 150 µM fatostatin (x-axis, log-scale), 
using Alamar Blue fluorescence as a surrogate for viable cell number.  Data are 
represented as mean ± SEM from three independent experiments, performed in 
triplicate, with GraphPad used to interpolate the curves and calculate IC50 values.  (B) 
Proliferation curves are presented for AU565, SKBR3, HMC18, and MDAMB231 cell 
lines treated with either 10, 20, or 40 µM fatostatin.  Cell viability relative to vehicle-
treated cells (y-axis) was assayed each day for 5 days after the initial fatostatin 
treatment (x-axis).  Data are represented as mean ± SEM from two independent 
experiments, performed in triplicate.   
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viability decreased to below 50% of vehicle-treated cells by 72 hours after treatment 
with all fatostatin doses (Figure 6.2.3Biv).  Reductions in cell viability continued 
beyond 72 hours for all fatostatin doses, plateauing at approximately 25% and 35% for 
10-20 µM and 40 µM fatostatin, respectively.  
 
6.2.2.3 Viability of TPD52-depleted and -overexpressing cancer cell lines 
following fatostatin treatment 
To ascertain whether the observed responses to fatostatin might be altered with 
reduced TPD52 expression, we then tested fatostatin in a panel of stably-transfected 
SKBR3 cell lines, including four TPD52-depleted cell lines (9B, 4B, 7C, and 7D) and 
one non-targeting control cell line (8C) (Roslan et al., 2014).  We found similar 
responses to fatostatin with varying degrees of stable TPD52 knockdown (Figure 
6.2.4A and C).  Drug insolubility prevented us from testing concentrations higher than 
150 µM, which resulted in undefined IC50 values for 3 cell lines, since SKBR3 was 
already the most fatostatin-resistant of the cell lines tested.  Differences between IC50 
values did not clearly segregate with TPD52 expression (Figure 6.2.4A).  Fatostatin 
treatment was also variously efficacious across the cell lines, with no clear segregation 
according to TPD52 expression.  Exposure to the maximum fatostatin dose (150 µM) 
for 72 hours reduced cell viabilities to between 30% and 60% of vehicle-treated cells 
(Figure 6.2.4A). 
Finally, to ascertain whether the observed drug response phenotypes might be 
altered with increased TPD52 expression, we tested fatostatin in a panel of stably-
transfected MDAMB231 cells, including two TPD52-overexpressing cell lines (H1 
and H2) and two vector control cell lines (PG-10 and PG-13).  The dose-response 
curves reveal a reduction in viability for all cell lines at fatostatin concentrations 
between 1 µM and 10 µM, with minimal differences between IC50 values (Figure 
6.2.4B).  These differences are likely to be of little significance, particularly given that 
the curve has been fitted with limited data points between 1 µM and 10 µM fatostatin.  
The efficacy of fatostatin treatment showed no clear segregation according to TPD52 
expression.  Exposure to the maximum fatostatin dose (150 µM) for 72 hours reduced 
cell viabilities to between 10% and 20% of vehicle-treated cells (Figure 6.2.4B). 
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Figure 6.2.4: (legend on the following page) 
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Figure 6.2.4. Fatostatin sensitivity following TPD52 knockdown or 
overexpression. Dose-response curves following treatment with fatostatin are 
presented for (A) a panel of SKBR3 cell lines, comprised of parental, non-targeting 
control (8C), and stably TPD52-depleted cells (9B, 4B, 7C, and 7D), and (B) a panel 
of MDAMB231 cell lines, comprised of parental, vector control (PG-10 and PG-13), 
and stably TPD52-overexpressing cells (H1 and H2).  Cell viability relative to vehicle-
treated cells (y-axis) was assayed 72 hours after treatment with 37 nM to 150 µM 
fatostatin (x-axis, log-scale), using Alamar Blue fluorescence as a surrogate for viable 
cell number.  Data are represented as mean ± SEM from three independent 
experiments, performed in triplicate, with GraphPad used to interpolate the curves and 
calculate IC50 values.  (C) Total cell lysates from SKBR3 and MDAMB231, and their 
derivative cell lines, were subjected to Western blot analyses to determine TPD52 
levels, with HSP90 used as a loading control.  The image shown is representative of 
three independent experiments, with the proteins analysed and the molecular weights 
of the detected species labelled to the left and right, respectively.  TPD52 levels in 
parental SKBR3 and MDAMB231 cells have been shown previously in Figure 3.2.8. 
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Taken together, these data indicate that sensitivity to fatostatin differs across the four 
breast cancer cell lines studied, but shows little variation according to TPD52 
expression level in either SKBR3 or MDAMB231 cells. 
 
6.2.3 BFA treatment in cancer cell lines 
6.2.3.1 Predicted drug-gene relationship between BFA and TPD52 copy number   
Predictive modelling suggested that increased TPD52 copy number was 
significantly associated with sensitivity to BFA (Table 5.2.5).  This relationship is 
visualised in Figure 6.2.5.   The waterfall plot for BFA assigns 66% (87/131) of cancer 
cell lines to the intermediate response category, with 23% (30/131) cell lines 
displaying sensitivity and 11% (14/131) displaying resistance (Figure 6.2.5B).  All five 
global gene expression clusters are represented by cell lines below the threshold for 
sensitivity, while all but cluster 4 are represented by at least one cell line above the 
threshold for resistance (Figure 6.2.5Ai and C).  The median AUC for cell lines within 
cluster 4 was found to be significantly different to that for the reference cluster 1 and 
fell below the threshold of sensitivity (Figure 6.2.5C and data not shown).  Cluster 4 
was predominantly comprised of cell lines derived from cancers of the large intestine, 
plus one cell line each from lung and stomach cancer (Table 5.2.3).  The median 
TPD52 copy number for cell lines in cluster 4 was also significantly lower than that for 
cluster 1 (Figure 5.2.4Bi).  However, there was no significant interaction detected 
between TPD52 copy number and global gene expression cluster (Appendix Table 
6.1).  
 
6.2.3.2 Viability of cancer cell lines following BFA treatment 
We therefore investigated whether TPD52-amplified cell lines displayed 
increased sensitivity to BFA, as predicted by our modelling approach.  BFA is 
generally cytotoxic and we therefore narrowed the concentration range to 0.64 nM to 
10 µM during assay optimisation, keeping the DMSO vehicle content constant at 
0.03%.  Exposure to BFA for 72 hours was toxic for all four cell lines tested (Figure 
6.2.6).  The dose-response curves for all cell lines reveal a sharp transition between 
near 100% viability and less than 20% viability at concentrations of BFA between 10 
and 100 nM (Figure 6.2.6A).  Within this region, there were minor differences in the 
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Figure 6.2.5: (legend on the following page) 
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Figure 6.2.5. Visualisation of the predicted drug-gene relationship between 
brefeldin A (BFA) and TPD52 copy number.  (A) The series of plots visualises the 
relationship between TPD52 copy number, reported as log2 copy number ratio, and 
response to BFA (BRD-A31107743).  (i) Data points represent cancer cell lines that 
have been plotted according to their TPD52 copy number (x-axis) and their responses 
to BFA, reported as area under the dose response curve (AUC; y-axis).  (ii) Data points 
represent the median responses observed at copy number increments (obtained by 
rounding to the nearest integer), within each of the 5 colour-coded global gene 
expression clusters.  (iii) Box and whisker plots represent the distribution of responses 
observed at copy number increments, for all cancer cell lines, with a line connecting 
the medians to show the overall trend.  (B) The waterfall plot shows cancer cell lines 
(x-axis) sorted from least to most responsive to BFA (y-axis), with the inflection point 
marked.  Cell lines with responses falling within 1.2-fold of this inflection point were 
classified as having an intermediate response (blue), while those with responses lower 
or higher than this range were classified as sensitive (green) or resistant (red), 
respectively.  These classifications were then used to discretise drug response and 
correspond to the green and red dashed lines on (A) and (C).  (C) The plot shows the 
distribution of responses to BFA within each of the global gene expression clusters.  
Cancer cell lines were sorted into 1 of 5 clusters based on the expression of the 500 
most highly varying genes, and the data points in (A) were colour-coded accordingly.  
There were 33, 51, 19, 17, and 11 cell lines in clusters 1, 2, 3, 4, and 5, respectively.   
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Figure 6.2.6. Viability of cancer cell lines following brefeldin A (BFA) treatment.  
(A) Dose-response curves are presented for AU565, SKBR3, HMC18, and 
MDAMB231 cells treated with BFA.  Cell viability relative to vehicle-treated cells (y-
axis) was assayed 72 hours after treatment with 0.64 nM to 10 µM BFA (x-axis, log-
scale), using Alamar Blue fluorescence as a surrogate for viable cell number.  Data are 
represented as mean ± SEM from three independent experiments, performed in 
triplicate, with GraphPad used to interpolate the curves and calculate IC50 values.  (B) 
Proliferation curves are presented for AU565, SKBR3, HMC18, and MDAMB231 cell 
lines treated with 50 nM BFA.  Cell viability relative to vehicle-treated cells (y-axis) 
was assayed each day for 5 days from the initial BFA treatment (x-axis).  Data are 
represented as mean ± SEM from two independent experiments, performed in 
triplicate.   
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IC50 values for each cell line: 81 nM and 50 nM for AU565 and SKBR3, respectively; 
42 nM for HMC18; and 64 nM for MDAMB231.  These IC50 values did not segregate 
according to TPD52 copy number or expression, nor were the IC50 values for AU565 
and SKBR3 closer to each other than to those for the other cell lines.  The minor 
differences in IC50 values are unlikely to be significant, particularly since limited data 
points were available for curve-fitting between 10 and 100 nM BFA.  These IC50 
values underline the potency of BFA, being approximately 25-40 times lower than the 
IC50 values for the ERBB2-targeted drug lapatinib in ERBB2-overepxressing cell 
lines.  BFA was also broadly efficacious, with exposure to the maximum BFA dose 
(10 µM) for 72 hours decreasing cell viability to approximately 14% and 10% of 
vehicle-treated cells for AU565 and SKBR3, respectively, and approximately 4% and 
7% of vehicle-treated cells for HMC18 and MDAMB231, respectively.   
We also tracked cell viability, relative to vehicle-treated cells, for 5 days 
following treatment with 50 nM BFA (Figure 6.2.6B).  Cell viability decreased to 
below 50% for all four cell lines within the first 24 hours.  Maximum reductions in cell 
viability were achieved after 72 hours for HMC18 and MDAMB231 cells, while the 
viability of AU565 and SKBR3 cells continued to decrease after 4 and 5 days. 
 
6.2.3.3 Viability of TPD52-depleted and -overexpressing cancer cell lines 
following BFA treatment 
We then compared the responses of the SKBR3 cell line panel and found no 
meaningful differences in sensitivity to BFA in cell lines with varying degrees of 
stable TPD52 knockdown (9B, 4B, 7C, and 7D) when compared to non-targeting 
control (8C) and parental cell lines (Figure 6.2.7A).  The dose-response curves for all 
cell lines again revealed a sharp transition between near 100% viability and less than 
20% viability, with limited data points around the calculated IC50 values.  Minor 
differences between IC50 values were measured, however, these did not clearly 
segregate with TPD52 expression. As noted previously, these differences in IC50 are 
likely insignificant, particularly as they fall within the range of IC50 values of the 
parental cell line SKBR3 (IC50 = 50 nM) and the closely-related cell line AU565  
(IC50 = 81 nM).  BFA treatment showed similar efficacies across the cell lines, with 
exposure to the maximum BFA dose (10 µM) for 72 hours reducing cell viabilities to 
between 5% and 17% of the corresponding vehicle-treated cells. 
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Figure 6.2.7. Brefeldin A (BFA) sensitivity following TPD52 knockdown or 
overexpression.  Dose-response curves following treatment with BFA are presented 
for (A) a panel of SKBR3 cell lines, comprised of parental, non-targeting control (8C), 
and stably TPD52-depleted cells (9B, 4B, 7C, and 7D), and (B) a panel of 
MDAMB231 cell lines, comprised of parental, vector control (PG-10 and PG-13), and 
stably TPD52-overexpressing cells (H1 and H2).  Cell viability relative to vehicle-
treated cells (y-axis) was assayed 72 hours after treatment with 0.64 nM to 10 µM 
BFA (x-axis, log-scale), using Alamar Blue fluorescence as a surrogate for viable cell 
number.  Data are represented as mean ± SEM from three independent experiments, 
performed in triplicate, with GraphPad used to interpolate the curves and calculate IC50 
values.  
		 224 
We also found no difference in sensitivity to BFA in the MDAMB231 panel, 
when comparing cell lines with stable TPD52 overexpression (H1 and H2) to vector 
control (PG-10 and PG-13) and parental cell lines (Figure 6.2.7B).  The dose-response 
curves for all cell lines were essentially superimposed in the region of transition and 
the corresponding IC50 values ranged between 60 nM and 64 nM.  BFA treatment was 
similarly efficacious across the cell lines, with exposure to the maximum BFA dose 
(10 µM) for 72 hours reducing cell viabilities to between 6% and 8% of vehicle-treated 
cells.  Taken together, these data indicate that sensitivity to BFA differed minimally 
across the four breast cancer cell lines studied, and showed no meaningful variation 
according to TPD52 expression level in either SKBR3 or MDAMB231 cells. 
 
6.3 Discussion    
 In this chapter, we investigated whether TPD52 expression level was 
associated with altered sensitivity of cancer cell lines to BFA and fatostatin.  Predictive 
modelling suggested that TPD52-amplified cell lines would display increased 
sensitivity to BFA, while TPD52-overexpressing cell lines would display increased 
resistance to fatostatin.  To test these predictions in vitro, we investigated cell 
viabilities following drug treatment in four cell lines: AU565 and SKBR3, which 
feature TPD52 amplification and high TPD52 protein levels; HMC18, which features 
TPD52 gain and low TPD52 protein levels; and MDAMB231, which is diploid for 
TPD52 and features low TPD52 protein levels.  All cell lines were derived from breast 
cancers, to eliminate the potentially confounding influence of cell lineage on drug 
response.  We generated dose-response and proliferation curves to determine whether 
chemo-sensitivity or -resistance segregated according to TPD52 amplification and/or 
overexpression as predicted.  Finally, we investigated whether stable TPD52 
knockdown or overexpression altered the observed sensitivities for SKBR3 and 
MDAMB231 cell lines, respectively.   
 
6.3.1 TPD52 expression and response to fatostatin in cancer cell lines 
 Fatostatin treatment resulted in both dosage- and time-dependent reductions in 
cell viability for all cell lines investigated.  Although cell line responses to fatostatin 
varied with respect to both its potency (that is, the dose at which cell viability was 
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reduced to 50% of vehicle-treated cells) and efficacy (that is, the maximum observed 
reduction in cell viability), there was no clear segregation with TPD52 expression.  As 
noted above, the difference between SKBR3 and AU565 IC50 values (72 µM and 13 
µM, respectively) was surprising since these cell lines were derived from the same 
patient (Neve et al., 2006).  With no data points between AU565 cell viabilities 
corresponding to 80% and 40% of vehicle-treated controls, the curve-fitting algorithm 
produced a sharp decline that may have resulted in an artificially low IC50.  However, 
the IC50 calculated from this 72-hour dose-response curve is consistent with the results 
of the proliferation experiments, which found that AU565 cell viability decreased to 
below 50% of vehicle-treated cells by 72 hours after 20 and 40 µM, but not 10 µM, 
fatostatin.  The proliferation experiments also corroborate the higher IC50 for SKBR3, 
since cell viability did not decrease below 50% of vehicle-treated cells with the 
maximum dose of 40 µM fatostatin.  This may therefore represent a hitherto unknown 
difference between these cell lines and their responses to the dysregulation of SREBP 
signaling that may be worthy of further exploration.   
The effects of fatostatin on cell viability and proliferation have been previously 
examined in prostate (Li et al., 2014b) and pancreatic (Shao et al., 2016; Siqingaowa 
et al., 2017) cancer cell lines, and were comparable to those measured for our breast 
cancer cell lines.  Prostate cancer cell lines LNCaP and C4-2B were both relatively 
sensitive to fatostatin treatment, with IC50 values of 10.4 µM and 9.1 µM, respectively 
(Li et al., 2014b).  Both cell lines cells are known to express TPD52, or the prostate-
specific isoform PrLZ (Wang et al., 2004).  The pancreatic cancer cell line MIA PaCa-
2 was also relatively sensitive to fatostatin, with cell viability at 72 hours decreasing 
below 50% of vehicle-treated controls after 20 µM, but not 10 µM, fatostatin 
(Siqingaowa et al., 2017).  Another pancreatic cancer cell line Pa03c was slightly more 
resistant to fatostatin, with an IC50 of approximately 30 µM (Shao et al., 2016).  It is 
important to note that the presence of lipids in the culture medium has the potential to 
influence response to fatostatin, since SREBP is activated and translocates to the 
nucleus when sterol levels are low (Goldstein et al., 2006).  The minimum dose of 
fatostatin required for growth inhibition was found to be lower in lipoprotein-deficient 
media (2.5 µM) than in media supplemented with lipids (5 µM) (Shao et al., 2016).  
However, lipid supplementation failed to rescue cell growth in the presence of  
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fatostatin (Shao et al., 2016) and fatostatin-induced apoptosis has been observed in 
both lipid-depleted and lipid-rich media (Brovkovych et al., 2017).  We elected to 
perform our experiments using lipid-rich media (that is, retaining the standard 10% 
FBS media supplementation) because lipid availability was not restricted when 
generating the drug response data upon which our predictive models were based (Basu 
et al., 2013).  However, future experiments to delineate the mechanistic effects of 
fatostatin treatment in our breast cancer cell lines could benefit from lipid depletion.  
The effects of fatostatin on cell viability were first thought to stem from its 
inhibition of SREBP activity and the resultant dysregulation of lipid homeostasis 
(Williams et al., 2013; Li et al., 2015b) but have recently also been attributed to 
SREBP- and lipid-independent effects, including the destabilisation of mitotic 
microtubule spindles, activation of the spindle assembly checkpoint, and induction of 
mitotic catastrophe (Shao et al., 2016; Gholkar et al., 2016).  Future experiments are 
required to ascertain whether there is a similar mechanistic basis for the cell viability 
reductions observed in our breast cancer cell lines.  Interestingly, increased fatty acid 
desaturation and elongation, as well as the accumulation of triacylglycerides in lipid 
droplets, was recently demonstrated as a cellular defense mechanism against fatostatin-
triggered lipotoxicity in breast cancer cells (Brovkovych et al., 2017).  If TPD52 
overexpression indeed modulates lipid storage, as we hypothesised in Chapter 4, this 
could explain its predicted association with resistance to fatostatin.  It would also be 
interesting to investigate whether TPD52 expression changes after fatostatin treatment, 
with preliminary experiments indicating that TPD52 protein levels may respond to 
treatment with 10, 20 or 40 µM fatostatin (data not shown).  Finally, future 
experiments could investigate whether responses to fatostatin differed according to the 
amount of stored intracellular lipid within cancer cells.   
 
6.3.2 TPD52 expression and response to BFA in cancer cell lines 
BFA treatment resulted in both dosage- and time-dependent reductions in cell 
viability for all cell lines investigated.  There was very little difference in chemo-
sensitivity between cell lines, with respect to either potency or efficacy, and no clear 
segregation with either TPD52 copy number or expression.  BFA was shown to be 
approximately 1000-fold more potent than fatostatin in our breast cancer cell lines,  
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with IC50 values in the nanomolar range.  As part of the National Cancer Institute 
(NCI) cancer drug screen, responses to BFA were measured for six different breast 
cancer cell lines, with a mean IC50 of 57 nM and a standard deviation of 59 nM 
(Sausville et al., 1996).  This is consistent with the range of IC50 values (42 – 81 nM) 
measured for our breast cancer cell lines, although it must be noted that IC50 values 
from the NCI cancer drug screen were obtained after 48 hours treatment rather than 72 
hours.  Our laboratory has demonstrated target engagement in cultured human and 
mouse cell lines after just 5 hours treatment with 7.1 µM BFA, with confocal 
microscopy revealing disassembly of the Golgi apparatus as well as changes in lipid 
droplet number and size (Chen et al., manuscript submitted).      
 
6.3.3 Validation of predictive modelling through in vitro experiments  
 As well as investigating the effect of TPD52 expression on cell line response to 
drugs that impact lipid droplet accumulation, our in vitro experiments allowed us to 
pursue two drugs that were identified through predictive modelling and thereby assess 
the validity of this approach.  Neither of the predicted associations between TPD52 
status and fatostatin or BFA were clearly supported by their potency or efficacy in the 
four breast cancer cell lines (AU565, SKBR3, HMC18, and MDMB231), which 
featured varied TPD52 levels.  Nor were these associations clearly supported by these 
drugs’ potency or efficacy in the SKBR3 panel, comprised of non-targeting control 
(8C) and stably TPD52-depleted cells (9B, 4B, 7C, and 7D), or the MDAMB231 
panel, comprised of vector control (PG-10 and PG-13) and stably TPD52-
overexpressing cells (H1 and H2).  However, it is now being increasingly recognised 
that the traditional metrics for potency (IC50) and efficacy (Emax), as employed here, 
may be confounded by differences in the proliferation rates of the cell lines being 
assayed (Hafner et al., 2016; Hafner et al., 2017).  It is important to note that the drug 
response data used in our predictive modelling was not corrected for differential cell 
proliferation rates.  Nevertheless, future experiments to generate growth rate metrics 
are required before definitively concluding that there is no association between TPD52 
copy number or expression and cell line sensitivity to these drugs. 
Alternatively, it is possible that fatostatin and BFA may represent false 
positives, particularly given that neither prediction remained statistically significant  
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when p values were adjusted for multiple testing (Tables 5.2.5 and 5.2.6).  As  
mentioned in Chapter 5, many of the drugs that were identified through predictive 
modelling were not functionally annotated until the recent publication of version 2 of 
the Cancer Therapeutics Response Portal online interface (https://portals.broad 
institute.org/ctrp/).  This paucity of information, at the time when we were selecting 
drugs to be carried forward into in vitro testing, meant that BFA and fatostatin were 
selected less because of the strength of statistical results and more because of their 
known activity within pathways that are relevant to lipid metabolism. 
 Discrepancies in the results of predictive modelling and in vitro drug screening 
may arise in several ways.  Firstly, the predictions derived from modelling could be 
erroneous.  The identification of the ERBB2-targeted drug lapatinib in association with 
both ERBB2 copy number and expression served as an important positive control and 
supported the validity of our predictive modelling approach.  This association was also 
clearly demonstrated by our in vitro experiments.  Secondly, the predictions derived 
from modelling could be correct but based on erroneous or non-reproducible data.  
Variability in drug response may be introduced through cell line growth conditions, 
including seeding densities and growth media, as well as through the choice of assay 
for determining cell viability (Hatzis et al., 2014).  Furthermore, the continuous 
passaging of cell lines may also lead to a ‘drift’ in drug sensitivities over time.  As 
discussed in Chapter 5, the degree of inconsistency to be expected between data from 
independent drug screening studies remains a point of contention, as does the best 
approach for combating this variability (Haibe-Kains et al., 2013; Stransky et al., 
2015; Safikhani et al., 2016).  This underscores the importance of conducting in vitro 
validation experiments, such as those described in this chapter. 
 
6.4 Summary and Conclusion 
We have investigated predicted associations between TPD52 copy number or 
expression and cancer cell line response to fatostatin and BFA.  These experiments 
constitute our first attempts to pursue the clinical ramifications of the recently-
discovered link between TPD52 overexpression and lipid metabolism in cancer cells.  
We hypothesised that TPD52 amplification and/or overexpression could alter the 
sensitivity of cancer cells to drugs that either directly or indirectly target lipid 
metabolism and related pathways.  These investigations are still in their infancy and 
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we anticipate that further study with additional lipid-relevant compounds will not only 
expand our understanding of the role that TPD52 plays in these pathways but may also 
identify new ways to therapeutically exploit the vulnerabilities of TPD52-
overexpressing cancers.  
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Chapter 7 
 
General discussion. 
 
 
7.1 Introduction  
The data presented in this thesis address a long-standing deficit in our 
understanding of how TPD52 amplification and/or overexpression promotes the 
development of cancer at a molecular level.  Furthermore, these data represent the first 
foray into applying this knowledge therapeutically, by associating TPD52 
amplification and/or overexpression with cancer cell line sensitivity (or resistance) to 
different drugs.  This study therefore sits at the intersection of several larger research 
endeavours, connecting one of the many complex genomic changes that occurs within 
cancer cells to phenotypic changes in both lipid metabolism and drug response (Figure 
7.1).  We began by exploring the frequency, magnitude, and context of TPD52 
amplification in 995 cancer cell lines from diverse tumour types (Chapter 3).  We then 
investigated whether TPD52 amplification and/or overexpression was broadly 
associated with altered lipid storage and/or metabolism (Chapter 4), or with altered 
responses to a variety of drugs, including those with lipid-relevant targets or activities 
(Chapters 5 and 6).   
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Figure 7.1. Overview of the research presented in this thesis. 
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7.2 TPD52 and altered lipid storage in cancer cells  
The first part of this thesis describes investigations designed to determine 
whether TPD52 amplification and/or overexpression in cancer cell lines is broadly 
associated with altered lipid storage and/or metabolism.  This first systematic analysis 
demonstrated that there is a significant positive association between TPD52 expression 
and lipid droplet staining, and revealed a dramatic increase in lipid droplet number and 
size upon the exogenous overexpression of TPD52 in MDAMB231 cells.  TPD52, but 
not the related TPD52L1, was found to interact directly with the lipid droplet-
associated proteins, adipophilin and TIP47; however, there was no significant 
association between the expression levels of TPD52 and adipophilin or TIP47.  This is 
consistent with additional findings from our laboratory, which revealed that a small 
proportion of TPD52 co-localised with adipophilin-coated lipid droplets under routine 
culture conditions and that this co-localisation was significantly increased upon 
supplementation of the media with oleic acid (Kamili et al., 2015).  Taken together, 
these data suggest a role for TPD52 in promoting intracellular lipid storage, which may 
be mediated by its interaction with lipid droplet-associated proteins and/or its activity 
at the lipid droplet surface. 
These findings represent a significant step forward in our understanding of how 
TPD52 amplification and/or overexpression may contribute to the development of 
cancer at a molecular level.  The demand for lipid is intensified in cancer cells, when 
compared to quiescent cells, because their ability to continue proliferating is 
contingent upon having enough lipids to produce daughter cell membranes, lipid 
cofactors and lipid-modified proteins (section 1.2.3.3).  To meet these demands, many 
cancers activate a programme of exacerbated de novo lipogenesis, which includes the 
overexpression and/or hyperactivity of key lipogenic enzymes such as fatty acid 
synthase (FASN), ATP citrate lyase (ACLY), and acetyl-CoA carboxylase (ACACA), 
as well as a myriad of complementary alterations (Menendez and Lupu, 2007; Santos 
and Schulze, 2012).  This so-called ‘lipogenic phenotype’ has been reported for 
numerous cancer types and has been associated with aggressive phenotypes and poor 
prognosis (Menendez and Lupu, 2007; Santos and Schulze, 2012).  An important 
corollary of increased lipogenesis in cancer cells is a heightened requirement for lipid 
storage, which enables the cells to avoid the toxicity associated with excess 
intracellular free fatty acids (Kamili and Byrne, 2014).  If TPD52 indeed promotes 
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lipid storage, its overexpression may therefore complement the lipogenic phenotype of 
certain cancer cells by allowing them to rely upon high levels of intracellular lipid 
without the associated risk of lipotoxicity.   
Crucially, these findings also represent the first time that protein partners 
specific to TPD52, and not the related TPD52L1, have been identified.  Until now, 
protein-protein interaction studies have been unable to sufficiently explain why 
TPD52, and not TPD52L1, displays such oncogenicity when expressed in cells beyond 
normal levels (Shahheydari et al., 2014).  In agreement with these findings, other 
members of our laboratory have shown that lipid droplet numbers in mouse 3T3 
fibroblasts increase with the ectopic expression of TPD52, but not with the ectopic 
expression of TPD52L1 (Kamili et al., 2015).  As well as providing a previously-
lacking explanation for the isoform-specific effects of TPD52 overexpression, our 
hypothesis that TPD52 promotes lipid storage when overexpressed in cancer cells is 
also consistent with its physiological role in secretory cells, where it is normally 
abundant.  TPD52 has been implicated in digestive enzyme secretion and membrane 
trafficking, partly through its association with several membrane-associated trafficking 
proteins, including MAL2, annexin VI, early endosomal antigen-1 (EEA-1), 
lysosomal-associated membrane protein (LAMP1), and RAB5 (Thomas et al., 2001; 
Wilson et al., 2001; Thomas et al., 2002; Thomas et al., 2004; Thomas et al., 2010; 
Shahheydari et al., 2014).  Other membrane trafficking proteins have been consistently 
found at lipid droplets, including the TPD52 partner Rab5 (Liu et al., 2007a; Liu et al., 
2008).  TPD52 could therefore affect the trafficking of proteins to and from the surface 
membrane of the lipid droplet.  
 The precise mechanisms by which TPD52 associates with lipid droplets and 
modulates intracellular lipid storage are yet to be delineated.  The ability of TPD52 to 
interact directly with adipophilin and TIP47 suggests that it could function with these 
proteins at the lipid droplet surface.  However, there is a substantial disparity between 
the relative proportions of adipophilin and TPD52 found at the lipid droplet surface 
(Kamili et al., 2015), which argues against binding to adipophilin as the primary 
determinant of TPD52 localisation to lipid droplets (Chen et al., 2016).  It is also 
possible that TPD52 may associate with lipid droplets and/or lipid species directly.  
TPD52 is predicted to include amphipathic helices (Chen et al., 2016), which have 
been shown to underpin protein associations with lipid droplets and other organelles 
that feature distinctly curved membranes (Drin et al., 2010; Thiam et al., 2013).  
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Furthermore, TPD52 was identified as a cholesterol-interacting protein in HeLa cells 
(Hulce et al., 2013) and was reported as binding to phosphatidylinositol (3,4,5)-
triphosphate, a plasma membrane phospholipid (Catimel et al., 2009).   
If the presence of TPD52 at the lipid droplet surface is indeed mediated by both 
direct and indirect interactions, then there are several possible mechanisms by which it 
could promote lipid storage (Figure 7.2).  On the one hand, TPD52 could traffic 
positive regulators of lipid storage to the lipid droplet, or even tether enzymes involved 
in triacylglyceride synthesis to the surface of the lipid droplet to expedite storage 
(Chen et al., 2016).  On the other hand, TPD52 could traffic negative regulators of 
lipid storage away from the lipid droplet, thus removing their inhibitory influence 
(Chen et al., 2016).  Yet another option is that TPD52 could ‘crowd out’ negative 
regulators of lipid storage, either alone or in association with a positive storage 
regulator, by competing with them for binding to the lipid droplet surface (Chen et al., 
2016).  It must be noted that these possibilities are not necessarily mutually exclusive 
and it is feasible that some combination of the above mechanisms may be occurring 
simultaneously.  Finally, in addition to being present at lipid droplets, TPD52 has also 
been detected at the Golgi apparatus, with this localisation increasing upon 
supplementation with oleic acid (Kamili et al., 2015).  The Golgi apparatus itself has 
been implicated in lipid droplet biogenesis (Guo et al., 2008; Beller et al., 2008) and 
other regulators of lipid storage have been shown to associate with both lipid droplets 
and the Golgi (Bouvet et al., 2013; Gannon et al., 2014).  Our laboratory has, 
therefore, been further studying TPD52 function by assessing the effects of treatment 
with brefeldin A, which alters both Golgi structure and lipid storage.  These 
experiments suggest that the recruitment of TPD52 to lipid droplets may be part of a 
delayed response to altered lipid storage requirements, perhaps representing a 
mechanism for fine-tuning or stabilising lipid droplet phenotypes (Chen et al., 
manuscript submitted).  A detailed description of these findings, however, is beyond 
the scope of this thesis. 
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Figure 7.2. Possible mechanisms by which TPD52 could promote lipid storage.  
TPD52 (red) could bind and then traffic positive regulators of lipid storage (green) to 
the lipid droplet surface (1), transiently interact with the phospholipid membrane (2), 
and then disassociate (3). TPD52 could also bind, and thereby remove, negative 
regulators of lipid storage (blue) from the lipid droplet (4).  When bound to the lipid 
droplet surface, TPD52 might also ‘crowd out’ negative regulators of lipid storage (7), 
either in association with a positive storage regulator (5) or alone (6). Figure 
reproduced from Chen et al., 2016. 
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7.3 TPD52 and altered drug response in cancer cells 
The second part of this thesis describes investigations designed to determine 
whether TPD52 amplification and/or overexpression in cancer cell lines is broadly 
associated with altered sensitivity or resistance to different drugs, including those with 
lipid-relevant targets or activities.  This is the first time that TPD52 amplification 
and/or overexpression has been investigated as a potential biomarker of drug 
sensitivity or resistance in different cancers.  Predictive modelling identified several 
lead compounds for future experimental validation, of which we pursued fatostatin and 
brefeldin A (BFA).  As previously discussed, our analyses were limited by the 
incompleteness of early versions of the large-scale pharmacogenomic datasets made 
available by the Cancer Cell Line Encylopedia and the Cancer Therapeutics Response 
Portal (section 5.3.4).  However, as early consumers of these resources, our study has 
provided a framework for the utilisation of these datasets and affirmed the potential of 
undertaking similar studies in the future.  Other studies that have mined the data 
generated by these resources to identify genomic biomarkers of drug response have 
begun to emerge (Covell, 2015; Covell, 2017), which emphasises the importance of 
our investigations. 
While in vitro testing did not reveal a clear segregation in cell line responses to 
fatostatin or BFA according to their TPD52 expression, these drugs could still prove 
useful for elucidating the role played by TPD52 in promoting lipid storage.  Pursuing 
the predicted association between increased TPD52 expression and resistance to 
fatostatin in a larger number of cell lines, cultured with and without lipid-depleted 
media, would also be valuable.  Another finding worthy of further investigation is the 
predicted association between increased TPD52 expression and resistance to agonists 
of retinoic acid receptors, which was identified through three different compounds.  
This is particularly interesting given that retinoic acid is known to suppress 
adipogenesis in mouse 3T3-L1 pre-adipocytes (Kawada et al., 1990; Schwarz et al., 
1997), modulate lipid accumulation via altered expression of sterol regulatory element-
binding protein 1 (SREBP1) and fatty acid synthase (FASN) (Abd Eldaim et al., 
2017), and suppress several enzymes involved in lipid biosynthesis including FASN 
and HMG-CoA reductase (HMGCR) (Lee et al., 2009).  This suggests that agonists of 
retinoic acid receptors could represent another drug class that is effective in the 
treatment of lipogenic cancers. 
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7.4 Future directions 
In the future, it would be worthwhile to merge the two threads of this thesis by 
investigating potential associations between lipid droplet phenotypes and chemo-
sensitivity or -resistance.  With mounting evidence for the importance of altered lipid 
metabolism in numerous cancer types, considerable research effort is now being 
expended to develop and trial drugs that target key nodes within these pathways 
(section 1.2.4; Currie et al., 2013; Beloribi-Djefaflia et al., 2016).  Our experiments 
have laid the technical groundwork for capturing variations in lipid droplet number and 
size, which can now be applied using high-content microscopy to profile lipid droplet 
phenotypes across many more cancer cell lines.  Such studies could also analyse 
whether TPD52 associates with specific sub-populations of lipid droplets, as defined 
through the protein composition of the lipid droplet, its neutral lipid content, or its 
response to lipid loading or deprivation.  Combining changes in lipid storage and cell 
viability as read-outs in future drug screens could help to identify drugs that are 
particularly effective against cancers that display a lipogenic phenotype.  These 
experiments could also ascertain whether TPD52 amplification and/or overexpression 
might serve as a biomarker of sensitivity to any of these drugs and whether changes in 
TPD52 expression might alter the observed drug responses.  Finally, it will be 
important to determine whether TPD52 overexpression in tumour samples is similarly 
associated with increased lipid storage and/or a lipogenic phenotype.  
 
7.5 Concluding remarks 
In the 20 years since the TPD52 gene was first identified, its amplification and 
overexpression has been demonstrated in tumours of diverse cellular origins and 
associated with poor prognosis.  Although the breadth and clinical significance of 
TPD52 overexpression in cancer is now well-established, this knowledge has not yet 
been translated into treatment.  This has been, in part, due to a dearth in our 
understanding of the functional significance of TPD52 in cancer.  The data presented 
in this thesis suggest that TPD52 functions to modulate lipid storage in cancer cells, 
which we hypothesise contributes to a lipogenic phenotype that promotes cancer 
development.  This offers several new therapeutic opportunities.  Firstly, TPD52 
amplification and/or overexpression could be applied clinically as a predictive marker 
		 238 
for cancers that are reliant upon high lipid levels for survival.  These cancers could 
then be treated with increased efficacy by including drugs to interfere with lipogenesis 
in combinational therapies.  Secondly, TPD52 could be pursued as a therapeutic target 
in its own right.  Unlike agents targeting the more broadly-expressed lipogenic 
proteins, which often have unacceptable anorexic consequences, TPD52-inibititors 
could be employed more widely and with less detrimental side-effects.  Furthermore, 
TPD52-inhibitors could prove to be useful beyond cancer, since dysfunctional lipid 
storage is also implicated in diseases such as diabetes and obesity.  A better 
understanding of the precise mechanisms by which TPD52 modulates lipid storage is 
therefore an important focus for future studies. 
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Appendix 1.  Copy numbers for TPD52-, MYC- and/or ERBB2-amplified cancer 
cell lines from the Cancer Cell Line Encyclopedia (CCLE).  Genes were defined as 
amplified if their log2 copy number ratios were greater than or equal to 0.848.  Dashes 
(-) indicate that the log2 copy number ratio for the respective gene was below 0.848 
and has therefore been omitted for clarity.  Abbreviations: H&L = haematopoietic and 
lymphoid tissue; CNS = central nervous system.  
 
Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
2313287 Stomach - 1.139 - 
59M Ovary - 1.422 - 
AU565 Breast 2.382 2.280 2.706 
BFTC905 Urinary tract - 1.928 - 
BFTC909 Kidney 1.044 - - 
BHT101 Thyroid 2.015 2.414 - 
BICR16 Upper aerodigestive tract - - 2.314 
BICR31 Upper aerodigestive tract - - 1.099 
BT474 Breast - - 3.956 
BT483 Breast 0.874 0.907 - 
BV173 H&L 1.223 1.201 - 
CADOES1 Bone 0.919 0.901 - 
CAL120 Breast - 1.309 - 
CALU3 Lung - - 3.207 
CAOV4 Ovary - 2.474 - 
CAPAN1 Pancreas - - 0.972 
CFPAC1 Pancreas - 0.989 - 
CHP212 Autonomic ganglia - - 0.972 
COLO320 Large intestine - 3.494 - 
COLO678 Large intestine - - 0.997 
CORL23 Lung - 3.332 - 
CORL311 Lung - 2.022 - 
COV362 Ovary - 1.171 - 
COV504 Ovary - 0.918 - 
CPCN Lung - 2.682 - 
D283MED CNS 1.226 1.491 - 
D341MED CNS - 2.507 - 
DMS273 Lung - 3.393 - 
DMS454 Lung 0.932 - - 
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Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
ECC12 Stomach - 0.860 - 
ECGI10 Oesophagus - - 1.26 
EFE184 Endometrium - 1.570 - 
EFM192A Breast 2.446 2.235 2.725 
EVSAT Breast 1.622 1.446 - 
FADU Upper aerodigestive tract - 0.984 - 
FUOV1 Ovary - 1.508 - 
G292CLONEA
141B1 Bone - 1.245 - 
GCIY Stomach - 2.895 - 
GRM Skin - 1.897 - 
HCC1143 Breast - 1.14 - 
HCC1195 Lung - 1.118 - 
HCC1395 Breast - 1.031 - 
HCC1419 Breast - 1.712 2.516 
HCC1428 Breast 1.390 1.354 - 
HCC1500 Breast - 0.884 - 
HCC1569 Breast 0.849 1.387 3.241 
HCC1599 Breast - 1.082 - 
HCC1806 Breast - 1.051 - 
HCC1954 Breast 0.868 0.906 3.463 
HCC202 Breast - - 2.447 
HCC2157 Breast 1.060 1.503 - 
HCC2218 Breast 0.972 0.959 2.709 
HCC2279 Lung - 1.198 - 
HCC366 Lung - 0.934 - 
HCC38 Breast 1.280 0.867 - 
HCC44 Lung - 2.179 - 
HCC827 Lung 1.719 1.688 - 
HDMYZ H&L - 0.901 - 
HDQP1 Breast - 0.965 - 
HGC27 Stomach - 2.642 - 
HL60 H&L - 2.264 - 
HMC18 Breast 0.929 - - 
HS578T Breast 0.883 0.894 - 
HT29 Large intestine - 1.365 - 
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Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
HUPT3 Pancreas - 2.049 - 
IALM Lung - 0.931 - 
ISTMES1 Pleura - 0.983 - 
ISTMES2 Pleura - 1.066 - 
JEKO1 H&L - 1.961 - 
JHH6 Liver - 0.870 - 
JHH7 Liver - - 1.057 
JHOS4 Ovary - 0.860 - 
JHUEM3 Endometrium 0.991 1.166 - 
JIMT1 Breast - - 2.461 
JURLMK1 H&L - 2.388 - 
KE39 Stomach 1.036 1.136 0.852 
KG1 H&L 1.208 1.177 - 
KMS12BM H&L - 1.393 - 
KMS34 H&L - 1.036 - 
KP4 Pancreas - 1.394 - 
KPL1 Breast - 0.934 - 
KURAMOCHI Ovary - 1.232 - 
KYSE180 Oesophagus - 0.900 - 
KYSE410 Oesophagus - - 3.099 
KYSE450 Oesophagus - 2.487 - 
KYSE510 Oesophagus - 2.339 - 
LMSU Stomach 1.103 1.430 - 
LS123 Large intestine - 0.940 - 
LU65 Lung - 2.367 - 
LU99 Lung 1.147 1.082 - 
M07E H&L - 1.012 - 
MCF7 Breast - 1.339 - 
MDAMB361 Breast - - 2.218 
MDAMB436 Breast - 0.884 - 
MDAMB453 Breast - - 1.159 
MEG01 H&L - 1.218 - 
MFE280 Endometrium - - 1.169 
MG63 Bone - 1.779 - 
MKN1 Stomach - 0.963 - 
MKN7 Stomach - 1.662 3.606 
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Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
MKN74 Stomach - 1.191 - 
ML1 Thyroid - 1.24 - 
MOLM13 H&L 0.993 0.993 - 
MSTO211H Pleura - 3.015 - 
NB4 H&L - 1.711 - 
NCIH1299 Lung 1.084 - - 
NCIH1341 Lung - 1.306 - 
NCIH1395 Lung - 2.572 - 
NCIH1435 Lung - 0.936 - 
NCIH1437 Lung 0.848 0.948 - 
NCIH1563 Lung - - 1.26 
NCIH1581 Lung - 0.864 - 
NCIH1618 Lung 0.873 - - 
NCIH1650 Lung - 0.939 - 
NCIH1651 Lung 0.849 - - 
NCIH1693 Lung - - 1.452 
NCIH1781 Lung - 1.038 - 
NCIH1792 Lung - 3.199 - 
NCIH1869 Lung - 0.879 - 
NCIH1975 Lung - 2.597 - 
NCIH2052 Pleura 1.068 1.039 - 
NCIH2066 Lung - - 1.021 
NCIH2073 Lung - 0.874 - 
NCIH2081 Lung - 1.660 - 
NCIH2087 Lung - 1.643 - 
NCIH211 Lung - 1.458 - 
NCIH2122 Lung - 2.454 - 
NCIH2170 Lung - 3.592 4.320 
NCIH2171 Lung - 2.531 - 
NCIH23 Lung - 1.182 - 
NCIH2342 Lung - 1.156 - 
NCIH441 Lung - 0.886 - 
NCIH446 Lung - 2.555 - 
NCIH460 Lung - 2.357 - 
NCIH510 Lung - 1.362 - 
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Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
NCIH524 Lung - 3.235 - 
NCIH647 Lung - 2.185 - 
NCIH660 Prostate 1.140 1.086 - 
NCIH716 Large intestine - 2.908 - 
NCIH810 Lung - 2.498 - 
NCIH82 Lung - 3.239 - 
NCIN87 Stomach - - 4.026 
NUGC4 Stomach - - 1.116 
OCILY19 H&L - 1.385 - 
OE19 Oesophagus - - 5.298 
OE33 Oesophagus - - 2.723 
OVCAR4 Ovary - 0.931 - 
OVCAR8 Ovary - 0.969 - 
PANC0203 Pancreas - 1.180 - 
PANC0813 Pancreas - 0.901 - 
PC3 Prostate 0.965 0.953 - 
PK1 Pancreas - - 0.919 
PSN1 Pancreas - 2.655 - 
RKO Large intestine 0.900 - - 
RMGI Ovary - - 1.208 
SCLC21H Lung - 3.530 - 
SF172 CNS - 1.035 - 
SKBR3 Breast 2.471 2.470 2.781 
SKM1 H&L - 1.156 - 
SKMM2 H&L 1.287 1.223 - 
SKNMC Bone 0.944 0.982 - 
SKOV3 Ovary - - 1.822 
SNU1077 Endometrium - 1.021 - 
SNU119_OVA
RY Ovary - 1.531 - 
SNU1196 Biliary tract 0.871 0.871 - 
SNU16 Stomach - 3.320 - 
SNU216 Stomach - 1.136 1.984 
SNU478 Biliary tract - 3.472 - 
SNU601 Stomach - 1.255 - 
SNU61 Large intestine - 1.908 - 
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Cell line Tumour type 
Log2 gene copy number ratio 
TPD52 MYC ERBB2 
SNU668 Stomach 0.901 1.022 - 
SNU685 Endometrium - 2.597 - 
SNU899 Upper aerodigestive tract - - 0.946 
SUDHL4 H&L - 0.895 - 
SUPB15 H&L 0.896 - - 
SUPT11 H&L - 0.967 - 
SW480 Large intestine - 1.840 - 
SW620 Large intestine - 1.846 - 
TC71 Bone - 1.598 - 
TE10 Oesophagus - 1.118 - 
TE11 Oesophagus - 0.964 - 
TE4 Oesophagus 1.184 1.080 3.346 
TE6 Oesophagus - - 1.551 
TE8 Oesophagus - 2.398 - 
TE9 Oesophagus - 2.335 - 
TEN Endometrium - - 1.958 
TM31 CNS - 1.520 - 
TT Thyroid - 1.109 - 
UACC812 Breast - - 2.421 
UACC893 Breast - 1.140 3.229 
VCAP Prostate - 0.873 - 
VMRCLCP Lung - - 5.355 
ZR7530 Breast - 1.589 2.737 
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Appendix 2. Drug and cell line testing combinations in the Cancer Cell Line 
Encylopedia (CCLE). 
Drug Number of cell lines screened 
17-AAG 485 
AEW541 486 
AZD0530 487 
AZD6244 (selumetinib) 486 
Erlotinib 486 
Irinotecan 303 
L-685458 474 
Lapatinib 487 
LBW242 486 
Nilotinib 403 
Nutlin-3 487 
Paclitaxel 485 
Panobinostat 483 
PD-0325901 487 
PD-0332991 417 
PF-2341066 487 
PHA-665752 486 
PLX4720 479 
RAF265 443 
Sorafenib 486 
TAE684 487 
TKI258 487 
Topotecan 487 
ZD-6474 479 
Mean cell lines screened per drug 469 
Drug-cell line combinations 11,263 
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Appendix 3. Drug and cell line testing combinations in the Cancer Therapeutics 
Response Portal (CTRP). 
Drug CTRP identifier Number of cell lines screened 
10-DEBC BRD-K70792160 89 
10-methoxy-harmalan BRD-K54906270 23 
16-beta-
bromoandrosterone BRD-K98404142 230 
16,16-
dimethylprostaglandin-E2 BRD-K92301463 228 
2-bromopyruvate BRD-K92980438 108 
2-deoxyglucose BRD-A73690687 122 
2-fluoropalmitic acid BRD-A94451536 106 
2541665-P2 BRD-K61053657 107 
3-aminobenzamide BRD-K08703257 50 
3-chloroalanine BRD-K01976263 109 
4-methylfasudil BRD-K12683773 108 
5-benzylpaullone BRD-K47254568 122 
6-NBDG BRD-K12293034 122 
7-nitroindazole BRD-K04430056 107 
AA-COCF3 BRD-K07303502 107 
ABT-737 BRD-K56301217 230 
ABT-751 BRD-K91623615 211 
AC55649 BRD-K93176058 230 
AGK-2 BRD-K32536677 230 
Alda-1 BRD-K06890060 107 
Alpha-cyano-4-
hydroxycinnamic acid BRD-K60302405 122 
AM-580 BRD-K06854232 107 
APO-866 BRD-K85563610 131 
Aspirin BRD-K11433652 122 
AZD1775 BRD-K54256913 199 
AZD7545 BRD-K52836380 108 
B02 BRD-K10882151 50 
Batimatstat BRD-K82818427 108 
Bax channel blocker BRD-A18763547 230 
BEC BRD-K53792571 108 
BG-IX-360 BRD-K10012762 107 
BI-2536 BRD-K64890080 132 
BIBR-1532 BRD-K04623885 108 
BIX-01294 BRD-K26818574 229 
Blebbistatin BRD-A75817871 108 
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Drug CTRP identifier Number of cell lines screened 
BML-259 BRD-K71799778 107 
BMS-191011 BRD-K95609758 229 
BMS-299897 BRD-K02950022 131 
BMS-536924 BRD-K34581968 230 
BMS-641988 BRD-K48923948 230 
BMS-754807 BRD-K13049116 132 
Bortezomib BRD-K88510285 108 
Bovinocidin BRD-K61331723 122 
BRD-A03397005 BRD-A03397005 23 
BRD-A12409803 BRD-A12409803 106 
BRD-A13195221 BRD-A13195221 122 
BRD-A24054354 BRD-A24054354 65 
BRD-A60366732 BRD-A60366732 23 
BRD-A71390734 BRD-A71390734 131 
BRD-A73680854 BRD-A73680854 228 
BRD-A73779038 BRD-A73779038 122 
BRD-A89352139 BRD-A89352139 122 
BRD-K00615600 BRD-K00615600 50 
BRD-K05649647 BRD-K05649647 39 
BRD-K08121566 BRD-K08121566 65 
BRD-K11853856 BRD-K11853856 50 
BRD-K14696368 BRD-K14696368 230 
BRD-K16554956 BRD-K16554956 230 
BRD-K18595892 BRD-K18595892 23 
BRD-K20436150 BRD-K20436150 106 
BRD-K22014046 BRD-K22014046 107 
BRD-K25690923 BRD-K25690923 108 
BRD-K26863634 BRD-K26863634 122 
BRD-K28112517 BRD-K28112517 230 
BRD-K28506825 BRD-K28506825 107 
BRD-K30982572 BRD-K30982572 106 
BRD-K33218418 BRD-K33218418 107 
BRD-K35716340 BRD-K35716340 65 
BRD-K39319571 BRD-K39319571 89 
BRD-K40758391 BRD-K40758391 108 
BRD-K40892394 BRD-K40892394 230 
BRD-K43009525 BRD-K43009525 23 
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Drug CTRP identifier Number of cell lines screened 
BRD-K43620258 BRD-K43620258 107 
BRD-K50650713 BRD-K50650713 107 
BRD-K50776152 BRD-K50776152 108 
BRD-K51608872 BRD-K51608872 131 
BRD-K52904470 BRD-K52904470 50 
BRD-K54331210 BRD-K54331210 122 
BRD-K57011718 BRD-K57011718 50 
BRD-K58244372 BRD-K58244372 108 
BRD-K59424479 BRD-K59424479 89 
BRD-K60538097 BRD-K60538097 107 
BRD-K63069658 BRD-K63069658 107 
BRD-K73135802 BRD-K73135802 107 
BRD-K73261812 BRD-K73261812 198 
BRD-K76188144 BRD-K76188144 108 
BRD-K77432048 BRD-K77432048 50 
BRD-K78716413 BRD-K78716413 50 
BRD-K78867378 BRD-K78867378 89 
BRD-K86574132 BRD-K86574132 65 
BRD-K88560311 BRD-K88560311 50 
BRD-K89329876 BRD-K89329876 89 
BRD-K90735586 BRD-K90735586 50 
BRD-K90826279 BRD-K90826279 106 
BRD-K90999434 BRD-K90999434 132 
BRD-K92317137 BRD-K92317137 230 
BRD-K93120823 BRD-K93120823 122 
BRD-K93725829 BRD-K93725829 89 
BRD-K94679786 BRD-K94679786 103 
BRD-K95606637 BRD-K95606637 129 
BRD-K97046835 BRD-K97046835 122 
BRD-M86331534 BRD-M86331534 107 
BRD0476 BRD-K11540476 27 
BRD2662 BRD-K38012662 23 
BRD8899 BRD-K22828899 27 
BRD8958 BRD-K68548958 106 
Brefeldin-a BRD-A31107743 131 
BX-795 BRD-K47983010 131 
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Drug CTRP identifier Number of cell lines screened 
Capsaicin BRD-K50590187 108 
Carbamazepine BRD-K71799949 65 
CAY10594 BRD-K61662457 90 
CAY10618 BRD-K83289131 50 
CCT036477 BRD-A22997170 132 
CD-1530 BRD-K25737009 108 
CD-437 BRD-K28907958 230 
Cerulenin BRD-K52075040 108 
Chaetocin BRD-A85860691 109 
CHIR-99021 BRD-K16189898 107 
CHM-1 BRD-K94145482 107 
CI-976 BRD-K88544581 107 
Ciclosporin BRD-A38030642 230 
Compound 1541A BRD-K30064966 230 
Compound 7d-cis BRD-K61829047 230 
COT-10b BRD-K18190982 108 
CT-200783 BRD-K02822062 65 
Curcumin BRD-K74148702 89 
Cyanoquinoline 11 BRD-K00088062 107 
CYT-997 BRD-K23363278 65 
Cytochalasin B BRD-K26664453 229 
Cytosporone B BRD-K86191271 230 
Dactolisib BRD-K12184916 109 
Daporinad BRD-K58550667 107 
Darinaparsin BRD-K35723520 89 
Dexamethasone BRD-A35108200 230 
DG-041 BRD-K33272502 106 
Diazooxonorleucine BRD-K84924563 107 
Dichloroacetic acid BRD-M97302542 122 
DL-TBOA BRD-A05874290 108 
Eflornithine BRD-A96292436 122 
Endo-IWR-1 BRD-K61314889 129 
Epigallocatechin-3-gallate BRD-K19216856 107 
Erismodegib BRD-K19796430 50 
Ethylidene glucose BRD-A56646115 122 
Etimoxir BRD-K32405725 108 
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Drug CTRP identifier Number of cell lines screened 
Etoposide BRD-A79067928 131 
EX-527 BRD-K76964878 107 
Fatostatin BRD-K99696746 230 
Fedratinib BRD-K12502280 230 
FGIN-1-27 BRD-K09778810 131 
Fluoropyruvate BRD-K01779529 107 
Flutamide BRD-K28307902 107 
FMK-PA BRD-K40513024 122 
Fumonisin B1 BRD-A63646118 89 
GANT-58 BRD-K64451768 89 
GDC-0449 BRD-K44827188 230 
Gemcitabine BRD-K15108141 108 
Glibenclamide BRD-K36927236 230 
Gly-Gly-PALO BRD-K16701932 108 
GMX-1778 BRD-K47335880 131 
Gossypol BRD-K19295594 230 
GSK-2334470 BRD-K70642949 89 
GW-405833 BRD-K10705233 107 
GW-843682X BRD-K90382497 199 
HA-1004 BRD-K05434375 23 
HLI 373 BRD-K17349619 131 
Importazole BRD-A02481876 50 
Indisulam BRD-K17610631 229 
Isoevodiamine BRD-A68631409 131 
Isoliquiritigenin BRD-K33583600 129 
ISOX BRD-K69840642 50 
Itraconazole BRD-A34817987 229 
IWP-2 BRD-K82924899 23 
JTT-705 BRD-K18849474 108 
JZL184 BRD-K45446451 230 
Kinetin riboside BRD-K94325918 229 
Ko-143 BRD-K64642496 108 
KU 0060648 BRD-K09499853 50 
L-685458 BRD-K87317732 122 
LDN-193189 BRD-K04853698 198 
LE-135 BRD-K06593056 108 
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Drug CTRP identifier Number of cell lines screened 
Lenalidomide BRD-A17883755 107 
LFM-A13 BRD-A30655177 107 
Linsitinib BRD-K08589866 129 
Lonidamine BRD-K78513633 107 
Losartan BRD-K76205745 108 
lovastatin BRD-A70155556 107 
LY-2183240 BRD-K37865504 230 
LY-231514 BRD-K55395145 108 
LY-2365109 BRD-K13888115 122 
m-3M3-FBS BRD-K09635314 107 
Manumycin A BRD-K78599730 132 
Maraviroc BRD-A04352665 230 
MDV-3100 BRD-K56851771 89 
Minoxidil BRD-K14888893 89 
Mitomycin BRD-K59670716 23 
MK-2206 BRD-K68065987 50 
MK-591 BRD-K39503511 108 
ML-4-054 BRD-K90072296 89 
ML006 BRD-K89692698 107 
ML029 BRD-K59962020 230 
ML031 BRD-K38985961 107 
ML050 BRD-A83255679 106 
ML083 BRD-K44241590 228 
ML162 BRD-A36275421 131 
ML203 BRD-K80672993 108 
ML210 BRD-K01877528 107 
MLN2238 BRD-K78659596 50 
MPEP BRD-K60690191 89 
MST-312 BRD-K19894101 230 
Myriocin BRD-A76279427 131 
N5-iminoethyl-L-ornithine BRD-K33377378 122 
N9-isopropylolomoucine BRD-K71726959 107 
Narciclasine BRD-K06792661 50 
Navitoclax BRD-K82746043 229 
Necrostatin-1 BRD-A36318220 107 
Neratinib BRD-K85606544 131 
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Drug CTRP identifier Number of cell lines screened 
Neuronal differentiation 
inducer III BRD-K53903639 108 
Nifedipine BRD-K96354014 229 
Nimodipine BRD-A58048407 89 
NSC 74859 BRD-K40853697 107 
NSC23766 BRD-A80213327 107 
NSC632839 BRD-K74402642 230 
NSC95397 BRD-K68143200 229 
NU-1025 BRD-K48692744 50 
Nutlin-3 BRD-A12230535 107 
NVP-AUY922 BRD-K41859756 108 
Olaparib BRD-K02113016 107 
Oligomycin A BRD-A81541225 230 
Oxythiamine BRD-K82813588 103 
PAC-1 BRD-K92991072 230 
Parbendazole BRD-K02407574 106 
Parthenolide BRD-K81651477 90 
PDMP BRD-K05653692 107 
Penfluridol BRD-K15409150 89 
Pevonedistat BRD-K67844266 230 
PF-04217903 BRD-K73319509 107 
PF-3845 BRD-K68997413 229 
PF-750 BRD-K83213911 108 
Phloretin BRD-K15563106 107 
Phosphomycin BRD-K81101512 122 
PI-103 BRD-K67868012 230 
Pifithrin-alpha BRD-K66874953 107 
Pifithrin-mu BRD-K96799727 229 
PIK-75 BRD-K49371609 131 
PIK-90 BRD-K99818283 23 
Piperlongumine BRD-K24132293 230 
PK-11195 BRD-A41451487 108 
PL-DI BRD-K83336168 27 
Pluripotin BRD-K98538768 122 
PNU-74654 BRD-K30707190 107 
PP-110 BRD-K03618428 108 
PP-30 BRD-K30677119 230 
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Drug CTRP identifier Number of cell lines screened 
PRIMA-1 BRD-K15318909 107 
PRIMA-1-Met BRD-K49456190 131 
PRL-3 inhibitor I BRD-K09907482 107 
Purmorphamine BRD-K73397362 107 
PX-12 BRD-A56592690 89 
QS-11 BRD-K02526760 107 
Quinoclamine BRD-K66792149 230 
QW-BI-011 BRD-K72264770 131 
RepSox BRD-K80480517 122 
RG-108 BRD-K89391146 107 
RITA BRD-K00317371 230 
Ro-28-1675 BRD-K21672174 107 
Rosiglitazone BRD-A97437073 107 
Rotenone BRD-K08316444 108 
RS-23597-190 BRD-K01868942 107 
Salermide BRD-A67788537 89 
SB-225002 BRD-K61323504 230 
SCH-529074 BRD-K24376488 107 
SCH-79797 BRD-K17140735 229 
SD-6-087 BRD-K26312649 103 
Selumetinib BRD-K57080016 107 
Sepantronium bromide BRD-K76703230 109 
Serdemetan BRD-K60219430 199 
SID 26681509 BRD-K08417745 107 
Sildenafil BRD-K50128260 107 
Simvastatin BRD-K22134346 230 
Sirolimus (rapamycin) BRD-A23770159 230 
SJ-172550 BRD-K93095519 228 
SKI-II BRD-K20755323 108 
SN-38 BRD-A36630025 131 
SNX-2112 BRD-K71281111 131 
Sparfosic acid BRD-K00766422 107 
SRT-1720 BRD-K53855319 230 
STX-64 BRD-K87777313 23 
Tacrolimus BRD-K08845546 106 
Tamatinib BRD-K20285085 132 
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Drug CTRP identifier Number of cell lines screened 
Tamoxifen BRD-K93754473 108 
Tanespimycin BRD-K81473043 131 
Teniposide BRD-A35588707 108 
TGX-115 BRD-K67075780 107 
Thiazolopyrimidine BRD-A75517195 108 
Tipifarnib BRD-K62965247 230 
Tipifarnib-P1 BRD-K63195589 230 
Tivozanib BRD-K53414658 199 
Tosedostat BRD-K92241597 107 
Tozasertib BRD-K87947369 230 
Tretinoin BRD-K64634304 108 
Triacsin C BRD-K80527266 230 
Triazolothiadiazine BRD-K05402890 131 
Trifluoperazine BRD-K89732114 89 
Triptolide BRD-A13122391 132 
TTNBP BRD-K49685476 131 
Tubastatin-a BRD-K00627859 132 
TW-37 BRD-K28360340 106 
Tyrphostin BRD-K68336408 107 
Ubistatin BRD-K06163326 108 
UNC0321 BRD-K74236984 50 
UNC0638 BRD-K86856088 132 
Ursolic acid BRD-K68185022 107 
Valdecoxib BRD-K12994359 107 
Veliparib BRD-K87142802 50 
Vemurafenib BRD-K49213416 199 
VER-155008 BRD-K32330832 230 
Vorinostat BRD-K81418486 229 
WT-171 BRD-K74761218 230 
XAV-939 BRD-K12762134 230 
YK 4-279 BRD-A62182663 50 
YM-022 BRD-A29228457 122 
Zebularine BRD-A01145011 108 
Zileuton BRD-A56359832 107 
ZM336372 BRD-K73789395 107 
Mean cell lines screened per drug 128 
Drug-cell line combinations 41,334 
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Appendix 4. Clustering of Cancer Cell Line Encylopedia (CCLE) cell lines into 
five groups based on global gene expression.  Agglomerative hierarchical clustering 
was performed using the 500 most highly varying genes within the CCLE cohort of 
487 cell lines. 
Cell line Cell lineage Cluster 
A172 Central nervous system 1 
A204 Soft tissue 2 
A2058 Skin 1 
A253 Salivary gland 3 
A2780 Ovary 2 
A375 Skin 1 
A549 Lung 5 
A673 Bone 2 
ACHN Kidney 5 
ALLSIL Haematopoietic and lymphoid tissue 4 
AMO1 Haematopoietic and lymphoid tissue 4 
AN3CA Endometrium 2 
ASPC1 Pancreas 5 
AU565 Breast 3 
AZ521 Stomach 2 
BCPAP Thyroid 1 
BDCM Haematopoietic and lymphoid tissue 4 
BFTC909 Kidney 1 
BL41 Haematopoietic and lymphoid tissue 4 
BL70 Haematopoietic and lymphoid tissue 4 
BT20 Breast 3 
BT474 Breast 3 
BT549 Breast 1 
BXPC3 Pancreas 3 
C2BBE1 Large intestine 5 
C32 Skin 1 
C3A Liver 5 
CAKI2 Kidney 5 
CAL12T Lung 3 
CAL27 Upper aerodigestive tract 3 
CAL78 Bone 1 
CAL851 Breast 3 
CALU1 Lung 1 
CALU3 Lung 3 
CALU6 Lung 5 
CAMA1 Breast 3 
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Cell line Cell lineage Cluster 
CAPAN2 Pancreas 3 
CAS1 Central nervous system 1 
CCK81 Large intestine 3 
CHL1 Skin 2 
CHP212 Autonomic ganglia 1 
CI1 Haematopoietic and lymphoid tissue 4 
CMK86 Haematopoietic and lymphoid tissue 4 
COLO205 Large intestine 3 
COLO320 Large intestine 2 
COLO678 Large intestine 3 
COLO679 Skin 1 
COLO741 Skin 1 
CORL105 Lung 5 
CORL23 Lung 3 
COV318 Ovary 5 
COV504 Ovary 1 
DAOY Central nervous system 1 
DBTRG05MG Central nervous system 1 
DEL Haematopoietic and lymphoid tissue 4 
DETROIT562 Upper aerodigestive tract 3 
DKMG Central nervous system 1 
DMS114 Lung 2 
DOHH2 Haematopoietic and lymphoid tissue 4 
DU145 Prostate 3 
DV90 Lung 3 
EB1 Haematopoietic and lymphoid tissue 4 
EB2 Haematopoietic and lymphoid tissue 4 
EBC1 Lung 3 
EFE184 Endometrium 5 
EFM19 Breast 3 
EFO21 Ovary 5 
EFO27 Ovary 5 
EM2 Haematopoietic and lymphoid tissue 4 
EN Endometrium 2 
ES2 Ovary 1 
ESS1 Endometrium 1 
F36P Haematopoietic and lymphoid tissue 4 
FADU Upper aerodigestive tract 3 
FU97 Stomach 2 
FUOV1 Ovary 5 
G361 Skin 1 
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Cell line Cell lineage Cluster 
G401 Soft tissue 2 
G402 Soft tissue 2 
GAMG Central nervous system 1 
GB1 Central nervous system 1 
GCIY Stomach 5 
GCT Soft tissue 1 
GI1 Central nervous system 1 
GMS10 Central nervous system 1 
GRANTA519 Haematopoietic and lymphoid tissue 4 
H4 Central nervous system 1 
HARA Lung 3 
HCC1187 Breast 2 
HCC1395 Breast 5 
HCC15 Lung 5 
HCC1569 Breast 2 
HCC1806 Breast 3 
HCC1954 Breast 3 
HCC2935 Lung 3 
HCC4006 Lung 3 
HCC44 Lung 5 
HCC56 Large intestine 3 
HCC70 Breast 3 
HCC78 Lung 3 
HCC827 Lung 3 
HCT116 Large intestine 3 
HCT15 Large intestine 3 
HDMYZ Haematopoietic and lymphoid tissue 1 
HDQP1 Breast 3 
HEC151 Endometrium 5 
HEC1A Endometrium 5 
HEC1B Endometrium 5 
HEC251 Endometrium 5 
HEC265 Endometrium 5 
HEC59 Endometrium 5 
HEC6 Endometrium 5 
HEL9217 Haematopoietic and lymphoid tissue 4 
HEP3B217 Liver 5 
HEPG2 Liver 5 
HEYA8 Ovary 1 
HGC27 Stomach 2 
HH Haematopoietic and lymphoid tissue 4 
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Cell line Cell lineage Cluster 
HLE Liver 1 
HLF Liver 1 
HMC18 Breast 2 
HMCB Skin 2 
HOS Bone 1 
HPAC Pancreas 3 
HPAFII Pancreas 3 
HS229T Lung 1 
HS294T Skin 1 
HS578T Breast 1 
HS683 Central nervous system 1 
HS695T Skin 1 
HS729 Soft tissue 1 
HS739T Breast 1 
HS746T Stomach 1 
HS766T Pancreas 5 
HS840T Upper aerodigestive tract 1 
HS852T Skin 1 
HS895T Skin 1 
HS936T Skin 1 
HS939T Skin 1 
HS944T Skin 1 
HSC2 Upper aerodigestive tract 3 
HT Haematopoietic and lymphoid tissue 4 
HT1080 Soft tissue 1 
HT1197 Urinary tract 3 
HT1376 Urinary tract 3 
HT144 Skin 1 
HT29 Large intestine 3 
HUCCT1 Biliary tract 3 
HUH1 Liver 5 
HUPT3 Pancreas 3 
HUPT4 Pancreas 3 
HUT78 Haematopoietic and lymphoid tissue 4 
IALM Lung 1 
IGR37 Skin 1 
IGR39 Skin 1 
IGROV1 Ovary 5 
IM95 Stomach 3 
IMR32 Autonomic ganglia 2 
IPC298 Skin 1 
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Appendix 4. Continued… 
Cell line Cell lineage Cluster 
ISHIKAWAHERAKLIO02ER Endometrium 5 
ISTMES1 Pleura 1 
ISTMES2 Pleura 1 
J82 Urinary tract 1 
JHH2 Liver 5 
JHH4 Liver 5 
JHH5 Liver 5 
JHH6 Liver 5 
JHH7 Liver 5 
JHOS2 Ovary 3 
JHOS4 Ovary 5 
JHUEM2 Endometrium 2 
JM1 Haematopoietic and lymphoid tissue 4 
JMSU1 Urinary tract 1 
JURKAT Haematopoietic and lymphoid tissue 4 
JVM3 Haematopoietic and lymphoid tissue 4 
K029AX Skin 1 
KALS1 Central nervous system 1 
KARPAS299 Haematopoietic and lymphoid tissue 4 
KARPAS422 Haematopoietic and lymphoid tissue 4 
KARPAS620 Haematopoietic and lymphoid tissue 4 
KASUMI2 Haematopoietic and lymphoid tissue 4 
KCIMOH1 Pancreas 3 
KCL22 Haematopoietic and lymphoid tissue 4 
KE39 Stomach 3 
KE97 Haematopoietic and lymphoid tissue 4 
KELLY Autonomic ganglia 2 
KG1 Haematopoietic and lymphoid tissue 4 
KHM1B Haematopoietic and lymphoid tissue 4 
KLE Endometrium 5 
KMBC2 Urinary tract 3 
KMM1 Haematopoietic and lymphoid tissue 4 
KMRC1 Kidney 5 
KMRC2 Kidney 5 
KMS11 Haematopoietic and lymphoid tissue 4 
KMS12BM Haematopoietic and lymphoid tissue 4 
KMS26 Haematopoietic and lymphoid tissue 4 
KMS34 Haematopoietic and lymphoid tissue 4 
KNS42 Central nervous system 1 
KNS60 Central nervous system 1 
KNS62 Lung 3 
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Cell line Cell lineage Cluster 
KNS81 Central nervous system 1 
KO52 Haematopoietic and lymphoid tissue 4 
KP2 Pancreas 3 
KP3 Pancreas 5 
KP4 Pancreas 2 
KPNSI9S Autonomic ganglia 1 
KU812 Haematopoietic and lymphoid tissue 4 
KURAMOCHI Ovary 5 
KYM1 Soft tissue 2 
KYSE140 Oesophagus 3 
KYSE150 Oesophagus 3 
KYSE180 Oesophagus 3 
KYSE30 Oesophagus 3 
KYSE410 Oesophagus 3 
KYSE450 Oesophagus 3 
KYSE510 Oesophagus 3 
KYSE520 Oesophagus 3 
KYSE70 Oesophagus 3 
L33 Pancreas 3 
L363 Haematopoietic and lymphoid tissue 4 
L428 Haematopoietic and lymphoid tissue 4 
LC1SQSF Lung 3 
LCLC103H Lung 1 
LN18 Central nervous system 1 
LN229 Central nervous system 1 
LOUNH91 Lung 1 
LOXIMVI Skin 1 
LP1 Haematopoietic and lymphoid tissue 4 
LS123 Large intestine 3 
LS411N Large intestine 3 
LS513 Large intestine 3 
LU99 Lung 1 
LUDLU1 Lung 3 
MALME3M Skin 1 
MC116 Haematopoietic and lymphoid tissue 4 
MCAS Ovary 3 
MCF7 Breast 3 
MDAMB157 Breast 1 
MDAMB175VII Breast 3 
MDAMB415 Breast 3 
MDAMB435S Skin 1 
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Cell line Cell lineage Cluster 
MDAMB436 Breast 1 
MDAMB453 Breast 3 
MDAMB468 Breast 3 
MEC1 Haematopoietic and lymphoid tissue 4 
MEG01 Haematopoietic and lymphoid tissue 4 
MELHO Skin 1 
MESSA Soft tissue 2 
MEWO Skin 1 
MFE280 Endometrium 5 
MFE296 Endometrium 2 
MFE319 Endometrium 5 
MG63 Bone 1 
MHHES1 Bone 2 
MIAPACA2 Pancreas 2 
MINO Haematopoietic and lymphoid tissue 4 
MJ Haematopoietic and lymphoid tissue 4 
MKN45 Stomach 3 
MKN7 Stomach 3 
MKN74 Stomach 3 
MOGGCCM Central nervous system 1 
MOLP8 Haematopoietic and lymphoid tissue 4 
MOLT16 Haematopoietic and lymphoid tissue 4 
MONOMAC1 Haematopoietic and lymphoid tissue 4 
MORCPR Lung 3 
MPP89 Pleura 1 
MSTO211H Pleura 1 
NCIH1048 Lung 2 
NCIH1092 Lung 2 
NCIH1155 Lung 2 
NCIH1184 Lung 2 
NCIH1299 Lung 2 
NCIH1339 Lung 1 
NCIH1341 Lung 2 
NCIH1355 Lung 5 
NCIH1373 Lung 3 
NCIH1563 Lung 5 
NCIH1568 Lung 3 
NCIH1573 Lung 3 
NCIH1581 Lung 2 
NCIH1648 Lung 3 
NCIH1650 Lung 3 
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Cell line Cell lineage Cluster 
NCIH1651 Lung 5 
NCIH1666 Lung 3 
NCIH1693 Lung 3 
NCIH1694 Lung 2 
NCIH1703 Lung 2 
NCIH1792 Lung 5 
NCIH1793 Lung 5 
NCIH1869 Lung 3 
NCIH1915 Lung 1 
NCIH1944 Lung 5 
NCIH1975 Lung 3 
NCIH2009 Lung 3 
NCIH2023 Lung 5 
NCIH2030 Lung 5 
NCIH2052 Pleura 1 
NCIH2085 Lung 3 
NCIH2087 Lung 3 
NCIH211 Lung 2 
NCIH2122 Lung 3 
NCIH2170 Lung 3 
NCIH2172 Lung 5 
NCIH2228 Lung 5 
NCIH226 Lung 1 
NCIH2286 Lung 2 
NCIH23 Lung 2 
NCIH2444 Lung 3 
NCIH2452 Pleura 1 
NCIH28 Pleura 5 
NCIH322 Lung 3 
NCIH3255 Lung 3 
NCIH358 Lung 3 
NCIH441 Lung 3 
NCIH460 Lung 5 
NCIH520 Lung 2 
NCIH522 Lung 2 
NCIH647 Lung 5 
NCIH650 Lung 1 
NCIH661 Lung 2 
NCIH727 Lung 5 
NCIH747 Large intestine 3 
NCIH810 Lung 2 
		320 
Appendix 4. Continued… 
Cell line Cell lineage Cluster 
NCIN87 Stomach 3 
NCO2 Haematopoietic and lymphoid tissue 4 
NIHOVCAR3 Ovary 5 
NUGC3 Stomach 3 
NUGC4 Stomach 3 
OC314 Ovary 5 
OC316 Ovary 5 
OCIAML2 Haematopoietic and lymphoid tissue 4 
OCIAML5 Haematopoietic and lymphoid tissue 4 
OCILY10 Haematopoietic and lymphoid tissue 4 
OCUM1 Stomach 3 
OE33 Oesophagus 3 
ONCODG1 Ovary 5 
ONS76 Central nervous system 1 
OPM2 Haematopoietic and lymphoid tissue 4 
OV90 Ovary 5 
OVCAR4 Ovary 5 
OVCAR8 Ovary 1 
OVMANA Ovary 5 
OVSAHO Ovary 5 
OVTOKO Ovary 5 
P12ICHIKAWA Haematopoietic and lymphoid tissue 4 
P31FUJ Haematopoietic and lymphoid tissue 4 
P3HR1 Haematopoietic and lymphoid tissue 4 
PANC0203 Pancreas 3 
PANC0327 Pancreas 3 
PANC0403 Pancreas 3 
PANC1005 Pancreas 3 
PATU8902 Pancreas 3 
PC14 Lung 3 
PC3 Prostate 3 
PFEIFFER Haematopoietic and lymphoid tissue 4 
PK1 Pancreas 3 
PK45H Pancreas 5 
PK59 Pancreas 3 
PL45 Pancreas 3 
PLCPRF5 Liver 5 
PSN1 Pancreas 5 
QGP1 Pancreas 2 
RAJI Haematopoietic and lymphoid tissue 4 
RD Soft tissue 1 
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Cell line Cell lineage Cluster 
REH Haematopoietic and lymphoid tissue 4 
RERFGC1B Stomach 3 
RERFLCAI Lung 1 
RERFLCMS Lung 5 
RKO Large intestine 2 
RL952 Endometrium 3 
RPMI7951 Skin 1 
RPMI8402 Haematopoietic and lymphoid tissue 4 
RT112 Urinary tract 3 
RT4 Urinary tract 3 
RVH421 Skin 1 
SBC5 Lung 2 
SCABER Urinary tract 3 
SCC25 Upper aerodigestive tract 3 
SCC9 Upper aerodigestive tract 3 
SF126 Central nervous system 1 
SF295 Central nervous system 1 
SH10TC Stomach 2 
SHP77 Lung 2 
SIGM5 Haematopoietic and lymphoid tissue 4 
SIMA Autonomic ganglia 2 
SJRH30 Soft tissue 1 
SJSA1 Bone 1 
SKBR3 Breast 3 
SKCO1 Large intestine 3 
SKES1 Bone 2 
SKHEP1 Liver 1 
SKLMS1 Soft tissue 1 
SKLU1 Lung 1 
SKMEL2 Skin 1 
SKMEL24 Skin 1 
SKMEL30 Skin 1 
SKMEL31 Skin 1 
SKMEL5 Skin 1 
SKMES1 Lung 5 
SKMM2 Haematopoietic and lymphoid tissue 4 
SKNAS Autonomic ganglia 1 
SKNBE2 Autonomic ganglia 2 
SKNDZ Autonomic ganglia 2 
SKNFI Autonomic ganglia 2 
SKNSH Autonomic ganglia 1 
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Cell line Cell lineage Cluster 
SKOV3 Ovary 5 
SNGM Endometrium 5 
SNU1 Stomach 2 
SNU16 Stomach 3 
SNU182 Liver 1 
SNU387 Liver 5 
SNU398 Liver 2 
SNU423 Liver 1 
SNU449 Liver 5 
SNU475 Liver 1 
SNUC2A Large intestine 3 
SQ1 Lung 3 
SU8686 Pancreas 3 
SUDHL10 Haematopoietic and lymphoid tissue 4 
SUDHL4 Haematopoietic and lymphoid tissue 4 
SUDHL6 Haematopoietic and lymphoid tissue 4 
SUDHL8 Haematopoietic and lymphoid tissue 4 
SUIT2 Pancreas 5 
SUPM2 Haematopoietic and lymphoid tissue 4 
SUPT1 Haematopoietic and lymphoid tissue 4 
SW1088 Central nervous system 1 
SW1271 Lung 2 
SW1353 Bone 1 
SW1417 Large intestine 3 
SW1573 Lung 2 
SW1990 Pancreas 5 
SW403 Large intestine 3 
SW48 Large intestine 3 
SW480 Large intestine 3 
SW579 Thyroid 1 
SW620 Large intestine 3 
SW780 Urinary tract 3 
SW900 Lung 3 
T24 Urinary tract 1 
T47D Breast 3 
T84 Large intestine 3 
T98G Central nervous system 1 
TC71 Bone 2 
TCCSUP Urinary tract 5 
TE1 Oesophagus 3 
TE11 Oesophagus 3 
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Cell line Cell lineage Cluster 
TE15 Oesophagus 3 
TE5 Oesophagus 3 
TE617T Soft tissue 2 
TE9 Oesophagus 3 
TEN Endometrium 5 
TOLEDO Haematopoietic and lymphoid tissue 4 
TOV112D Ovary 2 
TOV21G Ovary 5 
TT2609C02 Thyroid 1 
TYKNU Ovary 2 
U118MG Central nervous system 1 
U2OS Bone 1 
U87MG Central nervous system 1 
U937 Haematopoietic and lymphoid tissue 4 
UACC257 Skin 1 
UACC62 Skin 1 
UACC812 Breast 3 
UMUC3 Urinary tract 2 
VMRCLCD Lung 2 
VMRCRCW Kidney 5 
VMRCRCZ Kidney 5 
WM115 Skin 1 
WM1799 Skin 1 
WM2664 Skin 1 
WM793 Skin 1 
WM88 Skin 1 
WM983B Skin 1 
X1321N1 Central nervous system 1 
X22RV1 Prostate 2 
X42MGBA Central nervous system 1 
X5637 Urinary tract 3 
X639V Urinary tract 2 
X697 Haematopoietic and lymphoid tissue 4 
X769P Kidney 5 
X786O Kidney 5 
X8305C Thyroid 1 
X8505C Thyroid 1 
X8MGBA Central nervous system 1 
YKG1 Central nervous system 1 
ZR751 Breast 3 
ZR7530 Breast 3 
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Appendix 5. Clustering of Cancer Therapeutics Response Portal (CTRP) cell lines 
into five groups based on global gene expression.  Agglomerative hierarchical 
clustering was performed using the 500 most highly varying genes within the CTRP 
cohort of 230 cell lines. 
Cell line Cell lineage Cluster 
A2780 Ovary 1 
A375 Skin 1 
A549 Lung 1 
AGS Stomach 2 
AMO1 Haematopoietic and lymphoid tissue 3 
BEN Lung 5 
BL70 Haematopoietic and lymphoid tissue 3 
C2BBE1 Large intestine 2 
CAL12T Lung 2 
CALU3 Lung 2 
CALU6 Lung 1 
CAOV3 Ovary 2 
CAPAN2 Pancreas 2 
CFPAC1 Pancreas 2 
CHAGOK1 Lung 2 
CL34 Large intestine 4 
CL40 Large intestine 4 
COLO205 Large intestine 4 
COLO320 Large intestine 5 
COLO668 Lung 5 
COLO678 Large intestine 2 
COLO741 Skin 1 
CORL23 Lung 2 
CORL51 Lung 5 
CORL88 Lung 5 
COV318 Ovary 2 
COV362 Ovary 2 
COV434 Ovary 1 
COV644 Ovary 2 
CW2 Large intestine 4 
DLD1 Large intestine 2 
DMS273 Lung 5 
DV90 Lung 4 
EBC1 Lung 2 
EFO21 Ovary 2 
EFO27 Ovary 2 
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Cell line Cell lineage Cluster 
EJM Haematopoietic and lymphoid tissue 3 
EPLC272H Lung 2 
FU97 Stomach 2 
G361 Skin 1 
G401 Soft tissue 1 
GAMG Central nervous system 1 
GDM1 Haematopoietic and lymphoid tissue 3 
GP2D Large intestine 4 
HARA Lung 2 
HCC1195 Lung 2 
HCC15 Lung 1 
HCC2935 Lung 2 
HCC33 Lung 5 
HCC4006 Lung 2 
HCC44 Lung 1 
HCC78 Lung 2 
HCC827 Lung 2 
HCT116 Large intestine 2 
HEC108 Endometrium 2 
HEC151 Endometrium 2 
HEC251 Endometrium 2 
HEC265 Endometrium 2 
HEC59 Endometrium 2 
HEC6 Endometrium 2 
HEPG2 Liver 2 
HEYA8 Ovary 1 
HPAC Pancreas 2 
HS852T Skin 1 
HS936T Skin 1 
HS944T Skin 1 
HSC2 Upper aerodigestive tract 2 
HT Haematopoietic and lymphoid tissue 3 
HT1080 Soft tissue 1 
HT115 Large intestine 4 
HT1376 Urinary tract 2 
HT29 Large intestine 4 
HT55 Large intestine 4 
HUPT4 Pancreas 2 
IGROV1 Ovary 2 
ISHIKAWAHERAKLIO02ER Endometrium 2 
JHH6 Liver 1 
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Cell line Cell lineage Cluster 
JHOC5 Ovary 1 
JHOM1 Ovary 1 
JHOS4 Ovary 2 
JHUEM2 Endometrium 1 
KLE Endometrium 2 
KM12 Large intestine 4 
KMBC2 Urinary tract 2 
KMS11 Haematopoietic and lymphoid tissue 3 
KNS62 Lung 2 
KP3 Pancreas 1 
KU812 Haematopoietic and lymphoid tissue 3 
KYSE140 Oesophagus 2 
KYSE410 Oesophagus 2 
KYSE450 Oesophagus 2 
LC1SQSF Lung 2 
LCLC103H Lung 1 
LCLC97TM1 Lung 2 
LN229 Central nervous system 1 
LOVO Large intestine 4 
LP1 Haematopoietic and lymphoid tissue 3 
LS123 Large intestine 2 
LS180 Large intestine 4 
LS411N Large intestine 4 
LS513 Large intestine 4 
LU65 Lung 1 
LU99 Lung 1 
LXF289 Lung 1 
MC116 Haematopoietic and lymphoid tissue 3 
MCF7 Breast 2 
MFE319 Endometrium 2 
MKN7 Stomach 2 
MKN74 Stomach 2 
MOLM16 Haematopoietic and lymphoid tissue 3 
MSTO211H Pleura 1 
NCIH1048 Lung 5 
NCIH1105 Lung 5 
NCIH1299 Lung 1 
NCIH1355 Lung 1 
NCIH1373 Lung 2 
NCIH1435 Lung 2 
NCIH1437 Lung 2 
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Cell line Cell lineage Cluster 
NCIH1568 Lung 2 
NCIH1573 Lung 2 
NCIH1666 Lung 2 
NCIH1694 Lung 5 
NCIH1755 Lung 1 
NCIH1781 Lung 2 
NCIH1792 Lung 1 
NCIH1793 Lung 1 
NCIH1836 Lung 5 
NCIH1876 Lung 5 
NCIH1915 Lung 1 
NCIH1930 Lung 5 
NCIH1944 Lung 1 
NCIH1963 Lung 5 
NCIH1975 Lung 2 
NCIH2009 Lung 2 
NCIH2023 Lung 1 
NCIH2029 Lung 5 
NCIH2030 Lung 1 
NCIH2052 Pleura 1 
NCIH2081 Lung 5 
NCIH2110 Lung 2 
NCIH2122 Lung 2 
NCIH2126 Lung 2 
NCIH2172 Lung 1 
NCIH2286 Lung 1 
NCIH23 Lung 1 
NCIH2342 Lung 2 
NCIH2405 Lung 1 
NCIH28 Pleura 1 
NCIH3255 Lung 2 
NCIH358 Lung 2 
NCIH441 Lung 2 
NCIH460 Lung 1 
NCIH508 Large intestine 4 
NCIH522 Lung 1 
NCIH596 Lung 2 
NCIH650 Lung 1 
NCIH661 Lung 1 
NCIH727 Lung 2 
NCIH810 Lung 5 
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Cell line Cell lineage Cluster 
NCIH82 Lung 5 
NCIH841 Lung 1 
NOMO1 Haematopoietic and lymphoid tissue 3 
NUDUL1 Haematopoietic and lymphoid tissue 3 
NUGC4 Stomach 4 
OAW42 Ovary 2 
OCIAML3 Haematopoietic and lymphoid tissue 3 
OCILY10 Haematopoietic and lymphoid tissue 3 
OV7 Ovary 1 
OV90 Ovary 2 
OVCAR4 Ovary 2 
OVCAR8 Ovary 1 
OVK18 Ovary 1 
OVKATE Ovary 2 
OVMANA Ovary 2 
P3HR1 Haematopoietic and lymphoid tissue 3 
PANC0327 Pancreas 2 
PANC1005 Pancreas 2 
PATU8902 Pancreas 2 
PC3 Prostate 2 
PL21 Haematopoietic and lymphoid tissue 3 
QGP1 Pancreas 5 
RCC10RGB Kidney 1 
RCM1 Large intestine 4 
RERFLCKJ Lung 2 
RKO Large intestine 2 
RMGI Ovary 2 
RMUGS Ovary 2 
RPMI8226 Haematopoietic and lymphoid tissue 3 
RT4 Urinary tract 2 
SCC9 Upper aerodigestive tract 2 
SCLC21H Lung 5 
SF295 Central nervous system 1 
SH10TC Stomach 1 
SHP77 Lung 5 
SKCO1 Large intestine 4 
SKLU1 Lung 1 
SKM1 Haematopoietic and lymphoid tissue 3 
SKMEL1 Skin 1 
SKMEL28 Skin 1 
SKMEL5 Skin 1 
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Cell line Cell lineage Cluster 
SKOV3 Ovary 2 
SNGM Endometrium 2 
SNU1040 Large intestine 4 
SNU175 Large intestine 4 
SNU398 Liver 1 
SNU449 Liver 1 
SNU61 Large intestine 4 
SNU81 Large intestine 4 
SNU840 Ovary 2 
SNUC2A Large intestine 2 
SNUC4 Large intestine 4 
SNUC5 Large intestine 2 
SQ1 Lung 2 
SUDHL4 Haematopoietic and lymphoid tissue 3 
SUDHL5 Haematopoietic and lymphoid tissue 3 
SUIT2 Pancreas 1 
SW403 Large intestine 4 
SW48 Large intestine 2 
SW480 Large intestine 2 
SW620 Large intestine 2 
SW948 Large intestine 4 
THP1 Haematopoietic and lymphoid tissue 3 
TYKNU Ovary 1 
U2OS Bone 1 
U937 Haematopoietic and lymphoid tissue 3 
UMUC3 Urinary tract 1 
VMRCLCD Lung 5 
VMRCRCW Kidney 1 
WSUDLCL2 Haematopoietic and lymphoid tissue 3 
X5637 Urinary tract 2 
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Appendix 6. Additional statistics pertaining to drug-gene models. 
 
Table 6.1. Drugs predicted by multivariate linear regression to be associated with 
TPD52 copy number.  
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between copy 
number and 
cluster c 
Full 
model p 
value 
Se
ns
iti
ve
 
PL-DI 0.10 0 0 5.20E-02 
KU 0060648 0.39 2 0 5.77E-06 
Importazole 0.18 1 0 8.37E-03 
MLN2238 0.12 0 0 2.05E-02 
Ubistatin 0.15 1 0 5.09E-04 
Kinetin riboside 0.12 1 0 1.20E-06 
Brefeldin A 0.15 1 0 2.13E-04 
Nilotinib 0.11 1 0 4.18E-10 
Lapatinib 0.24 2 1 0.00E+00 
 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
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Table 6.2. Drugs predicted by multivariate linear regression to be associated with 
TPD52 expression.   
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
expression 
and cluster c 
Full model 
p value 
Se
n.
 BEC 0.25 1 0 1.66E-08 
BRD-K78716413 0.08 0 0 2.96E-03 
SN-38 0.10 0 0 1.23E-02 
R
es
is
ta
nt
 
Selumetinib 0.06 0 0 2.34E-02 
Tanespimycin 0.33 2 1 1.28E-08 
All-trans retinoic 
acid 0.08 0 0 1.57E-02 
BRD-K11853856 0.21 1 1 5.31E-08 
TTNBP 0.10 1 0 1.83E-03 
NSC 74859 0.26 2 0 1.76E-06 
GW-405833 0.24 1 0 1.77E-13 
AC55649 0.04 0 0 7.08E-02 
PDMP 0.14 1 0 4.37E-04 
Sildenafil 0.38 1 0 1.18E-05 
B02 0.28 2 0 9.05E-09 
CCT036477 0.14 1 0 3.38E-04 
SNX-2112 0.06 0 0 8.81E-03 
7-nitroindazole 0.17 1 0 3.49E-03 
Sonidegib 0.04 0 0 1.52E-01 
CAY10594 0.04 0 0 2.55E-03 
BRD-K90072296 0.02 0 0 1.42E-01 
Fatostatin 0.16 1 0 3.68E-04 
BRD-A12409803 0.13 1 0 3.23E-04 
BRD-K22014046 0.07 0 0 3.69E-02 
GSK-2334470 0.14 1 0 7.07E-04 
BRD-K40758391 0.25 1 1 3.51E-13 
16,16-dimethyl 
prostaglandin-E2 0.15 0 0 1.64E-02 
BRD-K52904470 0.19 1 0 3.83E-05 
BRD-K28506825 0.25 3 0 0.00E+00 
TAE684 0.05 2 0 8.25E-06 
TKI258 0.07 1 1 9.12E-10 
PF2341066 0.09 2 0 2.87E-09 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
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Table 6.3. Drugs predicted by multivariate linear regression to be associated with 
MYC copy number.   
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
copy number 
and cluster c 
Full model 
p value 
Se
ns
iti
ve
 Linsitinib 0.14 0 0 1.99E-02 
Itraconazole 0.32 2 0 1.39E-10 
Paclitaxel 0.40 1 0 1.36E-05 
Nilotinib 0.42 4 0 6.44E-10 
R
es
is
ta
nt
 
PL-DI 0.17 2 0 6.96E-05 
Etoposide 0.42 3 0 9.03E-10 
KU 0060648 0.24 1 0 4.81E-06 
BRD-K78867378 0.15 3 0 4.40E-04 
Tyrphostin 0.43 4 0 8.89E-10 
PX-12 0.06 1 0 3.31E-03 
Teniposide 0.10 1 1 1.31E-03 
Batimatstat 0.17 2 0 1.80E-08 
Parthenolide 0.26 2 0 1.17E-13 
RITA 0.10 1 0 1.87E-05 
Navitoclax 0.13 1 0 4.01E-04 
ABT-737 0.19 2 1 3.31E-10 
SNX-2112 0.14 2 0 1.04E-14 
16-beta-
bromoandrosterone 0.10 2 0 2.74E-04 
BRD-K73261812 0.12 1 1 4.50E-10 
Erlotinib 0.22 2 0 0.00E+00 
PHA-665752 0.04 1 0 1.20E-04 
Nutlin-3 0.03 0 1 1.69E-03 
 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
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Table 6.4. Drugs predicted by multivariate linear regression to be associated with 
MYC expression.   
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
expression 
and cluster c 
Full model 
p value 
Se
ns
iti
ve
 
BRD-K93725829 0.08 0 0 5.34E-04 
Itraconazole 0.35 2 0 4.99E-05 
Kinetin riboside 0.46 1 1 1.83E-06 
Simvastatin 0.13 1 0 3.45E-03 
PD-0325901 0.22 1 0 7.11E-03 
RAF265 0.41 2 0 1.43E-05 
17-AAG 0.06 0 0 3.55E-02 
BRD-K50650713 0.16 1 0 1.22E-04 
Selumetinib 0.24 2 1 1.93E-14 
Nilotinib 0.40 2 0 2.31E-14 
Alda-1 0.13 1 0 4.13E-02 
Gly-Gly-PALO 0.34 2 0 3.72E-09 
Sorafenib 0.07 0 0 9.93E-03 
TKI258 0.10 2 0 1.01E-06 
R
es
is
ta
nt
 
BRD-K88560311 0.26 1 0 1.45E-06 
BRD-K00615600 0.17 3 1 6.64E-04 
MK-2206 0.16 1 0 4.59E-05 
Veliparib 0.03 0 0 3.15E-02 
Importazole 0.17 1 1 2.32E-05 
KU 0060648 0.25 1 1 1.76E-07 
Ursolic acid 0.11 1 0 2.52E-06 
Olaparib 0.26 1 0 1.30E-09 
ABT-737 0.14 0 0 1.45E-04 
Manumycin A 0.12 2 0 1.80E-03 
BRD-K11853856 0.11 2 0 1.28E-05 
PRIMA-1 0.04 3 0 7.77E-05 
AA-COCF3 0.09 0 0 4.71E-03 
Batimatstat 0.05 4 0 1.63E-06 
SNX-2112 0.02 0 1 2.68E-03 
JTT-705 0.10 1 0 9.19E-03 
QW-BI-011 0.09 0 1 2.39E-03 
PRIMA-1-Met 0.15 0 0 1.14E-03 
CCT036477 0.05 1 0 1.46E-03 
Necrostatin-1 0.14 1 0 4.91E-04 
Cerulenin 0.03 0 0 5.49E-03 
Tacrolimus 0.08 0 0 6.92E-03 
PF-04217903 0.11 1 0 4.37E-03 
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Table 6.4. Continued… 
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
expression 
and cluster c 
Full model 
p value 
 ML050 0.09 1 1 1.79E-10 
Quinoclamine 0.16 0 0 3.13E-04 
LFM-A13 0.10 1 0 2.53E-03 
Lonidamine 0.08 1 0 4.55E-02 
BRD-K61053657 0.08 1 0 3.22E-12 
Losartan 0.01 0 0 1.67E-01 
ML083 0.07 1 0 7.88E-08 
 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
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Table 6.5. Drugs predicted by multivariate linear regression to be associated with 
ERBB2 copy number.   
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
copy number 
and cluster c 
Full model 
p value 
Se
n.
 Lapatinib 0.11 0 0 5.95E-04 
Panobinostat 0.13 0 0 8.18E-05 
R
es
is
ta
nt
 
MLN2238 0.13 0 1 1.19E-04 
Dactolisib 0.32 1 0 1.06E-08 
Blebbistatin 0.07 0 0 3.24E-02 
CHM-1 0.14 0 0 1.38E-03 
TW-37 0.37 1 0 3.51E-10 
Epigallocatechin-
3-monogallate 0.15 0 0 7.83E-04 
Parbendazole 0.15 3 0 1.16E-04 
Olaparib 0.08 0 0 1.29E-02 
BMS-754807 0.20 1 0 5.65E-05 
BRD-K03618428 0.27 3 0 1.11E-16 
4-methylfasudil 0.23 1 0 6.97E-06 
SB-225002 0.08 1 0 2.08E-02 
PNU-74654 0.17 1 1 3.82E-10 
ML006 0.22 2 0 3.37E-07 
PI-103 0.26 3 0 4.54E-09 
BX-795 0.28 1 0 4.01E-09 
CCT036477 0.17 1 0 3.42E-11 
Triazolothiadiazine 0.05 1 0 3.54E-03 
Fedratinib 0.08 0 0 2.51E-02 
RITA 0.05 1 0 1.35E-03 
PF-750 0.10 1 1 2.14E-05 
BMS-536924 0.20 2 0 4.97E-10 
CD-437 0.08 0 0 2.83E-02 
AZD1775 0.14 0 0 9.46E-04 
m-3M3-FBS 0.02 0 0 2.47E-01 
ML050 0.11 3 0 2.73E-06 
Myriocin 0.206 2 1 0.00E+00 
BRD-K74761218 0.25 2 0 2.58E-14 
LY-2183240 0.36 0 1 1.81E-02 
BRD-A60366732 0.20 2 0 4.38E-11 
NSC95397 0.20 1 0 5.08E-12 
Tipifarnib-P1 0.10 1 0 1.32E-05 
Gossypol 0.043 1 0 6.01E-05 
PD-0325901 0.26 1 0 4.44E-15 
Tipifarnib-P2 0.24 3 0 2.20E-13 
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Table 6.5. Continued… 
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
copy number 
and cluster c 
Full model 
p value 
 Piperlongumine 0.07 1 0 1.22E-03 
Quinoclamine 0.133 2 0 1.67E-15 
Paclitaxel 0.19 1 0 1.48E-10 
SCH-79797 0.03 0 0 1.70E-01 
DL-TBOA 0.04 1 0 1.14E-02 
AGK-2 0.027 0 0 1.84E-03 
Selumetinib 0.05 0 0 4.31E-03 
XAV-939 0.06 1 0 1.12E-03 
JZL184 0.046 1 0 1.05E-05 
TAE684 0.04 0 0 9.39E-03 
BRD-K40892394 0.02 0 0 5.04E-02 
Glibenclamide 0.018 0 0 6.78E-03 
AEW541 0.234 2 0 0.00E+00 
GDC-0449 0.04 1 0 9.33E-03 
TKI258 0.066 1 0 6.08E-08 
Nutlin-3 0.027 0 0 2.21E-03 
 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
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Table 6.6. Drugs predicted by multivariate linear regression to be associated with 
ERBB2 expression.   
 
Drug Relative contribution a 
Clusters 
different to 
reference b 
Interaction 
between 
expression 
and cluster c 
Full model 
p value 
Se
ns
iti
ve
 
Ursolic acid 0.12 2 0 1.44E-03 
Tyrphostin 0.12 0 0 6.07E-06 
BRD-K78867378 0.13 0 0 1.91E-03 
Parthenolide 0.07 0 0 2.59E-03 
ML006 0.43 2 0 8.66E-10 
BRD-K43620258 0.43 2 0 4.15E-10 
Lapatinib 0.13 1 0 6.99E-09 
Navitoclax 0.11 1 0 1.22E-02 
BRD-K33218418 0.21 1 2 3.33E-16 
BRD-K52904470 0.12 2 0 4.73E-03 
Panobinostat 0.15 1 0 1.51E-07 
R
es
is
ta
nt
 
MLN2238 0.10 2 0 2.17E-06 
Rotenone 0.20 2 1 9.72E-06 
Pevonedistat 0.15 3 0 0.00E+00 
SB-225002 0.17 2 0 1.62E-08 
BX-795 0.12 1 0 1.03E-07 
Tozasertib 0.12 1 2 1.64E-08 
PNU-74654 0.19 3 0 8.53E-10 
ABT-751 0.15 1 0 4.07E-09 
MST-312 0.05 2 0 4.60E-05 
AZD1775 0.09 0 0 3.58E-02 
PI-103 0.12 3 0 3.22E-15 
PD-0325901 0.16 0 0 2.22E-02 
Paclitaxel 0.03 0 0 2.65E-03 
Selumetinib 0.02 1 0 1.68E-02 
AEW541 0.23 2 0 0.00E+00 
 
a  Relative contribution made by global gene expression cluster to the variation in drug 
sensitivity 
b  The number of global gene expression clusters for which the drug response was found 
to be significantly different to that displayed by reference cluster 1 
c  A significant interaction between predictor variables was detected if the regression 
coefficients (effect sizes) differed significantly across the five global gene expression 
clusters (0 = no interaction; 1 = interaction) 
 
